{"0a60911da5cd26b915a667843c296179d810d78e": [["IntroductionDendritic cells (DCs) are potent antigen presenting cells that are required for the initiation of T cell responses and function as a bridge between the innate and adaptive immune systems [1] .", [["IntroductionDendritic cells", "ANATOMY", 0, 27], ["DCs", "ANATOMY", 29, 32], ["antigen presenting cells", "ANATOMY", 45, 69], ["T cell", "ANATOMY", 110, 116], ["IntroductionDendritic cells", "CELL", 0, 27], ["DCs", "CELL", 29, 32], ["cells", "CELL", 64, 69], ["T cell", "CELL", 110, 116], ["IntroductionDendritic cells", "CELL_TYPE", 0, 27], ["DCs", "CELL_TYPE", 29, 32], ["antigen presenting cells", "CELL_TYPE", 45, 69], ["IntroductionDendritic cells", "PROBLEM", 0, 27], ["potent antigen presenting cells", "PROBLEM", 38, 69], ["T cell responses", "TREATMENT", 110, 126], ["a bridge between the innate and adaptive immune systems", "TREATMENT", 143, 198]]], ["They are localized to and circulated within distinct compartments of the lymphoid and peripheral nonlymphoid organs at different stages of maturation.", [["compartments", "ANATOMY", 53, 65], ["lymphoid", "ANATOMY", 73, 81], ["peripheral nonlymphoid organs", "ANATOMY", 86, 115], ["lymphoid", "CELL", 73, 81], ["peripheral nonlymphoid organs", "TISSUE", 86, 115], ["lymphoid", "ANATOMY", 73, 81], ["peripheral", "ANATOMY_MODIFIER", 86, 96], ["nonlymphoid organs", "OBSERVATION", 97, 115], ["different stages", "OBSERVATION_MODIFIER", 119, 135], ["maturation", "OBSERVATION_MODIFIER", 139, 149]]], ["DCs normally reside in an immature state within the peripheral nonlymphoid tissues, where they serve as sentinels for incoming antigens, such as those associated with microbial pathogens and tumors.", [["DCs", "ANATOMY", 0, 3], ["peripheral nonlymphoid tissues", "ANATOMY", 52, 82], ["tumors", "ANATOMY", 191, 197], ["tumors", "DISEASE", 191, 197], ["DCs", "CELL", 0, 3], ["peripheral nonlymphoid tissues", "TISSUE", 52, 82], ["tumors", "CANCER", 191, 197], ["DCs", "CELL_TYPE", 0, 3], ["microbial pathogens", "PROBLEM", 167, 186], ["tumors", "PROBLEM", 191, 197], ["immature state", "OBSERVATION", 26, 40], ["peripheral", "ANATOMY_MODIFIER", 52, 62], ["nonlymphoid tissues", "ANATOMY", 63, 82], ["tumors", "OBSERVATION", 191, 197]]], ["Therefore, upon antigen capture and process in the peripheral nonlymphoid tissues, DCs migrate through the afferent lymphatic vessels to the secondary lymphoid organs, where they stimulate na\u00efve T cells and undergo the morphological, phenotypic, and functional changes characteristic of maturation [2] .", [["peripheral nonlymphoid tissues", "ANATOMY", 51, 81], ["DCs", "ANATOMY", 83, 86], ["afferent lymphatic vessels", "ANATOMY", 107, 133], ["lymphoid organs", "ANATOMY", 151, 166], ["T cells", "ANATOMY", 195, 202], ["peripheral nonlymphoid tissues", "TISSUE", 51, 81], ["DCs", "CELL", 83, 86], ["lymphatic vessels", "MULTI-TISSUE_STRUCTURE", 116, 133], ["lymphoid organs", "MULTI-TISSUE_STRUCTURE", 151, 166], ["na\u00efve T cells", "CELL", 189, 202], ["DCs", "CELL_TYPE", 83, 86], ["na\u00efve T cells", "CELL_TYPE", 189, 202], ["DCs", "TREATMENT", 83, 86], ["peripheral", "ANATOMY_MODIFIER", 51, 61], ["nonlymphoid tissues", "ANATOMY", 62, 81], ["afferent", "ANATOMY_MODIFIER", 107, 115], ["lymphatic vessels", "ANATOMY", 116, 133], ["secondary lymphoid organs", "OBSERVATION", 141, 166]]], ["Mature DCs possess immunostimulatory properties such as reduced phagocytic activity, increased surface expression of the major histocompatibility complexes (MHC) that present Agpeptides, increased expression of costimulatory molecules and increased secretion of cytokines and chemokines [3, 4] .", [["DCs", "ANATOMY", 7, 10], ["surface", "ANATOMY", 95, 102], ["DCs", "CELL", 7, 10], ["DCs", "CELL_TYPE", 7, 10], ["major histocompatibility complexes", "PROTEIN", 121, 155], ["MHC", "PROTEIN", 157, 160], ["Agpeptides", "PROTEIN", 175, 185], ["costimulatory molecules", "PROTEIN", 211, 234], ["cytokines", "PROTEIN", 262, 271], ["chemokines", "PROTEIN", 276, 286], ["immunostimulatory properties", "TREATMENT", 19, 47], ["reduced phagocytic activity", "PROBLEM", 56, 83], ["costimulatory molecules", "PROBLEM", 211, 234], ["increased secretion of cytokines", "PROBLEM", 239, 271], ["immunostimulatory properties", "OBSERVATION", 19, 47], ["phagocytic activity", "OBSERVATION", 64, 83], ["increased", "OBSERVATION_MODIFIER", 187, 196], ["costimulatory molecules", "OBSERVATION", 211, 234], ["increased", "OBSERVATION_MODIFIER", 239, 248]]], ["In contrast to the enhanced T cell immunity associated with mature DCs, immature DCs fail to stimulate T cell responses and are involved in the induction of peripheral T cell tolerance by generating functional Treg cells [5, 6] .", [["T cell", "ANATOMY", 28, 34], ["DCs", "ANATOMY", 67, 70], ["DCs", "ANATOMY", 81, 84], ["T cell", "ANATOMY", 103, 109], ["peripheral T cell", "ANATOMY", 157, 174], ["Treg cells", "ANATOMY", 210, 220], ["T cell", "CELL", 28, 34], ["DCs", "CELL", 67, 70], ["DCs", "CELL", 81, 84], ["T cell", "CELL", 103, 109], ["peripheral T cell", "CELL", 157, 174], ["Treg cells", "CELL", 210, 220], ["mature DCs", "CELL_TYPE", 60, 70], ["immature DCs", "CELL_TYPE", 72, 84], ["Treg cells", "CELL_TYPE", 210, 220], ["mature DCs", "PROBLEM", 60, 70], ["peripheral T cell tolerance", "TREATMENT", 157, 184], ["Treg cells", "OBSERVATION", 210, 220]]], ["Thus, the potential to harness the power of DCs makes these cells attractive pharmacological targets [7] [8] [9] [10] [11] [12] . http Recently, the development of other indications or rediscovery of the inherent values of FDA-approved drugs is a growing trend in the pharmaceutical industry.", [["DCs", "ANATOMY", 44, 47], ["cells", "ANATOMY", 60, 65], ["DCs", "CELL", 44, 47], ["cells", "CELL", 60, 65], ["[7] [8] [9] [10] [11", "SIMPLE_CHEMICAL", 101, 121], ["DCs", "CELL_TYPE", 44, 47], ["drugs", "TREATMENT", 236, 241], ["pharmaceutical industry", "OBSERVATION", 268, 291]]], ["The repurposing or repositioning of an existing drug can accelerate the timeline and reduce the cost of bringing the drug to market because it eliminates the need for additional toxicological and pharmacokinetic assessments [13, 14] .IntroductionNiclosamide is a Food and Drug Administration-approved oral antihelminthic drug used to treat most tapeworms, including beef tapeworms and dwarf tapeworms.", [["oral", "ANATOMY", 301, 305], ["Niclosamide", "CHEMICAL", 246, 257], ["tapeworms", "DISEASE", 345, 354], ["beef tapeworms", "DISEASE", 366, 380], ["dwarf tapeworms", "DISEASE", 385, 400], ["Niclosamide", "CHEMICAL", 246, 257], ["Niclosamide", "SIMPLE_CHEMICAL", 246, 257], ["oral", "ORGANISM_SUBDIVISION", 301, 305], ["dwarf tapeworms", "ORGANISM", 385, 400], ["beef", "SPECIES", 366, 370], ["dwarf", "SPECIES", 385, 390], ["beef", "SPECIES", 366, 370], ["repositioning", "TREATMENT", 19, 32], ["pharmacokinetic assessments", "TEST", 196, 223], ["IntroductionNiclosamide", "TREATMENT", 234, 257], ["Drug Administration", "TREATMENT", 272, 291], ["oral antihelminthic drug", "TREATMENT", 301, 325], ["most tapeworms", "PROBLEM", 340, 354], ["dwarf tapeworms", "PROBLEM", 385, 400], ["dwarf tapeworms", "OBSERVATION", 385, 400]]], ["It has been used in humans for nearly 50 years.", [["humans", "ORGANISM", 20, 26], ["humans", "SPECIES", 20, 26], ["humans", "SPECIES", 20, 26]]], ["It is also used as a molluscicide for water treatment in schistosomiasis control programs [15] .", [["molluscicide", "CHEMICAL", 21, 33], ["schistosomiasis", "DISEASE", 57, 72], ["molluscicide", "SIMPLE_CHEMICAL", 21, 33], ["a molluscicide for water treatment", "TREATMENT", 19, 53], ["schistosomiasis control programs", "TREATMENT", 57, 89]]], ["The activity of niclosamide against these parasites is believed to be due to the inhibition of mitochondrial oxidative phosphorylation and anaerobic ATP production [16] .", [["mitochondrial", "ANATOMY", 95, 108], ["niclosamide", "CHEMICAL", 16, 27], ["ATP", "CHEMICAL", 149, 152], ["niclosamide", "CHEMICAL", 16, 27], ["ATP", "CHEMICAL", 149, 152], ["niclosamide", "SIMPLE_CHEMICAL", 16, 27], ["mitochondrial", "CELLULAR_COMPONENT", 95, 108], ["ATP", "SIMPLE_CHEMICAL", 149, 152], ["niclosamide", "TREATMENT", 16, 27], ["these parasites", "PROBLEM", 36, 51], ["mitochondrial oxidative phosphorylation", "TREATMENT", 95, 134], ["anaerobic ATP production", "PROBLEM", 139, 163]]], ["However, niclosamide is receiving renewed attention in light of new data showing that it has strong anti-neoplastic activity against a broad spectrum of cancer types.", [["cancer", "ANATOMY", 153, 159], ["niclosamide", "CHEMICAL", 9, 20], ["cancer", "DISEASE", 153, 159], ["niclosamide", "CHEMICAL", 9, 20], ["niclosamide", "SIMPLE_CHEMICAL", 9, 20], ["cancer", "CANCER", 153, 159], ["niclosamide", "TREATMENT", 9, 20], ["new data", "TEST", 64, 72], ["cancer types", "PROBLEM", 153, 165], ["cancer", "OBSERVATION", 153, 159]]], ["For example, several reports have indicated that niclosamide can suppress Wnt/b-catenin signaling by targeting the Wnt co-receptor LRP6 on the cell surface, an activity that is closely associated with anti-proliferation and pro-apoptotic activities in prostate and breast cancer cells [17, 18] .", [["cell surface", "ANATOMY", 143, 155], ["prostate", "ANATOMY", 252, 260], ["breast cancer cells", "ANATOMY", 265, 284], ["niclosamide", "CHEMICAL", 49, 60], ["prostate and breast cancer", "DISEASE", 252, 278], ["niclosamide", "CHEMICAL", 49, 60], ["niclosamide", "SIMPLE_CHEMICAL", 49, 60], ["Wnt", "GENE_OR_GENE_PRODUCT", 74, 77], ["b-catenin", "GENE_OR_GENE_PRODUCT", 78, 87], ["Wnt", "GENE_OR_GENE_PRODUCT", 115, 118], ["LRP6", "GENE_OR_GENE_PRODUCT", 131, 135], ["cell surface", "CELLULAR_COMPONENT", 143, 155], ["prostate", "CELL", 252, 260], ["breast cancer cells", "CELL", 265, 284], ["catenin", "PROTEIN", 80, 87], ["Wnt co-receptor", "PROTEIN", 115, 130], ["LRP6", "PROTEIN", 131, 135], ["prostate and breast cancer cells", "CELL_TYPE", 252, 284], ["niclosamide", "TREATMENT", 49, 60], ["catenin signaling", "PROBLEM", 80, 97], ["the cell surface", "TREATMENT", 139, 155], ["anti-proliferation and pro-apoptotic activities in prostate", "PROBLEM", 201, 260], ["breast cancer cells", "PROBLEM", 265, 284], ["cell surface", "OBSERVATION_MODIFIER", 143, 155], ["pro-apoptotic activities", "OBSERVATION", 224, 248], ["prostate", "ANATOMY", 252, 260], ["breast", "ANATOMY", 265, 271], ["cancer", "OBSERVATION", 272, 278]]], ["In addition, Jin et al. reported that niclosamide can inhibit the NF\u00c0jb pathway and increase ROS levels in acute myelogenous leukemia stem cells; niclosamide also potently inhibited the growth of AML cells in vitro and in nude mice [19] .", [["acute myelogenous leukemia stem cells", "ANATOMY", 107, 144], ["AML cells", "ANATOMY", 196, 205], ["niclosamide", "CHEMICAL", 38, 49], ["ROS", "CHEMICAL", 93, 96], ["acute myelogenous leukemia", "DISEASE", 107, 133], ["niclosamide", "CHEMICAL", 146, 157], ["AML", "DISEASE", 196, 199], ["niclosamide", "CHEMICAL", 38, 49], ["niclosamide", "CHEMICAL", 146, 157], ["niclosamide", "SIMPLE_CHEMICAL", 38, 49], ["NF\u00c0jb", "GENE_OR_GENE_PRODUCT", 66, 71], ["ROS", "SIMPLE_CHEMICAL", 93, 96], ["acute myelogenous leukemia stem cells", "CELL", 107, 144], ["niclosamide", "SIMPLE_CHEMICAL", 146, 157], ["AML cells", "CELL", 196, 205], ["nude mice", "ORGANISM", 222, 231], ["NF\u00c0jb", "PROTEIN", 66, 71], ["acute myelogenous leukemia stem cells", "CELL_TYPE", 107, 144], ["AML cells", "CELL_TYPE", 196, 205], ["mice", "SPECIES", 227, 231], ["mice", "SPECIES", 227, 231], ["niclosamide", "TREATMENT", 38, 49], ["the NF\u00c0jb pathway", "TEST", 62, 79], ["increase ROS levels", "PROBLEM", 84, 103], ["acute myelogenous leukemia stem cells", "PROBLEM", 107, 144], ["niclosamide", "TREATMENT", 146, 157], ["AML cells", "PROBLEM", 196, 205], ["acute", "OBSERVATION_MODIFIER", 107, 112], ["myelogenous leukemia stem cells", "OBSERVATION", 113, 144], ["AML cells", "OBSERVATION", 196, 205]]], ["A study by Ren et al. demonstrated that niclosamide is a selective inhibitor of STAT3.", [["niclosamide", "CHEMICAL", 40, 51], ["niclosamide", "CHEMICAL", 40, 51], ["niclosamide", "SIMPLE_CHEMICAL", 40, 51], ["STAT3", "GENE_OR_GENE_PRODUCT", 80, 85], ["STAT3", "PROTEIN", 80, 85], ["A study", "TEST", 0, 7], ["niclosamide", "TREATMENT", 40, 51], ["a selective inhibitor of STAT3", "TREATMENT", 55, 85]]], ["Treatment with niclosamide inhibited the EGF-mediated STAT3 activity and inhibited the growth of several types of cancer cells with constitutive STAT3 activation (e.g., DU145, HeLa, A549) [20] .", [["cancer cells", "ANATOMY", 114, 126], ["DU145", "ANATOMY", 169, 174], ["HeLa", "ANATOMY", 176, 180], ["A549", "ANATOMY", 182, 186], ["niclosamide", "CHEMICAL", 15, 26], ["cancer", "DISEASE", 114, 120], ["niclosamide", "CHEMICAL", 15, 26], ["niclosamide", "SIMPLE_CHEMICAL", 15, 26], ["EGF", "GENE_OR_GENE_PRODUCT", 41, 44], ["STAT3", "GENE_OR_GENE_PRODUCT", 54, 59], ["cancer cells", "CELL", 114, 126], ["STAT3", "GENE_OR_GENE_PRODUCT", 145, 150], ["DU145", "CELL", 169, 174], ["HeLa", "CELL", 176, 180], ["A549", "CELL", 182, 186], ["EGF", "PROTEIN", 41, 44], ["STAT3", "PROTEIN", 54, 59], ["cancer cells", "CELL_TYPE", 114, 126], ["STAT3", "PROTEIN", 145, 150], ["niclosamide", "TREATMENT", 15, 26], ["the EGF", "TREATMENT", 37, 44], ["cancer cells", "PROBLEM", 114, 126], ["constitutive STAT3 activation", "PROBLEM", 132, 161], ["cancer cells", "OBSERVATION", 114, 126], ["constitutive STAT3", "OBSERVATION", 132, 150]]], ["Moreover, using an automated cell-based screening assay, Balgi et al. observed that niclosamide can increase autophagy by inhibiting mammalian target of rapamycin complex 1 (mTORC1) signaling [21] .", [["cell", "ANATOMY", 29, 33], ["niclosamide", "CHEMICAL", 84, 95], ["rapamycin", "CHEMICAL", 153, 162], ["niclosamide", "CHEMICAL", 84, 95], ["rapamycin", "CHEMICAL", 153, 162], ["cell", "CELL", 29, 33], ["niclosamide", "SIMPLE_CHEMICAL", 84, 95], ["mammalian target of rapamycin complex 1", "GENE_OR_GENE_PRODUCT", 133, 172], ["mTORC1", "GENE_OR_GENE_PRODUCT", 174, 180], ["mammalian target of rapamycin complex 1", "PROTEIN", 133, 172], ["mTORC1", "PROTEIN", 174, 180], ["an automated cell", "TEST", 16, 33], ["screening assay", "TEST", 40, 55], ["niclosamide", "TREATMENT", 84, 95], ["rapamycin complex", "TREATMENT", 153, 170]]], ["Independently, Fonseca et al. demonstrated that niclosamide suppresses mTORC1 signaling through the modulation of cytoplasmic pH in MCF-7 breast cancer cells [22] .", [["cytoplasmic", "ANATOMY", 114, 125], ["MCF-7 breast cancer cells", "ANATOMY", 132, 157], ["niclosamide", "CHEMICAL", 48, 59], ["breast cancer", "DISEASE", 138, 151], ["niclosamide", "CHEMICAL", 48, 59], ["niclosamide", "SIMPLE_CHEMICAL", 48, 59], ["mTORC1", "GENE_OR_GENE_PRODUCT", 71, 77], ["cytoplasmic", "ORGANISM_SUBSTANCE", 114, 125], ["MCF-7 breast cancer cells", "CELL", 132, 157], ["mTORC1", "PROTEIN", 71, 77], ["MCF-7 breast cancer cells", "CELL_LINE", 132, 157], ["MCF-7", "SPECIES", 132, 137], ["niclosamide suppresses", "TREATMENT", 48, 70], ["cytoplasmic pH", "TEST", 114, 128], ["MCF", "TEST", 132, 135], ["breast cancer cells", "PROBLEM", 138, 157], ["cytoplasmic pH", "OBSERVATION", 114, 128], ["breast", "ANATOMY", 138, 144], ["cancer", "OBSERVATION", 145, 151]]], ["Furthermore, Wang et al. reported that niclosamide potently suppresses the Notch-regulated gene C promoter-binding factor-1 (CBF-1) in K562 leukemia cells [23] .", [["K562 leukemia cells", "ANATOMY", 135, 154], ["niclosamide", "CHEMICAL", 39, 50], ["leukemia", "DISEASE", 140, 148], ["niclosamide", "CHEMICAL", 39, 50], ["niclosamide", "SIMPLE_CHEMICAL", 39, 50], ["Notch", "GENE_OR_GENE_PRODUCT", 75, 80], ["C promoter-binding factor-1", "GENE_OR_GENE_PRODUCT", 96, 123], ["CBF-1", "GENE_OR_GENE_PRODUCT", 125, 130], ["K562 leukemia cells", "CELL", 135, 154], ["Notch-regulated gene C promoter-binding factor-1 (CBF-1", "PROTEIN", 75, 130], ["K562 leukemia cells", "CELL_LINE", 135, 154], ["niclosamide", "TREATMENT", 39, 50], ["the Notch", "TEST", 71, 80], ["gene C promoter", "TREATMENT", 91, 106], ["binding factor", "TEST", 107, 121], ["CBF", "TEST", 125, 128], ["K562 leukemia cells", "PROBLEM", 135, 154], ["K562", "ANATOMY", 135, 139], ["leukemia cells", "OBSERVATION", 140, 154]]], ["Taken together, these data suggest that the antitumor activity of niclosamide may be due to its ability to target multiple signaling pathways.", [["antitumor", "ANATOMY", 44, 53], ["niclosamide", "CHEMICAL", 66, 77], ["niclosamide", "CHEMICAL", 66, 77], ["antitumor", "CANCER", 44, 53], ["niclosamide", "SIMPLE_CHEMICAL", 66, 77], ["these data", "TEST", 16, 26], ["niclosamide", "TREATMENT", 66, 77]]], ["However, until now, the cellular and molecular targets of this drug in the immune system have remained unknown, and the ability of niclosamide to modulate the functions of DCs, the most potent of the APCs, has not been defined.IntroductionIn this initial study, we designed experiments to examine the potential therapeutic effects of niclosamide on the functional properties of DCs and to elucidate the molecular mechanisms involved.", [["cellular", "ANATOMY", 24, 32], ["immune system", "ANATOMY", 75, 88], ["DCs", "ANATOMY", 172, 175], ["APCs", "ANATOMY", 200, 204], ["DCs", "ANATOMY", 378, 381], ["niclosamide", "CHEMICAL", 131, 142], ["niclosamide", "CHEMICAL", 334, 345], ["niclosamide", "CHEMICAL", 131, 142], ["niclosamide", "CHEMICAL", 334, 345], ["cellular", "CELL", 24, 32], ["immune system", "ANATOMICAL_SYSTEM", 75, 88], ["niclosamide", "SIMPLE_CHEMICAL", 131, 142], ["DCs", "CELL", 172, 175], ["APCs", "CELL", 200, 204], ["niclosamide", "SIMPLE_CHEMICAL", 334, 345], ["DCs", "CELL", 378, 381], ["DCs", "CELL_TYPE", 172, 175], ["APCs", "CELL_TYPE", 200, 204], ["DCs", "CELL_TYPE", 378, 381], ["this drug in the immune system", "PROBLEM", 58, 88], ["niclosamide", "TREATMENT", 131, 142], ["this initial study", "TEST", 242, 260], ["niclosamide", "TREATMENT", 334, 345], ["most potent", "OBSERVATION_MODIFIER", 181, 192]]], ["The present study demonstrates that niclosamide inhibits the ability of LPS-induced mouse bone marrow-derived DCs to secrete proinflammatory cytokines and affects the expression of costimulatory molecules, the ability of DCs to prime a T cell immune response in an syngeneic DC/T cell coculture and prevents 2,4-dinitro-1-fluorobenzene-induced contact hypersensitivity (CHS) in vivo.", [["bone marrow", "ANATOMY", 90, 101], ["DCs", "ANATOMY", 110, 113], ["DCs", "ANATOMY", 221, 224], ["T cell", "ANATOMY", 236, 242], ["DC/T cell", "ANATOMY", 275, 284], ["niclosamide", "CHEMICAL", 36, 47], ["LPS", "CHEMICAL", 72, 75], ["2,4-dinitro-1-fluorobenzene", "CHEMICAL", 308, 335], ["contact hypersensitivity", "DISEASE", 344, 368], ["CHS", "DISEASE", 370, 373], ["niclosamide", "CHEMICAL", 36, 47], ["2,4-dinitro-1-fluorobenzene", "CHEMICAL", 308, 335], ["niclosamide", "SIMPLE_CHEMICAL", 36, 47], ["LPS", "SIMPLE_CHEMICAL", 72, 75], ["mouse", "ORGANISM", 84, 89], ["bone marrow-derived DCs", "CELL", 90, 113], ["DCs", "CELL", 221, 224], ["T cell", "CELL", 236, 242], ["T cell", "CELL", 278, 284], ["2,4-dinitro-1-fluorobenzene", "SIMPLE_CHEMICAL", 308, 335], ["mouse bone marrow-derived DCs", "CELL_TYPE", 84, 113], ["proinflammatory cytokines", "PROTEIN", 125, 150], ["costimulatory molecules", "PROTEIN", 181, 204], ["DCs", "CELL_TYPE", 221, 224], ["syngeneic DC/T cell coculture", "CELL_LINE", 265, 294], ["mouse", "SPECIES", 84, 89], ["mouse", "SPECIES", 84, 89], ["The present study", "TEST", 0, 17], ["niclosamide", "TREATMENT", 36, 47], ["LPS", "TEST", 72, 75], ["mouse bone marrow", "PROBLEM", 84, 101], ["secrete proinflammatory cytokines", "PROBLEM", 117, 150], ["a T cell immune response", "TREATMENT", 234, 258], ["an syngeneic DC/T cell coculture", "TREATMENT", 262, 294], ["dinitro", "TEST", 312, 319], ["fluorobenzene", "TREATMENT", 322, 335], ["contact hypersensitivity", "PROBLEM", 344, 368], ["bone", "ANATOMY", 90, 94]]], ["Consequently, blocking the LPS-induced NF-jB, ERK and JNK activation in DCs may explain the inhibitory effect of niclosamide on DC activation.", [["DCs", "ANATOMY", 72, 75], ["DC", "ANATOMY", 128, 130], ["LPS", "CHEMICAL", 27, 30], ["niclosamide", "CHEMICAL", 113, 124], ["niclosamide", "CHEMICAL", 113, 124], ["LPS", "SIMPLE_CHEMICAL", 27, 30], ["NF-jB", "GENE_OR_GENE_PRODUCT", 39, 44], ["ERK", "GENE_OR_GENE_PRODUCT", 46, 49], ["JNK", "GENE_OR_GENE_PRODUCT", 54, 57], ["DCs", "CELL", 72, 75], ["niclosamide", "SIMPLE_CHEMICAL", 113, 124], ["DC", "CELL", 128, 130], ["NF-jB", "PROTEIN", 39, 44], ["ERK", "PROTEIN", 46, 49], ["JNK", "PROTEIN", 54, 57], ["DCs", "CELL_TYPE", 72, 75], ["DC", "CELL_TYPE", 128, 130], ["the LPS", "TEST", 23, 30], ["JNK activation in DCs", "PROBLEM", 54, 75], ["niclosamide", "TREATMENT", 113, 124], ["DC activation", "TREATMENT", 128, 141], ["jB", "ANATOMY", 42, 44]]], ["These results show for the first time that niclosamide can manipulate the immunostimulatory properties of DCs and may be useful in suppressing chronic inflammatory disorders or autoimmune diseases.Mice and preparation of mouse bone marrow-derived DCsFemale C57BL/6 (H-2 b ) mice (4-6 weeks old) were purchased from the National Laboratory Animal Center (Taipei, Taiwan).", [["DCs", "ANATOMY", 106, 109], ["bone marrow", "ANATOMY", 227, 238], ["niclosamide", "CHEMICAL", 43, 54], ["autoimmune diseases", "DISEASE", 177, 196], ["niclosamide", "CHEMICAL", 43, 54], ["niclosamide", "SIMPLE_CHEMICAL", 43, 54], ["DCs", "CELL", 106, 109], ["Mice", "ORGANISM", 197, 201], ["mouse", "ORGANISM", 221, 226], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 227, 238], ["DCsFemale C57BL/6 (H-2 b )", "ORGANISM", 247, 273], ["mice", "ORGANISM", 274, 278], ["DCs", "CELL_TYPE", 106, 109], ["Mice", "SPECIES", 197, 201], ["mouse", "SPECIES", 221, 226], ["mice", "SPECIES", 274, 278], ["mouse", "SPECIES", 221, 226], ["mice", "SPECIES", 274, 278], ["niclosamide", "TREATMENT", 43, 54], ["suppressing chronic inflammatory disorders", "PROBLEM", 131, 173], ["autoimmune diseases", "PROBLEM", 177, 196], ["mouse bone marrow", "TEST", 221, 238], ["chronic", "OBSERVATION_MODIFIER", 143, 150], ["inflammatory", "OBSERVATION", 151, 163]]], ["OT-I TCR transgenic mice were purchased from Jackson Laboratory (Bar Harbor, ME, USA).", [["OT-I TCR", "GENE_OR_GENE_PRODUCT", 0, 8], ["mice", "ORGANISM", 20, 24], ["TCR", "PROTEIN", 5, 8], ["mice", "SPECIES", 20, 24], ["mice", "SPECIES", 20, 24]]], ["OT-II TCR transgenic mice were provided by Dr. Clifford Lowell (UCSF, San Francisco, CA).", [["OT-II TCR", "CHEMICAL", 0, 9], ["OT-II TCR", "GENE_OR_GENE_PRODUCT", 0, 9], ["mice", "ORGANISM", 21, 25], ["TCR", "PROTEIN", 6, 9], ["mice", "SPECIES", 21, 25], ["mice", "SPECIES", 21, 25]]], ["The mice were housed in a barrier facility at Taichung Veterans General Hospital (Taiwan) under the guidelines of the Institutional Animal Care and Use Committee, and all experiments were conducted in accordance with the institution's guidelines for animal experimentation.", [["mice", "ORGANISM", 4, 8], ["mice", "SPECIES", 4, 8], ["mice", "SPECIES", 4, 8], ["animal experimentation", "TREATMENT", 250, 272]]], ["Mouse bone marrow-derived DCs were generated using a previously described method [24, 25] .", [["bone marrow", "ANATOMY", 6, 17], ["DCs", "ANATOMY", 26, 29], ["Mouse", "ORGANISM", 0, 5], ["bone marrow-derived DCs", "CELL", 6, 29], ["Mouse bone marrow-derived DCs", "CELL_LINE", 0, 29], ["Mouse", "SPECIES", 0, 5], ["Mouse", "SPECIES", 0, 5], ["bone", "ANATOMY", 6, 10]]], ["Briefly, bone marrow cells were flushed from the femurs and tibias of C57BL/6 mice with RPMI 1640 using a syringe and a 25-gauge needle, and the erythrocytes were lysed with red blood cell lysis buffer.", [["bone marrow cells", "ANATOMY", 9, 26], ["femurs", "ANATOMY", 49, 55], ["tibias", "ANATOMY", 60, 66], ["erythrocytes", "ANATOMY", 145, 157], ["red blood cell", "ANATOMY", 174, 188], ["RPMI 1640", "CHEMICAL", 88, 97], ["bone marrow cells", "CELL", 9, 26], ["femurs", "ORGAN", 49, 55], ["tibias", "ORGAN", 60, 66], ["C57BL/6 mice", "ORGANISM", 70, 82], ["erythrocytes", "CELL", 145, 157], ["blood", "ORGANISM_SUBSTANCE", 178, 183], ["cell", "CELL", 184, 188], ["bone marrow cells", "CELL_TYPE", 9, 26], ["erythrocytes", "CELL_TYPE", 145, 157], ["mice", "SPECIES", 78, 82], ["mice", "SPECIES", 78, 82], ["bone marrow cells", "TREATMENT", 9, 26], ["a syringe", "TREATMENT", 104, 113], ["a 25-gauge needle", "TREATMENT", 118, 135], ["the erythrocytes", "TREATMENT", 141, 157], ["red blood cell lysis buffer", "TREATMENT", 174, 201], ["bone", "ANATOMY", 9, 13], ["marrow cells", "OBSERVATION", 14, 26], ["femurs", "ANATOMY", 49, 55], ["tibias", "ANATOMY", 60, 66], ["erythrocytes", "ANATOMY", 145, 157], ["blood cell lysis", "OBSERVATION", 178, 194]]], ["The bone marrow cells were suspended in RPMI-1640 medium supplemented with 10% heat-inactivated fetal bovine serum, 100 U/ml penicillin G, 100 lg/ml streptomycin, 20 ng/ml recombinant mouse granulocyte macrophage colonystimulating factor (PeproTech) and 20 ng/ml recombinant mouse IL-4 and placed into a 24-well plate.", [["bone marrow cells", "ANATOMY", 4, 21], ["fetal bovine serum", "ANATOMY", 96, 114], ["RPMI-1640", "CHEMICAL", 40, 49], ["penicillin", "CHEMICAL", 125, 135], ["streptomycin", "CHEMICAL", 149, 161], ["penicillin G", "CHEMICAL", 125, 137], ["streptomycin", "CHEMICAL", 149, 161], ["bone marrow cells", "CELL", 4, 21], ["bovine", "ORGANISM", 102, 108], ["serum", "ORGANISM_SUBSTANCE", 109, 114], ["penicillin G", "SIMPLE_CHEMICAL", 125, 137], ["streptomycin", "SIMPLE_CHEMICAL", 149, 161], ["mouse", "ORGANISM", 184, 189], ["granulocyte macrophage colonystimulating factor", "GENE_OR_GENE_PRODUCT", 190, 237], ["PeproTech", "GENE_OR_GENE_PRODUCT", 239, 248], ["mouse", "ORGANISM", 275, 280], ["IL-4", "GENE_OR_GENE_PRODUCT", 281, 285], ["bone marrow cells", "CELL_TYPE", 4, 21], ["recombinant mouse granulocyte macrophage colonystimulating factor", "PROTEIN", 172, 237], ["PeproTech", "PROTEIN", 239, 248], ["recombinant mouse IL-4", "PROTEIN", 263, 285], ["bovine", "SPECIES", 102, 108], ["mouse", "SPECIES", 184, 189], ["mouse", "SPECIES", 275, 280], ["bovine", "SPECIES", 102, 108], ["mouse", "SPECIES", 184, 189], ["mouse", "SPECIES", 275, 280], ["RPMI", "TEST", 40, 44], ["fetal bovine serum", "TREATMENT", 96, 114], ["penicillin G", "TREATMENT", 125, 137], ["streptomycin", "TREATMENT", 149, 161], ["recombinant mouse granulocyte macrophage colonystimulating factor (PeproTech)", "TREATMENT", 172, 249], ["recombinant mouse IL", "TREATMENT", 263, 283], ["bone", "ANATOMY", 4, 8], ["marrow cells", "OBSERVATION", 9, 21]]], ["The cells were incubated at 37\u00b0C in a 5% CO 2 atmosphere.", [["cells", "ANATOMY", 4, 9], ["CO", "CHEMICAL", 41, 43], ["cells", "CELL", 4, 9]]], ["Fresh culture medium was added to the cells every 2 days.", [["cells", "ANATOMY", 38, 43], ["cells", "CELL", 38, 43], ["Fresh culture medium", "TEST", 0, 20]]], ["On day 7, the non-adherent or loosely adherent cells were harvested and classified as immature DCs.", [["cells", "ANATOMY", 47, 52], ["DCs", "ANATOMY", 95, 98], ["cells", "CELL", 47, 52], ["DCs", "CELL", 95, 98], ["non-adherent or loosely adherent cells", "CELL_TYPE", 14, 52], ["immature DCs", "CELL_TYPE", 86, 98], ["the non-adherent or loosely adherent cells", "PROBLEM", 10, 52], ["non-adherent", "OBSERVATION_MODIFIER", 14, 26], ["loosely", "OBSERVATION_MODIFIER", 30, 37], ["adherent cells", "OBSERVATION", 38, 52], ["immature DCs", "OBSERVATION", 86, 98]]], ["More than 80% of the cells expressed CD11c, as determined by flow cytometry (data not shown).", [["cells", "ANATOMY", 21, 26], ["cells", "CELL", 21, 26], ["CD11c", "GENE_OR_GENE_PRODUCT", 37, 42], ["CD11c", "PROTEIN", 37, 42], ["flow cytometry", "TEST", 61, 75]]], ["CD11c + DCs were further prepared by immunomagnetic selection from CD11c + -enriched BM cells by positive selection using anti-CD11-coated beads (Miltenyi Biotec, Auburn, CA, USA) according to the manufacturer's instructions; these cells were used for experiments.", [["DCs", "ANATOMY", 8, 11], ["CD11c + -enriched BM cells", "ANATOMY", 67, 93], ["cells", "ANATOMY", 232, 237], ["CD11c", "GENE_OR_GENE_PRODUCT", 0, 5], ["CD11c", "GENE_OR_GENE_PRODUCT", 67, 72], ["BM cells", "CELL", 85, 93], ["anti-CD11", "SIMPLE_CHEMICAL", 122, 131], ["cells", "CELL", 232, 237], ["CD11c", "PROTEIN", 0, 5], ["DCs", "CELL_TYPE", 8, 11], ["CD11c", "PROTEIN", 67, 72], ["-enriched BM cells", "CELL_TYPE", 75, 93], ["anti-CD11", "PROTEIN", 122, 131], ["Miltenyi Biotec", "PROTEIN", 146, 161], ["CD11c", "TEST", 0, 5], ["DCs", "PROBLEM", 8, 11], ["CD11c + -enriched BM cells", "TREATMENT", 67, 93], ["anti-CD11-coated beads", "TREATMENT", 122, 144], ["Miltenyi Biotec", "TREATMENT", 146, 161], ["these cells", "TREATMENT", 226, 237], ["BM cells", "OBSERVATION", 85, 93]]], ["The purity of the CD11c + cells was confirmed to be >90% by flow cytometry.Flow cytometric analysisDCs were cultured in the presence of 0.1% DMSO or 1.25 lM niclosamide (Sigma, St. Louis, MO, USA; stock solution of 10 mM in DMSO) for 1 h followed by stimulation with 100 ng/ml of lipopolysaccharide (LPS) for 18 h.", [["CD11c + cells", "ANATOMY", 18, 31], ["DMSO", "CHEMICAL", 141, 145], ["1.25 lM niclosamide", "CHEMICAL", 149, 168], ["DMSO", "CHEMICAL", 224, 228], ["lipopolysaccharide", "CHEMICAL", 280, 298], ["LPS", "CHEMICAL", 300, 303], ["DMSO", "CHEMICAL", 141, 145], ["niclosamide", "CHEMICAL", 157, 168], ["DMSO", "CHEMICAL", 224, 228], ["CD11c", "GENE_OR_GENE_PRODUCT", 18, 23], ["DMSO", "SIMPLE_CHEMICAL", 141, 145], ["niclosamide", "SIMPLE_CHEMICAL", 157, 168], ["DMSO", "SIMPLE_CHEMICAL", 224, 228], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 280, 298], ["LPS", "SIMPLE_CHEMICAL", 300, 303], ["CD11c", "PROTEIN", 18, 23], ["the CD11c + cells", "TEST", 14, 31], ["flow cytometry", "TEST", 60, 74], ["Flow cytometric analysisDCs", "TEST", 75, 102], ["DMSO", "TREATMENT", 141, 145], ["lipopolysaccharide (LPS", "TREATMENT", 280, 303], ["CD11c", "ANATOMY", 18, 23], ["flow cytometry", "OBSERVATION", 60, 74]]], ["After incubation, the DCs were harvested and stained with specific antibodies.", [["DCs", "ANATOMY", 22, 25], ["DCs", "CELL", 22, 25], ["DCs", "CELL_TYPE", 22, 25], ["specific antibodies", "PROTEIN", 58, 77], ["the DCs", "TREATMENT", 18, 25]]], ["After mAb staining, the samples were analyzed for fluorescence on a FACSCalibur flow cytometer (BD Biosciences, Heidelberg, Germany).", [["samples", "ANATOMY", 24, 31], ["mAb", "GENE_OR_GENE_PRODUCT", 6, 9], ["mAb", "PROTEIN", 6, 9], ["mAb staining", "TEST", 6, 18], ["the samples", "TEST", 20, 31], ["fluorescence", "TEST", 50, 62], ["a FACSCalibur flow cytometer", "TREATMENT", 66, 94]]], ["We used FITC-or phycoerythrin (PE)-conjugated monoclonal antibodies (mAbs) to stain for mouse CD11c, CD40, CD80, CD86, and MHC class II and class I expression (all from BD Biosciences, Mountain View, CA).Cytokine release assaysCulture supernatants were collected from DCs propagated in the presence of 0.1% DMSO or indicated dose of niclosamide for 1 h before or after stimulation with LPS (100 ng/ml) or other TLR ligands, including peptidoglycan (1 lg/ml, TLR1/TLR2), polyI:C (250 lg/ml, TLR3), CpG ODN 1826 (200 nM, TLR-9) or imiquimod (5 lg/ml, TLR-7) for 18 h or TNF-alpha for 4 h.", [["supernatants", "ANATOMY", 235, 247], ["DCs", "ANATOMY", 268, 271], ["PE", "CHEMICAL", 31, 33], ["DMSO", "CHEMICAL", 307, 311], ["niclosamide", "CHEMICAL", 333, 344], ["LPS", "CHEMICAL", 386, 389], ["ODN 1826", "CHEMICAL", 501, 509], ["TLR-9", "CHEMICAL", 519, 524], ["imiquimod", "CHEMICAL", 529, 538], ["FITC", "CHEMICAL", 8, 12], ["DMSO", "CHEMICAL", 307, 311], ["niclosamide", "CHEMICAL", 333, 344], ["imiquimod", "CHEMICAL", 529, 538], ["FITC", "SIMPLE_CHEMICAL", 8, 12], ["phycoerythrin", "SIMPLE_CHEMICAL", 16, 29], ["PE", "SIMPLE_CHEMICAL", 31, 33], ["mouse", "ORGANISM", 88, 93], ["CD11c", "GENE_OR_GENE_PRODUCT", 94, 99], ["CD40", "GENE_OR_GENE_PRODUCT", 101, 105], ["CD80", "GENE_OR_GENE_PRODUCT", 107, 111], ["CD86", "GENE_OR_GENE_PRODUCT", 113, 117], ["MHC class II", "GENE_OR_GENE_PRODUCT", 123, 135], ["class I", "GENE_OR_GENE_PRODUCT", 140, 147], ["Cytokine", "GENE_OR_GENE_PRODUCT", 204, 212], ["DCs", "CELL", 268, 271], ["DMSO", "SIMPLE_CHEMICAL", 307, 311], ["niclosamide", "SIMPLE_CHEMICAL", 333, 344], ["LPS", "SIMPLE_CHEMICAL", 386, 389], ["TLR", "GENE_OR_GENE_PRODUCT", 411, 414], ["peptidoglycan", "SIMPLE_CHEMICAL", 434, 447], ["TLR1", "GENE_OR_GENE_PRODUCT", 458, 462], ["TLR2", "GENE_OR_GENE_PRODUCT", 463, 467], ["polyI:C", "SIMPLE_CHEMICAL", 470, 477], ["TLR3", "GENE_OR_GENE_PRODUCT", 490, 494], ["imiquimod", "SIMPLE_CHEMICAL", 529, 538], ["TLR-7", "GENE_OR_GENE_PRODUCT", 549, 554], ["TNF-alpha", "GENE_OR_GENE_PRODUCT", 568, 577], ["FITC-or phycoerythrin (PE)-conjugated monoclonal antibodies", "PROTEIN", 8, 67], ["mAbs", "PROTEIN", 69, 73], ["CD11c", "PROTEIN", 94, 99], ["CD40", "PROTEIN", 101, 105], ["CD80", "PROTEIN", 107, 111], ["CD86", "PROTEIN", 113, 117], ["MHC class II", "PROTEIN", 123, 135], ["class I", "PROTEIN", 140, 147], ["Cytokine", "PROTEIN", 204, 212], ["DCs", "CELL_TYPE", 268, 271], ["TLR", "PROTEIN", 411, 414], ["TLR1", "PROTEIN", 458, 462], ["TLR2", "PROTEIN", 463, 467], ["TLR3", "PROTEIN", 490, 494], ["TLR", "PROTEIN", 519, 522], ["TLR", "PROTEIN", 549, 552], ["TNF", "PROTEIN", 568, 571], ["mouse", "SPECIES", 88, 93], ["mouse", "SPECIES", 88, 93], ["FITC", "TREATMENT", 8, 12], ["phycoerythrin (PE", "TREATMENT", 16, 33], ["conjugated monoclonal antibodies (mAbs", "TREATMENT", 35, 73], ["CD40", "TEST", 101, 105], ["Cytokine release assaysCulture supernatants", "TREATMENT", 204, 247], ["0.1% DMSO", "TREATMENT", 302, 311], ["niclosamide", "TREATMENT", 333, 344], ["LPS", "TREATMENT", 386, 389], ["other TLR ligands", "TREATMENT", 405, 422], ["peptidoglycan", "TEST", 434, 447], ["TLR1/TLR2)", "TREATMENT", 458, 468], ["TLR3), CpG ODN", "TREATMENT", 490, 504], ["TLR", "TEST", 519, 522], ["imiquimod", "TREATMENT", 529, 538], ["TLR", "TEST", 549, 552], ["PE", "OBSERVATION", 31, 33]]], ["All TLR ligands were purchased from InvivoGen, San Diego, CA.", [["TLR", "GENE_OR_GENE_PRODUCT", 4, 7], ["TLR", "PROTEIN", 4, 7], ["TLR ligands", "OBSERVATION", 4, 15]]], ["After incubation, the cytokine and chemokine levels in the supernatants of the DC cultures were determined using sandwich ELISA kits (R&D Systems, Minneapolis, MN).", [["supernatants", "ANATOMY", 59, 71], ["DC cultures", "ANATOMY", 79, 90], ["DC cultures", "CELL", 79, 90], ["cytokine", "PROTEIN", 22, 30], ["chemokine", "PROTEIN", 35, 44], ["DC cultures", "CELL_LINE", 79, 90], ["the cytokine", "TEST", 18, 30], ["chemokine levels", "TEST", 35, 51], ["the DC cultures", "TEST", 75, 90]]], ["The viability of the cultured cells was assessed using the CCK-8 colorimetric assay kit according to the manufacturer's instructions (Sigma, St. Louis, MO).", [["cells", "ANATOMY", 30, 35], ["cells", "CELL", 30, 35], ["cultured cells", "CELL_LINE", 21, 35], ["the cultured cells", "TEST", 17, 35], ["the CCK", "TEST", 55, 62], ["viability", "OBSERVATION_MODIFIER", 4, 13]]], ["Cell viability of greater than 90% was observed in all of the experiments in this study.OVA-specific T cell activation in vitroThe protocol for this assay was modified from our previous report [24] .", [["Cell", "ANATOMY", 0, 4], ["T cell", "ANATOMY", 101, 107], ["Cell", "CELL", 0, 4], ["OVA", "SIMPLE_CHEMICAL", 88, 91], ["T cell", "CELL", 101, 107], ["Cell viability", "TEST", 0, 14], ["this study", "TEST", 77, 87], ["OVA", "PROBLEM", 88, 91], ["vitro", "TREATMENT", 122, 127], ["The protocol", "TREATMENT", 127, 139], ["this assay", "TEST", 144, 154], ["viability", "OBSERVATION_MODIFIER", 5, 14], ["greater", "OBSERVATION_MODIFIER", 18, 25]]], ["The BMDCs generated from C57BL/6 were incubated with 2 lg/ ml OVA 257-264 (OVAP 1 ) or OVA 323-339 (OVAP 2 ) (synthesized by Echo Chemical Co., Taiwan) in the presence of 0.1% DMSO or niclosamide (1.25 lM) at 37\u00b0C for 1 h.", [["BMDCs", "ANATOMY", 4, 9], ["OVA 257-264", "CHEMICAL", 62, 73], ["OVA 323-339", "CHEMICAL", 87, 98], ["DMSO", "CHEMICAL", 176, 180], ["niclosamide", "CHEMICAL", 184, 195], ["DMSO", "CHEMICAL", 176, 180], ["niclosamide", "CHEMICAL", 184, 195], ["BMDCs", "CELL", 4, 9], ["C57BL/6", "ORGANISM", 25, 32], ["OVA 323-339", "SIMPLE_CHEMICAL", 87, 98], ["DMSO", "SIMPLE_CHEMICAL", 176, 180], ["niclosamide", "SIMPLE_CHEMICAL", 184, 195], ["BMDCs", "CELL_TYPE", 4, 9], ["The BMDCs", "TEST", 0, 9], ["lg/ ml OVA", "TEST", 55, 65], ["OVAP", "TEST", 75, 79], ["OVA", "TEST", 87, 90], ["Echo", "TEST", 125, 129], ["0.1% DMSO", "TREATMENT", 171, 180], ["niclosamide", "TREATMENT", 184, 195]]], ["Subsequently, DCs were stimulated with LPS (100 ng/ml) for 18 h.", [["DCs", "ANATOMY", 14, 17], ["LPS", "CHEMICAL", 39, 42], ["DCs", "CELL", 14, 17], ["LPS", "SIMPLE_CHEMICAL", 39, 42], ["DCs", "CELL_TYPE", 14, 17], ["LPS", "TREATMENT", 39, 42]]], ["Control was untreated group.", [["untreated", "OBSERVATION", 12, 21]]], ["After incubation, the cells were harvested and washed with PBS.", [["cells", "ANATOMY", 22, 27], ["cells", "CELL", 22, 27], ["the cells", "TREATMENT", 18, 27], ["PBS", "TREATMENT", 59, 62]]], ["OVAP 1 -specific CD8 + T cells or OVAP 2 -specific CD4 + T cells were enriched from the splenocytes of OT-I and OT-II TCR transgenic mice (C57BL/6) by MACS cell separation according to the manufacturer's protocol (Miltenyi Biotec).", [["CD8 + T cells", "ANATOMY", 17, 30], ["OVAP 2 -specific CD4 + T cells", "ANATOMY", 34, 64], ["splenocytes", "ANATOMY", 88, 99], ["cell", "ANATOMY", 156, 160], ["OVAP 1", "GENE_OR_GENE_PRODUCT", 0, 6], ["CD8", "GENE_OR_GENE_PRODUCT", 17, 20], ["OVAP 2", "GENE_OR_GENE_PRODUCT", 34, 40], ["CD4", "GENE_OR_GENE_PRODUCT", 51, 54], ["splenocytes", "CELL", 88, 99], ["OT-I", "GENE_OR_GENE_PRODUCT", 103, 107], ["OT-II TCR", "GENE_OR_GENE_PRODUCT", 112, 121], ["mice", "ORGANISM", 133, 137], ["C57BL/6", "ORGANISM", 139, 146], ["MACS cell", "CELL", 151, 160], ["OVAP 1 -specific CD8 + T cells", "CELL_LINE", 0, 30], ["OVAP 2 -specific CD4 + T cells", "CELL_TYPE", 34, 64], ["splenocytes", "CELL_TYPE", 88, 99], ["TCR", "PROTEIN", 118, 121], ["Miltenyi Biotec", "PROTEIN", 214, 229], ["mice", "SPECIES", 133, 137], ["mice", "SPECIES", 133, 137], ["OVAP", "TEST", 0, 4], ["T cells", "PROBLEM", 23, 30], ["OVAP", "TEST", 34, 38], ["T cells", "PROBLEM", 57, 64], ["the splenocytes", "TEST", 84, 99], ["OT", "TEST", 103, 105], ["OT", "TEST", 112, 114], ["MACS cell separation", "TREATMENT", 151, 171], ["the manufacturer's protocol", "TREATMENT", 185, 212], ["splenocytes", "ANATOMY", 88, 99]]], ["The enriched CD8 + and CD4 + T cells were cultured with stimulated DCs at various DC:T cell ratios for 96 h, and the proliferation of the cells was estimated based on [ 3 H] thymidine uptake.", [["CD8 +", "ANATOMY", 13, 18], ["CD4 + T cells", "ANATOMY", 23, 36], ["DCs", "ANATOMY", 67, 70], ["DC", "ANATOMY", 82, 84], ["T cell", "ANATOMY", 85, 91], ["cells", "ANATOMY", 138, 143], ["thymidine", "CHEMICAL", 174, 183], ["[ 3 H] thymidine", "CHEMICAL", 167, 183], ["CD8", "GENE_OR_GENE_PRODUCT", 13, 16], ["CD4", "GENE_OR_GENE_PRODUCT", 23, 26], ["DCs", "CELL", 67, 70], ["T cell", "CELL", 85, 91], ["cells", "CELL", 138, 143], ["[ 3 H] thymidine", "SIMPLE_CHEMICAL", 167, 183], ["CD8 + and CD4 + T cells", "CELL_TYPE", 13, 36], ["DCs", "CELL_TYPE", 67, 70], ["DC", "CELL_TYPE", 82, 84], ["The enriched CD8", "TEST", 0, 16], ["CD4 + T cells", "PROBLEM", 23, 36], ["T cell ratios", "TEST", 85, 98], ["the proliferation of the cells", "PROBLEM", 113, 143], ["thymidine uptake", "TEST", 174, 190]]], ["In addition, the supernatants from the DC/T cell cultures were collected after 96 h, and the levels of IFN-gamma production were measured using an ELISA kit.", [["supernatants", "ANATOMY", 17, 29], ["DC/T cell cultures", "ANATOMY", 39, 57], ["DC", "CELL", 39, 41], ["T cell cultures", "CELL", 42, 57], ["IFN-gamma", "GENE_OR_GENE_PRODUCT", 103, 112], ["DC", "CELL_TYPE", 39, 41], ["T cell cultures", "CELL_LINE", 42, 57], ["IFN", "PROTEIN", 103, 106], ["the supernatants", "TEST", 13, 29], ["the DC/T cell cultures", "TEST", 35, 57], ["the levels", "TEST", 89, 99], ["IFN", "TEST", 103, 106], ["an ELISA kit", "TEST", 144, 156]]], ["The proportion of the CD8 + IFNgamma + or CD4 + IFN-gamma + double-positive T cells were measured by intracellular cytokine staining using a FACSCalibur flow cytometry (BD Biosceince, MA, USA) as previous described [25] .OT-I/OT-II adoptive transferA total of 3 \u00c2 10 7 CFSE (10 lM, Molecular Probes)-stained OT-I or OT-II spleen cells were injected intravenously (i.v.) into syngeneic C57BL/6 recipient mice on day 0.", [["T cells", "ANATOMY", 76, 83], ["intracellular", "ANATOMY", 101, 114], ["OT-II spleen cells", "ANATOMY", 316, 334], ["intravenously", "ANATOMY", 349, 362], ["CFSE", "CHEMICAL", 269, 273], ["CD8", "GENE_OR_GENE_PRODUCT", 22, 25], ["IFNgamma", "GENE_OR_GENE_PRODUCT", 28, 36], ["CD4", "GENE_OR_GENE_PRODUCT", 42, 45], ["IFN-gamma", "GENE_OR_GENE_PRODUCT", 48, 57], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 101, 114], ["CFSE", "SIMPLE_CHEMICAL", 269, 273], ["OT-I", "GENE_OR_GENE_PRODUCT", 308, 312], ["OT-II spleen cells", "CELL", 316, 334], ["intravenously", "IMMATERIAL_ANATOMICAL_ENTITY", 349, 362], ["syngeneic C57BL/6 recipient mice", "ORGANISM", 375, 407], ["CD8", "PROTEIN", 22, 25], ["IFNgamma", "PROTEIN", 28, 36], ["CD4", "PROTEIN", 42, 45], ["IFN-gamma + double-positive T cells", "CELL_LINE", 48, 83], ["cytokine", "PROTEIN", 115, 123], ["stained OT-I or OT-II spleen cells", "CELL_LINE", 300, 334], ["mice", "SPECIES", 403, 407], ["mice", "SPECIES", 403, 407], ["the CD8", "TEST", 18, 25], ["IFNgamma", "TEST", 28, 36], ["CD4", "TEST", 42, 45], ["IFN", "TEST", 48, 51], ["gamma", "TEST", 52, 57], ["double-positive T cells", "PROBLEM", 60, 83], ["intracellular cytokine staining", "TEST", 101, 132], ["a FACSCalibur flow cytometry", "TEST", 139, 167], ["OT", "TEST", 226, 228], ["Molecular Probes", "TEST", 282, 298], ["stained OT", "TEST", 300, 310], ["OT-II spleen cells", "TREATMENT", 316, 334], ["spleen", "ANATOMY", 322, 328]]], ["On day 1, BMDCs from C57BL/6 mice activated with with 2 lg/ml OVA 257-264 (OVAP 1 ) or OVA 323-339 (OVAP 2 ) for 1 h at 37\u00b0C, and 5 \u00c2 10 5 peptide-loaded BMDCs were i.v injected into the mice.", [["BMDCs", "ANATOMY", 10, 15], ["BMDCs", "ANATOMY", 154, 159], ["OVA 257-264", "CHEMICAL", 62, 73], ["OVA 323-339", "CHEMICAL", 87, 98], ["BMDCs", "CELL", 10, 15], ["C57BL/6 mice", "ORGANISM", 21, 33], ["BMDCs", "CELL", 154, 159], ["mice", "ORGANISM", 187, 191], ["BMDCs", "CELL_TYPE", 10, 15], ["BMDCs", "CELL_TYPE", 154, 159], ["mice", "SPECIES", 29, 33], ["mice", "SPECIES", 187, 191], ["mice", "SPECIES", 29, 33], ["mice", "SPECIES", 187, 191], ["OVAP", "TEST", 75, 79], ["OVA", "TEST", 87, 90], ["5 peptide-loaded BMDCs", "TREATMENT", 137, 159]]], ["At days 4, OT-I and OT-II cell proliferation were analyzed by dilution of CFSE labeling in the CD8 + or CD4 + population using flow cytometry.Endocytosis assayThe endocytosis by DCs was assessed by dextran-FITC or OVA-FITC uptake, as described previously [26] .", [["OT-II cell", "ANATOMY", 20, 30], ["CD8 +", "ANATOMY", 95, 100], ["CD4 + population", "ANATOMY", 104, 120], ["DCs", "ANATOMY", 178, 181], ["CFSE", "CHEMICAL", 74, 78], ["dextran-FITC", "CHEMICAL", 198, 210], ["CFSE", "CHEMICAL", 74, 78], ["dextran-FITC", "CHEMICAL", 198, 210], ["FITC", "CHEMICAL", 218, 222], ["OT-I", "GENE_OR_GENE_PRODUCT", 11, 15], ["OT-II cell", "CELL", 20, 30], ["CFSE", "SIMPLE_CHEMICAL", 74, 78], ["CD8", "GENE_OR_GENE_PRODUCT", 95, 98], ["CD4", "GENE_OR_GENE_PRODUCT", 104, 107], ["DCs", "CELL", 178, 181], ["dextran-FITC", "SIMPLE_CHEMICAL", 198, 210], ["OVA-FITC", "SIMPLE_CHEMICAL", 214, 222], ["CD8", "PROTEIN", 95, 98], ["CD4", "PROTEIN", 104, 107], ["DCs", "CELL_TYPE", 178, 181], ["dextran-FITC", "PROTEIN", 198, 210], ["OT-II cell proliferation", "TREATMENT", 20, 44], ["CFSE labeling", "TEST", 74, 87], ["the CD8", "TEST", 91, 98], ["CD4", "PROBLEM", 104, 107], ["flow cytometry", "TEST", 127, 141], ["Endocytosis assay", "TEST", 142, 159], ["cell proliferation", "OBSERVATION", 26, 44], ["flow cytometry", "OBSERVATION", 127, 141], ["FITC uptake", "OBSERVATION", 218, 229]]], ["Briefly, enriched CD11c + mouse bone marrow-derived DCs were treated with niclosamide (1.25 lM), 0.1% DMSO plus LPS (100 ng/ml) or niclosamide plus LPS for 18 h.", [["bone marrow", "ANATOMY", 32, 43], ["DCs", "ANATOMY", 52, 55], ["niclosamide", "CHEMICAL", 74, 85], ["DMSO", "CHEMICAL", 102, 106], ["LPS", "CHEMICAL", 112, 115], ["niclosamide", "CHEMICAL", 131, 142], ["LPS", "CHEMICAL", 148, 151], ["niclosamide", "CHEMICAL", 74, 85], ["DMSO", "CHEMICAL", 102, 106], ["niclosamide", "CHEMICAL", 131, 142], ["CD11c", "GENE_OR_GENE_PRODUCT", 18, 23], ["mouse", "ORGANISM", 26, 31], ["DCs", "CELL", 52, 55], ["niclosamide", "SIMPLE_CHEMICAL", 74, 85], ["DMSO", "SIMPLE_CHEMICAL", 102, 106], ["LPS", "SIMPLE_CHEMICAL", 112, 115], ["niclosamide", "SIMPLE_CHEMICAL", 131, 142], ["LPS", "SIMPLE_CHEMICAL", 148, 151], ["CD11c", "PROTEIN", 18, 23], ["mouse bone marrow-derived DCs", "CELL_LINE", 26, 55], ["mouse", "SPECIES", 26, 31], ["mouse", "SPECIES", 26, 31], ["niclosamide", "TREATMENT", 74, 85], ["LPS", "TREATMENT", 112, 115], ["niclosamide", "TREATMENT", 131, 142], ["LPS", "TREATMENT", 148, 151], ["bone marrow", "ANATOMY", 32, 43]]], ["The cells were then harvested and incubated at 37\u00b0for 1 h with 1 mg/ml dextran-FITC (molecular weight 42,000; Sigma) or 250 lg/ml OVA-FITC (Invitrogen-Molecular Probes).", [["cells", "ANATOMY", 4, 9], ["dextran", "CHEMICAL", 71, 78], ["FITC", "CHEMICAL", 79, 83], ["FITC", "CHEMICAL", 134, 138], ["cells", "CELL", 4, 9], ["dextran-FITC", "SIMPLE_CHEMICAL", 71, 83], ["OVA-FITC", "SIMPLE_CHEMICAL", 130, 138], ["dextran", "TREATMENT", 71, 78], ["weight", "TEST", 95, 101], ["OVA", "TEST", 130, 133], ["FITC", "TEST", 134, 138]]], ["The uptake of dextran-FITC or OVA-FITC by the DCs was analyzed using a FACSCalibur flow cytometer.", [["DCs", "ANATOMY", 46, 49], ["dextran-FITC", "CHEMICAL", 14, 26], ["OVA-FITC", "CHEMICAL", 30, 38], ["dextran-FITC", "CHEMICAL", 14, 26], ["FITC", "CHEMICAL", 34, 38], ["dextran-FITC", "SIMPLE_CHEMICAL", 14, 26], ["OVA-FITC", "SIMPLE_CHEMICAL", 30, 38], ["DCs", "CELL", 46, 49], ["dextran-FITC", "PROTEIN", 14, 26], ["OVA-FITC", "PROTEIN", 30, 38], ["DCs", "CELL_TYPE", 46, 49], ["dextran-FITC or OVA", "TREATMENT", 14, 33], ["a FACSCalibur flow cytometer", "TREATMENT", 69, 97]]], ["In addition, parallel experiments were performed at 4\u00b0C to demonstrate that the uptake of dextran by DCs is inhibited at low temperatures.Western blot analysis and NF-jb activity assayDCs were cultured in the presence of 0.1% DMSO or niclosamide (1.25 lM) for 1 h and subsequently stimulated with LPS (100 ng/ ml).", [["DCs", "ANATOMY", 101, 104], ["dextran", "CHEMICAL", 90, 97], ["DMSO", "CHEMICAL", 226, 230], ["niclosamide", "CHEMICAL", 234, 245], ["LPS", "CHEMICAL", 297, 300], ["DMSO", "CHEMICAL", 226, 230], ["niclosamide", "CHEMICAL", 234, 245], ["dextran", "SIMPLE_CHEMICAL", 90, 97], ["DCs", "CELL", 101, 104], ["NF-jb", "GENE_OR_GENE_PRODUCT", 164, 169], ["DMSO", "SIMPLE_CHEMICAL", 226, 230], ["niclosamide", "SIMPLE_CHEMICAL", 234, 245], ["LPS", "SIMPLE_CHEMICAL", 297, 300], ["DCs", "CELL_TYPE", 101, 104], ["parallel experiments", "TEST", 13, 33], ["dextran", "TREATMENT", 90, 97], ["Western blot analysis", "TEST", 138, 159], ["NF", "TEST", 164, 166], ["0.1% DMSO", "TREATMENT", 221, 230], ["niclosamide", "TREATMENT", 234, 245], ["LPS", "TREATMENT", 297, 300], ["low temperatures", "OBSERVATION_MODIFIER", 121, 137]]], ["The cells were harvested, and whole cell lysates were prepared at the 30 min after LPS stimulation.", [["cells", "ANATOMY", 4, 9], ["cell lysates", "ANATOMY", 36, 48], ["LPS", "CHEMICAL", 83, 86], ["cells", "CELL", 4, 9], ["cell lysates", "ORGANISM_SUBSTANCE", 36, 48], ["LPS", "SIMPLE_CHEMICAL", 83, 86], ["whole cell lysates", "TREATMENT", 30, 48], ["LPS stimulation", "TREATMENT", 83, 98], ["harvested", "OBSERVATION_MODIFIER", 15, 24]]], ["For protein detection, protein extracts (50 lg/ml) were boiled, electrophoresed on 10% SDS-polyacrylamide gels and transferred to nitrocellulose membranes.", [["extracts", "ANATOMY", 31, 39], ["membranes", "ANATOMY", 145, 154], ["SDS", "CHEMICAL", 87, 90], ["polyacrylamide", "CHEMICAL", 91, 105], ["nitrocellulose", "CHEMICAL", 130, 144], ["extracts", "ORGANISM_SUBSTANCE", 31, 39], ["membranes", "CELLULAR_COMPONENT", 145, 154], ["protein detection", "TEST", 4, 21], ["protein extracts", "TEST", 23, 39], ["polyacrylamide gels", "TREATMENT", 91, 110], ["nitrocellulose membranes", "TREATMENT", 130, 154]]], ["The membranes were blocked for 1 h with 5% skim milk in TBS + 0.05% Tween 20.", [["membranes", "ANATOMY", 4, 13], ["milk", "ANATOMY", 48, 52], ["Tween 20", "CHEMICAL", 68, 76], ["membranes", "CELLULAR_COMPONENT", 4, 13], ["milk", "ORGANISM_SUBSTANCE", 48, 52], ["Tween 20", "SIMPLE_CHEMICAL", 68, 76], ["TBS", "TEST", 56, 59]]], ["After blocking, the membranes were incubated with a primary antibody against phospho-p38, p38, phospho-p42/44, total p42/44, phospho JNK, b-Actin (Cell Signaling, Beverly, MA) or total JNK (SC-571; Santa Cruz Biotechnology, Santa Cruz, CA) overnight.", [["membranes", "ANATOMY", 20, 29], ["Cell", "ANATOMY", 147, 151], ["phospho", "CHEMICAL", 95, 102], ["phospho", "CHEMICAL", 125, 132], ["membranes", "CELLULAR_COMPONENT", 20, 29], ["phospho-p38", "GENE_OR_GENE_PRODUCT", 77, 88], ["p38", "GENE_OR_GENE_PRODUCT", 90, 93], ["phospho-p42/44", "GENE_OR_GENE_PRODUCT", 95, 109], ["p42/44", "GENE_OR_GENE_PRODUCT", 117, 123], ["phospho JNK", "GENE_OR_GENE_PRODUCT", 125, 136], ["b-Actin", "GENE_OR_GENE_PRODUCT", 138, 145], ["Cell", "CELL", 147, 151], ["JNK", "GENE_OR_GENE_PRODUCT", 185, 188], ["phospho", "PROTEIN", 77, 84], ["p38", "PROTEIN", 85, 88], ["p38", "PROTEIN", 90, 93], ["phospho", "PROTEIN", 95, 102], ["p42/44", "PROTEIN", 103, 109], ["p42/44", "PROTEIN", 117, 123], ["phospho JNK", "PROTEIN", 125, 136], ["b-Actin", "PROTEIN", 138, 145], ["JNK", "PROTEIN", 185, 188], ["Santa Cruz Biotechnology", "PROTEIN", 198, 222], ["a primary antibody", "TEST", 50, 68], ["phospho", "TEST", 77, 84], ["p38", "TEST", 90, 93], ["phospho", "TEST", 95, 102], ["total p42/44", "TEST", 111, 123], ["phospho JNK", "TEST", 125, 136], ["Beverly", "TEST", 163, 170], ["MA", "TEST", 172, 174], ["total JNK", "TEST", 179, 188]]], ["The membranes were then washed and incubated with horseradish peroxidase-labeled secondary Abs (Jackson ImmunoResearch, West Grove, PA).", [["membranes", "ANATOMY", 4, 13], ["membranes", "CELLULAR_COMPONENT", 4, 13], ["horseradish peroxidase", "SIMPLE_CHEMICAL", 50, 72], ["horseradish peroxidase", "PROTEIN", 50, 72], ["secondary Abs", "PROTEIN", 81, 94], ["horseradish", "SPECIES", 50, 61], ["horseradish peroxidase", "TREATMENT", 50, 72]]], ["Densitometric analysis was performed with ImageJ software (National Institutes of Health, Bethesda, MD, USA).", [["Densitometric analysis", "TEST", 0, 22]]], ["To measure the NF-jB transcriptional activity, purified BMDCs (1.5 \u00c2 10 6 cells/well) were stimulated with 0.1% DMSO or niclosamide (6.25, 12.5 lM) for 1 h and subsequently stimulated with LPS (100 ng/ml) for 30 min in 6-well plates.", [["BMDCs", "ANATOMY", 56, 61], ["cells", "ANATOMY", 74, 79], ["DMSO", "CHEMICAL", 112, 116], ["niclosamide", "CHEMICAL", 120, 131], ["LPS", "CHEMICAL", 189, 192], ["DMSO", "CHEMICAL", 112, 116], ["niclosamide", "CHEMICAL", 120, 131], ["NF-jB", "GENE_OR_GENE_PRODUCT", 15, 20], ["BMDCs", "CELL", 56, 61], ["cells", "CELL", 74, 79], ["DMSO", "SIMPLE_CHEMICAL", 112, 116], ["niclosamide", "SIMPLE_CHEMICAL", 120, 131], ["LPS", "SIMPLE_CHEMICAL", 189, 192], ["NF", "PROTEIN", 15, 17], ["jB", "PROTEIN", 18, 20], ["BMDCs", "CELL_TYPE", 56, 61], ["purified BMDCs", "TREATMENT", 47, 61], ["niclosamide", "TREATMENT", 120, 131], ["LPS", "TREATMENT", 189, 192]]], ["The cells were then harvested, and nuclear extracts were prepared using the NE-PER Nuclear and Cytoplasmic Extraction system (Pierce) according to the manufacturer's instructions.", [["cells", "ANATOMY", 4, 9], ["nuclear extracts", "ANATOMY", 35, 51], ["NE", "CHEMICAL", 76, 78], ["cells", "CELL", 4, 9], ["nuclear extracts", "ORGANISM_SUBSTANCE", 35, 51], ["NE", "PROTEIN", 76, 78], ["the NE", "TREATMENT", 72, 78]]], ["A BCA protein assay kit (Pierce, Rockford, IL, USA) was used to determine the protein concentration.", [["A BCA protein assay", "TEST", 0, 19]]], ["For each assay, a total of 10 lg nuclear extract was used in a TransAM NF-jB p65 ELISA kit (Active Motif, Carlsbad, CA) according to the manufacturer's instructions.2,4-Dinitro-1-fluorobenzene-induced contact hypersensitivity assayThe 2,4-dinitro-1-fluorobenzene (DNFB; Sigma-Aldrich)-induced contact hypersensitivity (CHS) model was constructed using previously described methods, with some modifications [26] .", [["2,4-Dinitro-1-fluorobenzene", "CHEMICAL", 165, 192], ["hypersensitivity", "DISEASE", 209, 225], ["2,4-dinitro-1-fluorobenzene", "CHEMICAL", 235, 262], ["DNFB", "CHEMICAL", 264, 268], ["contact hypersensitivity", "DISEASE", 293, 317], ["2,4-Dinitro-1-fluorobenzene", "CHEMICAL", 165, 192], ["2,4-dinitro-1-fluorobenzene", "CHEMICAL", 235, 262], ["DNFB", "CHEMICAL", 264, 268], ["Sigma-Aldrich", "CHEMICAL", 270, 283], ["2,4-Dinitro-1-fluorobenzene", "SIMPLE_CHEMICAL", 165, 192], ["2,4-dinitro-1-fluorobenzene", "SIMPLE_CHEMICAL", 235, 262], ["DNFB", "SIMPLE_CHEMICAL", 264, 268], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 270, 283], ["each assay", "TEST", 4, 14], ["Dinitro", "TEST", 169, 176], ["fluorobenzene", "TREATMENT", 179, 192], ["contact hypersensitivity assay", "TEST", 201, 231], ["dinitro", "TEST", 239, 246], ["fluorobenzene (DNFB", "TREATMENT", 249, 268], ["Sigma-Aldrich)", "TREATMENT", 270, 284], ["jB", "ANATOMY", 74, 76]]], ["The shaved belly of mice was painted daily with 20 ll vehicle (acetone/olive oil at ratio of 1:4) or 0.5% (w/v) DNFB plus with i.v daily 50 ll solvent solution (10% Cremophor EL; 0.9% NaCl) or 50 ll niclosamide (2 mg/kg).", [["olive oil", "ANATOMY", 71, 80], ["DNFB", "CHEMICAL", 112, 116], ["Cremophor EL", "CHEMICAL", 165, 177], ["NaCl", "CHEMICAL", 184, 188], ["niclosamide", "CHEMICAL", 199, 210], ["acetone", "CHEMICAL", 63, 70], ["DNFB", "CHEMICAL", 112, 116], ["Cremophor", "CHEMICAL", 165, 174], ["NaCl", "CHEMICAL", 184, 188], ["niclosamide", "CHEMICAL", 199, 210], ["belly", "ORGANISM_SUBDIVISION", 11, 16], ["mice", "ORGANISM", 20, 24], ["acetone", "SIMPLE_CHEMICAL", 63, 70], ["DNFB", "SIMPLE_CHEMICAL", 112, 116], ["niclosamide", "SIMPLE_CHEMICAL", 199, 210], ["mice", "SPECIES", 20, 24], ["mice", "SPECIES", 20, 24], ["20 ll vehicle (acetone/olive oil", "TREATMENT", 48, 80], ["DNFB", "TREATMENT", 112, 116], ["ll solvent solution (10% Cremophor EL", "TREATMENT", 140, 177], ["ll niclosamide", "TREATMENT", 196, 210], ["belly", "ANATOMY", 11, 16]]], ["Five days after sensitization, 20 ll of DNFB 0.2% (w/v) were painted on both sides of the right ears of all of the mice.", [["right ears", "ANATOMY", 90, 100], ["DNFB", "CHEMICAL", 40, 44], ["DNFB", "CHEMICAL", 40, 44], ["DNFB", "SIMPLE_CHEMICAL", 40, 44], ["ears", "ORGAN", 96, 100], ["mice", "ORGANISM", 115, 119], ["mice", "SPECIES", 115, 119], ["mice", "SPECIES", 115, 119], ["20 ll of DNFB", "TREATMENT", 31, 44], ["right", "ANATOMY_MODIFIER", 90, 95]]], ["The CHS response was determined 16 h after exposure to DNFB through histological analysis using H&E staining and by evaluating the increased thickness of the ear (thickness of the right (challenged) ear minus the thickness of the left (unchallenged) ear) using an engineer's spring-loaded micrometer (Mitutoyo, Tokyo, Japan).Statistical analysisAll statistical analyses were performed using GraphPad Prism software package version 4.0 (GraphPad Software; San Diego, CA, USA).", [["ear", "ANATOMY", 158, 161], ["ear", "ANATOMY", 199, 202], ["left", "ANATOMY", 230, 234], ["ear", "ANATOMY", 250, 253], ["DNFB", "CHEMICAL", 55, 59], ["DNFB", "CHEMICAL", 55, 59], ["DNFB", "SIMPLE_CHEMICAL", 55, 59], ["ear", "ORGAN", 158, 161], ["ear", "ORGAN", 199, 202], ["ear", "ORGAN", 250, 253], ["DNFB", "TREATMENT", 55, 59], ["histological analysis", "TEST", 68, 89], ["H&E staining", "TEST", 96, 108], ["an engineer's spring", "TREATMENT", 261, 281], ["Statistical analysis", "TEST", 325, 345], ["All statistical analyses", "TEST", 345, 369], ["increased", "OBSERVATION_MODIFIER", 131, 140], ["thickness", "OBSERVATION_MODIFIER", 141, 150], ["ear", "ANATOMY", 158, 161], ["thickness", "OBSERVATION_MODIFIER", 163, 172], ["right", "ANATOMY_MODIFIER", 180, 185], ["ear", "ANATOMY", 199, 202], ["thickness", "OBSERVATION_MODIFIER", 213, 222], ["left", "ANATOMY_MODIFIER", 230, 234], ["ear", "ANATOMY", 250, 253]]], ["Cytokine production, T cell proliferation in vitro and in vivo, IFN-gamma production, immunoblotting assay, and increased thickness of the ear were evaluated by one-way ANOVA followed by Tukey's post hoc test.", [["T cell", "ANATOMY", 21, 27], ["ear", "ANATOMY", 139, 142], ["Cytokine", "GENE_OR_GENE_PRODUCT", 0, 8], ["T cell", "CELL", 21, 27], ["IFN-gamma", "GENE_OR_GENE_PRODUCT", 64, 73], ["ear", "ORGAN", 139, 142], ["Cytokine", "PROTEIN", 0, 8], ["IFN", "PROTEIN", 64, 67], ["Cytokine production", "PROBLEM", 0, 19], ["T cell proliferation", "PROBLEM", 21, 41], ["IFN", "TEST", 64, 67], ["gamma production", "TEST", 68, 84], ["immunoblotting assay", "TEST", 86, 106], ["increased thickness of the ear", "PROBLEM", 112, 142], ["Tukey's post hoc test", "TEST", 187, 208], ["cell proliferation", "OBSERVATION", 23, 41], ["increased", "OBSERVATION_MODIFIER", 112, 121], ["thickness", "OBSERVATION_MODIFIER", 122, 131], ["ear", "ANATOMY", 139, 142]]], ["When p < 0.05, the difference was considered to be statistically significant.Niclosamide decreases cytokine and chemokine production by LPS-stimulated mouse bone marrow-derived DCsA major attribute of mature DCs is the synthesis and secretion of cytokines and chemokines that modulate inflammatory responses and T cell differentiation and are responsible for the adaptive immune response [2] [3] [4] .", [["bone marrow", "ANATOMY", 157, 168], ["DCsA", "ANATOMY", 177, 181], ["DCs", "ANATOMY", 208, 211], ["T cell", "ANATOMY", 312, 318], ["Niclosamide", "CHEMICAL", 77, 88], ["LPS", "CHEMICAL", 136, 139], ["Niclosamide", "CHEMICAL", 77, 88], ["Niclosamide", "SIMPLE_CHEMICAL", 77, 88], ["LPS", "SIMPLE_CHEMICAL", 136, 139], ["mouse", "ORGANISM", 151, 156], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 157, 168], ["DCsA", "CELL", 177, 181], ["DCs", "CELL", 208, 211], ["T cell", "CELL", 312, 318], ["cytokine", "PROTEIN", 99, 107], ["chemokine", "PROTEIN", 112, 121], ["mature DCs", "CELL_TYPE", 201, 211], ["cytokines", "PROTEIN", 246, 255], ["chemokines", "PROTEIN", 260, 270], ["mouse", "SPECIES", 151, 156], ["mouse", "SPECIES", 151, 156], ["Niclosamide decreases cytokine", "TREATMENT", 77, 107], ["chemokine production", "TREATMENT", 112, 132], ["LPS", "TEST", 136, 139], ["the synthesis", "TREATMENT", 215, 228], ["secretion of cytokines", "TREATMENT", 233, 255], ["chemokines", "TREATMENT", 260, 270], ["inflammatory responses", "PROBLEM", 285, 307], ["T cell differentiation", "PROBLEM", 312, 334], ["significant", "OBSERVATION", 65, 76], ["bone marrow", "ANATOMY", 157, 168]]], ["Therefore, in the first series of experiments, we investigated the effect of niclosamide on the production of pro-inflammatory cytokines and chemokines by LPS-stimulated mature mouse bone marrow-derived DCs.", [["bone marrow", "ANATOMY", 183, 194], ["DCs", "ANATOMY", 203, 206], ["niclosamide", "CHEMICAL", 77, 88], ["LPS", "CHEMICAL", 155, 158], ["niclosamide", "CHEMICAL", 77, 88], ["niclosamide", "SIMPLE_CHEMICAL", 77, 88], ["LPS", "SIMPLE_CHEMICAL", 155, 158], ["mouse", "ORGANISM", 177, 182], ["bone marrow-derived DCs", "CELL", 183, 206], ["pro-inflammatory cytokines", "PROTEIN", 110, 136], ["chemokines", "PROTEIN", 141, 151], ["LPS-stimulated mature mouse bone marrow-derived DCs", "CELL_LINE", 155, 206], ["mouse", "SPECIES", 177, 182], ["mouse", "SPECIES", 177, 182], ["niclosamide", "TREATMENT", 77, 88], ["pro-inflammatory cytokines", "TREATMENT", 110, 136], ["chemokines", "TREATMENT", 141, 151], ["LPS", "TEST", 155, 158], ["bone marrow", "OBSERVATION", 183, 194]]], ["First, the supernatants were collected from LPS-activated mouse DCs propagated in the presence or absence of niclosamide, and the cytokine and chemokine levels in the supernatants were quantified by ELI-SA.", [["supernatants", "ANATOMY", 11, 23], ["DCs", "ANATOMY", 64, 67], ["supernatants", "ANATOMY", 167, 179], ["LPS", "CHEMICAL", 44, 47], ["niclosamide", "CHEMICAL", 109, 120], ["niclosamide", "CHEMICAL", 109, 120], ["LPS", "SIMPLE_CHEMICAL", 44, 47], ["mouse", "ORGANISM", 58, 63], ["DCs", "CELL", 64, 67], ["niclosamide", "SIMPLE_CHEMICAL", 109, 120], ["LPS-activated mouse DCs", "CELL_LINE", 44, 67], ["cytokine", "PROTEIN", 130, 138], ["chemokine", "PROTEIN", 143, 152], ["mouse", "SPECIES", 58, 63], ["mouse", "SPECIES", 58, 63], ["LPS", "TREATMENT", 44, 47], ["activated mouse DCs", "TREATMENT", 48, 67], ["niclosamide", "TREATMENT", 109, 120], ["the cytokine and chemokine levels", "TEST", 126, 159]]], ["Bacterial LPS is widely used as a strong inducer of DC activation.", [["DC", "ANATOMY", 52, 54], ["LPS", "CHEMICAL", 10, 13], ["LPS", "SIMPLE_CHEMICAL", 10, 13], ["DC", "CELL", 52, 54], ["DC", "CELL_TYPE", 52, 54], ["Bacterial LPS", "TEST", 0, 13], ["LPS", "OBSERVATION", 10, 13]]], ["As shown in Fig. 1 , DCs exposed to niclosamide exhibited a significant dose-dependent decrease in the levels of the LPS-induced pro-inflammatory cytokines (TNF-alpha, IL-6, IL-12) and chemokines (RANTES, MCP-1, MIP-1 alpha).", [["DCs", "ANATOMY", 21, 24], ["niclosamide", "CHEMICAL", 36, 47], ["LPS", "CHEMICAL", 117, 120], ["niclosamide", "CHEMICAL", 36, 47], ["DCs", "CELL", 21, 24], ["niclosamide", "SIMPLE_CHEMICAL", 36, 47], ["LPS", "SIMPLE_CHEMICAL", 117, 120], ["TNF-alpha", "GENE_OR_GENE_PRODUCT", 157, 166], ["IL-6", "GENE_OR_GENE_PRODUCT", 168, 172], ["IL-12", "GENE_OR_GENE_PRODUCT", 174, 179], ["RANTES", "GENE_OR_GENE_PRODUCT", 197, 203], ["MCP-1", "GENE_OR_GENE_PRODUCT", 205, 210], ["MIP-1 alpha", "GENE_OR_GENE_PRODUCT", 212, 223], ["DCs", "CELL_TYPE", 21, 24], ["pro-inflammatory cytokines", "PROTEIN", 129, 155], ["TNF-alpha, IL-6, IL-12", "PROTEIN", 157, 179], ["chemokines", "PROTEIN", 185, 195], ["RANTES", "PROTEIN", 197, 203], ["MCP", "PROTEIN", 205, 208], ["MIP-1 alpha", "PROTEIN", 212, 223], ["niclosamide", "TREATMENT", 36, 47], ["dependent decrease", "PROBLEM", 77, 95], ["the LPS", "TEST", 113, 120], ["pro-inflammatory cytokines", "TEST", 129, 155], ["TNF", "TEST", 157, 160], ["alpha", "TEST", 161, 166], ["IL", "TEST", 168, 170], ["IL", "TEST", 174, 176], ["chemokines", "TEST", 185, 195], ["RANTES", "TEST", 197, 203], ["MCP", "TEST", 205, 208], ["MIP", "TEST", 212, 215], ["Fig", "OBSERVATION", 12, 15], ["significant", "OBSERVATION_MODIFIER", 60, 71], ["dependent", "OBSERVATION_MODIFIER", 77, 86], ["decrease", "OBSERVATION_MODIFIER", 87, 95], ["pro-inflammatory cytokines", "OBSERVATION", 129, 155]]], ["In addition, the level of these cytokine or chemokine did not significant differ between the niclosamide-treated and DMSO-treated DCs in the absence of LPS.", [["DCs", "ANATOMY", 130, 133], ["niclosamide", "CHEMICAL", 93, 104], ["DMSO", "CHEMICAL", 117, 121], ["LPS", "CHEMICAL", 152, 155], ["niclosamide", "CHEMICAL", 93, 104], ["DMSO", "CHEMICAL", 117, 121], ["niclosamide", "SIMPLE_CHEMICAL", 93, 104], ["DMSO", "SIMPLE_CHEMICAL", 117, 121], ["DCs", "CELL", 130, 133], ["LPS", "SIMPLE_CHEMICAL", 152, 155], ["cytokine", "PROTEIN", 32, 40], ["chemokine", "PROTEIN", 44, 53], ["niclosamide-treated and DMSO-treated DCs", "CELL_LINE", 93, 133], ["the niclosamide", "TREATMENT", 89, 104], ["DMSO", "TREATMENT", 117, 121], ["DCs", "TREATMENT", 130, 133], ["LPS", "PROBLEM", 152, 155]]], ["Moreover, the decrease in cytokine and chemokine levels was not due to an increase in the number of dead cells, as determined by CCK-8, because there were no marked differences in cell viability between 1.25 lM niclosamide-treated cultures and DMSO-treated control cultures (Supplemental Fig. 1) .", [["cells", "ANATOMY", 105, 110], ["cell", "ANATOMY", 180, 184], ["cultures", "ANATOMY", 231, 239], ["cultures", "ANATOMY", 265, 273], ["niclosamide", "CHEMICAL", 211, 222], ["DMSO", "CHEMICAL", 244, 248], ["niclosamide", "CHEMICAL", 211, 222], ["DMSO", "CHEMICAL", 244, 248], ["cells", "CELL", 105, 110], ["CCK-8", "GENE_OR_GENE_PRODUCT", 129, 134], ["cell", "CELL", 180, 184], ["lM", "SIMPLE_CHEMICAL", 208, 210], ["niclosamide", "SIMPLE_CHEMICAL", 211, 222], ["DMSO", "SIMPLE_CHEMICAL", 244, 248], ["cytokine", "PROTEIN", 26, 34], ["chemokine", "PROTEIN", 39, 48], ["dead cells", "CELL_TYPE", 100, 110], ["treated cultures", "CELL_LINE", 223, 239], ["DMSO-treated control cultures", "CELL_LINE", 244, 273], ["the decrease in cytokine and chemokine levels", "PROBLEM", 10, 55], ["an increase", "PROBLEM", 71, 82], ["dead cells", "PROBLEM", 100, 110], ["CCK", "TEST", 129, 132], ["marked differences in cell viability", "PROBLEM", 158, 194], ["lM niclosamide", "TREATMENT", 208, 222], ["cultures", "TEST", 231, 239], ["DMSO", "TREATMENT", 244, 248], ["cultures", "TEST", 265, 273], ["Supplemental Fig", "TREATMENT", 275, 291], ["decrease", "OBSERVATION_MODIFIER", 14, 22], ["increase", "OBSERVATION_MODIFIER", 74, 82], ["dead cells", "OBSERVATION", 100, 110], ["no", "UNCERTAINTY", 155, 157], ["marked", "OBSERVATION_MODIFIER", 158, 164], ["cell viability", "OBSERVATION", 180, 194]]], ["Thus, these results suggest that niclosamide suppresses the inflammatory and immunostimulatory activity of DCs stimulated with LPS.Niclosamide affects the expression of surface molecules and the endocytosis capacity of LPS-stimulated DCsThe activation of DCs is accompanied by the enhanced expression of surface molecules including the costimulatory molecules and major histocompatibility complex molecules (MHC) that mediate interactions with na\u00efve T cells and contribute to T cell activation [4] .", [["DCs", "ANATOMY", 107, 110], ["surface", "ANATOMY", 169, 176], ["DCs", "ANATOMY", 234, 237], ["DCs", "ANATOMY", 255, 258], ["surface", "ANATOMY", 304, 311], ["na\u00efve T cells", "ANATOMY", 444, 457], ["T cell", "ANATOMY", 476, 482], ["niclosamide", "CHEMICAL", 33, 44], ["LPS", "CHEMICAL", 127, 130], ["Niclosamide", "CHEMICAL", 131, 142], ["LPS", "CHEMICAL", 219, 222], ["niclosamide", "CHEMICAL", 33, 44], ["Niclosamide", "CHEMICAL", 131, 142], ["niclosamide", "SIMPLE_CHEMICAL", 33, 44], ["DCs", "CELL", 107, 110], ["LPS", "SIMPLE_CHEMICAL", 127, 130], ["Niclosamide", "SIMPLE_CHEMICAL", 131, 142], ["LPS", "SIMPLE_CHEMICAL", 219, 222], ["DCs", "CELL", 234, 237], ["DCs", "CELL", 255, 258], ["major histocompatibility complex molecules", "GENE_OR_GENE_PRODUCT", 364, 406], ["na\u00efve T cells", "CELL", 444, 457], ["T cell", "CELL", 476, 482], ["DCs", "CELL_TYPE", 107, 110], ["surface molecules", "PROTEIN", 169, 186], ["DCs", "CELL_TYPE", 234, 237], ["DCs", "CELL_TYPE", 255, 258], ["surface molecules", "PROTEIN", 304, 321], ["costimulatory molecules", "PROTEIN", 336, 359], ["major histocompatibility complex molecules", "PROTEIN", 364, 406], ["MHC", "PROTEIN", 408, 411], ["na\u00efve T cells", "CELL_TYPE", 444, 457], ["niclosamide", "TREATMENT", 33, 44], ["the inflammatory", "PROBLEM", 56, 72], ["LPS", "TREATMENT", 127, 130], ["Niclosamide", "TREATMENT", 131, 142], ["surface molecules", "PROBLEM", 169, 186], ["the endocytosis capacity", "PROBLEM", 191, 215], ["LPS", "TEST", 219, 222], ["DCs", "PROBLEM", 255, 258], ["surface molecules", "PROBLEM", 304, 321], ["na\u00efve T cells", "PROBLEM", 444, 457], ["T cell activation", "PROBLEM", 476, 493], ["inflammatory", "OBSERVATION_MODIFIER", 60, 72]]], ["Thus, we determined whether treatment with niclosamide affected the expression of surface molecules on mouse DCs.", [["surface", "ANATOMY", 82, 89], ["DCs", "ANATOMY", 109, 112], ["niclosamide", "CHEMICAL", 43, 54], ["niclosamide", "CHEMICAL", 43, 54], ["niclosamide", "SIMPLE_CHEMICAL", 43, 54], ["mouse", "ORGANISM", 103, 108], ["DCs", "CELL", 109, 112], ["surface molecules", "PROTEIN", 82, 99], ["mouse DCs", "CELL_TYPE", 103, 112], ["mouse", "SPECIES", 103, 108], ["mouse", "SPECIES", 103, 108], ["treatment", "TREATMENT", 28, 37], ["niclosamide", "TREATMENT", 43, 54], ["mouse DCs", "TREATMENT", 103, 112]]], ["As shown in Fig. 2A , niclosamide treatment significantly altered the expression of the costimulatory molecules (CD80, CD86 and CD40) and the major histocompatibility complex molecules (MHC class II, MHC class I) (Fig. 2B ) within 18 h compared to LPS-stimulated mature DCs that were not exposed to niclosamide.", [["DCs", "ANATOMY", 270, 273], ["niclosamide", "CHEMICAL", 22, 33], ["LPS", "CHEMICAL", 248, 251], ["niclosamide", "CHEMICAL", 299, 310], ["niclosamide", "CHEMICAL", 22, 33], ["niclosamide", "CHEMICAL", 299, 310], ["2A", "GENE_OR_GENE_PRODUCT", 17, 19], ["niclosamide", "SIMPLE_CHEMICAL", 22, 33], ["CD80", "GENE_OR_GENE_PRODUCT", 113, 117], ["CD86", "GENE_OR_GENE_PRODUCT", 119, 123], ["CD40", "GENE_OR_GENE_PRODUCT", 128, 132], ["MHC class I", "GENE_OR_GENE_PRODUCT", 200, 211], ["LPS", "SIMPLE_CHEMICAL", 248, 251], ["DCs", "CELL", 270, 273], ["niclosamide", "SIMPLE_CHEMICAL", 299, 310], ["costimulatory molecules", "PROTEIN", 88, 111], ["CD80", "PROTEIN", 113, 117], ["CD86", "PROTEIN", 119, 123], ["CD40", "PROTEIN", 128, 132], ["major histocompatibility complex molecules", "PROTEIN", 142, 184], ["MHC class II", "PROTEIN", 186, 198], ["MHC class I", "PROTEIN", 200, 211], ["Fig. 2B", "PROTEIN", 214, 221], ["LPS-stimulated mature DCs", "CELL_LINE", 248, 273], ["niclosamide treatment", "TREATMENT", 22, 43], ["CD80", "TEST", 113, 117], ["CD86", "TEST", 119, 123], ["CD40", "TEST", 128, 132], ["LPS", "TEST", 248, 251], ["niclosamide", "TREATMENT", 299, 310], ["Fig", "OBSERVATION", 12, 15]]], ["Thus, we suggest that niclosamide also impairs the LPS-induced phenotypic maturation of DCs.", [["DCs", "ANATOMY", 88, 91], ["niclosamide", "CHEMICAL", 22, 33], ["LPS", "CHEMICAL", 51, 54], ["niclosamide", "CHEMICAL", 22, 33], ["niclosamide", "SIMPLE_CHEMICAL", 22, 33], ["LPS", "SIMPLE_CHEMICAL", 51, 54], ["DCs", "CELL", 88, 91], ["DCs", "CELL_TYPE", 88, 91], ["niclosamide", "TREATMENT", 22, 33], ["the LPS", "TREATMENT", 47, 54], ["DCs", "PROBLEM", 88, 91]]], ["However, it is also important to note that immature DCs possess stronger endocytic activity than mature DCs [2, 3] .", [["DCs", "ANATOMY", 52, 55], ["DCs", "ANATOMY", 104, 107], ["DCs", "CELL", 52, 55], ["DCs", "CELL", 104, 107], ["immature DCs", "CELL_TYPE", 43, 55], ["mature DCs", "CELL_TYPE", 97, 107]]], ["Therefore, we examined the ability of niclosamide-treated DCs to endocytose dextran-FITC or OVA-FITC.", [["DCs", "ANATOMY", 58, 61], ["niclosamide", "CHEMICAL", 38, 49], ["niclosamide", "CHEMICAL", 38, 49], ["FITC", "CHEMICAL", 96, 100], ["niclosamide", "SIMPLE_CHEMICAL", 38, 49], ["DCs", "CELL", 58, 61], ["dextran-FITC", "SIMPLE_CHEMICAL", 76, 88], ["OVA-FITC", "SIMPLE_CHEMICAL", 92, 100], ["niclosamide-treated DCs", "CELL_LINE", 38, 61], ["dextran-FITC", "PROTEIN", 76, 88], ["OVA-FITC", "PROTEIN", 92, 100], ["niclosamide", "TREATMENT", 38, 49]]], ["As show in Fig. 3A and B, the percentage of dextran-FITC-and OVA-FITC positive cells did not significant differ between the niclosamide-treated DCs and DMSO-treated DCs at 37\u00b0C. Therefore, a lower percentage of LPS-stimulated DCs than DMSO-treated DCs were endocytic.", [["cells", "ANATOMY", 79, 84], ["DCs", "ANATOMY", 144, 147], ["DCs", "ANATOMY", 165, 168], ["DCs", "ANATOMY", 226, 229], ["DCs", "ANATOMY", 248, 251], ["niclosamide", "CHEMICAL", 124, 135], ["DMSO", "CHEMICAL", 152, 156], ["LPS", "CHEMICAL", 211, 214], ["DMSO", "CHEMICAL", 235, 239], ["FITC", "CHEMICAL", 52, 56], ["FITC", "CHEMICAL", 65, 69], ["niclosamide", "CHEMICAL", 124, 135], ["DMSO", "CHEMICAL", 152, 156], ["DMSO", "CHEMICAL", 235, 239], ["Fig. 3A", "CELL", 11, 18], ["B", "CELL", 23, 24], ["dextran-FITC", "SIMPLE_CHEMICAL", 44, 56], ["OVA-FITC", "SIMPLE_CHEMICAL", 61, 69], ["niclosamide", "SIMPLE_CHEMICAL", 124, 135], ["DCs", "CELL", 144, 147], ["DMSO", "SIMPLE_CHEMICAL", 152, 156], ["DCs", "CELL", 165, 168], ["LPS", "SIMPLE_CHEMICAL", 211, 214], ["DCs", "CELL", 226, 229], ["DMSO", "SIMPLE_CHEMICAL", 235, 239], ["DCs", "CELL", 248, 251], ["dextran-FITC", "PROTEIN", 44, 56], ["OVA-FITC positive cells", "CELL_LINE", 61, 84], ["niclosamide-treated DCs", "CELL_LINE", 124, 147], ["DMSO-treated DCs", "CELL_LINE", 152, 168], ["DCs", "CELL_TYPE", 226, 229], ["DCs", "CELL_TYPE", 248, 251], ["dextran-FITC", "TEST", 44, 56], ["OVA", "PROBLEM", 61, 64], ["FITC positive cells", "PROBLEM", 65, 84], ["the niclosamide", "TREATMENT", 120, 135], ["DMSO", "TREATMENT", 152, 156], ["a lower percentage of LPS", "TREATMENT", 189, 214], ["DMSO", "TREATMENT", 235, 239]]], ["Moreover, additional pretreatment with niclosamide also increased the endocytic capacity of LPS-stimulated DCs for dextran-FITC and OVA-FITC.", [["DCs", "ANATOMY", 107, 110], ["niclosamide", "CHEMICAL", 39, 50], ["LPS", "CHEMICAL", 92, 95], ["dextran-FITC", "CHEMICAL", 115, 127], ["niclosamide", "CHEMICAL", 39, 50], ["FITC", "CHEMICAL", 123, 127], ["FITC", "CHEMICAL", 136, 140], ["niclosamide", "SIMPLE_CHEMICAL", 39, 50], ["LPS", "SIMPLE_CHEMICAL", 92, 95], ["DCs", "CELL", 107, 110], ["dextran-FITC", "SIMPLE_CHEMICAL", 115, 127], ["OVA-FITC", "SIMPLE_CHEMICAL", 132, 140], ["DCs", "CELL_TYPE", 107, 110], ["dextran-FITC", "PROTEIN", 115, 127], ["OVA-FITC", "PROTEIN", 132, 140], ["niclosamide", "TREATMENT", 39, 50], ["dextran-FITC", "TREATMENT", 115, 127]]], ["These findings pertaining to the expression of surface molecules and endocytotic activity strongly suggest that niclosamide prevents the maturation of DCs.Niclosamide decreases the ability of LPS-stimulated DCs to stimulate OVA-specific T cell proliferationOne critical function of activated DCs is to induce T cell proliferation and differentiation.", [["surface", "ANATOMY", 47, 54], ["DCs", "ANATOMY", 151, 154], ["DCs", "ANATOMY", 207, 210], ["T cell", "ANATOMY", 237, 243], ["DCs", "ANATOMY", 292, 295], ["T cell", "ANATOMY", 309, 315], ["niclosamide", "CHEMICAL", 112, 123], ["Niclosamide", "CHEMICAL", 155, 166], ["LPS", "CHEMICAL", 192, 195], ["niclosamide", "CHEMICAL", 112, 123], ["Niclosamide", "CHEMICAL", 155, 166], ["niclosamide", "SIMPLE_CHEMICAL", 112, 123], ["DCs", "CELL", 151, 154], ["Niclosamide", "SIMPLE_CHEMICAL", 155, 166], ["LPS", "SIMPLE_CHEMICAL", 192, 195], ["DCs", "CELL", 207, 210], ["OVA", "SIMPLE_CHEMICAL", 224, 227], ["T cell", "CELL", 237, 243], ["DCs", "CELL", 292, 295], ["T cell", "CELL", 309, 315], ["surface molecules", "PROTEIN", 47, 64], ["DCs", "CELL_TYPE", 151, 154], ["DCs", "CELL_TYPE", 207, 210], ["activated DCs", "CELL_TYPE", 282, 295], ["surface molecules", "PROBLEM", 47, 64], ["niclosamide", "TREATMENT", 112, 123], ["Niclosamide", "TREATMENT", 155, 166], ["LPS", "TREATMENT", 192, 195], ["OVA", "PROBLEM", 224, 227], ["activated DCs", "TREATMENT", 282, 295], ["T cell proliferation", "PROBLEM", 309, 329], ["endocytotic activity", "OBSERVATION", 69, 89], ["cell proliferation", "OBSERVATION", 239, 257], ["cell proliferation", "OBSERVATION", 311, 329]]], ["Thus, we next studied the effects of niclosamide on the ability of DCs to induce OVA-specific T cell responses.", [["DCs", "ANATOMY", 67, 70], ["T cell", "ANATOMY", 94, 100], ["niclosamide", "CHEMICAL", 37, 48], ["niclosamide", "CHEMICAL", 37, 48], ["niclosamide", "SIMPLE_CHEMICAL", 37, 48], ["DCs", "CELL", 67, 70], ["OVA", "SIMPLE_CHEMICAL", 81, 84], ["T cell", "CELL", 94, 100], ["DCs", "CELL_TYPE", 67, 70], ["niclosamide", "TREATMENT", 37, 48], ["OVA", "PROBLEM", 81, 84]]], ["OVA 257-264 (OVAP 1 ) or OVA 323-339 (OVAP 2 ) peptideloaded immature mouse DCs were pretreated in the presence or absence of niclosamide, stimulated with LPS, and tested for their capacity to stimulate allogeneic OVA-specific CD8 + OT-I and CD4 + OT-II T cells.", [["DCs", "ANATOMY", 76, 79], ["CD8 + OT-I", "ANATOMY", 227, 237], ["CD4 + OT-II T cells", "ANATOMY", 242, 261], ["OVA 257-264", "CHEMICAL", 0, 11], ["OVA 323-339", "CHEMICAL", 25, 36], ["niclosamide", "CHEMICAL", 126, 137], ["LPS", "CHEMICAL", 155, 158], ["niclosamide", "CHEMICAL", 126, 137], ["OVA 323-339", "SIMPLE_CHEMICAL", 25, 36], ["mouse", "ORGANISM", 70, 75], ["DCs", "CELL", 76, 79], ["niclosamide", "SIMPLE_CHEMICAL", 126, 137], ["LPS", "SIMPLE_CHEMICAL", 155, 158], ["OVA", "SIMPLE_CHEMICAL", 214, 217], ["CD8", "GENE_OR_GENE_PRODUCT", 227, 230], ["OT-I", "GENE_OR_GENE_PRODUCT", 233, 237], ["CD4", "GENE_OR_GENE_PRODUCT", 242, 245], ["peptideloaded immature mouse DCs", "CELL_LINE", 47, 79], ["CD8 + OT-I and CD4 + OT-II T cells", "CELL_TYPE", 227, 261], ["mouse", "SPECIES", 70, 75], ["mouse", "SPECIES", 70, 75], ["OVA", "TEST", 0, 3], ["OVA", "PROBLEM", 25, 28], ["peptideloaded immature mouse DCs", "TREATMENT", 47, 79], ["niclosamide", "TREATMENT", 126, 137], ["LPS", "TREATMENT", 155, 158], ["their capacity", "TEST", 175, 189], ["allogeneic OVA", "TEST", 203, 217], ["specific CD8", "TEST", 218, 230], ["OT", "TEST", 233, 235], ["CD4", "TEST", 242, 245]]], ["T cell proliferation was measured by [ 3 H] thymidine incorporation.", [["T cell", "ANATOMY", 0, 6], ["thymidine", "CHEMICAL", 44, 53], ["[ 3 H] thymidine", "CHEMICAL", 37, 53], ["T cell", "CELL", 0, 6], ["[ 3 H] thymidine", "SIMPLE_CHEMICAL", 37, 53], ["T cell proliferation", "PROBLEM", 0, 20], ["thymidine incorporation", "TREATMENT", 44, 67], ["cell proliferation", "OBSERVATION", 2, 20]]], ["As shown in Fig. 4A , LPS-activated DCs promoted T cell proliferation, and this effect was abrogated by niclosamide.", [["DCs", "ANATOMY", 36, 39], ["T cell", "ANATOMY", 49, 55], ["LPS", "CHEMICAL", 22, 25], ["niclosamide", "CHEMICAL", 104, 115], ["niclosamide", "CHEMICAL", 104, 115], ["LPS", "SIMPLE_CHEMICAL", 22, 25], ["DCs", "CELL", 36, 39], ["T cell", "CELL", 49, 55], ["niclosamide", "SIMPLE_CHEMICAL", 104, 115], ["activated DCs", "CELL_TYPE", 26, 39], ["LPS", "TEST", 22, 25], ["T cell proliferation", "TREATMENT", 49, 69], ["niclosamide", "TREATMENT", 104, 115], ["cell proliferation", "OBSERVATION", 51, 69]]], ["This suggests that niclosamide decreases the ability of LPS-treated DCs to stimulate CD4 + T cells.", [["DCs", "ANATOMY", 68, 71], ["CD4 + T cells", "ANATOMY", 85, 98], ["niclosamide", "CHEMICAL", 19, 30], ["LPS", "CHEMICAL", 56, 59], ["niclosamide", "CHEMICAL", 19, 30], ["niclosamide", "SIMPLE_CHEMICAL", 19, 30], ["LPS", "SIMPLE_CHEMICAL", 56, 59], ["DCs", "CELL", 68, 71], ["CD4", "GENE_OR_GENE_PRODUCT", 85, 88], ["DCs", "CELL_TYPE", 68, 71], ["CD4", "PROTEIN", 85, 88], ["T cells", "CELL_TYPE", 91, 98], ["niclosamide", "TREATMENT", 19, 30], ["LPS", "TEST", 56, 59], ["DCs", "TREATMENT", 68, 71], ["niclosamide decreases", "OBSERVATION", 19, 40]]], ["We also evaluated the effects of CD4 + T cell coculture with niclosamide-treated DCs on IFN-gamma (Th1 cytokine) synthesis.", [["CD4 + T cell", "ANATOMY", 33, 45], ["DCs", "ANATOMY", 81, 84], ["niclosamide", "CHEMICAL", 61, 72], ["niclosamide", "CHEMICAL", 61, 72], ["CD4", "GENE_OR_GENE_PRODUCT", 33, 36], ["niclosamide", "SIMPLE_CHEMICAL", 61, 72], ["DCs", "CELL", 81, 84], ["IFN-gamma", "GENE_OR_GENE_PRODUCT", 88, 97], ["Th1 cytokine", "GENE_OR_GENE_PRODUCT", 99, 111], ["CD4", "PROTEIN", 33, 36], ["niclosamide-treated DCs", "CELL_LINE", 61, 84], ["IFN-gamma", "PROTEIN", 88, 97], ["Th1 cytokine", "PROTEIN", 99, 111], ["CD4", "TEST", 33, 36], ["T cell coculture", "TREATMENT", 39, 55], ["niclosamide", "TREATMENT", 61, 72], ["IFN", "TREATMENT", 88, 91], ["gamma (Th1 cytokine) synthesis", "TREATMENT", 92, 122], ["gamma", "ANATOMY", 92, 97]]], ["As shown in Fig. 4B and C, a cytokine analysis by ELISA and intracellular cytokine staining revealed that CD4 + T and CD8 + T cells cocultured with niclosamide-treated DCs produced significantly lower amounts of IFN-c in the medium (Fig. 4B ) and percentage of IFN-gamma producing CD4 + and CD8 + T cells (Fig. 4C ) than the DMSO-treated DCs did in the presence of LPS.", [["intracellular", "ANATOMY", 60, 73], ["CD4 + T", "ANATOMY", 106, 113], ["CD8 + T cells", "ANATOMY", 118, 131], ["DCs", "ANATOMY", 168, 171], ["CD4 + and CD8 + T cells", "ANATOMY", 281, 304], ["DCs", "ANATOMY", 338, 341], ["niclosamide", "CHEMICAL", 148, 159], ["DMSO", "CHEMICAL", 325, 329], ["LPS", "CHEMICAL", 365, 368], ["niclosamide", "CHEMICAL", 148, 159], ["DMSO", "CHEMICAL", 325, 329], ["C", "CELL", 24, 25], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 60, 73], ["CD4", "GENE_OR_GENE_PRODUCT", 106, 109], ["CD8", "GENE_OR_GENE_PRODUCT", 118, 121], ["niclosamide", "SIMPLE_CHEMICAL", 148, 159], ["DCs", "CELL", 168, 171], ["IFN-c", "GENE_OR_GENE_PRODUCT", 212, 217], ["IFN-gamma", "GENE_OR_GENE_PRODUCT", 261, 270], ["CD4", "GENE_OR_GENE_PRODUCT", 281, 284], ["CD8", "GENE_OR_GENE_PRODUCT", 291, 294], ["DMSO", "SIMPLE_CHEMICAL", 325, 329], ["DCs", "CELL", 338, 341], ["LPS", "SIMPLE_CHEMICAL", 365, 368], ["cytokine", "PROTEIN", 29, 37], ["CD4", "PROTEIN", 106, 109], ["T and CD8 + T cells", "CELL_TYPE", 112, 131], ["niclosamide-treated DCs", "CELL_LINE", 148, 171], ["IFN-c", "PROTEIN", 212, 217], ["IFN-gamma producing CD4 + and CD8 + T cells", "CELL_TYPE", 261, 304], ["DCs", "CELL_TYPE", 338, 341], ["a cytokine analysis", "TEST", 27, 46], ["ELISA", "TEST", 50, 55], ["intracellular cytokine staining", "TEST", 60, 91], ["CD4", "TEST", 106, 109], ["T", "TEST", 112, 113], ["CD8", "TEST", 118, 121], ["T cells", "PROBLEM", 124, 131], ["niclosamide", "TREATMENT", 148, 159], ["IFN", "TEST", 212, 215], ["IFN", "TEST", 261, 264], ["gamma", "TEST", 265, 270], ["CD4", "TEST", 281, 284], ["CD8 + T cells", "PROBLEM", 291, 304], ["the DMSO", "TREATMENT", 321, 329], ["LPS", "PROBLEM", 365, 368]]], ["Next, we extended the in vitro results obtained for the proliferation of T cells to in vivo model.", [["T cells", "ANATOMY", 73, 80], ["T cells", "CELL", 73, 80], ["T cells", "CELL_TYPE", 73, 80], ["the proliferation of T cells", "TREATMENT", 52, 80]]], ["For this, CFSE-labeled spleen cells either from OT-I or OT-II mice were i.v injected into syngeneic C57BL/6 mice.", [["spleen cells", "ANATOMY", 23, 35], ["CFSE", "CHEMICAL", 10, 14], ["CFSE", "CHEMICAL", 10, 14], ["CFSE", "SIMPLE_CHEMICAL", 10, 14], ["spleen cells", "CELL", 23, 35], ["OT-I", "GENE_OR_GENE_PRODUCT", 48, 52], ["OT-II mice", "ORGANISM", 56, 66], ["syngeneic C57BL/6 mice", "ORGANISM", 90, 112], ["CFSE-labeled spleen cells", "CELL_LINE", 10, 35], ["mice", "SPECIES", 62, 66], ["mice", "SPECIES", 108, 112], ["mice", "SPECIES", 62, 66], ["mice", "SPECIES", 108, 112], ["OT", "TEST", 48, 50], ["OT-II mice", "TREATMENT", 56, 66], ["spleen", "ANATOMY", 23, 29]]], ["24 h later, OVA 257-264 (OVAP 1 ) or OVA 323-339 (OVAP 2 ) peptide-loaded immature mouse DCs were pretreated in the presence or absence of niclosamide, stimulated with LPS and administrated by the same route.", [["DCs", "ANATOMY", 89, 92], ["OVA 257-264", "CHEMICAL", 12, 23], ["OVA 323-339", "CHEMICAL", 37, 48], ["OVAP 2 ) peptide", "CHEMICAL", 50, 66], ["niclosamide", "CHEMICAL", 139, 150], ["LPS", "CHEMICAL", 168, 171], ["niclosamide", "CHEMICAL", 139, 150], ["OVA 257-264", "SIMPLE_CHEMICAL", 12, 23], ["OVA 323-339", "SIMPLE_CHEMICAL", 37, 48], ["OVAP 2 ) peptide", "SIMPLE_CHEMICAL", 50, 66], ["mouse", "ORGANISM", 83, 88], ["DCs", "CELL", 89, 92], ["niclosamide", "SIMPLE_CHEMICAL", 139, 150], ["LPS", "SIMPLE_CHEMICAL", 168, 171], ["immature mouse DCs", "CELL_TYPE", 74, 92], ["mouse", "SPECIES", 83, 88], ["mouse", "SPECIES", 83, 88], ["OVA", "TEST", 12, 15], ["OVAP", "TEST", 25, 29], ["OVA", "PROBLEM", 37, 40], ["peptide", "TREATMENT", 59, 66], ["immature mouse DCs", "TREATMENT", 74, 92], ["niclosamide", "TREATMENT", 139, 150], ["LPS", "TREATMENT", 168, 171]]], ["Three days after DCs injection, proliferation of CD4 + and CD8 + T cells was evaluated in spleens of recipient mice by dilution of the CFSE signal.", [["DCs", "ANATOMY", 17, 20], ["CD4 + and CD8 + T cells", "ANATOMY", 49, 72], ["spleens", "ANATOMY", 90, 97], ["CFSE", "CHEMICAL", 135, 139], ["DCs", "CELL", 17, 20], ["CD4", "GENE_OR_GENE_PRODUCT", 49, 52], ["CD8", "GENE_OR_GENE_PRODUCT", 59, 62], ["spleens", "ORGAN", 90, 97], ["mice", "ORGANISM", 111, 115], ["CFSE", "SIMPLE_CHEMICAL", 135, 139], ["DCs", "CELL_TYPE", 17, 20], ["CD4", "PROTEIN", 49, 52], ["CD8 + T cells", "CELL_TYPE", 59, 72], ["mice", "SPECIES", 111, 115], ["mice", "SPECIES", 111, 115], ["DCs injection", "TREATMENT", 17, 30], ["CD4", "TEST", 49, 52], ["CD8 + T cells", "PROBLEM", 59, 72], ["the CFSE signal", "TEST", 131, 146], ["spleens", "ANATOMY", 90, 97], ["CFSE signal", "OBSERVATION", 135, 146]]], ["As shown in Fig. 4D , proliferation of CD8 + or CD4 + was observed in mice injected with LPS-matured DCs, however this effect was attenuated by niclosamide.", [["CD8 +", "ANATOMY", 39, 44], ["DCs", "ANATOMY", 101, 104], ["LPS", "CHEMICAL", 89, 92], ["niclosamide", "CHEMICAL", 144, 155], ["niclosamide", "CHEMICAL", 144, 155], ["CD8", "GENE_OR_GENE_PRODUCT", 39, 42], ["CD4", "GENE_OR_GENE_PRODUCT", 48, 51], ["mice", "ORGANISM", 70, 74], ["LPS", "SIMPLE_CHEMICAL", 89, 92], ["DCs", "CELL", 101, 104], ["niclosamide", "SIMPLE_CHEMICAL", 144, 155], ["CD8", "PROTEIN", 39, 42], ["CD4", "PROTEIN", 48, 51], ["DCs", "CELL_TYPE", 101, 104], ["mice", "SPECIES", 70, 74], ["mice", "SPECIES", 70, 74], ["CD8", "TEST", 39, 42], ["CD4", "PROBLEM", 48, 51], ["LPS", "TREATMENT", 89, 92], ["niclosamide", "TREATMENT", 144, 155]]], ["Overall, these data suggest that niclosamide impedes the ability of DCs to prime a T cells-biased immune response.Niclosamide attenuated the MAPK and NF-jB pathways in LPSstimulated DCsAs shown previously, the activation of MAPKs and NF-jB plays a pivotal role in the production of cytokines by DCs in response to inflammatory stimuli, including LPS, TNF-alpha, and interleukin-1 (IL-l) [27, 28] .", [["DCs", "ANATOMY", 68, 71], ["T cells", "ANATOMY", 83, 90], ["DCs", "ANATOMY", 295, 298], ["niclosamide", "CHEMICAL", 33, 44], ["Niclosamide", "CHEMICAL", 114, 125], ["niclosamide", "CHEMICAL", 33, 44], ["Niclosamide", "CHEMICAL", 114, 125], ["niclosamide", "SIMPLE_CHEMICAL", 33, 44], ["DCs", "CELL", 68, 71], ["T cells", "CELL", 83, 90], ["Niclosamide", "SIMPLE_CHEMICAL", 114, 125], ["MAPK", "GENE_OR_GENE_PRODUCT", 141, 145], ["NF-jB", "GENE_OR_GENE_PRODUCT", 150, 155], ["MAPKs", "GENE_OR_GENE_PRODUCT", 224, 229], ["NF-jB", "GENE_OR_GENE_PRODUCT", 234, 239], ["DCs", "CELL", 295, 298], ["LPS", "SIMPLE_CHEMICAL", 346, 349], ["TNF-alpha", "GENE_OR_GENE_PRODUCT", 351, 360], ["interleukin-1", "GENE_OR_GENE_PRODUCT", 366, 379], ["IL-l", "GENE_OR_GENE_PRODUCT", 381, 385], ["DCs", "CELL_TYPE", 68, 71], ["T cells", "CELL_TYPE", 83, 90], ["MAPK", "PROTEIN", 141, 145], ["jB", "PROTEIN", 153, 155], ["LPSstimulated DCsAs", "CELL_LINE", 168, 187], ["MAPKs", "PROTEIN", 224, 229], ["NF-jB", "PROTEIN", 234, 239], ["cytokines", "PROTEIN", 282, 291], ["DCs", "CELL_TYPE", 295, 298], ["TNF", "PROTEIN", 351, 354], ["interleukin-1", "PROTEIN", 366, 379], ["niclosamide", "TREATMENT", 33, 44], ["a T cells", "TREATMENT", 81, 90], ["Niclosamide", "TREATMENT", 114, 125], ["cytokines", "TREATMENT", 282, 291], ["inflammatory stimuli", "TEST", 314, 334], ["LPS", "TEST", 346, 349], ["TNF", "TEST", 351, 354], ["alpha", "TEST", 355, 360], ["interleukin-1", "TEST", 366, 379], ["IL", "TEST", 381, 383], ["inflammatory stimuli", "OBSERVATION", 314, 334], ["alpha", "ANATOMY", 355, 360]]], ["To gain insight into the mechanism of this inhibitory action of niclosamide, we investigated whether the activation of MAPKs and NF-jB were altered by niclosamide in LPS-stimulated mouse DCs.", [["DCs", "ANATOMY", 187, 190], ["niclosamide", "CHEMICAL", 64, 75], ["niclosamide", "CHEMICAL", 151, 162], ["LPS", "CHEMICAL", 166, 169], ["niclosamide", "CHEMICAL", 64, 75], ["niclosamide", "CHEMICAL", 151, 162], ["niclosamide", "SIMPLE_CHEMICAL", 64, 75], ["MAPKs", "GENE_OR_GENE_PRODUCT", 119, 124], ["NF-jB", "GENE_OR_GENE_PRODUCT", 129, 134], ["niclosamide", "SIMPLE_CHEMICAL", 151, 162], ["LPS", "SIMPLE_CHEMICAL", 166, 169], ["mouse", "ORGANISM", 181, 186], ["DCs", "CELL", 187, 190], ["MAPKs", "PROTEIN", 119, 124], ["NF-jB", "PROTEIN", 129, 134], ["LPS-stimulated mouse DCs", "CELL_LINE", 166, 190], ["mouse", "SPECIES", 181, 186], ["mouse", "SPECIES", 181, 186], ["niclosamide", "TREATMENT", 64, 75], ["niclosamide in LPS", "TREATMENT", 151, 169], ["stimulated mouse DCs", "TREATMENT", 170, 190]]], ["Our results showed that pretreatment with niclosamide attenuated LPS-induced ERK and JNK-MAPK phosphorylation but did not affect p38 phosphorylation (Fig. 5A) .", [["niclosamide", "CHEMICAL", 42, 53], ["LPS", "CHEMICAL", 65, 68], ["niclosamide", "CHEMICAL", 42, 53], ["niclosamide", "SIMPLE_CHEMICAL", 42, 53], ["LPS", "SIMPLE_CHEMICAL", 65, 68], ["ERK", "GENE_OR_GENE_PRODUCT", 77, 80], ["JNK-MAPK", "GENE_OR_GENE_PRODUCT", 85, 93], ["p38", "GENE_OR_GENE_PRODUCT", 129, 132], ["ERK", "PROTEIN", 77, 80], ["JNK", "PROTEIN", 85, 88], ["MAPK", "PROTEIN", 89, 93], ["p38", "PROTEIN", 129, 132], ["niclosamide attenuated LPS", "TREATMENT", 42, 68], ["ERK", "TEST", 77, 80], ["JNK", "TEST", 85, 88], ["MAPK phosphorylation", "TEST", 89, 109]]], ["To further determine whether niclosamide decreases the LPS-induced activation of the NF-jB pathway, nuclear extracts were prepared, and NF-jB binding activity was assessed using the TransAM NF-jB transcription factor assay kit.", [["nuclear extracts", "ANATOMY", 100, 116], ["niclosamide", "CHEMICAL", 29, 40], ["LPS", "CHEMICAL", 55, 58], ["niclosamide", "CHEMICAL", 29, 40], ["niclosamide", "SIMPLE_CHEMICAL", 29, 40], ["LPS", "SIMPLE_CHEMICAL", 55, 58], ["NF-jB", "GENE_OR_GENE_PRODUCT", 85, 90], ["nuclear extracts", "ORGANISM_SUBSTANCE", 100, 116], ["NF-jB", "GENE_OR_GENE_PRODUCT", 136, 141], ["NF-jB", "GENE_OR_GENE_PRODUCT", 190, 195], ["NF", "PROTEIN", 85, 87], ["jB", "PROTEIN", 88, 90], ["jB", "PROTEIN", 139, 141], ["TransAM NF-jB transcription factor", "PROTEIN", 182, 216], ["niclosamide", "TREATMENT", 29, 40], ["the LPS", "TEST", 51, 58]]], ["As shown in Fig. 5B , LPS induced a significant level of p65 nuclear translocation and upregulated NF-jB binding activity by 30 min after stimulation.", [["nuclear", "ANATOMY", 61, 68], ["LPS", "CHEMICAL", 22, 25], ["5B", "GENE_OR_GENE_PRODUCT", 17, 19], ["LPS", "SIMPLE_CHEMICAL", 22, 25], ["p65", "GENE_OR_GENE_PRODUCT", 57, 60], ["NF-jB", "GENE_OR_GENE_PRODUCT", 99, 104], ["p65", "PROTEIN", 57, 60], ["NF", "PROTEIN", 99, 101], ["jB", "PROTEIN", 102, 104], ["significant", "OBSERVATION_MODIFIER", 36, 47]]], ["However, the NF-jB binding activity was dramatically reduced in niclosamide-treated BMDCs.", [["BMDCs", "ANATOMY", 84, 89], ["niclosamide", "CHEMICAL", 64, 75], ["niclosamide", "CHEMICAL", 64, 75], ["NF-jB", "GENE_OR_GENE_PRODUCT", 13, 18], ["niclosamide", "SIMPLE_CHEMICAL", 64, 75], ["BMDCs", "CELL", 84, 89], ["NF", "PROTEIN", 13, 15], ["jB", "PROTEIN", 16, 18], ["niclosamide-treated BMDCs", "CELL_LINE", 64, 89], ["niclosamide", "TREATMENT", 64, 75]]], ["Therefore, these results may partially explain the inhibitory effect of niclosamide on the maturation of LPS-induced DCs.Niclosamide weakened the 2,4-dinitro-1-fluorobenzene-induced contact hypersensitivity (CHS) response in vivoContact hypersensitivity (CHS) is a typical DC mediated T cell-dependent, Ag-specific inflammatory response that is induced when the skin is exposed to haptens, such as DNFB [29] .", [["DCs", "ANATOMY", 117, 120], ["DC", "ANATOMY", 273, 275], ["T cell", "ANATOMY", 285, 291], ["skin", "ANATOMY", 362, 366], ["niclosamide", "CHEMICAL", 72, 83], ["LPS", "CHEMICAL", 105, 108], ["Niclosamide", "CHEMICAL", 121, 132], ["2,4-dinitro-1-fluorobenzene", "CHEMICAL", 146, 173], ["contact hypersensitivity", "DISEASE", 182, 206], ["CHS", "DISEASE", 208, 211], ["vivoContact hypersensitivity", "DISEASE", 225, 253], ["CHS", "DISEASE", 255, 258], ["Ag", "CHEMICAL", 303, 305], ["DNFB", "CHEMICAL", 398, 402], ["niclosamide", "CHEMICAL", 72, 83], ["Niclosamide", "CHEMICAL", 121, 132], ["2,4-dinitro-1-fluorobenzene", "CHEMICAL", 146, 173], ["Ag", "CHEMICAL", 303, 305], ["DNFB", "CHEMICAL", 398, 402], ["niclosamide", "SIMPLE_CHEMICAL", 72, 83], ["LPS", "SIMPLE_CHEMICAL", 105, 108], ["DCs", "CELL", 117, 120], ["Niclosamide", "SIMPLE_CHEMICAL", 121, 132], ["2,4-dinitro-1-fluorobenzene", "SIMPLE_CHEMICAL", 146, 173], ["DC", "CELL", 273, 275], ["T cell", "CELL", 285, 291], ["Ag", "GENE_OR_GENE_PRODUCT", 303, 305], ["skin", "ORGAN", 362, 366], ["DCs", "CELL_TYPE", 117, 120], ["DC", "CELL_TYPE", 273, 275], ["Ag", "PROTEIN", 303, 305], ["niclosamide", "TREATMENT", 72, 83], ["the maturation of LPS", "TREATMENT", 87, 108], ["Niclosamide", "TREATMENT", 121, 132], ["dinitro", "TEST", 150, 157], ["fluorobenzene", "TREATMENT", 160, 173], ["contact hypersensitivity", "PROBLEM", 182, 206], ["vivoContact hypersensitivity", "PROBLEM", 225, 253], ["specific inflammatory response", "PROBLEM", 306, 336], ["inflammatory response", "OBSERVATION", 315, 336], ["skin", "ANATOMY", 362, 366]]], ["This model was used to investigate the in vivo effect of niclosamide on the DC-mediated immune response.", [["DC", "ANATOMY", 76, 78], ["niclosamide", "CHEMICAL", 57, 68], ["niclosamide", "CHEMICAL", 57, 68], ["niclosamide", "SIMPLE_CHEMICAL", 57, 68], ["DC", "CELL", 76, 78], ["DC", "CELL_TYPE", 76, 78], ["niclosamide", "TREATMENT", 57, 68], ["the DC", "TREATMENT", 72, 78]]], ["Our results showed that i.v injection of niclosamide (2 mg/kg) elicited less ear swelling than injection with vehicle control group (Fig. 6) , suggests that niclosamide could potentially be used to prevent delayed-type hypersensitive diseases, such as allergic contact dermatitis.DiscussionsNiclosamide is a Food and Drug Administration-approved antihelminthic agent of choice for the treatment of most tapeworm infections.", [["ear", "ANATOMY", 77, 80], ["niclosamide", "CHEMICAL", 41, 52], ["ear swelling", "DISEASE", 77, 89], ["niclosamide", "CHEMICAL", 157, 168], ["delayed-type hypersensitive diseases", "DISEASE", 206, 242], ["allergic contact dermatitis", "DISEASE", 252, 279], ["Niclosamide", "CHEMICAL", 291, 302], ["tapeworm infections", "DISEASE", 403, 422], ["niclosamide", "CHEMICAL", 41, 52], ["niclosamide", "CHEMICAL", 157, 168], ["Niclosamide", "CHEMICAL", 291, 302], ["niclosamide", "SIMPLE_CHEMICAL", 41, 52], ["ear", "ORGAN", 77, 80], ["niclosamide", "SIMPLE_CHEMICAL", 157, 168], ["Niclosamide", "SIMPLE_CHEMICAL", 291, 302], ["niclosamide", "TREATMENT", 41, 52], ["less ear swelling", "PROBLEM", 72, 89], ["niclosamide", "TREATMENT", 157, 168], ["delayed-type hypersensitive diseases", "PROBLEM", 206, 242], ["allergic contact dermatitis", "PROBLEM", 252, 279], ["Niclosamide", "TREATMENT", 291, 302], ["Drug Administration", "TREATMENT", 317, 336], ["antihelminthic agent", "TREATMENT", 346, 366], ["the treatment", "TREATMENT", 381, 394], ["most tapeworm infections", "PROBLEM", 398, 422], ["ear", "ANATOMY", 77, 80], ["swelling", "OBSERVATION", 81, 89], ["hypersensitive diseases", "OBSERVATION", 219, 242], ["allergic contact dermatitis", "OBSERVATION", 252, 279], ["tapeworm infections", "OBSERVATION", 403, 422]]], ["It was recently shown to have large spectrum of biological effects, including activity against the SARS virus and anti-toxin and anti-tumor activities in various systems [30, 31, [17] [18] [19] [20] [21] [22] [23] .", [["SARS", "DISEASE", 99, 103], ["SARS virus", "ORGANISM", 99, 109], ["anti-toxin", "SIMPLE_CHEMICAL", 114, 124], ["anti-tumor", "CANCER", 129, 139], ["[17] [18] [19] [20] [21] [22] [23]", "SIMPLE_CHEMICAL", 179, 213], ["SARS virus", "SPECIES", 99, 109], ["large spectrum of biological effects", "PROBLEM", 30, 66], ["the SARS virus", "PROBLEM", 95, 109], ["anti-toxin", "TREATMENT", 114, 124], ["anti-tumor activities in various systems", "TEST", 129, 169], ["large", "OBSERVATION_MODIFIER", 30, 35], ["biological effects", "OBSERVATION", 48, 66]]], ["Our present data show that niclosamide attenuates the LPS-induced pro-inflammatory cytokines and chemokines production, surface costimulatory and MHC molecules expression, the reduction in antigen uptake by DCs, and inhibits DC-triggered allogeneic T cell proliferation.", [["surface", "ANATOMY", 120, 127], ["DCs", "ANATOMY", 207, 210], ["DC", "ANATOMY", 225, 227], ["T cell", "ANATOMY", 249, 255], ["niclosamide", "CHEMICAL", 27, 38], ["LPS", "CHEMICAL", 54, 57], ["niclosamide", "CHEMICAL", 27, 38], ["niclosamide", "SIMPLE_CHEMICAL", 27, 38], ["LPS", "SIMPLE_CHEMICAL", 54, 57], ["antigen", "GENE_OR_GENE_PRODUCT", 189, 196], ["DCs", "CELL", 207, 210], ["DC", "CELL", 225, 227], ["T cell", "CELL", 249, 255], ["pro-inflammatory cytokines", "PROTEIN", 66, 92], ["chemokines", "PROTEIN", 97, 107], ["MHC molecules", "PROTEIN", 146, 159], ["DCs", "CELL_TYPE", 207, 210], ["DC", "CELL_TYPE", 225, 227], ["niclosamide", "TREATMENT", 27, 38], ["the LPS", "TREATMENT", 50, 57], ["pro-inflammatory cytokines", "PROBLEM", 66, 92], ["chemokines production", "PROBLEM", 97, 118], ["surface costimulatory", "TREATMENT", 120, 141], ["allogeneic T cell proliferation", "TREATMENT", 238, 269], ["pro-inflammatory cytokines", "OBSERVATION", 66, 92], ["reduction", "OBSERVATION_MODIFIER", 176, 185], ["allogeneic T cell proliferation", "OBSERVATION", 238, 269]]], ["To the best of our knowledge, this is the first study to report that niclosamide can modulate the phenotype and functional properties of DCs.DiscussionsBoth IL-6 and TNF-alpha are important mediators of a wide range of biologic activities and play numerous beneficial roles in the modulation of pro-inflammatory immune responses [32] .", [["DCs", "ANATOMY", 137, 140], ["niclosamide", "CHEMICAL", 69, 80], ["niclosamide", "CHEMICAL", 69, 80], ["niclosamide", "SIMPLE_CHEMICAL", 69, 80], ["DCs", "CELL", 137, 140], ["IL-6", "GENE_OR_GENE_PRODUCT", 157, 161], ["TNF-alpha", "GENE_OR_GENE_PRODUCT", 166, 175], ["DCs", "CELL_TYPE", 137, 140], ["IL-6", "PROTEIN", 157, 161], ["TNF-alpha", "PROTEIN", 166, 175], ["niclosamide", "TREATMENT", 69, 80], ["a wide range of biologic activities", "TREATMENT", 203, 238]]], ["However, the dysregulation of the production of these two cytokines by DCs has been implicated in the pathogenesis of a variety of acute and chronic inflammatory diseases, as well as autoimmune diseases such as rheumatoid arthritis, ankylosing spondylitis, psoriasis and refractory asthma [33] [34] [35] .", [["DCs", "ANATOMY", 71, 74], ["autoimmune diseases", "DISEASE", 183, 202], ["rheumatoid arthritis", "DISEASE", 211, 231], ["ankylosing spondylitis", "DISEASE", 233, 255], ["psoriasis", "DISEASE", 257, 266], ["asthma", "DISEASE", 282, 288], ["DCs", "CELL", 71, 74], ["cytokines", "PROTEIN", 58, 67], ["DCs", "CELL_TYPE", 71, 74], ["acute and chronic inflammatory diseases", "PROBLEM", 131, 170], ["autoimmune diseases", "PROBLEM", 183, 202], ["rheumatoid arthritis", "PROBLEM", 211, 231], ["ankylosing spondylitis", "PROBLEM", 233, 255], ["psoriasis", "PROBLEM", 257, 266], ["refractory asthma", "PROBLEM", 271, 288], ["variety", "OBSERVATION_MODIFIER", 120, 127], ["acute", "OBSERVATION_MODIFIER", 131, 136], ["chronic", "OBSERVATION_MODIFIER", 141, 148], ["inflammatory", "OBSERVATION", 149, 161], ["rheumatoid arthritis", "OBSERVATION", 211, 231], ["ankylosing spondylitis", "OBSERVATION", 233, 255]]], ["Therefore, small molecule inhibitors or monoclonal antibodies targeting these cytokines have been used in the clinical treatment of immunerelated diseases.", [["monoclonal antibodies", "PROTEIN", 40, 61], ["cytokines", "PROTEIN", 78, 87], ["small molecule inhibitors", "TREATMENT", 11, 36], ["monoclonal antibodies", "TREATMENT", 40, 61], ["these cytokines", "TREATMENT", 72, 87], ["immunerelated diseases", "PROBLEM", 132, 154], ["small", "OBSERVATION_MODIFIER", 11, 16], ["molecule inhibitors", "OBSERVATION", 17, 36]]], ["For example, multiple monoclonal antibodies against TNF, including infliximab, adalimumab and certolizumab pegol, have been used therapeutically, and the circulating receptor fusion protein etanercept (Enbrel) also targets TNF [36] .", [["infliximab", "CHEMICAL", 67, 77], ["adalimumab", "CHEMICAL", 79, 89], ["certolizumab pegol", "CHEMICAL", 94, 112], ["etanercept", "CHEMICAL", 190, 200], ["Enbrel", "CHEMICAL", 202, 208], ["TNF", "GENE_OR_GENE_PRODUCT", 52, 55], ["infliximab", "SIMPLE_CHEMICAL", 67, 77], ["adalimumab", "SIMPLE_CHEMICAL", 79, 89], ["certolizumab pegol", "SIMPLE_CHEMICAL", 94, 112], ["etanercept", "SIMPLE_CHEMICAL", 190, 200], ["Enbrel", "SIMPLE_CHEMICAL", 202, 208], ["TNF", "GENE_OR_GENE_PRODUCT", 223, 226], ["multiple monoclonal antibodies", "PROTEIN", 13, 43], ["TNF", "PROTEIN", 52, 55], ["circulating receptor fusion protein", "PROTEIN", 154, 189], ["TNF", "PROTEIN", 223, 226], ["multiple monoclonal antibodies", "TEST", 13, 43], ["TNF", "TREATMENT", 52, 55], ["infliximab", "TREATMENT", 67, 77], ["adalimumab", "TREATMENT", 79, 89], ["certolizumab pegol", "TREATMENT", 94, 112], ["the circulating receptor fusion protein etanercept", "TREATMENT", 150, 200], ["TNF", "TEST", 223, 226], ["multiple", "OBSERVATION_MODIFIER", 13, 21], ["monoclonal", "OBSERVATION_MODIFIER", 22, 32]]], ["Other drugs, such as Tocilizumab, a humanized anti-IL-6R monoclonal antibody, target IL-6 [37] .", [["Tocilizumab", "CHEMICAL", 21, 32], ["Tocilizumab", "CHEMICAL", 21, 32], ["Tocilizumab", "SIMPLE_CHEMICAL", 21, 32], ["anti-IL-6R", "GENE_OR_GENE_PRODUCT", 46, 56], ["IL-6", "GENE_OR_GENE_PRODUCT", 85, 89], ["humanized anti-IL-6R monoclonal antibody", "PROTEIN", 36, 76], ["IL", "PROTEIN", 85, 87], ["Other drugs", "TREATMENT", 0, 11], ["Tocilizumab", "TREATMENT", 21, 32], ["a humanized anti-IL", "TREATMENT", 34, 53], ["6R monoclonal antibody", "TREATMENT", 54, 76]]], ["Because our results indicate that niclosamide strongly inhibits the functions of the inflammatory cytokines TNF-alpha and IL-6 without toxicity, niclosamide should be further evaluated as a clinical immunosuppressive therapy or adjuvant immunotherapy drug.", [["niclosamide", "CHEMICAL", 34, 45], ["toxicity", "DISEASE", 135, 143], ["niclosamide", "CHEMICAL", 145, 156], ["niclosamide", "CHEMICAL", 34, 45], ["niclosamide", "CHEMICAL", 145, 156], ["niclosamide", "SIMPLE_CHEMICAL", 34, 45], ["TNF-alpha", "GENE_OR_GENE_PRODUCT", 108, 117], ["IL-6", "GENE_OR_GENE_PRODUCT", 122, 126], ["niclosamide", "SIMPLE_CHEMICAL", 145, 156], ["inflammatory cytokines", "PROTEIN", 85, 107], ["TNF", "PROTEIN", 108, 111], ["IL-6", "PROTEIN", 122, 126], ["niclosamide", "TREATMENT", 34, 45], ["the inflammatory cytokines TNF", "TEST", 81, 111], ["alpha and IL", "TREATMENT", 112, 124], ["toxicity", "PROBLEM", 135, 143], ["niclosamide", "TREATMENT", 145, 156], ["a clinical immunosuppressive therapy", "TREATMENT", 188, 224], ["adjuvant immunotherapy drug", "TREATMENT", 228, 255], ["inflammatory", "OBSERVATION_MODIFIER", 85, 97]]], ["IL-12 has been identified as a cytokine that strongly influences the differentiation of na\u00efve CD4 cells into T helper 1 (Th1) cells that produce IFN-gamma and aid in cell-mediated immunity [38] .", [["CD4 cells", "ANATOMY", 94, 103], ["T helper 1 (Th1) cells", "ANATOMY", 109, 131], ["cell", "ANATOMY", 166, 170], ["IL-12", "GENE_OR_GENE_PRODUCT", 0, 5], ["CD4 cells", "CELL", 94, 103], ["T helper 1", "CELL", 109, 119], ["IFN-gamma", "GENE_OR_GENE_PRODUCT", 145, 154], ["cell", "CELL", 166, 170], ["IL-12", "PROTEIN", 0, 5], ["cytokine", "PROTEIN", 31, 39], ["na\u00efve CD4 cells", "CELL_TYPE", 88, 103], ["T helper 1 (Th1) cells", "CELL_TYPE", 109, 131], ["IFN-gamma", "PROTEIN", 145, 154], ["IFN", "TEST", 145, 148], ["gamma", "ANATOMY", 149, 154]]], ["The present study demonstrated that niclosamide can significantly reduce LPS-induced IL-12 production in BMDCs and can also down regulate the capacity of LPS-stimulated DCs to induce IFN-gamma expression by allogeneic CD4 + T and CD8 + T cells (Fig. 3B) .", [["BMDCs", "ANATOMY", 105, 110], ["DCs", "ANATOMY", 169, 172], ["CD4 + T", "ANATOMY", 218, 225], ["CD8 + T cells", "ANATOMY", 230, 243], ["niclosamide", "CHEMICAL", 36, 47], ["LPS", "CHEMICAL", 73, 76], ["LPS", "CHEMICAL", 154, 157], ["niclosamide", "CHEMICAL", 36, 47], ["niclosamide", "SIMPLE_CHEMICAL", 36, 47], ["LPS", "SIMPLE_CHEMICAL", 73, 76], ["IL-12", "GENE_OR_GENE_PRODUCT", 85, 90], ["BMDCs", "CELL", 105, 110], ["LPS", "SIMPLE_CHEMICAL", 154, 157], ["DCs", "CELL", 169, 172], ["IFN-gamma", "GENE_OR_GENE_PRODUCT", 183, 192], ["CD4", "GENE_OR_GENE_PRODUCT", 218, 221], ["CD8", "GENE_OR_GENE_PRODUCT", 230, 233], ["BMDCs", "CELL_TYPE", 105, 110], ["DCs", "CELL_TYPE", 169, 172], ["IFN", "PROTEIN", 183, 186], ["allogeneic CD4 + T and CD8 + T cells", "CELL_TYPE", 207, 243], ["The present study", "TEST", 0, 17], ["niclosamide", "TREATMENT", 36, 47], ["LPS", "TEST", 73, 76], ["LPS", "TEST", 154, 157], ["IFN", "TEST", 183, 186], ["gamma expression", "TEST", 187, 203], ["allogeneic CD4", "TEST", 207, 221], ["T", "TEST", 224, 225]]], ["These observations suggest that niclosamide may be effective in several chronic inflammatory diseases described as Th1-dominant diseases.", [["niclosamide", "CHEMICAL", 32, 43], ["niclosamide", "CHEMICAL", 32, 43], ["niclosamide", "SIMPLE_CHEMICAL", 32, 43], ["Th1", "GENE_OR_GENE_PRODUCT", 115, 118], ["niclosamide", "TREATMENT", 32, 43], ["several chronic inflammatory diseases", "PROBLEM", 64, 101], ["Th1-dominant diseases", "PROBLEM", 115, 136], ["may be", "UNCERTAINTY", 44, 50], ["effective", "OBSERVATION_MODIFIER", 51, 60], ["several", "OBSERVATION_MODIFIER", 64, 71], ["chronic", "OBSERVATION_MODIFIER", 72, 79], ["inflammatory", "OBSERVATION", 80, 92], ["Th1", "OBSERVATION_MODIFIER", 115, 118], ["dominant", "OBSERVATION_MODIFIER", 119, 127], ["diseases", "OBSERVATION", 128, 136]]], ["However, we cannot exclude the possibility that niclosamide may modulate the responses of other types of T lymphocytes.", [["T lymphocytes", "ANATOMY", 105, 118], ["niclosamide", "CHEMICAL", 48, 59], ["niclosamide", "CHEMICAL", 48, 59], ["niclosamide", "SIMPLE_CHEMICAL", 48, 59], ["T lymphocytes", "CELL", 105, 118], ["T lymphocytes", "CELL_TYPE", 105, 118], ["niclosamide", "TREATMENT", 48, 59], ["T lymphocytes", "PROBLEM", 105, 118], ["T lymphocytes", "OBSERVATION", 105, 118]]], ["Specifically, the TLR-4 ligand LPS was used in our study to stimulate DC maturation.", [["DC", "ANATOMY", 70, 72], ["LPS", "CHEMICAL", 31, 34], ["TLR-4", "GENE_OR_GENE_PRODUCT", 18, 23], ["LPS", "SIMPLE_CHEMICAL", 31, 34], ["DC", "CELL", 70, 72], ["TLR", "PROTEIN", 18, 21], ["DC", "CELL_TYPE", 70, 72], ["the TLR-4 ligand LPS", "TREATMENT", 14, 34], ["our study", "TEST", 47, 56]]], ["LPS has been shown to induce strong Th1-like responses instead of Th2 immune responses [39] .", [["LPS", "CHEMICAL", 0, 3], ["LPS", "SIMPLE_CHEMICAL", 0, 3], ["LPS", "TEST", 0, 3]]], ["Our data did not indicate that IL-4 was expressed in DCs after LPS stimulation (data not shown).", [["DCs", "ANATOMY", 53, 56], ["LPS", "CHEMICAL", 63, 66], ["IL-4", "GENE_OR_GENE_PRODUCT", 31, 35], ["DCs", "CELL", 53, 56], ["LPS", "SIMPLE_CHEMICAL", 63, 66], ["IL-4", "PROTEIN", 31, 35], ["DCs", "CELL_TYPE", 53, 56], ["Our data", "TEST", 0, 8], ["LPS stimulation", "TEST", 63, 78]]], ["Therefore, the utilization of agents capable of stimulating a Th2 response, such as dust mite allergens [40] , to further determine the effects of niclosamide on DC-mediated Th2 polarization should be examined in the future.DiscussionsTo determine the mechanism by which niclosamide inhibits DC function, we examined TLR4-related downstream signaling pathways.", [["DC", "ANATOMY", 162, 164], ["DC", "ANATOMY", 292, 294], ["niclosamide", "CHEMICAL", 147, 158], ["niclosamide", "CHEMICAL", 271, 282], ["niclosamide", "CHEMICAL", 147, 158], ["niclosamide", "CHEMICAL", 271, 282], ["niclosamide", "SIMPLE_CHEMICAL", 147, 158], ["DC", "CELL", 162, 164], ["niclosamide", "SIMPLE_CHEMICAL", 271, 282], ["DC", "CELL", 292, 294], ["TLR4", "GENE_OR_GENE_PRODUCT", 317, 321], ["DC", "CELL_TYPE", 162, 164], ["DC", "CELL_TYPE", 292, 294], ["TLR4", "PROTEIN", 317, 321], ["agents", "TREATMENT", 30, 36], ["niclosamide", "TREATMENT", 147, 158], ["DC-mediated Th2 polarization", "TREATMENT", 162, 190]]], ["NF-jB has been demonstrated to regulate the expression of pro-inflammatory mediators, including costimulatory molecules, cytokines and adhesion molecules, in DCs, and it is upregulated as DCs mature [41] .", [["DCs", "ANATOMY", 158, 161], ["DCs", "ANATOMY", 188, 191], ["NF-jB", "GENE_OR_GENE_PRODUCT", 0, 5], ["DCs", "CELL", 158, 161], ["DCs", "CELL", 188, 191], ["NF-jB", "PROTEIN", 0, 5], ["pro-inflammatory mediators", "PROTEIN", 58, 84], ["costimulatory molecules", "PROTEIN", 96, 119], ["cytokines", "PROTEIN", 121, 130], ["adhesion molecules", "PROTEIN", 135, 153], ["DCs", "CELL_TYPE", 158, 161], ["DCs", "CELL_TYPE", 188, 191], ["pro-inflammatory mediators", "TREATMENT", 58, 84], ["costimulatory molecules", "TREATMENT", 96, 119], ["cytokines and adhesion molecules", "TREATMENT", 121, 153], ["jB", "ANATOMY", 3, 5]]], ["In addition, experiments in NF-jB subunit knockout mice further indicated that c-Rel and p50 control the expression of costimulatory molecules (CD40) and cytokines (IL-12, IL-18) during the T cell responses induced by lipopolysaccharide (LPS)-stimulated DCs.", [["T cell", "ANATOMY", 190, 196], ["DCs", "ANATOMY", 254, 257], ["lipopolysaccharide", "CHEMICAL", 218, 236], ["LPS", "CHEMICAL", 238, 241], ["NF-jB", "GENE_OR_GENE_PRODUCT", 28, 33], ["mice", "ORGANISM", 51, 55], ["c-Rel", "GENE_OR_GENE_PRODUCT", 79, 84], ["p50", "GENE_OR_GENE_PRODUCT", 89, 92], ["CD40", "GENE_OR_GENE_PRODUCT", 144, 148], ["IL-12", "GENE_OR_GENE_PRODUCT", 165, 170], ["IL-18", "GENE_OR_GENE_PRODUCT", 172, 177], ["T cell", "CELL", 190, 196], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 218, 236], ["LPS", "SIMPLE_CHEMICAL", 238, 241], ["DCs", "CELL", 254, 257], ["NF-jB subunit", "PROTEIN", 28, 41], ["Rel", "PROTEIN", 81, 84], ["p50", "PROTEIN", 89, 92], ["costimulatory molecules", "PROTEIN", 119, 142], ["CD40", "PROTEIN", 144, 148], ["cytokines", "PROTEIN", 154, 163], ["IL-12, IL-18", "PROTEIN", 165, 177], ["DCs", "CELL_TYPE", 254, 257], ["mice", "SPECIES", 51, 55], ["c-Rel and p50", "TREATMENT", 79, 92], ["cytokines", "TEST", 154, 163], ["IL", "TEST", 165, 167], ["IL", "TEST", 172, 174], ["the T cell responses", "TREATMENT", 186, 206], ["lipopolysaccharide (LPS", "TREATMENT", 218, 241]]], ["A previous study demonstrated that the TNF-alpha-induced NF-jB activity in acute myelogenous leukemia stem cells was significantly suppressed by niclosamide [19] .", [["acute myelogenous leukemia stem cells", "ANATOMY", 75, 112], ["acute myelogenous leukemia", "DISEASE", 75, 101], ["niclosamide", "CHEMICAL", 145, 156], ["niclosamide", "CHEMICAL", 145, 156], ["TNF-alpha", "GENE_OR_GENE_PRODUCT", 39, 48], ["NF-jB", "GENE_OR_GENE_PRODUCT", 57, 62], ["acute myelogenous leukemia stem cells", "CELL", 75, 112], ["niclosamide", "SIMPLE_CHEMICAL", 145, 156], ["TNF-alpha", "PROTEIN", 39, 48], ["NF-jB", "PROTEIN", 57, 62], ["acute myelogenous leukemia stem cells", "CELL_LINE", 75, 112], ["A previous study", "TEST", 0, 16], ["the TNF", "TEST", 35, 42], ["acute myelogenous leukemia stem cells", "PROBLEM", 75, 112], ["niclosamide", "TREATMENT", 145, 156], ["jB", "ANATOMY", 60, 62], ["acute", "OBSERVATION_MODIFIER", 75, 80], ["myelogenous leukemia stem cells", "OBSERVATION", 81, 112]]], ["Our present study showed that niclosamide inhibited NF-jB activity in LPS-treated DCs (Fig. 5B) , suggesting that the inhibition of NF-jB activation might be an important mechanism of the inhibition of DC maturation by niclosamide.", [["DCs", "ANATOMY", 82, 85], ["DC", "ANATOMY", 202, 204], ["niclosamide", "CHEMICAL", 30, 41], ["LPS", "CHEMICAL", 70, 73], ["niclosamide", "CHEMICAL", 219, 230], ["niclosamide", "CHEMICAL", 30, 41], ["niclosamide", "CHEMICAL", 219, 230], ["niclosamide", "SIMPLE_CHEMICAL", 30, 41], ["NF-jB", "GENE_OR_GENE_PRODUCT", 52, 57], ["LPS", "SIMPLE_CHEMICAL", 70, 73], ["DCs", "CELL", 82, 85], ["Fig. 5B", "CELL", 87, 94], ["NF-jB", "GENE_OR_GENE_PRODUCT", 132, 137], ["DC", "CELL", 202, 204], ["niclosamide", "SIMPLE_CHEMICAL", 219, 230], ["NF-jB", "PROTEIN", 52, 57], ["DCs", "CELL_TYPE", 82, 85], ["NF-jB", "PROTEIN", 132, 137], ["DC", "CELL_TYPE", 202, 204], ["Our present study", "TEST", 0, 17], ["niclosamide", "TREATMENT", 30, 41], ["DC maturation", "TREATMENT", 202, 215], ["niclosamide", "TREATMENT", 219, 230], ["jB activity", "OBSERVATION_MODIFIER", 55, 66]]], ["In addition, the mitogen-activated protein kinase (MAPK) pathways: c-Jun N-terminal (JNK), extracellular signal-regulated kinase (ERK) and p38, which direct the expression of various genes related to DC maturation and plays a major role in DCs function [27, 28] .", [["DC", "ANATOMY", 200, 202], ["DCs", "ANATOMY", 240, 243], ["N", "CHEMICAL", 73, 74], ["mitogen-activated protein kinase", "GENE_OR_GENE_PRODUCT", 17, 49], ["MAPK", "GENE_OR_GENE_PRODUCT", 51, 55], ["c-Jun N-terminal", "GENE_OR_GENE_PRODUCT", 67, 83], ["JNK", "GENE_OR_GENE_PRODUCT", 85, 88], ["extracellular signal-regulated kinase", "GENE_OR_GENE_PRODUCT", 91, 128], ["ERK", "GENE_OR_GENE_PRODUCT", 130, 133], ["p38", "GENE_OR_GENE_PRODUCT", 139, 142], ["DC", "CELL", 200, 202], ["DCs", "CELL", 240, 243], ["mitogen-activated protein kinase", "PROTEIN", 17, 49], ["MAPK", "PROTEIN", 51, 55], ["Jun N-terminal", "PROTEIN", 69, 83], ["JNK", "PROTEIN", 85, 88], ["extracellular signal-regulated kinase", "PROTEIN", 91, 128], ["ERK", "PROTEIN", 130, 133], ["p38", "PROTEIN", 139, 142], ["DC", "CELL_TYPE", 200, 202], ["DCs", "CELL_TYPE", 240, 243], ["the mitogen", "TEST", 13, 24], ["activated protein kinase", "TEST", 25, 49], ["pathways", "TEST", 57, 65], ["c", "TEST", 67, 68], ["Jun N", "TEST", 69, 74], ["extracellular signal", "TEST", 91, 111], ["p38", "TEST", 139, 142], ["DC maturation", "TREATMENT", 200, 213]]], ["In this study, we also observed that niclosamide moderately decreased ERK and JNK but did not change p38 activation in LPS-treated BMDCs, suggesting that niclosamide inhibits TLR-related signaling, perhaps including the NF-jB and MAPK-ERK, JNK signaling pathways.", [["BMDCs", "ANATOMY", 131, 136], ["niclosamide", "CHEMICAL", 37, 48], ["LPS", "CHEMICAL", 119, 122], ["niclosamide", "CHEMICAL", 154, 165], ["niclosamide", "CHEMICAL", 37, 48], ["niclosamide", "CHEMICAL", 154, 165], ["niclosamide", "SIMPLE_CHEMICAL", 37, 48], ["ERK", "GENE_OR_GENE_PRODUCT", 70, 73], ["JNK", "GENE_OR_GENE_PRODUCT", 78, 81], ["p38", "GENE_OR_GENE_PRODUCT", 101, 104], ["LPS", "SIMPLE_CHEMICAL", 119, 122], ["BMDCs", "CELL", 131, 136], ["niclosamide", "SIMPLE_CHEMICAL", 154, 165], ["TLR", "GENE_OR_GENE_PRODUCT", 175, 178], ["NF-jB", "GENE_OR_GENE_PRODUCT", 220, 225], ["MAPK", "GENE_OR_GENE_PRODUCT", 230, 234], ["ERK", "GENE_OR_GENE_PRODUCT", 235, 238], ["JNK", "GENE_OR_GENE_PRODUCT", 240, 243], ["ERK", "PROTEIN", 70, 73], ["JNK", "PROTEIN", 78, 81], ["p38", "PROTEIN", 101, 104], ["BMDCs", "CELL_TYPE", 131, 136], ["TLR", "PROTEIN", 175, 178], ["jB", "PROTEIN", 223, 225], ["MAPK", "PROTEIN", 230, 234], ["ERK", "PROTEIN", 235, 238], ["JNK", "PROTEIN", 240, 243], ["this study", "TEST", 3, 13], ["niclosamide", "TREATMENT", 37, 48], ["LPS", "TEST", 119, 122], ["BMDCs", "TREATMENT", 131, 136], ["niclosamide", "TREATMENT", 154, 165], ["the NF", "TEST", 216, 222], ["MAPK", "TEST", 230, 234], ["jB", "ANATOMY", 223, 225]]], ["However, niclosamide has been demonstrated to regulate multiple signaling pathways, and some of these pathways are involved in immune responses, such as AKT [19] and STAT3 [20] .", [["niclosamide", "CHEMICAL", 9, 20], ["niclosamide", "CHEMICAL", 9, 20], ["niclosamide", "SIMPLE_CHEMICAL", 9, 20], ["AKT [19]", "GENE_OR_GENE_PRODUCT", 153, 161], ["STAT3", "GENE_OR_GENE_PRODUCT", 166, 171], ["niclosamide", "PROTEIN", 9, 20], ["AKT", "PROTEIN", 153, 156], ["STAT3", "PROTEIN", 166, 171], ["niclosamide", "TREATMENT", 9, 20], ["AKT", "TEST", 153, 156]]], ["Thus, additional studies are needed to determine whether other pathways are involved in this effect and to fully elucidate the signaling pathway(s) responsible for the inhibition of DC maturation by niclosamide.DiscussionsIt is worth noting that although our current study demonstrates for the first time that niclosamide can inhibit the LPS-induced MAPK-ERK signaling pathway in BMDCs, it was recently reported that niclosamide dose not affect the induction of the MEK/ERK/ MNK pathway by serum starvation in MCF-7 cells [22] .", [["DC", "ANATOMY", 182, 184], ["BMDCs", "ANATOMY", 380, 385], ["serum", "ANATOMY", 490, 495], ["MCF-7 cells", "ANATOMY", 510, 521], ["niclosamide", "CHEMICAL", 199, 210], ["niclosamide", "CHEMICAL", 310, 321], ["LPS", "CHEMICAL", 338, 341], ["niclosamide", "CHEMICAL", 417, 428], ["niclosamide", "CHEMICAL", 199, 210], ["niclosamide", "CHEMICAL", 310, 321], ["niclosamide", "CHEMICAL", 417, 428], ["DC", "CELL", 182, 184], ["niclosamide", "SIMPLE_CHEMICAL", 199, 210], ["niclosamide", "SIMPLE_CHEMICAL", 310, 321], ["LPS", "SIMPLE_CHEMICAL", 338, 341], ["MAPK", "GENE_OR_GENE_PRODUCT", 350, 354], ["ERK", "GENE_OR_GENE_PRODUCT", 355, 358], ["BMDCs", "CELL", 380, 385], ["niclosamide", "SIMPLE_CHEMICAL", 417, 428], ["MEK", "GENE_OR_GENE_PRODUCT", 466, 469], ["ERK", "GENE_OR_GENE_PRODUCT", 470, 473], ["MNK", "GENE_OR_GENE_PRODUCT", 475, 478], ["serum", "ORGANISM_SUBSTANCE", 490, 495], ["MCF-7 cells", "CELL", 510, 521], ["DC", "CELL_TYPE", 182, 184], ["MAPK", "PROTEIN", 350, 354], ["ERK", "PROTEIN", 355, 358], ["BMDCs", "CELL_TYPE", 380, 385], ["MEK", "PROTEIN", 466, 469], ["ERK", "PROTEIN", 470, 473], ["MNK", "PROTEIN", 475, 478], ["MCF-7 cells", "CELL_LINE", 510, 521], ["MCF-7", "SPECIES", 510, 515], ["additional studies", "TEST", 6, 24], ["DC maturation", "TREATMENT", 182, 195], ["niclosamide", "TREATMENT", 199, 210], ["our current study", "TEST", 255, 272], ["niclosamide", "TREATMENT", 310, 321], ["the LPS", "TEST", 334, 341], ["niclosamide dose", "TREATMENT", 417, 433], ["the MEK", "TEST", 462, 469], ["MNK pathway", "TEST", 475, 486], ["serum starvation", "TEST", 490, 506], ["MCF", "TEST", 510, 513]]], ["Our preliminary inferences suggest at least two possible causes for the differences in the results.", [["at least", "OBSERVATION_MODIFIER", 35, 43]]], ["First, the difference in the effect of ERK activation by niclosamide may be due to species-specific or cell-type differences.", [["cell", "ANATOMY", 103, 107], ["niclosamide", "CHEMICAL", 57, 68], ["niclosamide", "CHEMICAL", 57, 68], ["ERK", "GENE_OR_GENE_PRODUCT", 39, 42], ["niclosamide", "SIMPLE_CHEMICAL", 57, 68], ["cell", "CELL", 103, 107], ["ERK", "PROTEIN", 39, 42], ["ERK activation", "PROBLEM", 39, 53], ["niclosamide", "TREATMENT", 57, 68], ["species", "PROBLEM", 83, 90], ["difference", "OBSERVATION_MODIFIER", 11, 21], ["may be due to", "UNCERTAINTY", 69, 82]]], ["Second, niclosamide may be not directly target ERK but may instead regulate the pathway upstream of ERK.", [["niclosamide", "CHEMICAL", 8, 19], ["niclosamide", "CHEMICAL", 8, 19], ["niclosamide", "SIMPLE_CHEMICAL", 8, 19], ["ERK", "GENE_OR_GENE_PRODUCT", 47, 50], ["ERK", "GENE_OR_GENE_PRODUCT", 100, 103], ["ERK", "PROTEIN", 47, 50], ["ERK", "PROTEIN", 100, 103], ["niclosamide", "TREATMENT", 8, 19]]], ["Thus, niclosamide has different effects on ERK activation in serum-starved MCF-7 cells and LPS-treated BMDCs.", [["serum", "ANATOMY", 61, 66], ["MCF-7 cells", "ANATOMY", 75, 86], ["BMDCs", "ANATOMY", 103, 108], ["niclosamide", "CHEMICAL", 6, 17], ["LPS", "CHEMICAL", 91, 94], ["niclosamide", "CHEMICAL", 6, 17], ["niclosamide", "SIMPLE_CHEMICAL", 6, 17], ["ERK", "GENE_OR_GENE_PRODUCT", 43, 46], ["serum", "ORGANISM_SUBSTANCE", 61, 66], ["MCF-7 cells", "CELL", 75, 86], ["LPS", "SIMPLE_CHEMICAL", 91, 94], ["BMDCs", "CELL", 103, 108], ["ERK", "PROTEIN", 43, 46], ["serum-starved MCF-7 cells", "CELL_LINE", 61, 86], ["BMDCs", "CELL_TYPE", 103, 108], ["niclosamide", "TREATMENT", 6, 17], ["ERK activation", "TEST", 43, 57], ["serum", "TEST", 61, 66], ["LPS", "TEST", 91, 94]]], ["However, the identification of possible mechanisms responsible for these different effects may lead to future applications for niclosamide in the treatment of clinical diseases.DiscussionsIn a separate study, we found that niclosamide was able to repress the expression of pro-inflammatory cytokines regardless of whether it was administered before or after LPS stimulation The level of MAPK phosphorylation was examined by western blot analysis with antibodies against ERK, JNK, p38 and MAPK (both phosphorylated and unphosphorylated).", [["niclosamide", "CHEMICAL", 127, 138], ["niclosamide", "CHEMICAL", 223, 234], ["LPS", "CHEMICAL", 358, 361], ["niclosamide", "CHEMICAL", 127, 138], ["niclosamide", "CHEMICAL", 223, 234], ["niclosamide", "SIMPLE_CHEMICAL", 127, 138], ["niclosamide", "SIMPLE_CHEMICAL", 223, 234], ["LPS", "SIMPLE_CHEMICAL", 358, 361], ["MAPK", "GENE_OR_GENE_PRODUCT", 387, 391], ["ERK", "GENE_OR_GENE_PRODUCT", 470, 473], ["JNK", "GENE_OR_GENE_PRODUCT", 475, 478], ["p38", "GENE_OR_GENE_PRODUCT", 480, 483], ["MAPK", "GENE_OR_GENE_PRODUCT", 488, 492], ["pro-inflammatory cytokines", "PROTEIN", 273, 299], ["MAPK", "PROTEIN", 387, 391], ["ERK", "PROTEIN", 470, 473], ["JNK", "PROTEIN", 475, 478], ["p38", "PROTEIN", 480, 483], ["MAPK", "PROTEIN", 488, 492], ["niclosamide", "TREATMENT", 127, 138], ["clinical diseases", "PROBLEM", 159, 176], ["a separate study", "TEST", 191, 207], ["niclosamide", "TREATMENT", 223, 234], ["pro-inflammatory cytokines", "TREATMENT", 273, 299], ["LPS stimulation", "TREATMENT", 358, 373], ["MAPK phosphorylation", "TEST", 387, 407], ["blot analysis", "TEST", 432, 445], ["antibodies", "TEST", 451, 461], ["ERK", "TEST", 470, 473], ["JNK", "TEST", 475, 478], ["p38", "TEST", 480, 483], ["MAPK", "TEST", 488, 492], ["phosphorylated", "TEST", 499, 513]]], ["Bands were analyzed by ImageJ and normalized to actin.", [["Bands", "GENE_OR_GENE_PRODUCT", 0, 5], ["actin", "GENE_OR_GENE_PRODUCT", 48, 53], ["actin", "PROTEIN", 48, 53], ["Bands", "TEST", 0, 5], ["ImageJ", "TEST", 23, 29]]], ["(B) The NF-jB assay was performed as described in the Materials and Methods.", [["NF-jB", "GENE_OR_GENE_PRODUCT", 8, 13], ["NF", "PROTEIN", 8, 10], ["jB", "PROTEIN", 11, 13], ["The NF-jB assay", "TEST", 4, 19]]], ["The data shown are the mean \u00b1 SD of samples from three wells. n.s p > 0.05, \u2044 p < 0.05, \u2044\u2044\u2044 p < 0.001 indicates a significant difference between the niclosamide-treated and 0.1% DMSO-treated LPS-activated DCs.", [["samples", "ANATOMY", 36, 43], ["DCs", "ANATOMY", 205, 208], ["niclosamide", "CHEMICAL", 149, 160], ["DMSO", "CHEMICAL", 178, 182], ["LPS", "CHEMICAL", 191, 194], ["niclosamide", "CHEMICAL", 149, 160], ["DMSO", "CHEMICAL", 178, 182], ["niclosamide", "SIMPLE_CHEMICAL", 149, 160], ["DMSO", "SIMPLE_CHEMICAL", 178, 182], ["LPS", "SIMPLE_CHEMICAL", 191, 194], ["DCs", "CELL", 205, 208], ["DCs", "CELL_TYPE", 205, 208], ["The data", "TEST", 0, 8], ["n.s p", "TEST", 62, 67], ["a significant difference", "PROBLEM", 112, 136], ["the niclosamide", "TREATMENT", 145, 160], ["LPS", "TREATMENT", 191, 194], ["activated DCs", "TREATMENT", 195, 208]]], ["All data are representative of three independent experiments with similar results.Discussions(Supplemental Fig. 2 ).", [["All data", "TEST", 0, 8]]], ["This suggests that the anti-inflammatory and immunomodulatory effects of niclosamide could be clinically effective for the prevention or treatment of various diseases.", [["niclosamide", "CHEMICAL", 73, 84], ["niclosamide", "CHEMICAL", 73, 84], ["niclosamide", "SIMPLE_CHEMICAL", 73, 84], ["the anti-inflammatory", "TREATMENT", 19, 40], ["niclosamide", "TREATMENT", 73, 84], ["various diseases", "PROBLEM", 150, 166], ["anti-inflammatory", "OBSERVATION_MODIFIER", 23, 40], ["various", "OBSERVATION_MODIFIER", 150, 157], ["diseases", "OBSERVATION", 158, 166]]], ["In addition, we also tested whether niclosamide could modulate the activation of immature DCs by other TLR ligands, namely peptidoglycan (TLR1/TLR2), polyI:C (TLR3), CpG ODN 1826 (TLR-9) and imiquimod (TLR-7).", [["DCs", "ANATOMY", 90, 93], ["niclosamide", "CHEMICAL", 36, 47], ["ODN 1826", "CHEMICAL", 170, 178], ["TLR-9", "CHEMICAL", 180, 185], ["imiquimod", "CHEMICAL", 191, 200], ["niclosamide", "CHEMICAL", 36, 47], ["imiquimod", "CHEMICAL", 191, 200], ["niclosamide", "SIMPLE_CHEMICAL", 36, 47], ["DCs", "CELL", 90, 93], ["TLR", "GENE_OR_GENE_PRODUCT", 103, 106], ["peptidoglycan", "GENE_OR_GENE_PRODUCT", 123, 136], ["TLR1", "GENE_OR_GENE_PRODUCT", 138, 142], ["TLR2", "GENE_OR_GENE_PRODUCT", 143, 147], ["polyI:C", "GENE_OR_GENE_PRODUCT", 150, 157], ["TLR3", "GENE_OR_GENE_PRODUCT", 159, 163], ["CpG ODN 1826", "SIMPLE_CHEMICAL", 166, 178], ["TLR-9", "GENE_OR_GENE_PRODUCT", 180, 185], ["imiquimod", "SIMPLE_CHEMICAL", 191, 200], ["TLR-7", "GENE_OR_GENE_PRODUCT", 202, 207], ["immature DCs", "CELL_TYPE", 81, 93], ["TLR ligands", "PROTEIN", 103, 114], ["TLR1", "PROTEIN", 138, 142], ["TLR2", "PROTEIN", 143, 147], ["polyI:C", "PROTEIN", 150, 157], ["TLR3", "PROTEIN", 159, 163], ["TLR", "PROTEIN", 180, 183], ["TLR", "PROTEIN", 202, 205], ["niclosamide", "TREATMENT", 36, 47], ["immature DCs", "PROBLEM", 81, 93], ["peptidoglycan (TLR1/TLR2)", "TREATMENT", 123, 148], ["polyI:C (TLR3), CpG ODN", "TREATMENT", 150, 173], ["TLR", "TEST", 180, 183], ["imiquimod (TLR", "TREATMENT", 191, 205], ["immature DCs", "OBSERVATION", 81, 93]]], ["Each TLR ligand increased the release of pro-inflammatory IL-6 and IL-12 into the culture medium, and this release was reduced by treatment with 1.25 lM niclosamide (Supplemental Fig. 3 ).", [["niclosamide", "CHEMICAL", 153, 164], ["niclosamide", "CHEMICAL", 153, 164], ["TLR ligand", "GENE_OR_GENE_PRODUCT", 5, 15], ["IL-6", "GENE_OR_GENE_PRODUCT", 58, 62], ["IL-12", "GENE_OR_GENE_PRODUCT", 67, 72], ["niclosamide", "SIMPLE_CHEMICAL", 153, 164], ["TLR ligand", "PROTEIN", 5, 15], ["pro-inflammatory IL-6", "PROTEIN", 41, 62], ["IL-12", "PROTEIN", 67, 72], ["pro-inflammatory IL", "TREATMENT", 41, 60], ["IL", "TREATMENT", 67, 69], ["the culture medium", "TEST", 78, 96], ["1.25 lM niclosamide", "TREATMENT", 145, 164]]], ["Although the mechanism through which niclosamide interferes with DC activation upon stimulation with different TLR ligands is largely unknown, we suggest that it may be related to the effect of niclosamide via the suppression of the MAPK and NF-jB signaling pathway.", [["DC", "ANATOMY", 65, 67], ["niclosamide", "CHEMICAL", 37, 48], ["niclosamide", "CHEMICAL", 194, 205], ["niclosamide", "CHEMICAL", 37, 48], ["niclosamide", "CHEMICAL", 194, 205], ["niclosamide", "SIMPLE_CHEMICAL", 37, 48], ["DC", "CELL", 65, 67], ["TLR", "GENE_OR_GENE_PRODUCT", 111, 114], ["niclosamide", "SIMPLE_CHEMICAL", 194, 205], ["MAPK", "GENE_OR_GENE_PRODUCT", 233, 237], ["NF-jB", "GENE_OR_GENE_PRODUCT", 242, 247], ["DC", "CELL_TYPE", 65, 67], ["TLR", "PROTEIN", 111, 114], ["MAPK", "PROTEIN", 233, 237], ["jB", "PROTEIN", 245, 247], ["niclosamide", "TREATMENT", 37, 48], ["DC activation upon stimulation", "TREATMENT", 65, 95], ["different TLR ligands", "PROBLEM", 101, 122], ["niclosamide", "TREATMENT", 194, 205], ["the MAPK", "TREATMENT", 229, 237]]], ["In this pathway, NF-jB is believed to play an important role in various TLR ligand-stimulated selective cytokine and chemokine secretions from dendritic cells [43] .DiscussionsPrevious studies showed that niclosamide has very low toxicity in mammals (oral LD50 in rats >5000 mg/kg) [44, 45] .", [["dendritic cells", "ANATOMY", 143, 158], ["oral", "ANATOMY", 251, 255], ["niclosamide", "CHEMICAL", 205, 216], ["toxicity", "DISEASE", 230, 238], ["LD50", "CHEMICAL", 256, 260], ["niclosamide", "CHEMICAL", 205, 216], ["NF-jB", "GENE_OR_GENE_PRODUCT", 17, 22], ["TLR ligand", "GENE_OR_GENE_PRODUCT", 72, 82], ["dendritic cells", "CELL", 143, 158], ["niclosamide", "SIMPLE_CHEMICAL", 205, 216], ["oral", "ORGANISM_SUBDIVISION", 251, 255], ["rats", "ORGANISM", 264, 268], ["NF-jB", "PROTEIN", 17, 22], ["TLR ligand", "PROTEIN", 72, 82], ["cytokine", "PROTEIN", 104, 112], ["dendritic cells", "CELL_TYPE", 143, 158], ["rats", "SPECIES", 264, 268], ["various TLR ligand", "TREATMENT", 64, 82], ["stimulated selective cytokine", "TREATMENT", 83, 112], ["chemokine secretions", "TEST", 117, 137], ["dendritic cells", "PROBLEM", 143, 158], ["Previous studies", "TEST", 176, 192], ["niclosamide", "TREATMENT", 205, 216], ["very low toxicity", "PROBLEM", 221, 238], ["oral LD50 in rats", "TREATMENT", 251, 268], ["dendritic cells", "OBSERVATION", 143, 158]]], ["In addition, a single oral administration of 5 mg/kg niclosamide can generate a maximal plasma concentration of 1.08 lM in rat [46] .", [["oral", "ANATOMY", 22, 26], ["plasma", "ANATOMY", 88, 94], ["niclosamide", "CHEMICAL", 53, 64], ["niclosamide", "CHEMICAL", 53, 64], ["oral", "ORGANISM_SUBDIVISION", 22, 26], ["niclosamide", "SIMPLE_CHEMICAL", 53, 64], ["plasma", "ORGANISM_SUBSTANCE", 88, 94], ["rat", "ORGANISM", 123, 126], ["rat", "SPECIES", 123, 126], ["niclosamide", "TREATMENT", 53, 64], ["a maximal plasma concentration", "TREATMENT", 78, 108]]], ["Another possibility to achieve higher plasma concentrations of the drug may be intravenous administration.", [["plasma", "ANATOMY", 38, 44], ["intravenous", "ANATOMY", 79, 90], ["plasma", "ORGANISM_SUBSTANCE", 38, 44], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 79, 90], ["the drug", "TREATMENT", 63, 71], ["intravenous administration", "TREATMENT", 79, 105]]], ["For instance, a single intravenous administration of 2 mg/kg niclosamide to rats gave rise to a peak plasma concentration of 25 lM [46] , which is sufficient to modulate DC function, as extrapolated from our data.DiscussionsNa\u00efve dendritic cells when activated using TLR ligands or proinflamtory cytokines, shift their metabolism from oxidative phosphorylation to aerobic glycolysis (i.e., the Warburg effect).", [["intravenous", "ANATOMY", 23, 34], ["plasma", "ANATOMY", 101, 107], ["DC", "ANATOMY", 170, 172], ["dendritic cells", "ANATOMY", 230, 245], ["niclosamide", "CHEMICAL", 61, 72], ["niclosamide", "CHEMICAL", 61, 72], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 23, 34], ["niclosamide", "SIMPLE_CHEMICAL", 61, 72], ["rats", "ORGANISM", 76, 80], ["plasma", "ORGANISM_SUBSTANCE", 101, 107], ["DC", "CELL", 170, 172], ["Na\u00efve dendritic cells", "CELL", 224, 245], ["TLR", "GENE_OR_GENE_PRODUCT", 267, 270], ["DC", "CELL_TYPE", 170, 172], ["Na\u00efve dendritic cells", "CELL_TYPE", 224, 245], ["TLR ligands", "PROTEIN", 267, 278], ["proinflamtory cytokines", "PROTEIN", 282, 305], ["rats", "SPECIES", 76, 80], ["a single intravenous administration", "TREATMENT", 14, 49], ["niclosamide", "TREATMENT", 61, 72], ["a peak plasma concentration", "TEST", 94, 121], ["TLR ligands", "TREATMENT", 267, 278], ["proinflamtory cytokines", "TREATMENT", 282, 305], ["oxidative phosphorylation", "TREATMENT", 335, 360], ["aerobic glycolysis", "TEST", 364, 382], ["dendritic cells", "OBSERVATION", 230, 245]]], ["Krawczyk et al. described this phenomenon in DCs and also demonstrated how TLR stimulation is essential for dendritic cell maturation [47] .", [["DCs", "ANATOMY", 45, 48], ["dendritic cell", "ANATOMY", 108, 122], ["DCs", "CELL", 45, 48], ["TLR", "GENE_OR_GENE_PRODUCT", 75, 78], ["dendritic cell", "CELL", 108, 122], ["DCs", "CELL_TYPE", 45, 48], ["TLR", "PROTEIN", 75, 78], ["TLR stimulation", "TREATMENT", 75, 90], ["dendritic cell maturation", "PROBLEM", 108, 133]]], ["Consequently, according to previous studies, uncoupling of mitochondrial oxidative phosphorylation was also believed to be its antihelminthic mechanism of action [48] .", [["mitochondrial", "ANATOMY", 59, 72], ["mitochondrial", "CELLULAR_COMPONENT", 59, 72], ["previous studies", "TEST", 27, 43], ["mitochondrial oxidative phosphorylation", "PROBLEM", 59, 98], ["oxidative phosphorylation", "OBSERVATION", 73, 98]]], ["Thus, we hypothesized that immunomodulatory effects of niclosamides on dendritic cells could, in part, be due to its disruption of metabolism.DiscussionsNiclosamide has been FDA approved for human use against parasitic helminthic infestations for decades.", [["dendritic cells", "ANATOMY", 71, 86], ["niclosamides", "CHEMICAL", 55, 67], ["Niclosamide", "CHEMICAL", 153, 164], ["parasitic helminthic infestations", "DISEASE", 209, 242], ["niclosamides", "CHEMICAL", 55, 67], ["Niclosamide", "CHEMICAL", 153, 164], ["niclosamides", "SIMPLE_CHEMICAL", 55, 67], ["dendritic cells", "CELL", 71, 86], ["Niclosamide", "SIMPLE_CHEMICAL", 153, 164], ["human", "ORGANISM", 191, 196], ["dendritic cells", "CELL_TYPE", 71, 86], ["human", "SPECIES", 191, 196], ["human", "SPECIES", 191, 196], ["niclosamides", "TREATMENT", 55, 67], ["dendritic cells", "PROBLEM", 71, 86], ["its disruption of metabolism", "PROBLEM", 113, 141], ["Niclosamide", "TREATMENT", 153, 164], ["parasitic helminthic infestations", "PROBLEM", 209, 242], ["dendritic cells", "OBSERVATION", 71, 86], ["disruption", "OBSERVATION", 117, 127]]], ["In recent years, niclosamide was shown to have antiviral effects.", [["niclosamide", "CHEMICAL", 17, 28], ["niclosamide", "CHEMICAL", 17, 28], ["niclosamide", "SIMPLE_CHEMICAL", 17, 28], ["niclosamide", "TREATMENT", 17, 28], ["antiviral effects", "TREATMENT", 47, 64]]], ["For example, Jurgeit et al. found that niclosamide is an entry inhibitor for a number of pHdependent respiratory viruses, including influenza virus and human rhinoviruses [49] .", [["niclosamide", "CHEMICAL", 39, 50], ["respiratory viruses", "DISEASE", 101, 120], ["influenza virus", "DISEASE", 132, 147], ["niclosamide", "CHEMICAL", 39, 50], ["niclosamide", "SIMPLE_CHEMICAL", 39, 50], ["pHdependent respiratory viruses", "ORGANISM", 89, 120], ["influenza virus", "ORGANISM", 132, 147], ["human", "ORGANISM", 152, 157], ["influenza virus", "SPECIES", 132, 147], ["human", "SPECIES", 152, 157], ["influenza virus", "SPECIES", 132, 147], ["human rhinoviruses", "SPECIES", 152, 170], ["niclosamide", "TREATMENT", 39, 50], ["an entry inhibitor", "TREATMENT", 54, 72], ["pHdependent respiratory viruses", "PROBLEM", 89, 120], ["influenza virus", "PROBLEM", 132, 147], ["human rhinoviruses", "PROBLEM", 152, 170], ["respiratory viruses", "OBSERVATION", 101, 120]]], ["Imperi et al. showed that at micromolar concentrations, niclosamide has high inhibitory activity against Pseudomonas aeruginosa QS and virulence both in vitro and in vivo [31] .", [["niclosamide", "CHEMICAL", 56, 67], ["niclosamide", "CHEMICAL", 56, 67], ["niclosamide", "SIMPLE_CHEMICAL", 56, 67], ["Pseudomonas aeruginosa", "ORGANISM", 105, 127], ["Pseudomonas aeruginosa", "SPECIES", 105, 127], ["Pseudomonas aeruginosa", "SPECIES", 105, 127], ["micromolar concentrations", "PROBLEM", 29, 54], ["niclosamide", "TREATMENT", 56, 67], ["Pseudomonas aeruginosa QS", "PROBLEM", 105, 130], ["virulence", "PROBLEM", 135, 144], ["high inhibitory", "OBSERVATION_MODIFIER", 72, 87]]], ["Moreover, Wu et al. demonstrated that niclosamide was able to inhibit replication of SARS-CoV; viral antigen synthesis was totally abolished at a niclosamide concentration of 1.56 lM, suggesting that this drug is a possible candidate for the treatment of SARS-CoV infection [30] .", [["niclosamide", "CHEMICAL", 38, 49], ["SARS", "DISEASE", 85, 89], ["niclosamide", "CHEMICAL", 146, 157], ["SARS-CoV infection", "DISEASE", 255, 273], ["niclosamide", "CHEMICAL", 38, 49], ["niclosamide", "CHEMICAL", 146, 157], ["niclosamide", "SIMPLE_CHEMICAL", 38, 49], ["SARS-CoV", "ORGANISM", 85, 93], ["viral antigen", "GENE_OR_GENE_PRODUCT", 95, 108], ["niclosamide", "SIMPLE_CHEMICAL", 146, 157], ["SARS-CoV", "ORGANISM", 255, 263], ["SARS-CoV", "SPECIES", 85, 93], ["SARS-CoV", "SPECIES", 255, 263], ["niclosamide", "TREATMENT", 38, 49], ["SARS", "PROBLEM", 85, 89], ["CoV", "PROBLEM", 90, 93], ["viral antigen synthesis", "PROBLEM", 95, 118], ["a niclosamide concentration", "TREATMENT", 144, 171], ["SARS", "PROBLEM", 255, 259], ["CoV infection", "PROBLEM", 260, 273]]], ["This is the first study demonstrating the ability of niclosamide in modulating the activation of immature DCs by several types of TLR ligands.", [["DCs", "ANATOMY", 106, 109], ["niclosamide", "CHEMICAL", 53, 64], ["niclosamide", "CHEMICAL", 53, 64], ["niclosamide", "SIMPLE_CHEMICAL", 53, 64], ["DCs", "CELL", 106, 109], ["TLR", "GENE_OR_GENE_PRODUCT", 130, 133], ["immature DCs", "CELL_TYPE", 97, 109], ["TLR ligands", "PROTEIN", 130, 141], ["the first study", "TEST", 8, 23], ["niclosamide", "TREATMENT", 53, 64], ["immature DCs", "PROBLEM", 97, 109], ["TLR ligands", "TREATMENT", 130, 141], ["immature DCs", "OBSERVATION", 97, 109]]], ["Since DCs are crucial for the elimination of pathogens and tumors [50, 51] , further studies also should examine the risks associated with long-term niclosamide use.DiscussionsIn summary, our results demonstrate for the first time that the FDA-approved drug niclosamide inhibits LPS-induced DC maturation and cytokine, costimulatory molecule, and MHC molecule expression.", [["DCs", "ANATOMY", 6, 9], ["tumors", "ANATOMY", 59, 65], ["DC", "ANATOMY", 291, 293], ["tumors", "DISEASE", 59, 65], ["niclosamide", "CHEMICAL", 149, 160], ["niclosamide", "CHEMICAL", 258, 269], ["LPS", "CHEMICAL", 279, 282], ["niclosamide", "CHEMICAL", 149, 160], ["niclosamide", "CHEMICAL", 258, 269], ["DCs", "CELL", 6, 9], ["tumors", "CANCER", 59, 65], ["niclosamide", "SIMPLE_CHEMICAL", 149, 160], ["niclosamide", "SIMPLE_CHEMICAL", 258, 269], ["LPS", "SIMPLE_CHEMICAL", 279, 282], ["DC", "CELL", 291, 293], ["MHC molecule", "GENE_OR_GENE_PRODUCT", 347, 359], ["DCs", "CELL_TYPE", 6, 9], ["DC", "CELL_TYPE", 291, 293], ["cytokine", "PROTEIN", 309, 317], ["costimulatory molecule", "PROTEIN", 319, 341], ["MHC molecule", "PROTEIN", 347, 359], ["pathogens", "PROBLEM", 45, 54], ["tumors", "PROBLEM", 59, 65], ["further studies", "TEST", 77, 92], ["long-term niclosamide use", "TREATMENT", 139, 164], ["the FDA", "TEST", 236, 243], ["drug niclosamide", "TREATMENT", 253, 269], ["LPS", "TREATMENT", 279, 282], ["DC maturation", "TREATMENT", 291, 304], ["cytokine, costimulatory molecule", "TREATMENT", 309, 341]]], ["In addition, niclosamide-treated DCs inhibited antigen specific T cell responses, prompting us to speculate that this might be an important function of niclosamide.", [["DCs", "ANATOMY", 33, 36], ["T cell", "ANATOMY", 64, 70], ["niclosamide", "CHEMICAL", 13, 24], ["niclosamide", "CHEMICAL", 152, 163], ["niclosamide", "CHEMICAL", 13, 24], ["niclosamide", "CHEMICAL", 152, 163], ["niclosamide", "SIMPLE_CHEMICAL", 13, 24], ["DCs", "CELL", 33, 36], ["T cell", "CELL", 64, 70], ["niclosamide", "SIMPLE_CHEMICAL", 152, 163], ["niclosamide-treated DCs", "CELL_LINE", 13, 36], ["niclosamide", "TREATMENT", 13, 24], ["niclosamide", "TREATMENT", 152, 163]]], ["However, we also believe that additional issues warrant future investigation including the molecular mechanisms underlying the ability of niclosamide to suppress DC function.", [["DC", "ANATOMY", 162, 164], ["niclosamide", "CHEMICAL", 138, 149], ["niclosamide", "CHEMICAL", 138, 149], ["niclosamide", "SIMPLE_CHEMICAL", 138, 149], ["DC", "CELL", 162, 164], ["DC", "CELL_TYPE", 162, 164], ["future investigation", "TEST", 56, 76], ["niclosamide", "TREATMENT", 138, 149]]], ["The increase in ear thickness was measured after 16 h.", [["ear", "ANATOMY", 16, 19], ["ear", "ORGAN", 16, 19], ["The increase in ear thickness", "PROBLEM", 0, 29], ["increase", "OBSERVATION_MODIFIER", 4, 12], ["ear", "ANATOMY", 16, 19], ["thickness", "OBSERVATION_MODIFIER", 20, 29]]], ["The data are shown as mean \u00b1 SD from six mice and representative of two independent experiments yielding similar result, \u2044\u2044 p < 0.01 indicates a significant difference between the DNFB + Solvent (i.v) and DNFB + (Niclosamide).", [["DNFB", "CHEMICAL", 180, 184], ["DNFB", "CHEMICAL", 205, 209], ["Niclosamide", "CHEMICAL", 213, 224], ["DNFB", "CHEMICAL", 180, 184], ["DNFB", "CHEMICAL", 205, 209], ["Niclosamide", "CHEMICAL", 213, 224], ["mice", "ORGANISM", 41, 45], ["DNFB", "SIMPLE_CHEMICAL", 180, 184], ["DNFB +", "SIMPLE_CHEMICAL", 205, 211], ["Niclosamide", "SIMPLE_CHEMICAL", 213, 224], ["mice", "SPECIES", 41, 45], ["mice", "SPECIES", 41, 45], ["The data", "TEST", 0, 8], ["the DNFB + Solvent", "TREATMENT", 176, 194], ["DNFB + (Niclosamide)", "TREATMENT", 205, 225], ["significant", "OBSERVATION_MODIFIER", 145, 156]]], ["Representative histopathology from the ear tissues.", [["ear tissues", "ANATOMY", 39, 50], ["ear tissues", "TISSUE", 39, 50], ["Representative histopathology", "TEST", 0, 29], ["histopathology", "OBSERVATION", 15, 29], ["ear tissues", "ANATOMY", 39, 50]]], ["Cryosection of ears from different treated mice prepared at 24 h after hapten challenge were stained with hematoxylin and eosin (H&E), original magnification \u00c2 100.", [["ears", "ANATOMY", 15, 19], ["hematoxylin", "CHEMICAL", 106, 117], ["eosin", "CHEMICAL", 122, 127], ["ears", "ORGAN", 15, 19], ["mice", "ORGANISM", 43, 47], ["hematoxylin", "SIMPLE_CHEMICAL", 106, 117], ["mice", "SPECIES", 43, 47], ["mice", "SPECIES", 43, 47], ["Cryosection of ears", "PROBLEM", 0, 19], ["hapten challenge", "TREATMENT", 71, 87], ["hematoxylin", "TREATMENT", 106, 117], ["eosin", "TREATMENT", 122, 127], ["ears", "ANATOMY", 15, 19]]]], "ba8fe1c2d78b3294ccd0a5252d86126b09cd2084": [["INTRODUCTIONIn December 2019, the Wuhan Municipal Health Commission reported the first cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in China, with the associated clinical manifestation termed COVID-19 (coronavirus disease 2019) that has since caused a global pandemic.", [["acute respiratory syndrome coronavirus", "DISEASE", 103, 141], ["coronavirus disease", "DISEASE", 227, 246], ["SARS-CoV-2", "ORGANISM", 145, 155], ["severe acute respiratory syndrome coronavirus", "SPECIES", 96, 141], ["SARS-CoV-2", "SPECIES", 145, 155], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 96, 141], ["SARS-CoV", "TEST", 145, 153], ["COVID", "TEST", 217, 222], ["coronavirus disease", "PROBLEM", 227, 246], ["a global pandemic", "PROBLEM", 275, 292], ["severe", "OBSERVATION_MODIFIER", 96, 102], ["acute", "OBSERVATION_MODIFIER", 103, 108], ["respiratory syndrome", "OBSERVATION", 109, 129], ["global", "OBSERVATION_MODIFIER", 277, 283], ["pandemic", "OBSERVATION", 284, 292]]], ["1, 2 Two family clusters were noted among these initial cases, with one cluster demonstrating evidence of person-toperson transmission.", [["person", "SPECIES", 106, 112]]], ["1 Since then, cases of family clusters have been reported worldwide, with disease severity ranging from mild flu-like symptoms to fatal acute respiratory failure.", [["respiratory", "ANATOMY", 142, 153], ["flu-like symptoms", "DISEASE", 109, 126], ["acute respiratory failure", "DISEASE", 136, 161], ["disease severity", "PROBLEM", 74, 90], ["mild flu-like symptoms", "PROBLEM", 104, 126], ["fatal acute respiratory failure", "PROBLEM", 130, 161], ["mild", "OBSERVATION_MODIFIER", 104, 108], ["flu", "OBSERVATION", 109, 112], ["fatal", "OBSERVATION_MODIFIER", 130, 135], ["acute", "OBSERVATION_MODIFIER", 136, 141], ["respiratory failure", "OBSERVATION", 142, 161]]], ["3 Preexisting comorbidities, sex, and race have been reported as risk factors for severe COVID-19.", [["Preexisting comorbidities", "PROBLEM", 2, 27], ["severe COVID", "PROBLEM", 82, 94], ["comorbidities", "OBSERVATION", 14, 27]]], ["[4] [5] [6] The evidence base for a familial predisposition toward severe complications secondary to COVID-19 is growing, as underscored by a New Jersey family cluster with multiple fatalities from COVID-19.", [["COVID", "DISEASE", 101, 106], ["fatalities", "DISEASE", 182, 192], ["a familial predisposition", "PROBLEM", 34, 59], ["severe complications", "PROBLEM", 67, 87], ["COVID", "TEST", 101, 106], ["COVID", "TEST", 198, 203]]], ["7 However, the number of published reports of family clusters of COVID-19 infections resulting in fatal respiratory disease is sparse.", [["respiratory", "ANATOMY", 104, 115], ["infections", "DISEASE", 74, 84], ["respiratory disease", "DISEASE", 104, 123], ["COVID-19", "ORGANISM", 65, 73], ["COVID-19 infections", "PROBLEM", 65, 84], ["fatal respiratory disease", "PROBLEM", 98, 123], ["fatal", "OBSERVATION_MODIFIER", 98, 103], ["respiratory disease", "OBSERVATION", 104, 123]]], ["8 We describe a family cluster of 4 COVID-19-positive patients who all developed acute respiratory distress syndrome (ARDS) that ultimately led to death.CASE SERIESIn early March 2020, 4 family members living in the same household were hospitalized with fever and respiratory symptoms.", [["respiratory", "ANATOMY", 87, 98], ["respiratory", "ANATOMY", 264, 275], ["acute respiratory distress syndrome", "DISEASE", 81, 116], ["ARDS", "DISEASE", 118, 122], ["death", "DISEASE", 147, 152], ["fever", "DISEASE", 254, 259], ["respiratory symptoms", "DISEASE", 264, 284], ["COVID-19", "GENE_OR_GENE_PRODUCT", 36, 44], ["patients", "ORGANISM", 54, 62], ["patients", "SPECIES", 54, 62], ["acute respiratory distress syndrome", "PROBLEM", 81, 116], ["ARDS", "PROBLEM", 118, 122], ["death", "PROBLEM", 147, 152], ["fever", "PROBLEM", 254, 259], ["respiratory symptoms", "PROBLEM", 264, 284], ["acute", "OBSERVATION_MODIFIER", 81, 86], ["respiratory distress syndrome", "OBSERVATION", 87, 116]]], ["Patient 1, the matriarch and index case in the family, reported possible exposures from caregivers who exhibited flu-like symptoms or from attending church services.Patient 1An 86-year-old African American female with a history of adequately controlled diabetes mellitus (HbA1c 6.4%), coronary artery disease, hypertension, and Alzheimer disease presented on March 8 for symptoms of fever, vomiting, and shortness of breath for 24 hours and a syncopal episode 1 day prior to symptom onset.", [["coronary artery", "ANATOMY", 285, 300], ["flu-like symptoms", "DISEASE", 113, 130], ["diabetes mellitus", "DISEASE", 253, 270], ["coronary artery disease", "DISEASE", 285, 308], ["hypertension", "DISEASE", 310, 322], ["Alzheimer disease", "DISEASE", 328, 345], ["fever", "DISEASE", 383, 388], ["vomiting", "DISEASE", 390, 398], ["shortness of breath", "DISEASE", 404, 423], ["syncopal", "DISEASE", 443, 451], ["American", "ORGANISM", 197, 205], ["female", "ORGANISM", 206, 212], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 285, 300], ["Patient", "SPECIES", 0, 7], ["Patient", "SPECIES", 165, 172], ["flu-like symptoms", "PROBLEM", 113, 130], ["adequately controlled diabetes mellitus", "PROBLEM", 231, 270], ["HbA1c", "TEST", 272, 277], ["coronary artery disease", "PROBLEM", 285, 308], ["hypertension", "PROBLEM", 310, 322], ["Alzheimer disease", "PROBLEM", 328, 345], ["symptoms", "PROBLEM", 371, 379], ["fever", "PROBLEM", 383, 388], ["vomiting", "PROBLEM", 390, 398], ["shortness of breath", "PROBLEM", 404, 423], ["a syncopal episode", "PROBLEM", 441, 459], ["symptom onset", "PROBLEM", 475, 488], ["adequately controlled", "OBSERVATION_MODIFIER", 231, 252], ["diabetes", "OBSERVATION", 253, 261], ["coronary artery", "ANATOMY", 285, 300], ["disease", "OBSERVATION", 301, 308], ["hypertension", "OBSERVATION", 310, 322], ["Alzheimer disease", "OBSERVATION", 328, 345], ["fever", "OBSERVATION", 383, 388]]], ["In the emergency department (ED), her chest x-ray was unremarkable, and influenza assay was negative.", [["her chest x-ray", "TEST", 34, 49], ["influenza assay", "TEST", 72, 87], ["chest", "ANATOMY", 38, 43], ["unremarkable", "OBSERVATION", 54, 66]]], ["She was febrile at 102.4\u00b0F in the ED and was admitted for observation.", [["febrile", "DISEASE", 8, 15], ["febrile", "PROBLEM", 8, 15]]], ["On March 10, the patient developed worsening dyspnea and was placed on 2 L of supplemental oxygen via nasal cannula.Patient 1Repeat chest x-ray showed bilateral ground-glass opacities, more severe on the right ( Figure 1A ).", [["nasal", "ANATOMY", 102, 107], ["dyspnea", "DISEASE", 45, 52], ["oxygen", "CHEMICAL", 91, 97], ["oxygen", "CHEMICAL", 91, 97], ["patient", "ORGANISM", 17, 24], ["oxygen", "SIMPLE_CHEMICAL", 91, 97], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 102, 115], ["patient", "SPECIES", 17, 24], ["Patient", "SPECIES", 116, 123], ["worsening dyspnea", "PROBLEM", 35, 52], ["supplemental oxygen", "TREATMENT", 78, 97], ["nasal cannula", "TREATMENT", 102, 115], ["Patient 1Repeat chest x-ray", "TEST", 116, 143], ["bilateral ground-glass opacities", "PROBLEM", 151, 183], ["worsening", "OBSERVATION_MODIFIER", 35, 44], ["dyspnea", "OBSERVATION", 45, 52], ["chest", "ANATOMY", 132, 137], ["bilateral", "ANATOMY_MODIFIER", 151, 160], ["ground", "OBSERVATION", 161, 167], ["glass opacities", "OBSERVATION", 168, 183], ["more", "OBSERVATION_MODIFIER", 185, 189], ["severe", "OBSERVATION_MODIFIER", 190, 196], ["right", "ANATOMY_MODIFIER", 204, 209]]], ["C-reactive protein was 155.9 mg/dL.", [["C-reactive protein", "GENE_OR_GENE_PRODUCT", 0, 18], ["C-reactive protein", "PROTEIN", 0, 18], ["reactive protein", "TEST", 2, 18], ["reactive protein", "OBSERVATION", 2, 18]]], ["Nasopharyngeal swab submitted for SARS-CoV-2 qualitative polymerase chain reaction (PCR) testing returned positive.", [["Nasopharyngeal swab", "ANATOMY", 0, 19], ["Nasopharyngeal swab", "CANCER", 0, 19], ["SARS-CoV", "SPECIES", 34, 42], ["Nasopharyngeal swab", "TEST", 0, 19], ["SARS", "PROBLEM", 34, 38], ["CoV", "TEST", 39, 42], ["qualitative polymerase chain reaction", "PROBLEM", 45, 82], ["PCR) testing", "TEST", 84, 96]]], ["The patient developed respiratory failure and was transferred to the intensive care unit (ICU) on March 12.", [["respiratory", "ANATOMY", 22, 33], ["respiratory failure", "DISEASE", 22, 41], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["respiratory failure", "PROBLEM", 22, 41], ["respiratory failure", "OBSERVATION", 22, 41]]], ["She was supported with noninvasive ventilation.", [["noninvasive ventilation", "TREATMENT", 23, 46]]], ["Urine antigen for Streptococcus pneumoniae collected March 12 tested positive, and the patient was started on methylprednisolone (60 mg intravenous [IV] daily), azithromycin (500 mg IV daily), ceftriaxone (1 g IV daily), and hydroxychloroquine (800 mg loading dose, followed by 400 mg daily).", [["methylprednisolone", "CHEMICAL", 110, 128], ["azithromycin", "CHEMICAL", 161, 173], ["ceftriaxone", "CHEMICAL", 193, 204], ["hydroxychloroquine", "CHEMICAL", 225, 243], ["methylprednisolone", "CHEMICAL", 110, 128], ["azithromycin", "CHEMICAL", 161, 173], ["ceftriaxone", "CHEMICAL", 193, 204], ["hydroxychloroquine", "CHEMICAL", 225, 243], ["Urine", "ORGANISM_SUBSTANCE", 0, 5], ["Streptococcus pneumoniae", "ORGANISM", 18, 42], ["patient", "ORGANISM", 87, 94], ["methylprednisolone", "SIMPLE_CHEMICAL", 110, 128], ["azithromycin", "SIMPLE_CHEMICAL", 161, 173], ["ceftriaxone", "SIMPLE_CHEMICAL", 193, 204], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 225, 243], ["Urine antigen", "PROTEIN", 0, 13], ["Streptococcus pneumoniae", "SPECIES", 18, 42], ["patient", "SPECIES", 87, 94], ["Streptococcus pneumoniae", "SPECIES", 18, 42], ["Urine antigen", "TEST", 0, 13], ["Streptococcus pneumoniae", "PROBLEM", 18, 42], ["methylprednisolone", "TREATMENT", 110, 128], ["azithromycin", "TREATMENT", 161, 173], ["ceftriaxone", "TREATMENT", 193, 204], ["hydroxychloroquine", "TREATMENT", 225, 243]]], ["On March 16, her respiratory status improved, and she was transferred out of the ICU.", [["respiratory", "ANATOMY", 17, 28]]], ["On March 18 (day 12 of symptoms), the patient again developed worsening dyspnea and hypoxemia with oxygen saturation of 86% with a non-rebreather mask.", [["dyspnea", "DISEASE", 72, 79], ["hypoxemia", "DISEASE", 84, 93], ["oxygen", "CHEMICAL", 99, 105], ["oxygen", "CHEMICAL", 99, 105], ["patient", "ORGANISM", 38, 45], ["oxygen", "SIMPLE_CHEMICAL", 99, 105], ["patient", "SPECIES", 38, 45], ["symptoms", "PROBLEM", 23, 31], ["worsening dyspnea", "PROBLEM", 62, 79], ["hypoxemia", "PROBLEM", 84, 93], ["oxygen saturation", "TEST", 99, 116], ["a non-rebreather mask", "TREATMENT", 129, 150], ["worsening", "OBSERVATION_MODIFIER", 62, 71], ["dyspnea", "OBSERVATION", 72, 79], ["hypoxemia", "OBSERVATION", 84, 93]]], ["The family made the decision to transition the patient to home hospice care.", [["patient", "ORGANISM", 47, 54], ["patient", "SPECIES", 47, 54], ["home hospice care", "TREATMENT", 58, 75]]], ["She was discharged on March 22 and died in her home on March 23.Patient 2The 58-year-old son of Patient 1 also had a history of adequately controlled diabetes mellitus (HbA1c 6.5%) and presented to the ED on March 12 for 3 days of cough, shortness of breath, and fever.", [["diabetes mellitus", "DISEASE", 150, 167], ["cough", "DISEASE", 231, 236], ["shortness of breath", "DISEASE", 238, 257], ["fever", "DISEASE", 263, 268], ["Patient", "SPECIES", 64, 71], ["Patient", "SPECIES", 96, 103], ["adequately controlled diabetes mellitus", "PROBLEM", 128, 167], ["HbA1c", "TEST", 169, 174], ["cough", "PROBLEM", 231, 236], ["shortness of breath", "PROBLEM", 238, 257], ["fever", "PROBLEM", 263, 268], ["cough", "OBSERVATION", 231, 236], ["fever", "OBSERVATION", 263, 268]]], ["In the ED, he had a fever of 102.2\u00b0F and hypoxemia, with an oxygen saturation of 90% on room air.Patient 2Influenza assay was negative.", [["fever", "DISEASE", 20, 25], ["hypoxemia", "DISEASE", 41, 50], ["oxygen", "CHEMICAL", 60, 66], ["oxygen", "CHEMICAL", 60, 66], ["oxygen", "SIMPLE_CHEMICAL", 60, 66], ["Patient", "SPECIES", 97, 104], ["a fever", "PROBLEM", 18, 25], ["hypoxemia", "PROBLEM", 41, 50], ["an oxygen saturation", "TEST", 57, 77], ["Patient 2Influenza assay", "TEST", 97, 121], ["hypoxemia", "OBSERVATION", 41, 50], ["oxygen", "OBSERVATION_MODIFIER", 60, 66], ["saturation", "OBSERVATION_MODIFIER", 67, 77]]], ["Chest x-ray showed bilateral airspace opacities ( Figure 1B ).", [["airspace", "ANATOMY", 29, 37], ["Chest x-ray", "TEST", 0, 11], ["bilateral airspace opacities", "PROBLEM", 19, 47], ["bilateral", "ANATOMY_MODIFIER", 19, 28], ["airspace", "ANATOMY_MODIFIER", 29, 37], ["opacities", "OBSERVATION", 38, 47]]], ["Nasopharyngeal swab submitted for SARS-CoV-2 PCR testing returned positive.", [["Nasopharyngeal swab", "ANATOMY", 0, 19], ["Nasopharyngeal swab", "CANCER", 0, 19], ["SARS-CoV", "SPECIES", 34, 42], ["Nasopharyngeal swab", "TEST", 0, 19], ["SARS", "TEST", 34, 38], ["CoV", "TEST", 39, 42], ["PCR testing", "TEST", 45, 56]]], ["The patient was admitted and started on ceftriaxone (1 g IV daily), azithromycin (500 mg IV daily), and hydroxychloroquine (800 mg loading dose, followed by 400 mg daily).", [["ceftriaxone", "CHEMICAL", 40, 51], ["azithromycin", "CHEMICAL", 68, 80], ["hydroxychloroquine", "CHEMICAL", 104, 122], ["ceftriaxone", "CHEMICAL", 40, 51], ["azithromycin", "CHEMICAL", 68, 80], ["hydroxychloroquine", "CHEMICAL", 104, 122], ["patient", "ORGANISM", 4, 11], ["ceftriaxone", "SIMPLE_CHEMICAL", 40, 51], ["azithromycin", "SIMPLE_CHEMICAL", 68, 80], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 104, 122], ["patient", "SPECIES", 4, 11], ["ceftriaxone", "TREATMENT", 40, 51], ["azithromycin", "TREATMENT", 68, 80], ["hydroxychloroquine", "TREATMENT", 104, 122]]], ["On March 14 (day 5 of symptoms), his hypoxemia worsened despite a non-rebreather mask, with oxygen saturation decreasing to as low as 70%.", [["hypoxemia", "DISEASE", 37, 46], ["oxygen", "CHEMICAL", 92, 98], ["oxygen", "CHEMICAL", 92, 98], ["oxygen", "SIMPLE_CHEMICAL", 92, 98], ["symptoms", "PROBLEM", 22, 30], ["his hypoxemia", "PROBLEM", 33, 46], ["a non-rebreather mask", "TREATMENT", 64, 85], ["oxygen saturation", "TEST", 92, 109], ["hypoxemia", "OBSERVATION", 37, 46], ["worsened", "OBSERVATION_MODIFIER", 47, 55]]], ["C-reactive protein was 142 mg/L, and ferritin was 2,188 ng/mL.", [["C-reactive protein", "GENE_OR_GENE_PRODUCT", 0, 18], ["ferritin", "GENE_OR_GENE_PRODUCT", 37, 45], ["C-reactive protein", "PROTEIN", 0, 18], ["ferritin", "PROTEIN", 37, 45], ["C-reactive protein", "TEST", 0, 18], ["ferritin", "TEST", 37, 45], ["reactive", "OBSERVATION_MODIFIER", 2, 10]]], ["He was transferred to the ICU where he was intubated and mechanically ventilated.", [["He", "ORGANISM", 0, 2], ["intubated", "TREATMENT", 43, 52], ["mechanically ventilated", "TREATMENT", 57, 80], ["mechanically ventilated", "OBSERVATION", 57, 80]]], ["The patient met criteria for severe ARDS with an arterial oxygen partial pressure (PaO 2 )/fraction of inspired oxygen (FiO 2 ) ratio as low as 98.", [["arterial", "ANATOMY", 49, 57], ["ARDS", "DISEASE", 36, 40], ["oxygen", "CHEMICAL", 58, 64], ["oxygen", "CHEMICAL", 112, 118], ["oxygen", "CHEMICAL", 58, 64], ["oxygen", "CHEMICAL", 112, 118], ["FiO 2 )", "CHEMICAL", 120, 127], ["patient", "ORGANISM", 4, 11], ["arterial", "MULTI-TISSUE_STRUCTURE", 49, 57], ["oxygen", "SIMPLE_CHEMICAL", 58, 64], ["oxygen", "SIMPLE_CHEMICAL", 112, 118], ["patient", "SPECIES", 4, 11], ["severe ARDS", "PROBLEM", 29, 40], ["an arterial oxygen partial pressure (PaO", "TREATMENT", 46, 86], ["inspired oxygen", "TREATMENT", 103, 118], ["FiO", "TEST", 120, 123], ["severe", "OBSERVATION_MODIFIER", 29, 35], ["ARDS", "OBSERVATION", 36, 40], ["arterial", "ANATOMY", 49, 57], ["pressure", "OBSERVATION_MODIFIER", 73, 81]]], ["He was treated with a protocol of daily prone positioning.", [["a protocol", "TREATMENT", 20, 30], ["daily prone positioning", "TREATMENT", 34, 57]]], ["The ICU used a protocol for prone positioning similar to that used in the Effect of Prone Positioning on Mortality in Patients With Severe and Persistent Acute Respiratory Distress Syndrome (PROSEVA) study.", [["Acute Respiratory Distress Syndrome", "DISEASE", 154, 189], ["Patients", "ORGANISM", 118, 126], ["Patients", "SPECIES", 118, 126], ["a protocol", "TREATMENT", 13, 23], ["prone positioning", "TREATMENT", 28, 45], ["Severe and Persistent Acute Respiratory Distress Syndrome", "PROBLEM", 132, 189], ["Persistent", "OBSERVATION_MODIFIER", 143, 153], ["Acute", "OBSERVATION_MODIFIER", 154, 159], ["Respiratory Distress", "OBSERVATION", 160, 180]]], ["9 On March 22, he developed acute kidney injury (AKI) requiring initiation of continuous renal replacement therapy (CRRT).", [["kidney", "ANATOMY", 34, 40], ["renal", "ANATOMY", 89, 94], ["acute kidney injury", "DISEASE", 28, 47], ["AKI", "DISEASE", 49, 52], ["kidney", "ORGAN", 34, 40], ["renal", "ORGAN", 89, 94], ["acute kidney injury", "PROBLEM", 28, 47], ["AKI", "PROBLEM", 49, 52], ["continuous renal replacement therapy", "TREATMENT", 78, 114], ["CRRT", "TREATMENT", 116, 120], ["acute", "OBSERVATION_MODIFIER", 28, 33], ["kidney", "ANATOMY", 34, 40], ["injury", "OBSERVATION", 41, 47], ["AKI", "OBSERVATION", 49, 52], ["renal", "ANATOMY", 89, 94], ["replacement", "OBSERVATION", 95, 106]]], ["Medical record review revealed no history of chronic kidney disease (CKD).", [["kidney", "ANATOMY", 53, 59], ["chronic kidney disease", "DISEASE", 45, 67], ["CKD", "DISEASE", 69, 72], ["kidney", "ORGAN", 53, 59], ["chronic kidney disease", "PROBLEM", 45, 67], ["CKD", "PROBLEM", 69, 72], ["no", "UNCERTAINTY", 31, 33], ["chronic", "OBSERVATION_MODIFIER", 45, 52], ["kidney", "ANATOMY", 53, 59], ["disease", "OBSERVATION", 60, 67], ["CKD", "OBSERVATION", 69, 72]]], ["Because of clotting of the dialysis circuit, he was treated with a continuous infusion of unfractionated heparin.", [["heparin", "CHEMICAL", 105, 112], ["heparin", "SIMPLE_CHEMICAL", 105, 112], ["the dialysis circuit", "TREATMENT", 23, 43], ["a continuous infusion of unfractionated heparin", "TREATMENT", 65, 112], ["clotting", "OBSERVATION", 11, 19], ["dialysis circuit", "OBSERVATION", 27, 43]]], ["On March 23, he developed bilateral pneumothoraces requiring chest tube placement.", [["chest tube", "ANATOMY", 61, 71], ["pneumothoraces", "DISEASE", 36, 50], ["chest tube", "MULTI-TISSUE_STRUCTURE", 61, 71], ["bilateral pneumothoraces", "PROBLEM", 26, 50], ["chest tube placement", "TREATMENT", 61, 81], ["bilateral", "ANATOMY_MODIFIER", 26, 35], ["pneumothoraces", "OBSERVATION", 36, 50], ["chest", "ANATOMY", 61, 66], ["tube placement", "OBSERVATION", 67, 81]]], ["His condition deteriorated despite these measures.", [["His condition", "PROBLEM", 0, 13], ["these measures", "TREATMENT", 35, 49], ["deteriorated", "OBSERVATION", 14, 26]]], ["The patient developed shock refractory to vasopressor therapy and died on March 26.Patient 3The 71-year-old son of Patient 1 with a history of hypertension, CKD (stage 3), and sarcoidosis (inactive disease, not on treatment) presented to the ED on March 15.", [["shock", "DISEASE", 22, 27], ["hypertension", "DISEASE", 143, 155], ["CKD", "DISEASE", 157, 160], ["sarcoidosis", "DISEASE", 176, 187], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["Patient", "SPECIES", 83, 90], ["Patient", "SPECIES", 115, 122], ["shock", "PROBLEM", 22, 27], ["vasopressor therapy", "TREATMENT", 42, 61], ["hypertension", "PROBLEM", 143, 155], ["CKD (stage 3)", "PROBLEM", 157, 170], ["sarcoidosis", "PROBLEM", 176, 187], ["inactive disease", "PROBLEM", 189, 205], ["treatment", "TREATMENT", 214, 223], ["shock", "OBSERVATION", 22, 27], ["vasopressor therapy", "OBSERVATION", 42, 61], ["hypertension", "OBSERVATION", 143, 155], ["CKD", "OBSERVATION", 157, 160], ["sarcoidosis", "OBSERVATION", 176, 187], ["inactive", "OBSERVATION_MODIFIER", 189, 197], ["disease", "OBSERVATION", 198, 205]]], ["Symptoms included cough, fever of 102.6\u00b0F, and shortness of breath.", [["cough", "DISEASE", 18, 23], ["fever", "DISEASE", 25, 30], ["shortness of breath", "DISEASE", 47, 66], ["Symptoms", "PROBLEM", 0, 8], ["cough", "PROBLEM", 18, 23], ["fever", "PROBLEM", 25, 30], ["shortness of breath", "PROBLEM", 47, 66], ["cough", "OBSERVATION", 18, 23]]], ["He was tachycardic and hypoxemic, with an oxygen saturation as low as 70% on room air.", [["hypoxemic", "DISEASE", 23, 32], ["oxygen", "CHEMICAL", 42, 48], ["oxygen", "CHEMICAL", 42, 48], ["He", "ORGANISM", 0, 2], ["oxygen", "SIMPLE_CHEMICAL", 42, 48], ["tachycardic", "PROBLEM", 7, 18], ["hypoxemic", "PROBLEM", 23, 32], ["an oxygen saturation", "TEST", 39, 59], ["tachycardic", "OBSERVATION_MODIFIER", 7, 18], ["hypoxemic", "OBSERVATION", 23, 32], ["oxygen saturation", "OBSERVATION", 42, 59]]], ["Influenza assay was negative.", [["Influenza assay", "TEST", 0, 15]]], ["Chest x-ray showed bilateral airspace opacities ( Figure 1C ).", [["airspace", "ANATOMY", 29, 37], ["Chest x-ray", "TEST", 0, 11], ["bilateral airspace opacities", "PROBLEM", 19, 47], ["bilateral", "ANATOMY_MODIFIER", 19, 28], ["airspace", "ANATOMY_MODIFIER", 29, 37], ["opacities", "OBSERVATION", 38, 47]]], ["C-reactive protein was 90.6 mg/L. Nasopharyngeal swab submitted for SARS-CoV-2 PCR testing returned positive.", [["Nasopharyngeal swab", "ANATOMY", 34, 53], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 0, 18], ["C-reactive protein", "PROTEIN", 0, 18], ["SARS-CoV", "SPECIES", 68, 76], ["C-reactive protein", "TEST", 0, 18], ["Nasopharyngeal swab", "TEST", 34, 53], ["SARS", "TEST", 68, 72], ["CoV", "TEST", 73, 76], ["PCR testing", "TEST", 79, 90], ["reactive", "OBSERVATION_MODIFIER", 2, 10], ["Nasopharyngeal", "ANATOMY", 34, 48]]], ["The patient was admitted directly to the ICU where he was intubated and mechanically ventilated.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["intubated", "TREATMENT", 58, 67], ["mechanically ventilated", "TREATMENT", 72, 95], ["mechanically ventilated", "OBSERVATION", 72, 95]]], ["He met criteria for severe ARDS with a PaO 2 /FiO 2 ratio as low as 76.", [["ARDS", "DISEASE", 27, 31], ["severe ARDS", "PROBLEM", 20, 31], ["a PaO", "TEST", 37, 42], ["FiO 2 ratio", "TEST", 46, 57], ["severe", "OBSERVATION_MODIFIER", 20, 26], ["ARDS", "OBSERVATION", 27, 31]]], ["He was treated with a protocol of daily prone position-ing.", [["He", "ORGANISM", 0, 2], ["a protocol", "TREATMENT", 20, 30], ["daily prone position", "TREATMENT", 34, 54]]], ["Medications included ceftriaxone (1 g IV twice daily) and hydroxychloroquine (800 mg loading dose, followed by 400 mg daily).", [["ceftriaxone", "CHEMICAL", 21, 32], ["hydroxychloroquine", "CHEMICAL", 58, 76], ["ceftriaxone", "CHEMICAL", 21, 32], ["hydroxychloroquine", "CHEMICAL", 58, 76], ["ceftriaxone", "SIMPLE_CHEMICAL", 21, 32], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 58, 76], ["Medications", "TREATMENT", 0, 11], ["ceftriaxone", "TREATMENT", 21, 32], ["hydroxychloroquine", "TREATMENT", 58, 76]]], ["The patient's condition deteriorated rapidly, and he died on March 20.Patient 4The 61-year-old son of Patient 1 with a history of hypertension, multiple sclerosis, and seizure disorder presented to the ED on March 14 with symptoms of fever, vomiting, and shortness of breath for 4 days.", [["hypertension", "DISEASE", 130, 142], ["multiple sclerosis", "DISEASE", 144, 162], ["seizure disorder", "DISEASE", 168, 184], ["fever", "DISEASE", 234, 239], ["vomiting", "DISEASE", 241, 249], ["shortness of breath", "DISEASE", 255, 274], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["Patient", "SPECIES", 70, 77], ["Patient", "SPECIES", 102, 109], ["hypertension", "PROBLEM", 130, 142], ["multiple sclerosis", "PROBLEM", 144, 162], ["seizure disorder", "PROBLEM", 168, 184], ["symptoms", "PROBLEM", 222, 230], ["fever", "PROBLEM", 234, 239], ["vomiting", "PROBLEM", 241, 249], ["shortness of breath", "PROBLEM", 255, 274], ["hypertension", "OBSERVATION", 130, 142], ["multiple", "OBSERVATION_MODIFIER", 144, 152], ["sclerosis", "OBSERVATION", 153, 162], ["seizure disorder", "OBSERVATION", 168, 184], ["fever", "OBSERVATION", 234, 239]]], ["He was hypoxemic with an oxygen saturation of 90% on room air and febrile at 101.3\u00b0F upon presentation.", [["hypoxemic", "DISEASE", 7, 16], ["oxygen", "CHEMICAL", 25, 31], ["febrile", "DISEASE", 66, 73], ["oxygen", "CHEMICAL", 25, 31], ["He", "ORGANISM", 0, 2], ["oxygen", "SIMPLE_CHEMICAL", 25, 31], ["hypoxemic", "PROBLEM", 7, 16], ["an oxygen saturation", "TEST", 22, 42], ["febrile", "PROBLEM", 66, 73], ["hypoxemic", "OBSERVATION", 7, 16]]], ["Chest x-ray showed bilateral airspace opacities, more severe on the right ( Figure 1D ).", [["airspace", "ANATOMY", 29, 37], ["opacities", "DISEASE", 38, 47], ["Chest x-ray", "TEST", 0, 11], ["bilateral airspace opacities", "PROBLEM", 19, 47], ["bilateral", "ANATOMY_MODIFIER", 19, 28], ["airspace", "ANATOMY_MODIFIER", 29, 37], ["opacities", "OBSERVATION", 38, 47], ["more", "OBSERVATION_MODIFIER", 49, 53], ["severe", "OBSERVATION_MODIFIER", 54, 60], ["right", "ANATOMY_MODIFIER", 68, 73]]], ["Influenza assay was negative.", [["Influenza assay", "TEST", 0, 15]]], ["Nasopharyngeal swab submitted for SARS-CoV-2 PCR testing returned positive.", [["Nasopharyngeal swab", "ANATOMY", 0, 19], ["Nasopharyngeal swab", "CANCER", 0, 19], ["SARS-CoV", "SPECIES", 34, 42], ["Nasopharyngeal swab", "TEST", 0, 19], ["SARS", "TEST", 34, 38], ["CoV", "TEST", 39, 42], ["PCR testing", "TEST", 45, 56]]], ["On March 15 (day 5 of symptoms), the patient's hypoxemia worsened, and he was moved to the ICU where he was intubated and mechanically ventilated.", [["hypoxemia", "DISEASE", 47, 56], ["patient", "ORGANISM", 37, 44], ["patient", "SPECIES", 37, 44], ["symptoms", "PROBLEM", 22, 30], ["the patient's hypoxemia", "PROBLEM", 33, 56], ["intubated", "TREATMENT", 108, 117], ["mechanically ventilated", "TREATMENT", 122, 145], ["hypoxemia", "OBSERVATION", 47, 56], ["worsened", "OBSERVATION_MODIFIER", 57, 65], ["mechanically ventilated", "OBSERVATION", 122, 145]]], ["C-reactive protein was 338 mg/dL, and lactate dehydrogenase was 714 U/L. He met criteria for severe ARDS with a PaO 2 /FiO 2 ratio of 73.", [["lactate", "CHEMICAL", 38, 45], ["ARDS", "DISEASE", 100, 104], ["lactate", "CHEMICAL", 38, 45], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 0, 18], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 38, 59], ["C-reactive protein", "PROTEIN", 0, 18], ["lactate dehydrogenase", "PROTEIN", 38, 59], ["C-reactive protein", "TEST", 0, 18], ["lactate dehydrogenase", "TEST", 38, 59], ["severe ARDS", "PROBLEM", 93, 104], ["a PaO", "TEST", 110, 115], ["FiO 2 ratio", "TEST", 119, 130], ["reactive", "OBSERVATION_MODIFIER", 2, 10], ["severe", "OBSERVATION_MODIFIER", 93, 99], ["ARDS", "OBSERVATION", 100, 104]]], ["He was treated with a protocol of daily prone positioning.", [["a protocol", "TREATMENT", 20, 30], ["daily prone positioning", "TREATMENT", 34, 57]]], ["He developed AKI requiring initiation of CRRT on March 17.", [["AKI", "DISEASE", 13, 16], ["AKI", "PROBLEM", 13, 16], ["CRRT", "TREATMENT", 41, 45], ["AKI", "OBSERVATION", 13, 16]]], ["Medical record review revealed no history of CKD.", [["CKD", "DISEASE", 45, 48], ["Medical record review", "TEST", 0, 21], ["CKD", "PROBLEM", 45, 48], ["no", "UNCERTAINTY", 31, 33], ["CKD", "OBSERVATION", 45, 48]]], ["Because of clotting of the dialysis circuit, he was treated with a continuous infusion of unfractionated heparin.", [["heparin", "CHEMICAL", 105, 112], ["heparin", "SIMPLE_CHEMICAL", 105, 112], ["the dialysis circuit", "TREATMENT", 23, 43], ["a continuous infusion of unfractionated heparin", "TREATMENT", 65, 112], ["clotting", "OBSERVATION", 11, 19], ["dialysis circuit", "OBSERVATION", 27, 43]]], ["Medications included azithromycin (500 mg IV daily), ceftriaxone (1 g IV daily), hydroxychloroquine (800 mg loading dose, followed by 400 mg daily), and dexamethasone (20 mg IV daily).", [["azithromycin", "CHEMICAL", 21, 33], ["ceftriaxone", "CHEMICAL", 53, 64], ["hydroxychloroquine", "CHEMICAL", 81, 99], ["dexamethasone", "CHEMICAL", 153, 166], ["azithromycin", "CHEMICAL", 21, 33], ["ceftriaxone", "CHEMICAL", 53, 64], ["hydroxychloroquine", "CHEMICAL", 81, 99], ["dexamethasone", "CHEMICAL", 153, 166], ["azithromycin", "SIMPLE_CHEMICAL", 21, 33], ["ceftriaxone", "SIMPLE_CHEMICAL", 53, 64], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 81, 99], ["dexamethasone", "SIMPLE_CHEMICAL", 153, 166], ["Medications", "TREATMENT", 0, 11], ["azithromycin", "TREATMENT", 21, 33], ["ceftriaxone", "TREATMENT", 53, 64], ["hydroxychloroquine", "TREATMENT", 81, 99], ["dexamethasone", "TREATMENT", 153, 166]]], ["Despite attempts to wean the patient off mechanical ventilation, he was unable to support his own respiratory efforts and remained on ventilation throughout his ICU stay.", [["respiratory", "ANATOMY", 98, 109], ["patient", "ORGANISM", 29, 36], ["patient", "SPECIES", 29, 36], ["mechanical ventilation", "TREATMENT", 41, 63], ["ventilation", "TREATMENT", 134, 145]]], ["On March 30, the patient developed shock refractory to vasopressor therapy and died.DISCUSSIONMultiple members of a family concurrently developing COVID-19 infections from the virus is not surprising.", [["shock", "DISEASE", 35, 40], ["COVID-19", "CHEMICAL", 147, 155], ["infections", "DISEASE", 156, 166], ["patient", "ORGANISM", 17, 24], ["COVID-19", "ORGANISM", 147, 155], ["patient", "SPECIES", 17, 24], ["shock", "PROBLEM", 35, 40], ["vasopressor therapy", "TREATMENT", 55, 74], ["COVID-19 infections", "PROBLEM", 147, 166], ["the virus", "PROBLEM", 172, 181], ["shock", "OBSERVATION", 35, 40], ["vasopressor therapy", "OBSERVATION", 55, 74]]], ["However, multiple members developing fatal disease should give pause.", [["fatal disease", "PROBLEM", 37, 50], ["multiple", "OBSERVATION_MODIFIER", 9, 17], ["fatal disease", "OBSERVATION", 37, 50]]], ["As of early May 2020, the observed case-fatality rate in the United States was 5.9%, 10 but the actual case-fatality rate was thought to be lower.", [["fatality rate", "TEST", 40, 53], ["fatality rate", "TEST", 108, 121]]], ["11 The family cluster reported here is an anomaly (Figure 2) .", [["an anomaly", "PROBLEM", 39, 49], ["anomaly", "OBSERVATION", 42, 49]]], ["A similar occurrence was reported in New Jersey where COVID-19 infection took the lives of 4 family members.", [["COVID-19", "CHEMICAL", 54, 62], ["infection", "DISEASE", 63, 72], ["COVID-19", "ORGANISM", 54, 62], ["COVID-19", "SPECIES", 54, 62], ["New", "OBSERVATION_MODIFIER", 37, 40], ["infection", "OBSERVATION", 63, 72]]], ["7 We suspect other family clusters of severe disease will emerge as COVID-19 infections are identified globally.DISCUSSIONFrom the onset of the COVID-19 pandemic, clinicians have struggled to understand why some infected patients experience only mild symptoms while others exhibit progressive, fatal disease.", [["infections", "DISEASE", 77, 87], ["patients", "ORGANISM", 221, 229], ["patients", "SPECIES", 221, 229], ["severe disease", "PROBLEM", 38, 52], ["infections", "PROBLEM", 77, 87], ["mild symptoms", "PROBLEM", 246, 259], ["progressive, fatal disease", "PROBLEM", 281, 307], ["severe", "OBSERVATION_MODIFIER", 38, 44], ["disease", "OBSERVATION", 45, 52], ["mild", "OBSERVATION_MODIFIER", 246, 250], ["progressive", "OBSERVATION_MODIFIER", 281, 292], ["fatal disease", "OBSERVATION", 294, 307]]], ["Inheritable traits that predispose to severe complications of COVID-19 infection may exist.", [["COVID", "DISEASE", 62, 67], ["infection", "DISEASE", 71, 80], ["COVID-19", "ORGANISM", 62, 70], ["Inheritable traits", "PROBLEM", 0, 18], ["severe complications", "PROBLEM", 38, 58], ["COVID-19 infection", "PROBLEM", 62, 80], ["severe", "OBSERVATION_MODIFIER", 38, 44], ["complications", "OBSERVATION", 45, 58], ["infection", "OBSERVATION", 71, 80]]], ["Family clusters, such as this one, could be a key to identifying host factors that predispose to a severe disease course and to understanding why subsets of our population are at increased risk.", [["a severe disease course", "PROBLEM", 97, 120], ["severe", "OBSERVATION_MODIFIER", 99, 105], ["disease", "OBSERVATION", 106, 113]]], ["Louisiana data as of April 2020 show hypertension as the leading comorbid condition associated with death in patients with COVID-19, followed by diabetes.", [["hypertension", "DISEASE", 37, 49], ["death", "DISEASE", 100, 105], ["diabetes", "DISEASE", 145, 153], ["patients", "ORGANISM", 109, 117], ["patients", "SPECIES", 109, 117], ["hypertension", "PROBLEM", 37, 49], ["the leading comorbid condition", "PROBLEM", 53, 83], ["death", "PROBLEM", 100, 105], ["COVID", "TEST", 123, 128], ["diabetes", "PROBLEM", 145, 153], ["hypertension", "OBSERVATION", 37, 49], ["diabetes", "OBSERVATION", 145, 153]]], ["12, 13 The Centers for Disease Control and Prevention (CDC) has identified both hypertension and diabetes as risk factors associated with severe disease, 14 and both conditions were present in this family cluster.", [["hypertension", "DISEASE", 80, 92], ["diabetes", "DISEASE", 97, 105], ["Disease Control", "TREATMENT", 23, 38], ["both hypertension", "PROBLEM", 75, 92], ["diabetes", "PROBLEM", 97, 105], ["risk factors", "PROBLEM", 109, 121], ["severe disease", "PROBLEM", 138, 152], ["both", "OBSERVATION_MODIFIER", 75, 79], ["hypertension", "OBSERVATION", 80, 92], ["diabetes", "OBSERVATION", 97, 105], ["severe", "OBSERVATION_MODIFIER", 138, 144], ["disease", "OBSERVATION", 145, 152]]], ["Age is another significant risk factor for mortality, with data from the CDC showing a consistent rise in mortality after the age of 40 years and doubling each decade after the age of 50 years.", [["the CDC", "TEST", 69, 76], ["significant", "OBSERVATION_MODIFIER", 15, 26], ["rise", "OBSERVATION_MODIFIER", 98, 102]]], ["In Louisiana, more than 70% of COVID-19-related deaths have occurred among African Americans who represent slightly more than 30% of the state's population.", [["deaths", "DISEASE", 48, 54], ["COVID-19", "ORGANISM", 31, 39], ["COVID", "TEST", 31, 36]]], ["13 Another important consideration is how viral mutations can manifest within a family cluster.", [["viral mutations", "PROBLEM", 42, 57]]], ["Other previously studied coronaviruses have demonstrated high mutation rates.", [["coronaviruses", "ORGANISM", 25, 38], ["Other previously studied coronaviruses", "PROBLEM", 0, 38], ["high mutation rates", "PROBLEM", 57, 76], ["high mutation", "OBSERVATION", 57, 70]]], ["16 As a result, a more pathogenic sublineage of the virus could emerge and manifest within a family by causing severe disease.", [["the virus", "PROBLEM", 48, 57], ["severe disease", "PROBLEM", 111, 125], ["virus", "OBSERVATION", 52, 57], ["severe", "OBSERVATION_MODIFIER", 111, 117], ["disease", "OBSERVATION", 118, 125]]], ["As researchers endeavor to trace signature mutations in the viral genome sequence, 17 including viral samples from family clusters such as this may prove informative.CONCLUSIONThis report provides evidence of the need for further investigation into family clusters of severe COVID-19 infection to identify both host and viral factors that may predispose to a severe disease course.", [["infection", "DISEASE", 284, 293], ["COVID-19", "ORGANISM", 275, 283], ["viral genome sequence", "DNA", 60, 81], ["viral factors", "PROTEIN", 320, 333], ["COVID-19", "SPECIES", 275, 283], ["trace signature mutations", "PROBLEM", 27, 52], ["the viral genome sequence", "TEST", 56, 81], ["viral samples", "TEST", 96, 109], ["further investigation", "TEST", 222, 243], ["severe COVID-19 infection", "PROBLEM", 268, 293], ["viral factors", "PROBLEM", 320, 333], ["a severe disease course", "PROBLEM", 357, 380], ["severe", "OBSERVATION_MODIFIER", 359, 365], ["disease", "OBSERVATION", 366, 373]]], ["Such investigations could improve our understanding of the disease and guide preventive measures for at-risk populations.", [["Such investigations", "TEST", 0, 19], ["the disease", "PROBLEM", 55, 66], ["preventive measures", "TREATMENT", 77, 96]]]], "5a399d50579b086b03dda1ef61b74d91755f273f": [["BackgroundMany low-and middle-income countries have implemented control measures against coronavirus disease 2019 (COVID- 19) .", [["coronavirus disease", "DISEASE", 89, 108], ["coronavirus", "ORGANISM", 89, 100], ["coronavirus disease", "PROBLEM", 89, 108], ["COVID", "TEST", 115, 120], ["low", "OBSERVATION_MODIFIER", 15, 18], ["middle", "ANATOMY_MODIFIER", 23, 29]]], ["However, it is not clear to what extent these measures explain the low numbers of recorded COVID-19 cases and deaths in Africa.", [["deaths", "DISEASE", 110, 116], ["Africa", "PROBLEM", 120, 126]]], ["One of the main aims of control measures is to reduce respiratory pathogen transmission through direct contact with others.", [["main", "OBSERVATION_MODIFIER", 11, 15], ["respiratory pathogen", "OBSERVATION", 54, 74]]], ["In this study we collect contact data from residents of informal settlements around Nairobi, Kenya to assess if control measures have changed contact patterns, and estimate the impact of changes on the basic reproduction number (R0).MethodsWe conducted a social contact survey with 213 residents of five informal settlements around Nairobi in early May 2020, four weeks after the Kenyan government introduced enhanced physical distancing measures and a curfew between 7pm and 5am.", [["this study", "TEST", 3, 13]]], ["Respondents were asked to report all direct physical and non-physical contacts made the previous day, alongside a questionnaire asking about the social and economic impact of COVID-19 and control measures.", [["COVID", "TREATMENT", 175, 180]]], ["We described the impact of COVID-19 and control measures on income and food security.", [["COVID", "TEST", 27, 32]]], ["We compared contact patterns during control measures to patterns from nonpandemic periods to estimate the change in R0.", [["the change in R0", "PROBLEM", 102, 118]]], ["Masks were worn by at least one person in 92% of contacts.", [["person", "SPECIES", 32, 38]]], ["86% of respondents reported a total or partial loss of income due to COVID-19, and 74% reported eating less or skipping meals due to having too little money for food.", [["COVID", "TEST", 69, 74]]], ["Interpretation COVID-19 control measures have had a large impact on direct contacts and therefore transmission, but have also caused considerable economic and food insecurity.", [["Interpretation COVID", "TEST", 0, 20], ["considerable economic and food insecurity", "PROBLEM", 133, 174], ["large", "OBSERVATION_MODIFIER", 52, 57], ["food insecurity", "OBSERVATION", 159, 174]]], ["Reductions in R0 are consistent with the linear epidemic growth in Kenya and other sub-Saharan African countries that implemented similar, early control measures.", [["Reductions in R0", "PROBLEM", 0, 16], ["the linear epidemic growth", "PROBLEM", 37, 63], ["consistent with", "UNCERTAINTY", 21, 36], ["linear", "OBSERVATION_MODIFIER", 41, 47], ["epidemic", "OBSERVATION_MODIFIER", 48, 56], ["growth", "OBSERVATION_MODIFIER", 57, 63]]], ["However, negative and inequitable impacts on economic and food security may mean control measures are not sustainable in the longer term.Research in contextEvidence before this studyResearch in contextWe conducted a PubMed search on 6 June 2020 with no language restrictions for studies published since inception, using the search terms (\"social mix\" OR \"contact pattern\").", [["economic and food security", "TREATMENT", 45, 71], ["this study", "TEST", 172, 182], ["negative", "OBSERVATION", 9, 17]]], ["The search yielded 53 articles, two of which reported changes in social contacts after COVID-19 control measures.", [["COVID-19 control measures", "TREATMENT", 87, 112]]], ["The first study reported changes in contact patterns in Wuhan and Shanghai, and the second changes in contact patterns in the UK.", [["UK", "GENE_OR_GENE_PRODUCT", 126, 128], ["The first study", "TEST", 0, 15]]], ["We found no studies examining changes in contact patterns due to control measures in sub-Saharan Africa, and no studies disaggregating contacts by socioeconomic status.Added value of this studyThis is the first study to estimate the reproduction number of COVID-19 under control measures in sub-Saharan Africa using primary contact data.", [["studies", "TEST", 12, 19], ["this study", "TEST", 183, 193], ["the first study", "TEST", 201, 216], ["COVID", "TEST", 256, 261], ["no", "UNCERTAINTY", 9, 11]]], ["This study also moves beyond existing work to i) measure contacts in densely populated informal settlements, ii) explore how social contacts vary across socioeconomic status, and iii) assess the impact of control measures on economic and food security in these areas.Added value of this studyImplications of all the evidence COVID-19 control measures have substantially reduced social contacts and disease transmission.", [["This study", "TEST", 0, 10], ["control measures", "TREATMENT", 205, 221], ["this study", "TEST", 282, 292], ["COVID-19 control measures", "TREATMENT", 325, 350], ["reduced", "OBSERVATION_MODIFIER", 370, 377]]], ["People of lower socioeconomic status face greater transmission risk as they report more contacts.", [["People", "ORGANISM", 0, 6], ["People", "SPECIES", 0, 6], ["lower", "ANATOMY_MODIFIER", 10, 15]]], ["Introduction Over 6.7 million cases and 394,000 deaths from COVID-19 have been recorded worldwide as of 6 June 2020[1].", [["deaths", "DISEASE", 48, 54], ["COVID", "TEST", 60, 65]]], ["Most recorded cases and deaths have occurred in high-income countries in Europe and North America.", [["deaths", "DISEASE", 24, 30]]], ["Many countries introduced extreme physical distancing control measures to control SARS-CoV2 transmission [2] .", [["SARS", "DISEASE", 82, 86], ["extreme physical distancing control measures", "TREATMENT", 26, 70]]], ["Modelling studies suggest that without substantial mitigation measures, most low-and middle-income (LMIC) settings, including sub-Saharan Africa, will experience a delayed, but severe epidemic [3, 4] .", [["Modelling studies", "TEST", 0, 17], ["substantial mitigation measures", "TREATMENT", 39, 70], ["without", "UNCERTAINTY", 31, 38], ["substantial", "OBSERVATION_MODIFIER", 39, 50], ["mitigation", "OBSERVATION", 51, 61]]], ["Yet to-date, the numbers of recorded cases and deaths in Africa are much lower than predictions, prompting speculation on why many African countries have so far avoided a severe uncontrolled epidemic.", [["deaths", "DISEASE", 47, 53], ["a severe uncontrolled epidemic", "PROBLEM", 169, 199], ["severe", "OBSERVATION_MODIFIER", 171, 177], ["uncontrolled", "OBSERVATION_MODIFIER", 178, 190], ["epidemic", "OBSERVATION", 191, 199]]], ["A range of reasons has been proposed, including differences between settings in case and death detection capacity, demographic factors such as population age distribution, and the role of temperature and aridity in transmission [5] [6] [7] [8] [9] [10] .", [["death", "DISEASE", 89, 94], ["[5] [6] [7] [8] [9]", "CHEMICAL", 228, 247], ["6] [7] [8] [9", "SIMPLE_CHEMICAL", 233, 246], ["death detection capacity", "PROBLEM", 89, 113]]], ["However, many sub-Saharan African countries implemented lockdown and curfew measures far earlier in their country's epidemic trajectories than most higher-income settings in Europe and North America.", [["many", "OBSERVATION_MODIFIER", 9, 13], ["sub", "OBSERVATION_MODIFIER", 14, 17]]], ["For example, Kenya -the focus of the current study -implemented a partial lockdown on 06 April 2020 when the country had recorded just 158 cases and 6 deaths.", [["deaths", "DISEASE", 151, 157], ["the current study", "TEST", 33, 50]]], ["In contrast, although case detection rates may differ between settings, the UK implemented its own lockdown on 23 March 2020 after recording 6,650 cases and 335 deaths [1, 2] .", [["deaths", "DISEASE", 161, 167]]], ["Suspension of international flights, including mandatory quarantine of incoming residents, closure of bars and restrictions on restaurant opening hours, and a ban on large gatherings were imposed on 25 March 2020, soon followed by an enactment of a nationwide curfew from 7pm to 5am.", [["closure of bars", "TREATMENT", 91, 106], ["international flights", "OBSERVATION", 14, 35]]], ["On 5 April 2020, the Kenyan government declared wearing face masks as mandatory in any public place.", [["face masks", "TREATMENT", 56, 66]]], ["Consequently, the government has indicated additional physical distancing measures may be authorised.Added value of this studyPhysical distancing control measures seek to reduce the number of contacts between people where transmission could occur.", [["people", "ORGANISM", 209, 215], ["people", "SPECIES", 209, 215], ["additional physical distancing measures", "TREATMENT", 43, 82], ["this study", "TEST", 116, 126], ["Physical distancing control measures", "TREATMENT", 126, 162]]], ["To predict the impact of control measures accurately, quantitative data on the number and type of contacts between people is required.", [["people", "ORGANISM", 115, 121], ["people", "SPECIES", 115, 121], ["control measures", "TREATMENT", 25, 41], ["quantitative data", "TEST", 54, 71]]], ["To-date, only a few empirical studies have been published to assess the impact of COVID-19 control measures on contacts; these have been conducted in China [11] , the USA [12] and Europe [13] ; but none were undertaken in sub-Saharan Africa.", [["empirical studies", "TEST", 20, 37], ["COVID-19 control measures", "TREATMENT", 82, 107]]], ["This lack of evidence means that many SARS-CoV-2 transmission models primarily use synthetic contact matrices for LMIC settings, which use demographic, household composition, classroom size and other data to adjust social contact data from primarily highincome settings [19, 20] .", [["SARS", "DISEASE", 38, 42], ["SARS-CoV-2", "ORGANISM", 38, 48], ["many SARS", "PROBLEM", 33, 42], ["synthetic contact matrices", "TREATMENT", 83, 109], ["LMIC settings", "TREATMENT", 114, 127]]], ["Although one social mixing study was conducted in Kilifi, a coastal area of Kenya [21] , outside of one study which collected data from a South African township [16] , no published contact data exist from informal settlements, which may be particularly vulnerable to COVID-19 due to high levels of population density, indoor crowding and household sizes, alongside intergenerational mixing within the household.Added value of this studyBetween-person contacts drive the transmission of respiratory pathogens, such as SARS-CoV-2.", [["respiratory", "ANATOMY", 486, 497], ["respiratory pathogens", "DISEASE", 486, 507], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 517, 527], ["SARS-CoV", "SPECIES", 517, 525], ["social mixing study", "TEST", 13, 32], ["one study", "TEST", 100, 109], ["COVID", "TEST", 267, 272], ["high levels of population density", "PROBLEM", 283, 316], ["this study", "TEST", 426, 436], ["respiratory pathogens", "PROBLEM", 486, 507], ["population", "OBSERVATION_MODIFIER", 298, 308], ["density", "OBSERVATION", 309, 316], ["respiratory", "ANATOMY", 486, 497], ["pathogens", "OBSERVATION", 498, 507]]], ["In this study, we describe a survey of contact patterns conducted among a sample of adults from five informal settlements in urban and peri-urban areas around Nairobi.", [["this study", "TEST", 3, 13]]], ["We estimate the impact of current control measures on the reproduction number, .", [["current control measures", "TREATMENT", 26, 50]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)Added value of this studyThe copyright holder for this preprint this version posted June 7, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["this study", "TEST", 211, 221], ["The copyright holder", "TREATMENT", 221, 241], ["med", "ANATOMY", 99, 102]]], ["R0, to evaluate whether these measures might be sufficient to control the epidemic.", [["the epidemic", "PROBLEM", 70, 82]]], ["We also describe income losses and food security that respondents attribute to COVID-19 and control measures.EthicsParticipation in the study was voluntary and analyses were conducted on anonymised data.", [["COVID", "TREATMENT", 79, 84], ["the study", "TEST", 132, 141], ["anonymised data", "TEST", 187, 202]]], ["The study was approved by the internal review board of the Population Council (study number 936), the ethics committee of the London School of Hygiene and Tropical Medicine (reference number 22294), and the AMREF Health Africa Ethics and Scientific Review Committee in Kenya (P803/2020).Survey methodologyAdult respondents were recruited from two existing Population Council cohorts in five informal settlements around Nairobi (Kibera, Huruma, Kariobangi, Dandora, and Mathare).", [["The study", "TEST", 0, 9]]], ["The cohorts were in place to study the impacts of multi-sectoral interventions on adolescents, and consisted of randomly-selected households from informal settlements which contained at least one adolescent in January 2015 (AGI-K) or January 2018 (NISITU) .", [["adolescents", "SPECIES", 82, 93], ["multi-sectoral interventions", "TREATMENT", 50, 78]]], ["In May 2020, 1750 respondents from AGI-K and NISITU cohorts completed a telephone survey on COVID-19 knowledge, attitudes, and perceptions (KAP).", [["AGI", "TEST", 35, 38], ["COVID", "TEST", 92, 97]]], ["Respondents were first asked a range of questions on COVID-19 including knowledge and experience of testing and symptoms, economic impacts on the household and food availability and cost.", [["testing", "TEST", 100, 107], ["symptoms", "PROBLEM", 112, 120]]], ["A direct contact was defined as someone respondents met in person and with whom they had either i) \"physical contact (any sort of skin-to-skin contact e.g. a handshake, embracing, kissing, sleeping on the same bed/mat/blanket, sharing a meal together out of the same bowl, playing football or other contact sports, sitting next to someone while touching shoulder to shoulder, etc.\", or ii) \"Non-physical contact (you did not touch the person, but exchanged at least a few words, face-to-face within 2 metres -for example, someone you bought something from in the market, or rode with on a minibus, or worked with in the same area)\".", [["skin", "ANATOMY", 130, 134], ["skin", "ANATOMY", 138, 142], ["shoulder", "ANATOMY", 354, 362], ["skin", "ORGAN", 130, 134], ["skin", "ORGAN", 138, 142], ["shoulder", "ORGANISM_SUBDIVISION", 354, 362], ["person", "SPECIES", 59, 65], ["person", "SPECIES", 435, 441], ["skin", "ANATOMY", 130, 134], ["skin", "ANATOMY", 138, 142], ["shoulder", "ANATOMY", 366, 374]]], ["All respondents were over the age of 18 so no contact data were collected from children, however respondents were able to list contacts under the age of 18.Survey methodologyWe made pragmatic adaptations to existing contact measurement tools to allow them to be conducted over the phone, primarily to reduce respondent burden and to ensure that aggregate contact data were not biased downwards by respondent fatigue.", [["fatigue", "DISEASE", 408, 415], ["children", "ORGANISM", 79, 87], ["children", "SPECIES", 79, 87], ["contact measurement tools", "TEST", 216, 241], ["fatigue", "PROBLEM", 408, 415]]], ["Those who reported nine or fewer outside household contacts were asked to describe each contact's age, gender, whether the contact was physical or non-physical, the duration of the contact, and whether a mask was worn by the respondent or contact.", [["a mask", "TREATMENT", 202, 208]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 7, 2020. . https://doi.org/10.1101/2020.06.06.20122689 doi: medRxiv preprint Statistical analysis R version 4.0.0 and Stata 15 were used for analyses; the code and data are publicly available here.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["medRxiv", "TREATMENT", 319, 326], ["R version", "TEST", 357, 366], ["Stata", "TEST", 377, 382], ["med", "ANATOMY", 99, 102]]], ["Data on household assets were used to classify respondents into wealth quintiles using principal component analysis; supplementary file 2 gives information on this, alongside methods used to estimate economic and food security.(which was not certified by peer review)We calculated the mean number of social contacts per person per day, stratified by respondent age, sex, household size, and education level.", [["person", "SPECIES", 320, 326], ["principal component analysis", "TEST", 87, 115]]], ["Kiti et al. collected data on physical contacts only, so we restrict our sample to physical contacts when comparing with this study.", [["this study", "TEST", 121, 131]]], ["We adjusted for symmetry after bootstrapping because one age range in our data (60+) had fewer than five respondents.", [["our data", "TEST", 70, 78]]], ["Bootstrapping was not possible with Prem et al. matrices as they do not relate to individual level data.(which was not certified by peer review)As respondents under the age of 18 were not included as survey respondents, we imputed child contacts using methods developed by Klepac et al. [23] , and implemented for the same purpose in a UK study [13] .", [["Bootstrapping", "TREATMENT", 0, 13], ["individual level data", "TEST", 82, 103], ["a UK study", "TEST", 334, 344], ["not possible", "UNCERTAINTY", 18, 30]]], ["This involved taking the ratio of the dominant eigenvalues between our matrices and the comparable setting-adjusted matrices to scale missing matrix elements.(which was not certified by peer review)Finally, we estimated the impact of control measures on the basic reproduction number (R0) in this population.", [["control measures", "TREATMENT", 234, 250], ["dominant", "OBSERVATION_MODIFIER", 38, 46], ["eigenvalues", "OBSERVATION", 47, 58]]], ["Because there are no baseline contact data from this population without control measures, we assume that contact patterns in this sample prior to control measures were similar to those estimated by Kiti et al. or Prem et al. We make the common assumption for respiratory infections that the next generation matrix is a function of the age-specific number of contacts, the per-contact transmission probability, and the duration of infectiousness, and that R0 is therefore proportional to the dominant eigenvalue of the contact matrix [18] [17] .We assume that existing matrices are comparable to the informal settlement setting of this study, that there were no changes in the duration of infectiousness during the study period, that per-contact transmission probability also remained constant, and that all age groups have the same per contact transmission probability, given infection.", [["respiratory infections", "DISEASE", 259, 281], ["infection", "DISEASE", 876, 885], ["matrix", "CELLULAR_COMPONENT", 307, 313], ["baseline contact data", "PROBLEM", 21, 42], ["control measures", "TREATMENT", 72, 88], ["respiratory infections", "PROBLEM", 259, 281], ["infectiousness", "PROBLEM", 430, 444], ["this study", "TEST", 630, 640], ["infectiousness", "PROBLEM", 688, 702], ["the study", "TEST", 710, 719], ["infection", "PROBLEM", 876, 885], ["no", "UNCERTAINTY", 18, 20], ["infections", "OBSERVATION", 271, 281], ["infection", "OBSERVATION", 876, 885]]], ["With these assumptions, the relative reduction in R0 can be estimated as the reduction in the dominant eigenvalue of the contact matrices.", [["the relative reduction in R0", "TREATMENT", 24, 52], ["reduction", "OBSERVATION_MODIFIER", 37, 46], ["reduction", "OBSERVATION_MODIFIER", 77, 86], ["dominant", "OBSERVATION_MODIFIER", 94, 102], ["eigenvalue", "OBSERVATION_MODIFIER", 103, 113], ["contact matrices", "OBSERVATION", 121, 137]]], ["Finally, our central estimate of the R0 of SARS-CoV2 is 2.6 (SD = 0.54), as estimated in a metaanalysis of published estimates of R0 prior to the introduction of control measures [13] .", [["SARS", "DISEASE", 43, 47], ["CoV2", "TEST", 48, 52], ["SD", "TEST", 61, 63], ["the introduction of control measures", "TREATMENT", 142, 178], ["central", "ANATOMY_MODIFIER", 13, 20], ["SARS", "OBSERVATION", 43, 47]]], ["Because studies in this meta-analysis were predominantly based on European and Asian countries, we explore a lower bound of 1.46 (SD = 0.38) based on the earliest estimate of the time-varying reproduction number in Kenya [24] .(which was not certified by peer review).", [["a lower bound", "PROBLEM", 107, 120]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 7, 2020. . https://doi.org/10.1101/2020.06.06.20122689 doi: medRxiv preprintRespondent and contact characteristicsOut of the 1970 people sampled for the KAP survey, 1745 interviews were completed.", [["CC", "CHEMICAL", 0, 2], ["people", "ORGANISM", 389, 395], ["people", "SPECIES", 389, 395], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["the KAP survey", "TEST", 408, 422], ["med", "ANATOMY", 99, 102]]], ["Compared to both groups there is some indication that our sample has more 18-29 year olds and fewer 60+ year olds than national data, whilst our sample is substantially older than that of Kiti et al.Contact patternsThe mean number of contacts reported was 18 (median 13, IQR 7-23), 4 household contacts (median 4, IQR 3-12) and 15 non-household contacts (median 10, IQR 4-20).", [["IQR", "TEST", 271, 274], ["mean", "OBSERVATION_MODIFIER", 219, 223]]], ["As shown in figure 1 , respondents in the poorest quintile reported 1.5 times as many contacts as those in the richest quintile and we find evidence of a downwards trend in contacts as socioeconomic status increases (non-parametric test for trend p=0.02).", [["non-parametric test", "TEST", 217, 236]]], ["There was weak evidence that men had more contacts than women (20.3 -15.5 = 4.8, t-test p=0.04) and contacts increased with age (non-parametric test for trend p=0.05).", [["men", "ORGANISM", 29, 32], ["women", "ORGANISM", 56, 61], ["men", "SPECIES", 29, 32], ["women", "SPECIES", 56, 61], ["t-test p", "TEST", 81, 89], ["non-parametric test", "TEST", 129, 148], ["weak", "OBSERVATION_MODIFIER", 10, 14]]], ["This lack of variation by household size is consistent with most contacts being outside of the household.", [["variation", "OBSERVATION_MODIFIER", 13, 22], ["size", "OBSERVATION_MODIFIER", 36, 40], ["consistent with", "UNCERTAINTY", 44, 59]]], ["Just 8% (27/324) of all contacts took place without a mask being worn by either the respondent or the contact.", [["a mask", "TREATMENT", 52, 58]]], ["Figure 3 shows age-specific contact matrices disaggregated by contact location and type; these are asymmetric and not adjusted for demography.", [["contact matrices", "OBSERVATION", 28, 44], ["asymmetric", "OBSERVATION_MODIFIER", 99, 109]]], ["Matrices are consistent with the majority of contacts occurring outside of the household and being non-physical.", [["consistent with", "UNCERTAINTY", 13, 28]]], ["We find a 62% reduction in physical contacts, and a 63-67% reduction in all contacts compared to before the epidemic.", [["reduction", "OBSERVATION_MODIFIER", 14, 23]]], ["We estimate R0 under control measures, shown in figure 5 .", [["R0", "OBSERVATION_MODIFIER", 12, 14]]], ["All comparisons to pre-COVID- 19 . .", [["pre-COVID- 19", "CHEMICAL", 19, 32], ["pre-COVID- 19", "DNA", 19, 32], ["pre-COVID", "TEST", 19, 28]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 7, 2020. . https://doi.org/10.1101/2020.06.06.20122689 doi: medRxiv preprint .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["medRxiv preprint", "TREATMENT", 319, 335], ["med", "ANATOMY", 99, 102]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 7, 2020. .Figure 1: Median number of direct contacts (physical and non-physical) by (A) socioeconomic status quintile, (B) gender, (C) respondent age, (D) education level, and (E) household size.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["med", "ANATOMY", 99, 102]]], ["Each panel shows the median, hinges (25th and 75th percentiles), and whiskers representing upper and lower adjacents.", [["upper", "ORGANISM_SUBDIVISION", 91, 96], ["Each panel", "TEST", 0, 10], ["whiskers representing upper and lower adjacents", "PROBLEM", 69, 116], ["median", "OBSERVATION_MODIFIER", 21, 27], ["upper", "ANATOMY_MODIFIER", 91, 96], ["lower", "ANATOMY_MODIFIER", 101, 106]]], ["Outliers are not displayed in boxplots for scale, these are plotted in (F) showing the distribution of the number of direct contacts reported..", [["scale", "TEST", 43, 48]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 7, 2020. . https://doi.org/10.1101/2020.06.06.20122689 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 7, 2020. . https://doi.org/10.1101/2020.06.06.20122689 doi: medRxiv preprint Discussion COVID-19 control measures in informal settlements appear to have led to a large reduction in social contacts.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["The copyright holder", "TREATMENT", 470, 490], ["medRxiv", "TREATMENT", 594, 601], ["COVID-19 control measures", "TREATMENT", 622, 647], ["a large reduction in social contacts", "PROBLEM", 694, 730], ["med", "ANATOMY", 99, 102], ["med", "ANATOMY", 374, 377], ["large", "OBSERVATION_MODIFIER", 696, 701], ["reduction", "OBSERVATION_MODIFIER", 702, 711]]], ["We find a 62-67% reduction in eigenvalues of contact matrices depending on the pre-COVID-19 matrix used; assuming an R0 of 2.6, this would translate to an R0 of between 0.5 and 0.7 at the time of data collection.", [["contact matrices", "PROBLEM", 45, 61], ["an R0", "TEST", 114, 119], ["an R0", "TEST", 152, 157], ["data collection", "TEST", 196, 211], ["contact matrices", "OBSERVATION", 45, 61]]], ["By contrast, simulation estimates of the R0 in an unmitigated COVID-19 epidemic in Kenya were between 1.78 (95%CI: 1.44 -2.14) and 3.46 (95% CI: 2.81-4.17)[25].", [["simulation estimates", "TEST", 13, 33], ["an unmitigated COVID", "TEST", 47, 67], ["CI", "TEST", 111, 113], ["CI", "TEST", 141, 143]]], ["The R0 we estimate here is consistent with the linear shape of the Kenyan epidemic to-date.", [["consistent with", "UNCERTAINTY", 27, 42], ["linear", "OBSERVATION_MODIFIER", 47, 53], ["shape", "OBSERVATION_MODIFIER", 54, 59]]], ["The large reductions in contacts we estimate are of similar magnitude to those seen in both the UK[13] -(74% reduction in contacts), in Wuhan and Shanghai [11] (86% reduction), and the USA (70% reduction) [12] .", [["The large reductions", "PROBLEM", 0, 20], ["large", "OBSERVATION_MODIFIER", 4, 9], ["reductions", "OBSERVATION_MODIFIER", 10, 20]]], ["We are not aware of any comparable post-lockdown studies from low-or middle-income settings to-date, including sub-Saharan Africa.(which was not certified by peer review)Considerable food and economic vulnerability was reported due to COVID-19 control measures.", [["Considerable food and economic vulnerability", "PROBLEM", 170, 214], ["COVID-19 control measures", "TREATMENT", 235, 260]]], ["Over 80% of respondents reported a partial or complete loss of income, and three quarters reported eating less or skipping meals due to COVID-19.", [["COVID", "TEST", 136, 141]]], ["Although the prevalence of COVID-19 was low, and these factors can largely be attributed to control measures rather than illness from COVID-19 itself, it is important to recognise the counterfactual of no control measures is an unmitigated epidemic, and not an absence of these harms.", [["illness", "DISEASE", 121, 128], ["COVID", "TEST", 27, 32], ["COVID", "TEST", 134, 139], ["control measures", "TREATMENT", 205, 221], ["harms", "OBSERVATION", 278, 283]]], ["This inequity would be exacerbated if socially patterned financial and access barriers inhibit the poor from seeking care for COVID-19 [26, 27] .", [["COVID", "TEST", 126, 131]]], ["Stringent control measures which cause economic and food insecurity are not likely to be sustainable in the long term if not accompanied by social protection mechanisms.(which was not certified by peer review)This study has a number of limitations.", [["Stringent control measures", "TREATMENT", 0, 26], ["economic and food insecurity", "PROBLEM", 39, 67], ["This study", "TEST", 209, 219], ["not likely", "UNCERTAINTY", 72, 82]]], ["In the absence of baseline contact data (i.e. before control measures were put in place), we use empirical matrices from a different area of Kenya and synthetic matrices based on adjusting contact surveys from higher income countries to household and other characteristics in Kenya.", [["control measures", "TREATMENT", 53, 69], ["empirical matrices", "TREATMENT", 97, 115], ["Kenya and synthetic matrices", "TREATMENT", 141, 169]]], ["The pre-COVID-19 setting of Kiti et al. is very different to this sample, not least as estimates place population density around 24 times greater in informal settlements (Kibera: 55000 persons/ km 2 ) compared to urban Kilifi (2325 persons/km 2 )[28].", [["persons", "SPECIES", 185, 192], ["The pre-COVID", "TEST", 0, 13], ["Kiti et al", "TREATMENT", 28, 38]]], ["Because we would expect contacts to be greater in more densely populated areas, the true reduction in contacts may be more than we estimate here.", [["densely", "OBSERVATION_MODIFIER", 55, 62], ["populated", "OBSERVATION", 63, 72], ["reduction", "OBSERVATION_MODIFIER", 89, 98]]], ["Although we have a range of background data on respondents from using existing sampling frames, households in the AGI-K and NITISU cohorts were initially selected as having an adolescent residing there in 2015 and 2018, respectively.(which was not certified by peer review)Other social contact surveys have used a prospective study design, asking respondents to record contacts in a daily diary [29] .", [["NITISU cohorts", "TREATMENT", 124, 138]]], ["Furthermore, we impute adjusted child contacts using the comparison studies.", [["the comparison studies", "TEST", 53, 75]]], ["An alternative approach, such as that taken by Kiti et al., would have been for respondents to record contacts for children in their householdarranging this was not possible during COVID-19 restrictions.", [["children", "ORGANISM", 115, 123], ["children", "SPECIES", 115, 123]]], ["Contacts reported in this way were a substantial proportion (70%) of the total sample.", [["the total sample", "TEST", 69, 85]]], ["The main risk of bias from this may stem from respondents rounding up or down to anchor .", [["main", "OBSERVATION_MODIFIER", 4, 8], ["bias", "OBSERVATION", 17, 21]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 7, 2020. . numbers (e.g. units of ten); figure 1 panel E shows a few respondents cluster around 50 and 100 contacts.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["med", "ANATOMY", 99, 102]]], ["Overall, the loss of granularity was beneficial to reducing respondent burden.(which was not certified by peer review)We do not calculate the net reproduction number, R, but because reported case numbers in Kenya are low, the proportion of the population that is no longer susceptible is likely minimal.", [["the loss of granularity", "PROBLEM", 9, 32], ["loss", "OBSERVATION_MODIFIER", 13, 17], ["granularity", "OBSERVATION", 21, 32], ["low", "OBSERVATION_MODIFIER", 217, 220], ["population", "OBSERVATION", 244, 254], ["no longer", "UNCERTAINTY", 263, 272], ["minimal", "OBSERVATION_MODIFIER", 295, 302]]], ["In addition, we do not account for the very high proportion of respondents who report that they or their direct contacts wore face masks.", [["face masks", "TREATMENT", 126, 136]]], ["Considering these factors would mean R is below the R0 estimated here.ConclusionKenya has implemented strict control measures in response to the COVID-19 pandemic.", [["strict control measures", "TREATMENT", 102, 125], ["the COVID", "TEST", 141, 150], ["pandemic", "PROBLEM", 154, 162]]], ["This study highlights the difficult decisions policymakers face as we find that control measures are likely to have substantially reduced COVID-19 transmission, but also negatively impacted food and economic security of informal settlement residents.", [["This study", "TEST", 0, 10], ["substantially reduced COVID", "PROBLEM", 116, 143]]], ["This is the first study to measure social contact patterns after COVID-19 control measures have been implemented in sub-Saharan Africa.", [["the first study", "TEST", 8, 23], ["COVID-19 control measures", "TREATMENT", 65, 90]]], ["There is evidence that impacts are inequitable, as the poorest quintile report 1.5 times more contacts than the richest quintile, and 86% of respondents reported complete or partial income losses.", [["partial income losses", "PROBLEM", 174, 195], ["impacts", "OBSERVATION_MODIFIER", 23, 30], ["inequitable", "OBSERVATION_MODIFIER", 35, 46]]], ["Negative and inequitable impacts on economic and food security may mean control measures are not sustainable in the longer term without social protection.Conclusion.", [["economic and food security", "TREATMENT", 36, 62], ["inequitable", "OBSERVATION_MODIFIER", 13, 24], ["impacts", "OBSERVATION_MODIFIER", 25, 32]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 7, 2020. . .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["med", "ANATOMY", 99, 102]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)25The copyright holder for this preprint this version posted June 7, 2020. . https://doi.org/10.1101/2020.06.06.20122689 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)25The copyright holder for this preprint this version posted June 7, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)25The copyright holder for this preprint this version posted June 7, 2020. . https://doi.org/10.1101/2020.06.06.20122689 doi: medRxiv preprint", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["medRxiv", "TREATMENT", 810, 817], ["med", "ANATOMY", 99, 102], ["med", "ANATOMY", 377, 380], ["med", "ANATOMY", 587, 590]]]], "53b8d0b9c0472feda728b084ce1e405ee0c834b2": [["| INTRODUCTIONHuman parainfluenza viruses (hPIVs) infect the upper and lower respiratory tract of humans causing symptoms ranging from mild acute respiratory infection (ARI) to severe acute respiratory infection (SARI); severe cases might lead to death. hPIVs were discovered in the late 1950s; they belong to the family Paramyxoviridae and are divided into four types-hPIV1, 2, 3, and 4, the latter subdivided in subtypes hPIV4a and hPIV4b-which belong to two different genera:| INTRODUCTIONRespirovirus (hPIV1 and 3) and Rubulavirus (hPIV2 and 4).", [["lower respiratory tract", "ANATOMY", 71, 94], ["respiratory", "ANATOMY", 146, 157], ["respiratory", "ANATOMY", 190, 201], ["parainfluenza viruses", "DISEASE", 20, 41], ["acute respiratory infection", "DISEASE", 140, 167], ["ARI", "DISEASE", 169, 172], ["acute respiratory infection", "DISEASE", 184, 211], ["SARI", "DISEASE", 213, 217], ["death", "DISEASE", 247, 252], ["INTRODUCTIONHuman parainfluenza viruses", "ORGANISM", 2, 41], ["hPIVs", "ORGANISM", 43, 48], ["upper", "ORGANISM_SUBDIVISION", 61, 66], ["lower", "ORGANISM_SUBDIVISION", 71, 76], ["respiratory tract", "ORGANISM_SUBDIVISION", 77, 94], ["humans", "ORGANISM", 98, 104], ["hPIVs", "GENE_OR_GENE_PRODUCT", 254, 259], ["Paramyxoviridae", "GENE_OR_GENE_PRODUCT", 321, 336], ["hPIV1", "GENE_OR_GENE_PRODUCT", 369, 374], ["2", "GENE_OR_GENE_PRODUCT", 376, 377], ["3", "GENE_OR_GENE_PRODUCT", 379, 380], ["4", "GENE_OR_GENE_PRODUCT", 386, 387], ["hPIV4a", "GENE_OR_GENE_PRODUCT", 423, 429], ["hPIV4b", "GENE_OR_GENE_PRODUCT", 434, 440], ["3", "GENE_OR_GENE_PRODUCT", 516, 517], ["hPIVs", "PROTEIN", 254, 259], ["hPIV1, 2, 3, and 4", "DNA", 369, 387], ["hPIV4b", "PROTEIN", 434, 440], ["parainfluenza", "SPECIES", 20, 33], ["humans", "SPECIES", 98, 104], ["INTRODUCTIONHuman parainfluenza viruses", "SPECIES", 2, 41], ["humans", "SPECIES", 98, 104], ["INTRODUCTIONHuman parainfluenza viruses (hPIVs", "TREATMENT", 2, 48], ["the upper and lower respiratory tract of humans", "PROBLEM", 57, 104], ["symptoms", "PROBLEM", 113, 121], ["mild acute respiratory infection", "PROBLEM", 135, 167], ["ARI)", "PROBLEM", 169, 173], ["severe acute respiratory infection", "PROBLEM", 177, 211], ["severe cases", "PROBLEM", 220, 232], ["death", "PROBLEM", 247, 252], ["Paramyxoviridae", "TREATMENT", 321, 336], ["parainfluenza viruses", "OBSERVATION", 20, 41], ["upper", "ANATOMY_MODIFIER", 61, 66], ["lower", "ANATOMY_MODIFIER", 71, 76], ["respiratory tract", "ANATOMY", 77, 94], ["mild", "OBSERVATION_MODIFIER", 135, 139], ["acute", "OBSERVATION_MODIFIER", 140, 145], ["respiratory", "ANATOMY", 146, 157], ["infection", "OBSERVATION", 158, 167], ["severe", "OBSERVATION_MODIFIER", 177, 183], ["acute", "OBSERVATION_MODIFIER", 184, 189], ["respiratory", "ANATOMY", 190, 201], ["infection", "OBSERVATION", 202, 211]]], ["1 The clinical profile of patients infected by hPIV may vary according to viral type: hPIV1 is known to cause laryngotracheobronchitis (croup) 2 ; hPIV2 is associated to hospitalizations, however, little is known about its epidemiology 2 ; hPIV3, which is the most prevalent type, is one of the main causes of pneumonia and bronchiolitis in children and newborns 2 ; and hPIV4 is associated with mild upper respiratory tract infections in children and adults.", [["upper respiratory tract", "ANATOMY", 401, 424], ["laryngotracheobronchitis", "DISEASE", 110, 134], ["croup", "DISEASE", 136, 141], ["pneumonia", "DISEASE", 310, 319], ["bronchiolitis", "DISEASE", 324, 337], ["respiratory tract infections", "DISEASE", 407, 435], ["patients", "ORGANISM", 26, 34], ["hPIV1", "GENE_OR_GENE_PRODUCT", 86, 91], ["hPIV2", "GENE_OR_GENE_PRODUCT", 147, 152], ["hPIV3", "GENE_OR_GENE_PRODUCT", 240, 245], ["children", "ORGANISM", 341, 349], ["hPIV4", "GENE_OR_GENE_PRODUCT", 371, 376], ["upper", "ORGANISM_SUBDIVISION", 401, 406], ["respiratory tract", "ORGANISM_SUBDIVISION", 407, 424], ["children", "ORGANISM", 439, 447], ["patients", "SPECIES", 26, 34], ["children", "SPECIES", 341, 349], ["children", "SPECIES", 439, 447], ["hPIV", "SPECIES", 47, 51], ["laryngotracheobronchitis", "PROBLEM", 110, 134], ["pneumonia", "PROBLEM", 310, 319], ["bronchiolitis in children and newborns 2", "PROBLEM", 324, 364], ["mild upper respiratory tract infections", "PROBLEM", 396, 435], ["most prevalent", "OBSERVATION_MODIFIER", 260, 274], ["pneumonia", "OBSERVATION", 310, 319], ["bronchiolitis", "OBSERVATION", 324, 337], ["associated with", "UNCERTAINTY", 380, 395], ["mild", "OBSERVATION_MODIFIER", 396, 400], ["upper", "ANATOMY_MODIFIER", 401, 406], ["respiratory tract", "ANATOMY", 407, 424], ["infections", "OBSERVATION", 425, 435]]], ["2, 3 Respiratory infections associated with hPIV are observed yearround, and trends in viral type circulation can be observed in some regions.", [["Respiratory infections", "DISEASE", 5, 27], ["hPIV", "SPECIES", 44, 48], ["3 Respiratory infections", "PROBLEM", 3, 27], ["hPIV", "PROBLEM", 44, 48], ["Respiratory", "ANATOMY", 5, 16], ["infections", "OBSERVATION", 17, 27], ["viral type", "OBSERVATION", 87, 97]]], ["Usually, during fall the main hPIV types are hPIV1 and 2, and during spring hPIV3 becomes dominant.", [["hPIV1", "GENE_OR_GENE_PRODUCT", 45, 50], ["hPIV3", "GENE_OR_GENE_PRODUCT", 76, 81], ["dominant", "PROBLEM", 90, 98], ["main", "OBSERVATION_MODIFIER", 25, 29], ["dominant", "OBSERVATION", 90, 98]]], ["2, 4 The factors that contribute to specific regional viral circulation are not well understood and do not necessarily depend on the climate; for example, a study reports high hPIV3 prevalence during summer and beginning of fall in the United Kingdom, and during winter in Norway and Denmark 5 ; in other geographic regions, this virus is more frequent from spring to summer.", [["specific regional viral circulation", "PROBLEM", 36, 71], ["a study", "TEST", 155, 162], ["this virus", "PROBLEM", 325, 335], ["viral circulation", "OBSERVATION", 54, 71]]], ["6 In Brazil, respiratory infections are the leading cause of hospitalization in children, 7 especially in the southern region, which includes the state of Rio Grande do Sul (RS).", [["respiratory", "ANATOMY", 13, 24], ["respiratory infections", "DISEASE", 13, 35], ["children", "ORGANISM", 80, 88], ["children", "SPECIES", 80, 88], ["respiratory infections", "PROBLEM", 13, 35], ["respiratory", "ANATOMY", 13, 24], ["infections", "OBSERVATION", 25, 35]]], ["An increase in the prevalence of respiratory viruses is usually observed in RS from May to August; nonetheless, respiratory virus outbreaks are also registered during the summer.", [["respiratory viruses", "DISEASE", 33, 52], ["RS", "DISEASE", 76, 78], ["respiratory virus outbreaks", "DISEASE", 112, 139], ["respiratory virus", "ORGANISM", 112, 129], ["respiratory viruses", "PROBLEM", 33, 52], ["respiratory virus outbreaks", "PROBLEM", 112, 139], ["increase", "OBSERVATION_MODIFIER", 3, 11], ["respiratory viruses", "OBSERVATION", 33, 52], ["respiratory virus", "OBSERVATION", 112, 129]]], ["4, 8, 9 Because of this, state health authorities in RS Epidemiological surveillance is the basis for the control and prevention of viral respiratory infections, however regional efforts regarding surveillance of respiratory viruses are directed mainly to influenza A virus (IAV) and human respiratory syncytial virus (hRSV), therefore little is known about other viral pathogens associated to ARI and SARI in RS.", [["respiratory", "ANATOMY", 138, 149], ["viral respiratory infections", "DISEASE", 132, 160], ["respiratory viruses", "DISEASE", 213, 232], ["influenza A virus", "DISEASE", 256, 273], ["respiratory syncytial virus", "DISEASE", 290, 317], ["ARI", "DISEASE", 394, 397], ["SARI", "DISEASE", 402, 406], ["RS", "DISEASE", 410, 412], ["influenza A virus", "ORGANISM", 256, 273], ["IAV", "ORGANISM", 275, 278], ["human respiratory syncytial virus", "ORGANISM", 284, 317], ["hRSV", "ORGANISM", 319, 323], ["influenza A virus", "SPECIES", 256, 273], ["human", "SPECIES", 284, 289], ["respiratory syncytial virus", "SPECIES", 290, 317], ["influenza A virus", "SPECIES", 256, 273], ["IAV", "SPECIES", 275, 278], ["human respiratory syncytial virus", "SPECIES", 284, 317], ["hRSV", "SPECIES", 319, 323], ["Epidemiological surveillance", "TEST", 56, 84], ["the control", "TREATMENT", 102, 113], ["viral respiratory infections", "PROBLEM", 132, 160], ["respiratory viruses", "PROBLEM", 213, 232], ["influenza A virus", "PROBLEM", 256, 273], ["human respiratory syncytial virus", "PROBLEM", 284, 317], ["other viral pathogens", "PROBLEM", 358, 379], ["ARI", "PROBLEM", 394, 397], ["SARI", "PROBLEM", 402, 406], ["viral", "OBSERVATION_MODIFIER", 132, 137], ["respiratory infections", "OBSERVATION", 138, 160], ["respiratory viruses", "OBSERVATION", 213, 232], ["respiratory syncytial", "ANATOMY", 290, 311]]], ["The present study describes the prevalence of hPIVs in RS from 1990 to 2017, providing important data and contributing to public health strategies regarding respiratory infections in South America.| MATERIALS AND METHODSThis study includes 34 038 patients with respiratory infection symptoms in RS from June 1990 to December 2017.", [["respiratory", "ANATOMY", 157, 168], ["respiratory", "ANATOMY", 261, 272], ["hPIVs", "DISEASE", 46, 51], ["RS", "DISEASE", 55, 57], ["respiratory infections", "DISEASE", 157, 179], ["respiratory infection", "DISEASE", 261, 282], ["patients", "ORGANISM", 247, 255], ["patients", "SPECIES", 247, 255], ["The present study", "TEST", 0, 17], ["respiratory infections", "PROBLEM", 157, 179], ["METHODSThis study", "TEST", 213, 230], ["respiratory infection symptoms", "PROBLEM", 261, 291], ["respiratory", "ANATOMY", 157, 168], ["infections", "OBSERVATION", 169, 179], ["respiratory", "ANATOMY", 261, 272], ["infection", "OBSERVATION", 273, 282]]], ["All patients that sought medical assistance at health units due to symptoms of respiratory infection and that were diagnosed with ARI or SARI were included in this study.", [["respiratory", "ANATOMY", 79, 90], ["respiratory infection", "DISEASE", 79, 100], ["ARI", "DISEASE", 130, 133], ["SARI", "DISEASE", 137, 141], ["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["symptoms", "PROBLEM", 67, 75], ["respiratory infection", "PROBLEM", 79, 100], ["ARI", "PROBLEM", 130, 133], ["SARI", "PROBLEM", 137, 141], ["this study", "TEST", 159, 169], ["respiratory", "ANATOMY", 79, 90], ["infection", "OBSERVATION", 91, 100]]], ["Clinical symptoms considered to define SARI were dyspnea (oxygen saturation below 95%), fever, myalgia, lethargy, cough, and sore throat.", [["SARI", "DISEASE", 39, 43], ["dyspnea", "DISEASE", 49, 56], ["oxygen", "CHEMICAL", 58, 64], ["fever", "DISEASE", 88, 93], ["myalgia", "DISEASE", 95, 102], ["lethargy", "DISEASE", 104, 112], ["cough", "DISEASE", 114, 119], ["sore throat", "DISEASE", 125, 136], ["oxygen", "CHEMICAL", 58, 64], ["oxygen", "SIMPLE_CHEMICAL", 58, 64], ["Clinical symptoms", "PROBLEM", 0, 17], ["SARI", "PROBLEM", 39, 43], ["dyspnea", "PROBLEM", 49, 56], ["oxygen saturation", "TEST", 58, 75], ["fever", "PROBLEM", 88, 93], ["myalgia", "PROBLEM", 95, 102], ["lethargy", "PROBLEM", 104, 112], ["cough", "PROBLEM", 114, 119], ["sore throat", "PROBLEM", 125, 136], ["myalgia", "OBSERVATION", 95, 102], ["cough", "OBSERVATION", 114, 119], ["sore throat", "ANATOMY", 125, 136]]], ["9, 10 For ARI definition, clinical symptoms were fever (above 37.5\u00b0C ), accompanied by cough or sore throat, and at least one of these symptoms: headache, myalgia, and arthralgia.", [["fever", "DISEASE", 49, 54], ["cough", "DISEASE", 87, 92], ["sore throat", "DISEASE", 96, 107], ["headache", "DISEASE", 145, 153], ["myalgia", "DISEASE", 155, 162], ["arthralgia", "DISEASE", 168, 178], ["ARI definition", "PROBLEM", 10, 24], ["clinical symptoms", "PROBLEM", 26, 43], ["fever", "PROBLEM", 49, 54], ["cough", "PROBLEM", 87, 92], ["sore throat", "PROBLEM", 96, 107], ["these symptoms", "PROBLEM", 129, 143], ["headache", "PROBLEM", 145, 153], ["myalgia", "PROBLEM", 155, 162], ["arthralgia", "PROBLEM", 168, 178], ["cough", "OBSERVATION", 87, 92], ["sore throat", "ANATOMY", 96, 107], ["headache", "OBSERVATION", 145, 153], ["myalgia", "OBSERVATION", 155, 162], ["arthralgia", "OBSERVATION", 168, 178]]], ["9 2.1 | Virus detection Nasopharyngeal secretion, including nasopharyngeal aspirates and swabs, was collected for laboratory analyses.", [["Nasopharyngeal", "ANATOMY", 24, 38], ["nasopharyngeal aspirates", "ANATOMY", 60, 84], ["swabs", "ANATOMY", 89, 94], ["Virus", "ORGANISM", 8, 13], ["Nasopharyngeal", "CANCER", 24, 38], ["nasopharyngeal aspirates", "MULTI-TISSUE_STRUCTURE", 60, 84], ["Virus detection", "TEST", 8, 23], ["Nasopharyngeal secretion", "TEST", 24, 48], ["nasopharyngeal aspirates", "TEST", 60, 84], ["swabs", "TEST", 89, 94], ["laboratory analyses", "TEST", 114, 133], ["nasopharyngeal", "ANATOMY", 60, 74], ["aspirates", "OBSERVATION", 75, 84]]], ["Samples were processed at LACEN-RS, a reference laboratory that belongs to the Brazilian network of Influenza and Other Respiratory Virus Surveillance and performs analyses of respiratory infections in RS.| MATERIALS AND METHODSFor respiratory virus detection, either molecular or immunoassays were used in routine laboratory analysis.", [["Samples", "ANATOMY", 0, 7], ["respiratory", "ANATOMY", 176, 187], ["Influenza", "DISEASE", 100, 109], ["Respiratory Virus", "DISEASE", 120, 137], ["respiratory infections", "DISEASE", 176, 198], ["RS", "DISEASE", 202, 204], ["Samples", "TEST", 0, 7], ["Influenza", "PROBLEM", 100, 109], ["Other Respiratory Virus Surveillance", "TEST", 114, 150], ["respiratory infections in RS", "PROBLEM", 176, 204], ["METHODSFor respiratory virus detection", "TEST", 221, 259], ["molecular or immunoassays", "TEST", 268, 293], ["routine laboratory analysis", "TEST", 307, 334], ["respiratory infections", "OBSERVATION", 176, 198]]], ["Influenza virus A and B were detected using the reverse-transcription quantitative polymerase chain reaction (PCR), 10| Statistical analysisFrequency plots were used to describe: age groups; the total number of cases positive for the respiratory virus and for hPIV types in each year of the study; and monthly circulation of hPIV types.", [["Influenza virus A", "ORGANISM", 0, 17], ["B", "GENE_OR_GENE_PRODUCT", 22, 23], ["Influenza virus", "SPECIES", 0, 15], ["Influenza virus", "SPECIES", 0, 15], ["hPIV", "SPECIES", 260, 264], ["Influenza virus A and B", "PROBLEM", 0, 23], ["PCR", "TEST", 110, 113], ["the respiratory virus", "PROBLEM", 230, 251], ["hPIV types", "PROBLEM", 260, 270], ["the study", "TEST", 287, 296], ["respiratory virus", "OBSERVATION", 234, 251]]], ["Statistical analysis was performed using SPSS Statistics 23.0 software (IBM, Armonk, NY).| Statistical analysisThe \u03c7 2 and Fisher exact tests were used to compare hPIV prevalence between male and female, and to analyze clinical symptoms.", [["Statistical analysis", "TEST", 0, 20], ["SPSS Statistics", "TEST", 41, 56], ["Statistical analysis", "TEST", 91, 111], ["Fisher exact tests", "TEST", 123, 141], ["clinical symptoms", "PROBLEM", 219, 236]]], ["Results were considered statistically significant when P < 0.05.| RESULTSIn this study, we assessed hPIV-positivity among patients with respiratory infection in southern Brazil from 1990 to 2017.", [["respiratory", "ANATOMY", 136, 147], ["respiratory infection", "DISEASE", 136, 157], ["hPIV", "GENE_OR_GENE_PRODUCT", 100, 104], ["patients", "ORGANISM", 122, 130], ["hPIV", "PROTEIN", 100, 104], ["patients", "SPECIES", 122, 130], ["this study", "TEST", 76, 86], ["hPIV", "TEST", 100, 104], ["respiratory infection", "PROBLEM", 136, 157], ["respiratory", "ANATOMY", 136, 147], ["infection", "OBSERVATION", 148, 157]]], ["Figure 1 shows the total number of viral respiratory infections throughout the period; cases positive for hPIV1-3 are also shown. hPIV positivity in each patient group (groups 1-3 as described in Section 2) is shown in Table 1 .", [["respiratory", "ANATOMY", 41, 52], ["respiratory infections", "DISEASE", 41, 63], ["hPIV1-3", "GENE_OR_GENE_PRODUCT", 106, 113], ["hPIV", "GENE_OR_GENE_PRODUCT", 130, 134], ["patient", "ORGANISM", 154, 161], ["hPIV1", "PROTEIN", 106, 111], ["hPIV", "PROTEIN", 130, 134], ["patient", "SPECIES", 154, 161], ["viral respiratory infections", "PROBLEM", 35, 63], ["hPIV1", "TEST", 106, 111], ["total", "OBSERVATION_MODIFIER", 19, 24], ["number", "OBSERVATION_MODIFIER", 25, 31], ["viral", "OBSERVATION_MODIFIER", 35, 40], ["respiratory infections", "OBSERVATION", 41, 63]]], ["16.24% were hPIV1, 41.33% hPIV3, and 42.43% hPIV2 ( Figure 1 and Table 1 ).", [["hPIV1", "TEST", 12, 17], ["hPIV3", "TEST", 26, 31], ["hPIV2", "TEST", 44, 49], ["Figure", "TEST", 52, 58]]], ["Of note, hPIV outbreaks were observed in the city of Table 1 ).| RESULTSF I G U R E 1 Total number of cases positive for respiratory viruses in Rio Grande do Sul (1990-2017) and cases positive for each hPIV type.", [["respiratory viruses", "DISEASE", 121, 140], ["hPIV outbreaks", "PROBLEM", 9, 23], ["cases", "TEST", 102, 107], ["respiratory viruses", "PROBLEM", 121, 140], ["cases", "TEST", 178, 183], ["respiratory viruses", "OBSERVATION", 121, 140]]], ["Between 1990 and 1999, only hPIV3 was tested; years from 2000 to 2017 include data for hPIV1-3. hPIV: human parainfluenza virus T A B L E 1 Cases of patients with ARI or SARI in RS (1990 RS ( -2017 Percentage in relation to the number of hPIV-positive cases in group 3. * The \u03c7 2 and Fisher exact tests were used.", [["ARI", "DISEASE", 163, 166], ["SARI", "DISEASE", 170, 174], ["RS", "DISEASE", 178, 180], ["hPIV1-3", "GENE_OR_GENE_PRODUCT", 87, 94], ["human", "ORGANISM", 102, 107], ["parainfluenza virus", "ORGANISM", 108, 127], ["patients", "ORGANISM", 149, 157], ["hPIV", "GENE_OR_GENE_PRODUCT", 238, 242], ["hPIV3", "DNA", 28, 33], ["human", "SPECIES", 102, 107], ["parainfluenza virus", "SPECIES", 108, 127], ["patients", "SPECIES", 149, 157], ["human parainfluenza virus", "SPECIES", 102, 127], ["hPIV1", "TEST", 87, 92], ["human parainfluenza virus", "PROBLEM", 102, 127], ["ARI", "PROBLEM", 163, 166], ["Fisher exact tests", "TEST", 284, 302]]], ["Results were considered statistically significant when P < 0.05.| RESULTSF I G U R E 2 Total number of hPIV-positive cases according to epidemiological weeks in Rio Grande do Sul (data accumulated monthly from 1990 to 2017); Max temp, average maximum temperature (in degrees Celsius) registered for each month during the period; Min temp, average minimum temperature (in degrees Celsius) registered for each month during the period. hPIV, human parainfluenza virus| hPIV circulationAll three hPIVs occur throughout the year, with some alternate circulation among viral types (Figures 1,2) .", [["hPIV", "GENE_OR_GENE_PRODUCT", 103, 107], ["human", "ORGANISM", 439, 444], ["parainfluenza virus| hPIV", "ORGANISM", 445, 470], ["human", "SPECIES", 439, 444], ["parainfluenza virus", "SPECIES", 445, 464], ["hPIV", "SPECIES", 433, 437], ["human parainfluenza virus| hPIV", "SPECIES", 439, 470], ["hPIV", "TEST", 103, 107], ["Max temp", "TEST", 225, 233], ["maximum temperature", "TEST", 243, 262], ["Min temp", "TEST", 329, 337], ["hPIV", "PROBLEM", 433, 437], ["human parainfluenza virus", "PROBLEM", 439, 464], ["parainfluenza virus", "OBSERVATION", 445, 464]]], ["Accordingly, hPIV1 and 3| hPIV circulationshow alternate prevalence: hPIV1 circulate more during fall and its incidence decreases with the appearance of hPIV3 in late fall; the latter displays a gradual increase, with the highest incidence during spring (September-October).", [["hPIV1", "GENE_OR_GENE_PRODUCT", 13, 18], ["3", "GENE_OR_GENE_PRODUCT", 23, 24], ["hPIV", "GENE_OR_GENE_PRODUCT", 26, 30], ["hPIV1", "GENE_OR_GENE_PRODUCT", 69, 74], ["hPIV1", "PROTEIN", 69, 74], ["hPIV3", "DNA", 153, 158], ["hPIV1", "TEST", 13, 18], ["gradual", "OBSERVATION_MODIFIER", 195, 202], ["increase", "OBSERVATION_MODIFIER", 203, 211]]], ["Cases of hPIV2 occur along the year, with peaks in April (fall) and September (early spring).| Patient demographicsPediatric patients were most of the cases in group 1, in which 84.54% were children younger than 10 years of age.", [["patients", "ORGANISM", 125, 133], ["children", "ORGANISM", 190, 198], ["hPIV2", "DNA", 9, 14], ["Patient", "SPECIES", 95, 102], ["patients", "SPECIES", 125, 133], ["children", "SPECIES", 190, 198]]], ["In addition, according to LACEN-RS records 62.87% of hPIV-positive cases in this group were observed in children younger than 6 months (data not shown).| Patient demographicsInterestingly, though 59.92% of all cases positive for the respiratory virus in group 1 were male and hPIV prevalence was higher in females (7.17% vs 4.7%, respectively; P = 0.026; Table 1 ).| 1427When patients with ARI symptoms were analyzed (group 2), results showed the occurrence of all three hPIVs in all age groups ( Figure 3A ).", [["respiratory virus", "DISEASE", 233, 250], ["ARI", "DISEASE", 390, 393], ["hPIVs", "DISEASE", 471, 476], ["hPIV", "GENE_OR_GENE_PRODUCT", 53, 57], ["children", "ORGANISM", 104, 112], ["hPIV", "CANCER", 276, 280], ["patients", "ORGANISM", 376, 384], ["LACEN", "DNA", 26, 31], ["children", "SPECIES", 104, 112], ["Patient", "SPECIES", 154, 161], ["patients", "SPECIES", 376, 384], ["hPIV", "SPECIES", 276, 280], ["hPIV", "TEST", 53, 57], ["all cases", "TEST", 206, 215], ["the respiratory virus", "PROBLEM", 229, 250], ["hPIV prevalence", "TEST", 276, 291], ["P", "TEST", 344, 345], ["ARI symptoms", "PROBLEM", 390, 402], ["respiratory virus", "OBSERVATION", 233, 250]]], ["Of note, in patients up to 5 years of age, hPIV3 was the most prevalent type and hPIV2 was highly prevalent among adults between 20 and 49 years of age.", [["patients", "ORGANISM", 12, 20], ["hPIV3", "GENE_OR_GENE_PRODUCT", 43, 48], ["hPIV2", "GENE_OR_GENE_PRODUCT", 81, 86], ["patients", "SPECIES", 12, 20], ["hPIV2", "SPECIES", 81, 86]]], ["Of all ARI cases with confirmed viral infection, 46.76% were male; the proportion of females among hPIVpositive cases was slightly higher (14.22% vs 11.57% males; P = 0.087), and no significant differences were found between sex regardless of hPIV types (hPIV1 P = 1.0, hPIV2 P = 0.383, and hPIV3 P = 0.46).| 1427For SARI cases notified in SINAN from 2010 to 2017 (n = 416), demographic data from 410 patients were obtained (group 3).| 1427Regardless of the virus type, 92.2% of hPIV infections occurred in children less than 5 years of age; notably, 68.29% were children younger than 1 year ( Figure 3B ).", [["ARI", "DISEASE", 7, 10], ["viral infection", "DISEASE", 32, 47], ["infections", "DISEASE", 484, 494], ["patients", "ORGANISM", 401, 409], ["hPIV", "CANCER", 479, 483], ["children", "ORGANISM", 507, 515], ["children", "ORGANISM", 563, 571], ["patients", "SPECIES", 401, 409], ["children", "SPECIES", 507, 515], ["children", "SPECIES", 563, 571], ["hPIV", "SPECIES", 243, 247], ["hPIV", "SPECIES", 479, 483], ["viral infection", "PROBLEM", 32, 47], ["hPIVpositive cases", "TEST", 99, 117], ["slightly higher", "PROBLEM", 122, 137], ["P", "TEST", 163, 164], ["significant differences", "PROBLEM", 182, 205], ["hPIV2 P", "TEST", 270, 277], ["demographic data", "TEST", 375, 391], ["the virus type", "PROBLEM", 454, 468], ["hPIV infections", "PROBLEM", 479, 494], ["viral", "OBSERVATION_MODIFIER", 32, 37], ["infection", "OBSERVATION", 38, 47], ["no", "UNCERTAINTY", 179, 181], ["significant", "OBSERVATION_MODIFIER", 182, 193], ["virus", "OBSERVATION", 458, 463], ["infections", "OBSERVATION", 484, 494]]], ["Interestingly, even though hPIV3 is more frequent than hPIV1, the latter seems to be more distributed in all age groups.", [["hPIV3", "GENE_OR_GENE_PRODUCT", 27, 32], ["hPIV3", "PROTEIN", 27, 32], ["hPIV1", "PROTEIN", 55, 60], ["more frequent", "OBSERVATION_MODIFIER", 36, 49], ["seems to be", "UNCERTAINTY", 73, 84], ["more", "OBSERVATION_MODIFIER", 85, 89], ["distributed", "OBSERVATION_MODIFIER", 90, 101]]], ["In general, people between 20 and 60 years of age are less susceptible to hPIV infections.", [["infections", "DISEASE", 79, 89], ["people", "ORGANISM", 12, 18], ["people", "SPECIES", 12, 18], ["hPIV", "SPECIES", 74, 78], ["hPIV infections", "PROBLEM", 74, 89], ["infections", "OBSERVATION", 79, 89]]], ["Of all positive respiratory viruses studied in LACEN-RS from 2010 to 2017, 52.12% were male; accordingly, hPIV prevalence was slightly higher in this group (5.31% vs 4.82% in female, P = 0.392), and no significant differences were found between sex regardless of hPIV types (hPIV1 P = 0.66, hPIV2 P = 0.073, and hPIV3 P = 0.219).| SymptomsThe most common symptoms among ARI patients infected by hPIV were fever, cough, and coryza regardless of the viral type (Table 2) .| SymptomsOf note, patients infected by hPIV2 reported nasal obstruction (77.35%), myalgia (60.37%), and arthralgia (34.9%); moreover, fever was less common among hPIV2 patients than in patients infected by either hPIV1 or 3.", [["nasal", "ANATOMY", 525, 530], ["ARI", "DISEASE", 370, 373], ["fever", "DISEASE", 405, 410], ["cough", "DISEASE", 412, 417], ["nasal obstruction", "DISEASE", 525, 542], ["myalgia", "DISEASE", 553, 560], ["arthralgia", "DISEASE", 575, 585], ["fever", "DISEASE", 605, 610], ["patients", "ORGANISM", 374, 382], ["patients", "ORGANISM", 489, 497], ["nasal obstruction", "PATHOLOGICAL_FORMATION", 525, 542], ["hPIV2", "ORGANISM", 633, 638], ["patients", "ORGANISM", 639, 647], ["patients", "ORGANISM", 656, 664], ["patients", "SPECIES", 374, 382], ["patients", "SPECIES", 489, 497], ["patients", "SPECIES", 639, 647], ["patients", "SPECIES", 656, 664], ["hPIV", "SPECIES", 106, 110], ["hPIV", "SPECIES", 395, 399], ["all positive respiratory viruses", "PROBLEM", 3, 35], ["hPIV prevalence", "TEST", 106, 121], ["P", "TEST", 183, 184], ["significant differences", "PROBLEM", 202, 225], ["hPIV2", "TEST", 291, 296], ["P", "TEST", 297, 298], ["Symptoms", "PROBLEM", 331, 339], ["The most common symptoms", "PROBLEM", 339, 363], ["ARI", "PROBLEM", 370, 373], ["fever", "PROBLEM", 405, 410], ["cough", "PROBLEM", 412, 417], ["coryza", "PROBLEM", 423, 429], ["nasal obstruction", "PROBLEM", 525, 542], ["myalgia", "PROBLEM", 553, 560], ["arthralgia", "PROBLEM", 575, 585], ["fever", "PROBLEM", 605, 610], ["positive", "OBSERVATION_MODIFIER", 7, 15], ["respiratory viruses", "OBSERVATION", 16, 35], ["most common", "OBSERVATION_MODIFIER", 343, 354], ["nasal", "ANATOMY", 525, 530], ["obstruction", "OBSERVATION", 531, 542], ["arthralgia", "OBSERVATION", 575, 585]]], ["In patients with hPIV3, fever (87.5%) and cough (89.28%) were the most common symptoms.", [["fever", "DISEASE", 24, 29], ["cough", "DISEASE", 42, 47], ["patients", "ORGANISM", 3, 11], ["patients", "SPECIES", 3, 11], ["hPIV3", "PROBLEM", 17, 22], ["fever", "PROBLEM", 24, 29], ["cough", "PROBLEM", 42, 47], ["the most common symptoms", "PROBLEM", 62, 86]]], ["Less common symptoms were earache, vomiting, cyanosis, muscular pain, and wheezing.| SymptomsPatients hospitalized with SARI exhibit cough, fever, and dyspnea, and these were the symptoms mostly observed in hPIV-infected patients in groups 1 and 3; however, because samples of group 1 were analyzed before implementation of the national information system for surveillance of respiratory infections, no clinical data were available for this group of patients.", [["muscular", "ANATOMY", 55, 63], ["samples", "ANATOMY", 266, 273], ["respiratory", "ANATOMY", 376, 387], ["earache", "DISEASE", 26, 33], ["vomiting", "DISEASE", 35, 43], ["cyanosis", "DISEASE", 45, 53], ["muscular pain", "DISEASE", 55, 68], ["wheezing", "DISEASE", 74, 82], ["SARI", "DISEASE", 120, 124], ["cough", "DISEASE", 133, 138], ["fever", "DISEASE", 140, 145], ["dyspnea", "DISEASE", 151, 158], ["hPIV-infected", "DISEASE", 207, 220], ["respiratory infections", "DISEASE", 376, 398], ["patients", "ORGANISM", 221, 229], ["patients", "ORGANISM", 450, 458], ["patients", "SPECIES", 221, 229], ["patients", "SPECIES", 450, 458], ["hPIV", "SPECIES", 207, 211], ["Less common symptoms", "PROBLEM", 0, 20], ["earache", "PROBLEM", 26, 33], ["vomiting", "PROBLEM", 35, 43], ["cyanosis", "PROBLEM", 45, 53], ["muscular pain", "PROBLEM", 55, 68], ["wheezing", "PROBLEM", 74, 82], ["SARI", "PROBLEM", 120, 124], ["cough", "PROBLEM", 133, 138], ["fever", "PROBLEM", 140, 145], ["dyspnea", "PROBLEM", 151, 158], ["the symptoms", "PROBLEM", 175, 187], ["respiratory infections", "PROBLEM", 376, 398], ["clinical data", "TEST", 403, 416], ["muscular", "ANATOMY", 55, 63], ["pain", "OBSERVATION", 64, 68], ["wheezing", "OBSERVATION", 74, 82], ["cough", "OBSERVATION", 133, 138], ["infected", "OBSERVATION", 212, 220], ["respiratory", "ANATOMY", 376, 387], ["infections", "OBSERVATION", 388, 398]]], ["Symptoms more frequent for each hPIV type are shown in Table 2 and included: dyspnea, sore throat, and myalgia for hPIV1; chills for hPIV2; and dyspnea for hPIV3.", [["dyspnea", "DISEASE", 77, 84], ["sore throat", "DISEASE", 86, 97], ["myalgia", "DISEASE", 103, 110], ["chills", "DISEASE", 122, 128], ["dyspnea", "DISEASE", 144, 151], ["Symptoms", "PROBLEM", 0, 8], ["dyspnea", "PROBLEM", 77, 84], ["sore throat", "PROBLEM", 86, 97], ["myalgia", "PROBLEM", 103, 110], ["hPIV1", "PROBLEM", 115, 120], ["chills", "PROBLEM", 122, 128], ["hPIV2", "PROBLEM", 133, 138], ["dyspnea", "PROBLEM", 144, 151], ["hPIV3", "PROBLEM", 156, 161], ["dyspnea", "OBSERVATION", 77, 84], ["sore throat", "ANATOMY", 86, 97], ["myalgia", "ANATOMY", 103, 110], ["dyspnea", "OBSERVATION", 144, 151]]], ["Other less reported symptoms included vomiting, tachypnea, wheezing, conjunctivitis, coryza, diarrhea, and headache.| SymptomsData regarding disease outcome (cure/fatality) were available only for group 2 (outpatients with ARI, n = 271) and group 3 (hPIVpositive patients hospitalized with SARI, n = 416); fatality outcomes were found only in group 3, with a total of 19 deaths (Table 3) .", [["vomiting", "DISEASE", 38, 46], ["tachypnea", "DISEASE", 48, 57], ["wheezing", "DISEASE", 59, 67], ["conjunctivitis", "DISEASE", 69, 83], ["coryza", "DISEASE", 85, 91], ["diarrhea", "DISEASE", 93, 101], ["headache", "DISEASE", 107, 115], ["ARI", "DISEASE", 223, 226], ["SARI", "DISEASE", 290, 294], ["deaths", "DISEASE", 371, 377], ["patients", "ORGANISM", 263, 271], ["patients", "SPECIES", 263, 271], ["Other less reported symptoms", "PROBLEM", 0, 28], ["vomiting", "PROBLEM", 38, 46], ["tachypnea", "PROBLEM", 48, 57], ["wheezing", "PROBLEM", 59, 67], ["conjunctivitis", "PROBLEM", 69, 83], ["coryza", "PROBLEM", 85, 91], ["diarrhea", "PROBLEM", 93, 101], ["headache", "PROBLEM", 107, 115], ["disease outcome", "PROBLEM", 141, 156], ["ARI", "PROBLEM", 223, 226], ["wheezing", "OBSERVATION", 59, 67], ["conjunctivitis", "OBSERVATION", 69, 83], ["coryza", "ANATOMY", 85, 91], ["diarrhea", "OBSERVATION", 93, 101]]], ["Thus, in this group, the mortality rate reached 4.57%; however, if all hPIVpositive cases are taken into account (n = 781), the mortality rate in hPIV infection was approximately 2.43%.", [["infection", "DISEASE", 151, 160], ["hPIV", "CANCER", 146, 150], ["hPIV", "SPECIES", 146, 150], ["the mortality rate", "TEST", 21, 39], ["the mortality rate", "TEST", 124, 142], ["hPIV infection", "PROBLEM", 146, 160], ["infection", "OBSERVATION", 151, 160]]], ["Notably, 68.4% of the fatalities were in female patients and at least one risk factor was present in 89.5% of deaths, including prematurity, children up to 2 years, and adult above 60 years and/or patients with chronic diseases (Table 3 ).| DISCUSSIONThe health burden of hPIV infection is underestimated due to lack of studies about this virus; a few studies analyzed hPIV infection in pediatric patients [11] [12] [13] [14] [15] ; apart from these, secondary data on hPIV can be found in some studies about influenza and hRSV.", [["fatalities", "DISEASE", 22, 32], ["deaths", "DISEASE", 110, 116], ["prematurity", "DISEASE", 128, 139], ["chronic diseases", "DISEASE", 211, 227], ["hPIV infection", "DISEASE", 272, 286], ["infection", "DISEASE", 374, 383], ["influenza", "DISEASE", 509, 518], ["patients", "ORGANISM", 48, 56], ["children", "ORGANISM", 141, 149], ["patients", "ORGANISM", 197, 205], ["hPIV", "ORGANISM", 369, 373], ["patients", "ORGANISM", 397, 405], ["hRSV", "CANCER", 523, 527], ["patients", "SPECIES", 48, 56], ["children", "SPECIES", 141, 149], ["patients", "SPECIES", 197, 205], ["patients", "SPECIES", 397, 405], ["hPIV", "SPECIES", 272, 276], ["hPIV", "SPECIES", 369, 373], ["hRSV", "SPECIES", 523, 527], ["prematurity", "PROBLEM", 128, 139], ["chronic diseases", "PROBLEM", 211, 227], ["hPIV infection", "PROBLEM", 272, 286], ["this virus", "PROBLEM", 334, 344], ["a few studies", "TEST", 346, 359], ["hPIV infection", "PROBLEM", 369, 383], ["secondary data on hPIV", "PROBLEM", 451, 473], ["influenza", "PROBLEM", 509, 518], ["hRSV", "PROBLEM", 523, 527], ["chronic", "OBSERVATION_MODIFIER", 211, 218], ["diseases", "OBSERVATION", 219, 227], ["infection", "OBSERVATION", 277, 286]]], ["6, [16] [17] [18] To help in the understanding of how hPIV impacts human health, this study describes hPIV infection in patients with respiratory infections in RS, southern Brazil, where the incidence of respiratory infections is one of the highest in the country.", [["respiratory", "ANATOMY", 134, 145], ["respiratory", "ANATOMY", 204, 215], ["hPIV infection", "DISEASE", 102, 116], ["respiratory infections", "DISEASE", 134, 156], ["RS", "DISEASE", 160, 162], ["respiratory infections", "DISEASE", 204, 226], ["[16] [17] [18", "SIMPLE_CHEMICAL", 3, 16], ["hPIV", "ORGANISM", 54, 58], ["human", "ORGANISM", 67, 72], ["hPIV", "ORGANISM", 102, 106], ["patients", "ORGANISM", 120, 128], ["hPIV", "PROTEIN", 54, 58], ["human", "SPECIES", 67, 72], ["patients", "SPECIES", 120, 128], ["human", "SPECIES", 67, 72], ["hPIV", "SPECIES", 102, 106], ["this study", "TEST", 81, 91], ["hPIV infection", "PROBLEM", 102, 116], ["respiratory infections in RS", "PROBLEM", 134, 162], ["respiratory infections", "PROBLEM", 204, 226], ["infection", "OBSERVATION", 107, 116], ["respiratory", "ANATOMY", 134, 145], ["infections", "OBSERVATION", 146, 156], ["respiratory", "ANATOMY", 204, 215], ["infections", "OBSERVATION", 216, 226]]], ["9 Southern Brazil is the coldest region in the country; it is known that exposure to cold can induce vasoconstriction in the respiratory tract and suppression of immune responses.", [["respiratory tract", "ANATOMY", 125, 142], ["respiratory tract", "ORGANISM_SUBDIVISION", 125, 142], ["vasoconstriction in the respiratory tract", "PROBLEM", 101, 142], ["respiratory tract", "ANATOMY", 125, 142]]], ["19 However, some studies describe peaks of hPIV activity in oddnumbered years, but we did not find biennial patterns of hPIV circulation along 28 years of analysis.", [["hPIV", "GENE_OR_GENE_PRODUCT", 43, 47], ["hPIV", "SPECIES", 120, 124], ["some studies", "TEST", 12, 24], ["hPIV activity", "PROBLEM", 43, 56], ["hPIV circulation", "PROBLEM", 120, 136], ["analysis", "TEST", 155, 163]]], ["2, 15, 27, 32 Viral dynamics in the human population is related to host, viral and environmental determinants, whose complexity is not well understood, especially when different viruses are involved in a pathological condition.", [["human", "ORGANISM", 36, 41], ["human", "SPECIES", 36, 41], ["human", "SPECIES", 36, 41], ["viral", "OBSERVATION", 73, 78]]], ["Accordingly, respiratory infections in RS can be caused by a plethora of pathogens, including IAV, IBV, hPIV, hRSV, hAdV, and metapneumovirus 9, 34 ; in this sense, our findings show that hPIV activity is high during fall and spring, just before and after influenza and hRSV season, which occur in winter (from May to August).", [["respiratory", "ANATOMY", 13, 24], ["respiratory infections", "DISEASE", 13, 35], ["RS", "DISEASE", 39, 41], ["IAV", "ORGANISM", 94, 97], ["IBV", "ORGANISM", 99, 102], ["hPIV", "GENE_OR_GENE_PRODUCT", 104, 108], ["hRSV", "GENE_OR_GENE_PRODUCT", 110, 114], ["hAdV", "GENE_OR_GENE_PRODUCT", 116, 120], ["metapneumovirus 9", "ORGANISM", 126, 143], ["hPIV", "GENE_OR_GENE_PRODUCT", 188, 192], ["IAV", "SPECIES", 94, 97], ["IBV", "SPECIES", 99, 102], ["hPIV", "SPECIES", 104, 108], ["hRSV", "SPECIES", 110, 114], ["hAdV", "SPECIES", 116, 120], ["hPIV", "SPECIES", 188, 192], ["hRSV", "SPECIES", 270, 274], ["respiratory infections in RS", "PROBLEM", 13, 41], ["pathogens", "PROBLEM", 73, 82], ["IAV", "PROBLEM", 94, 97], ["IBV", "PROBLEM", 99, 102], ["hPIV", "PROBLEM", 104, 108], ["hRSV", "PROBLEM", 110, 114], ["hAdV", "PROBLEM", 116, 120], ["metapneumovirus", "PROBLEM", 126, 141], ["hPIV activity", "PROBLEM", 188, 201], ["influenza", "PROBLEM", 256, 265], ["respiratory", "ANATOMY", 13, 24], ["infections", "OBSERVATION", 25, 35], ["high", "OBSERVATION_MODIFIER", 205, 209]]], ["35 Similarly, a study analyzed the circulation of hPIV, hRSV, and IAV in Fortaleza (Northeast Brazil) and found an inverse association between hPIV, hRSV, and IAV circulation.", [["hPIV", "GENE_OR_GENE_PRODUCT", 50, 54], ["hRSV", "GENE_OR_GENE_PRODUCT", 56, 60], ["hPIV", "GENE_OR_GENE_PRODUCT", 143, 147], ["hRSV", "GENE_OR_GENE_PRODUCT", 149, 153], ["hPIV", "SPECIES", 50, 54], ["hRSV", "SPECIES", 56, 60], ["IAV", "SPECIES", 66, 69], ["hPIV", "SPECIES", 143, 147], ["hRSV", "SPECIES", 149, 153], ["IAV", "SPECIES", 159, 162], ["a study", "TEST", 14, 21], ["hRSV", "PROBLEM", 56, 60], ["an inverse association between hPIV, hRSV, and IAV circulation", "PROBLEM", 112, 174], ["hRSV", "ANATOMY", 149, 153], ["IAV circulation", "ANATOMY", 159, 174]]], ["16 including influenza infection.", [["influenza infection", "DISEASE", 13, 32], ["influenza infection", "PROBLEM", 13, 32], ["influenza infection", "OBSERVATION", 13, 32]]], ["9 In England and Wales, 43 it has been estimated that three deaths occur per year due to infection by hPIV2 in children up to 1-year old.", [["deaths", "DISEASE", 60, 66], ["infection", "DISEASE", 89, 98], ["children", "ORGANISM", 111, 119], ["children", "SPECIES", 111, 119], ["infection", "PROBLEM", 89, 98], ["infection", "OBSERVATION", 89, 98]]], ["In addition, hPIV has also been associated with mortality and a greater impact in the elderly above 75 years.", [["hPIV", "PROTEIN", 13, 17], ["hPIV", "SPECIES", 13, 17], ["greater", "OBSERVATION_MODIFIER", 64, 71]]], ["44 In our study, we found a higher fatality rate among patients infected with hPIV2 (22.22%) compared to hPIV1 and 3 (8.57% and 2.74%, respectively), mainly in young infants and in the elderly hospitalized with SARI.| DISCUSSIONOne of the main limitations of this study was that only hPIV3 was assessed between 1990 and 1999, therefore data about hPIV1 and 2 infections were included in the analysis only from 2000 onwards.", [["SARI", "DISEASE", 211, 215], ["infections", "DISEASE", 359, 369], ["patients", "ORGANISM", 55, 63], ["infants", "ORGANISM", 166, 173], ["hPIV3", "GENE_OR_GENE_PRODUCT", 284, 289], ["patients", "SPECIES", 55, 63], ["infants", "SPECIES", 166, 173], ["our study", "TEST", 6, 15], ["a higher fatality rate", "PROBLEM", 26, 48], ["hPIV2", "TREATMENT", 78, 83], ["hPIV1", "TEST", 105, 110], ["SARI", "PROBLEM", 211, 215], ["this study", "TEST", 259, 269], ["hPIV1", "TEST", 347, 352], ["2 infections", "PROBLEM", 357, 369], ["the analysis", "TEST", 387, 399]]], ["In addition, data was lacking for some patients, mainly those reported before 2002, therefore some patients had to be excluded from the study due to incomplete epidemiological information, both related to clinical and demographic data as well as to viral type.", [["patients", "ORGANISM", 39, 47], ["patients", "ORGANISM", 99, 107], ["patients", "SPECIES", 39, 47], ["patients", "SPECIES", 99, 107], ["the study", "TEST", 132, 141], ["demographic data", "TEST", 218, 234]]], ["Another limitation was a change in the way that symptoms are reported in the system, and some important symptoms, including disease outcome, were included in the notification forms only after the 2009 influenza pandemics.| DISCUSSIONRecently, molecular methods based on singleplex-and multiplex-PCR have been developed for the diagnosis of viral respiratory infection; multiplex-PCR assays employ respiratory viruses panels which include, among other viruses, hPIVs.", [["respiratory", "ANATOMY", 346, 357], ["influenza pandemics", "DISEASE", 201, 220], ["viral respiratory infection", "DISEASE", 340, 367], ["symptoms", "PROBLEM", 48, 56], ["some important symptoms", "PROBLEM", 89, 112], ["disease outcome", "PROBLEM", 124, 139], ["the 2009 influenza pandemics", "PROBLEM", 192, 220], ["singleplex", "TEST", 270, 280], ["multiplex-PCR", "TEST", 285, 298], ["viral respiratory infection", "PROBLEM", 340, 367], ["multiplex-PCR assays", "TEST", 369, 389], ["respiratory viruses panels", "TEST", 397, 423], ["viral", "OBSERVATION_MODIFIER", 340, 345], ["respiratory", "ANATOMY", 346, 357], ["infection", "OBSERVATION", 358, 367], ["viruses", "OBSERVATION", 451, 458]]], ["[45] [46] [47] Though more sensitive than IFA, multiplex-PCR presents higher costs for implementation, therefore many reference laboratories in Brazil still rely on IFA for epidemiological surveillance of viral respiratory diseases.| DISCUSSIONThis represented a limitation for our study, and we cannot discard the possibility of finding a higher number of hPIV-positive cases if PCR-based methods had been used in our analyses.", [["respiratory", "ANATOMY", 211, 222], ["viral respiratory diseases", "DISEASE", 205, 231], ["[45] [46] [47", "SIMPLE_CHEMICAL", 0, 13], ["hPIV", "GENE_OR_GENE_PRODUCT", 357, 361], ["IFA", "TEST", 42, 45], ["multiplex-PCR", "TEST", 47, 60], ["IFA", "TEST", 165, 168], ["viral respiratory diseases", "PROBLEM", 205, 231], ["our study", "TEST", 278, 287], ["PCR", "TEST", 380, 383], ["viral", "OBSERVATION", 205, 210], ["respiratory diseases", "OBSERVATION", 211, 231]]], ["Nevertheless, we were able to detect a significant number of hPIV-positive cases, which reinforces the need for implementing molecular diagnostics for the respiratory virus in our region.", [["respiratory virus", "DISEASE", 155, 172], ["hPIV", "GENE_OR_GENE_PRODUCT", 61, 65], ["respiratory virus", "ORGANISM", 155, 172], ["molecular diagnostics", "TEST", 125, 146], ["the respiratory virus", "PROBLEM", 151, 172], ["respiratory virus", "OBSERVATION", 155, 172]]], ["As a matter of fact, as part of the improvement of epidemiological surveillance network in Brazil, a respiratory viruses panel to be used in multiplex-PCR is being implemented in some of the reference laboratories in the country, which will include IAV, IBV, hAdV, hPIVs, RSV, human metapneumovirus, human Bocavirus, human coronavirus, and rhinovirus.| DISCUSSIONDespite the difficulties found, we were able to perform historical analysis of cases of hPIV in RS along 28 years, with data about the epidemiological and laboratory surveillance of three hPIV types-hPIV1-3.", [["human metapneumovirus", "DISEASE", 277, 298], ["hPIV", "DISEASE", 451, 455], ["RS", "DISEASE", 459, 461], ["IAV", "ORGANISM", 249, 252], ["IBV", "ORGANISM", 254, 257], ["hAdV", "GENE_OR_GENE_PRODUCT", 259, 263], ["hPIVs", "GENE_OR_GENE_PRODUCT", 265, 270], ["RSV", "ORGANISM", 272, 275], ["human", "ORGANISM", 277, 282], ["metapneumovirus", "ORGANISM", 283, 298], ["human", "ORGANISM", 300, 305], ["Bocavirus", "ORGANISM", 306, 315], ["human", "ORGANISM", 317, 322], ["coronavirus", "ORGANISM", 323, 334], ["rhinovirus", "ORGANISM", 340, 350], ["hPIV1-3", "GENE_OR_GENE_PRODUCT", 562, 569], ["RSV", "SPECIES", 272, 275], ["human", "SPECIES", 277, 282], ["metapneumovirus", "SPECIES", 283, 298], ["human", "SPECIES", 300, 305], ["human", "SPECIES", 317, 322], ["coronavirus", "SPECIES", 323, 334], ["IAV", "SPECIES", 249, 252], ["IBV", "SPECIES", 254, 257], ["hAdV", "SPECIES", 259, 263], ["RSV", "SPECIES", 272, 275], ["human metapneumovirus", "SPECIES", 277, 298], ["human", "SPECIES", 300, 305], ["human coronavirus", "SPECIES", 317, 334], ["hPIV", "SPECIES", 451, 455], ["a respiratory viruses panel", "PROBLEM", 99, 126], ["multiplex-PCR", "TEST", 141, 154], ["IAV", "PROBLEM", 249, 252], ["IBV", "PROBLEM", 254, 257], ["hAdV", "PROBLEM", 259, 263], ["hPIVs", "TREATMENT", 265, 270], ["RSV", "PROBLEM", 272, 275], ["human metapneumovirus", "PROBLEM", 277, 298], ["human Bocavirus", "PROBLEM", 300, 315], ["human coronavirus", "PROBLEM", 317, 334], ["rhinovirus", "PROBLEM", 340, 350], ["historical analysis", "TEST", 419, 438], ["laboratory surveillance", "TEST", 518, 541], ["respiratory viruses", "OBSERVATION", 101, 120]]], ["Our analysis contributes to information about hPIV seasonality in South America, prevalence among age groups and most common symptoms observed in hPIV infection both in mild and severe acute respiratory infection.", [["respiratory", "ANATOMY", 191, 202], ["infection", "DISEASE", 151, 160], ["acute respiratory infection", "DISEASE", 185, 212], ["hPIV", "SPECIES", 146, 150], ["Our analysis", "TEST", 0, 12], ["most common symptoms", "PROBLEM", 113, 133], ["hPIV infection", "PROBLEM", 146, 160], ["mild and severe acute respiratory infection", "PROBLEM", 169, 212], ["infection", "OBSERVATION", 151, 160], ["mild", "OBSERVATION_MODIFIER", 169, 173], ["severe", "OBSERVATION_MODIFIER", 178, 184], ["acute", "OBSERVATION_MODIFIER", 185, 190], ["respiratory", "ANATOMY", 191, 202], ["infection", "OBSERVATION", 203, 212]]]], "PMC7227538": [["ConsentBoth women provided written informed consent for publication of this article and the accompanying images.Declaration of Competing InterestThe authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.", [["women", "ORGANISM", 12, 17], ["women", "SPECIES", 12, 17], ["the accompanying images", "TEST", 88, 111]]]], "PMC7269893": [["Werknemers kunnen via een cao wel m\u00e9\u00e9r vakantie-uren krijgen, maar niet minder.1 Hoeveel vakantie-uren heb ik en wanneer vervallen ze?Als je onder de cao VVT valt2: Je krijgt bovenop de wettelijke vakantie-uren 58,4 zogenoemde bovenwettelijke vakantie-uren, naar rato van het dienstverband, \u00e9n 35 \u2018extra bovenwettelijke vakantie-uren\u2019 ongeacht hoeveel je werkt.", [["Je krijgt bovenop de wettelijke vakantie-uren 58,4 zogenoemde bovenwettelijke vakantie-uren, naar rato van het dienstverband, \u00e9n 35 \u2018extra bovenwettelijke vakantie-uren\u2019 ongeacht hoeveel je werkt", "SPECIES", 165, 360], ["een cao", "TREATMENT", 22, 29], ["uren krijgen", "TREATMENT", 48, 60]]], ["Ben je wijkverpleegkundige en werk je 24 uur per week, dan krijg je op basis van de wet 24x4=96 vakantie-uren en op basis van de cao 39 uur + 35 uur = 170 vakantie-uren per jaar.", [["Ben je wijkverpleegkundige en werk je 24 uur per week, dan krijg je op basis van de wet 24x4=96 vakantie-uren en op basis van de cao 39 uur + 35 uur = 170 vakantie-uren", "SPECIES", 0, 168]]], ["Was je op 31 december 2011 50 jaar of ouder, dan heb je recht op nog meer vakantie-uren.", [["dan heb je recht op nog meer vakantie-uren", "SPECIES", 45, 87]]], ["De berekening voor die regeling staat in de cao.3 Voor verpleegkundigen in de VVT vervallen alle vakantie-uren (dus ook de wettelijke) 5 jaar na de laatste dag van het kalenderjaar waarin ze zijn opgebouwd.1 Hoeveel vakantie-uren heb ik en wanneer vervallen ze?", [["VVT vervallen alle vakantie-uren (dus ook de wettelijke) 5 jaar na de laatste dag van het kalenderjaar waarin ze zijn opgebouwd", "SPECIES", 78, 205]]]], "PMC7243393": [["TO THE EDITORThe catastrophic impact of the coronavirus disease 2019 (COVID-19) epidemic in Italy has been described previously [1, 2].", [["coronavirus disease", "DISEASE", 44, 63], ["COVID-19", "CHEMICAL", 70, 78], ["coronavirus", "ORGANISM", 44, 55], ["the coronavirus disease", "PROBLEM", 40, 63], ["COVID", "TEST", 70, 75], ["catastrophic", "OBSERVATION_MODIFIER", 17, 29], ["coronavirus disease", "OBSERVATION", 44, 63]]], ["We would like to contribute with some considerations on the shortcomings of Italy's response to the pandemic.TO THE EDITORAround the first COVID-19 cluster in Northern Italy, between the regions of Lombardy and Emilia-Romagna, the explosion in the caseload has been abrupt [4].", [["COVID-19 cluster", "DNA", 139, 155], ["the pandemic", "PROBLEM", 96, 108], ["Lombardy", "OBSERVATION_MODIFIER", 198, 206], ["abrupt", "OBSERVATION_MODIFIER", 266, 272]]], ["Soon, resources became insufficient to provide adequate assistance to all patients who required it [5] As the system got progressively overwhelmed, the death toll started to rise.TO THE EDITORDuring these weeks working among the communities paying the highest price to the epidemic, we have witnessed the relentless commitment of health care personnel at all levels.", [["death", "DISEASE", 152, 157], ["patients", "ORGANISM", 74, 82], ["patients", "SPECIES", 74, 82], ["the death", "PROBLEM", 148, 157]]], ["Faced with exhausting shifts and often without adequate personal protective equipment, health care workers have been unsurprisingly affected by high rates of infection and death [6].", [["infection", "DISEASE", 158, 167], ["death", "DISEASE", 172, 177], ["infection", "PROBLEM", 158, 167], ["death", "PROBLEM", 172, 177], ["infection", "OBSERVATION", 158, 167]]], ["Indeed, as shown by Nava and co-authors, 65% of the casualties among medical doctors occurred in the two aforementioned regions [3].TO THE EDITORAn obvious reason for Italy's inadequate outbreak response can be found in years of neglect for the public sector, increased private expenditure, and health care budget cuts by governments of all political affiliations [7].", [["neglect", "PROBLEM", 229, 236]]], ["Other major shortfalls stem, in our opinion, from the extreme regionalisation of health care, which has led to fragmentation of the decision-making process, increased inequalities, and lack of national coordination [8]TO THE EDITORFor instance, COVID-19 testing policies vary widely in Italy, where some regions perform mass contact tracing and outreach activities, while others prioritise severely-sick patients.", [["patients", "ORGANISM", 404, 412], ["patients", "SPECIES", 404, 412], ["COVID", "TEST", 245, 250], ["shortfalls stem", "OBSERVATION", 12, 27], ["mass", "OBSERVATION", 320, 324]]], ["This heterogeneity, coupled with ambiguous communication, has generated inefficiencies and confusion.TO THE EDITORResource allocation in the emergency was similarly impacted, in particular for the management of intensive care unit needs.", [["confusion", "DISEASE", 91, 100], ["This heterogeneity", "PROBLEM", 0, 18], ["generated inefficiencies", "PROBLEM", 62, 86], ["confusion", "PROBLEM", 91, 100], ["intensive care unit needs", "TREATMENT", 211, 236]]], ["During the last years, this number has been progressively tapered due to budget necessities, ignoring repeated warning by experts [10], and leading to complete unpreparedness to handle the burden of patients who required intensive support.", [["patients", "ORGANISM", 199, 207], ["patients", "SPECIES", 199, 207], ["intensive support", "TREATMENT", 221, 238], ["progressively", "OBSERVATION_MODIFIER", 44, 57], ["tapered", "OBSERVATION_MODIFIER", 58, 65]]], ["Most patient transfers to relieve overwhelmed intensive care units were indeed performed inside the same region, or towards foreign countries.TO THE EDITORFinally, the lack of standardisation also affected patient management, which was guided by regional - not national - guidelines.", [["patient", "ORGANISM", 5, 12], ["patient", "ORGANISM", 206, 213], ["patient", "SPECIES", 5, 12], ["patient", "SPECIES", 206, 213], ["intensive care units", "TREATMENT", 46, 66], ["patient management", "TREATMENT", 206, 224]]], ["Moreover, participation to clinical trials and access to investigational drugs were easier for bigger centers and University hospitals, where greater research experience and manpower facilitated their implementation.TO THE EDITORQuoting a famous colleague, Doctor Van Helsing from Bram Stoker's Dracula, we will have to pass through the bitter waters before reaching the sweet.", [["sweet", "ORGANISM_SUBDIVISION", 371, 376], ["investigational drugs", "TREATMENT", 57, 78]]], ["Once there, though, this historic opportunity for reform should be seised: strengthening our public health care system, reinforcing a central governance, reducing inequalities across regions, and going back from \u201caziende ospedaliere\u201d (hospital companies) to just hospitals.", [["a central governance", "TREATMENT", 132, 152]]]], "15d2fc3e49f105f84dc19bc236f4f11f66a6c4bd": [["IntroductionDue to the global COVID-19 pandemic, there has been an increased interest in studying the aerodynamic properties of aerosols and droplets.", [["the global COVID", "TEST", 19, 35], ["an increased interest", "PROBLEM", 64, 85], ["aerosols and droplets", "TREATMENT", 128, 149], ["increased", "OBSERVATION_MODIFIER", 67, 76], ["interest", "OBSERVATION", 77, 85]]], ["There is uncertainty whether aerosols may harbor enough viable SARS-CoV-2 virus to cause infection; a comprehensive understanding of aerosol and droplet behavior and mitigation strategies are needed in order to effectively limit infectious spread.", [["infection", "DISEASE", 89, 98], ["SARS-CoV-2 virus", "ORGANISM", 63, 79], ["CoV-2 virus", "SPECIES", 68, 79], ["SARS-CoV-2 virus", "SPECIES", 63, 79], ["viable SARS", "PROBLEM", 56, 67], ["CoV-2 virus", "PROBLEM", 68, 79], ["infection", "PROBLEM", 89, 98], ["aerosol and droplet behavior", "TREATMENT", 133, 161], ["mitigation strategies", "TREATMENT", 166, 187], ["infection", "OBSERVATION", 89, 98], ["infectious", "OBSERVATION", 229, 239]]], ["1 Otolaryngologists, in particular, are at high-risk of nosocomial SARS-CoV-2 infections due to the numerous aerosol and droplet generating procedures involving manipulation of potentially high viral load tissue.", [["tissue", "ANATOMY", 205, 211], ["SARS-CoV-2 infections", "DISEASE", 67, 88], ["tissue", "TISSUE", 205, 211], ["nosocomial SARS", "PROBLEM", 56, 71], ["CoV", "PROBLEM", 72, 75], ["2 infections", "PROBLEM", 76, 88], ["the numerous aerosol", "TREATMENT", 96, 116], ["droplet generating procedures", "TREATMENT", 121, 150], ["potentially high viral load tissue", "PROBLEM", 177, 211], ["nosocomial SARS", "OBSERVATION", 56, 71], ["numerous", "OBSERVATION_MODIFIER", 100, 108], ["aerosol", "OBSERVATION", 109, 116], ["high viral load tissue", "OBSERVATION", 189, 211]]], ["Distinctly characterizing aerosols and droplets based on aerodynamic diameter is critical to assessing risk of contamination due to the varying routes of transmission and infectious potential of viruses suspended in different sized particles.", [["contamination", "PROBLEM", 111, 124], ["viruses", "PROBLEM", 195, 202], ["aerosols", "OBSERVATION", 26, 34], ["droplets", "OBSERVATION_MODIFIER", 39, 47], ["aerodynamic diameter", "OBSERVATION_MODIFIER", 57, 77], ["contamination", "OBSERVATION", 111, 124], ["infectious", "OBSERVATION", 171, 181], ["viruses", "OBSERVATION", 195, 202], ["sized", "OBSERVATION_MODIFIER", 226, 231], ["particles", "OBSERVATION_MODIFIER", 232, 241]]], ["In this study, aerosols are defined as particles with an aerodynamic diameter \u226410 \u00b5m whereas droplets are characterized as those with diameters >10 \u00b5m.", [["this study", "TEST", 3, 13], ["an aerodynamic diameter", "TEST", 54, 77], ["diameters", "TEST", 134, 143], ["aerosols", "OBSERVATION", 15, 23], ["particles", "OBSERVATION_MODIFIER", 39, 48], ["aerodynamic diameter", "OBSERVATION", 57, 77], ["diameters", "OBSERVATION_MODIFIER", 134, 143]]], ["This is in accordance with differences in particle dispersion and deposition into upper and lower airways.", [["lower airways", "ANATOMY", 92, 105], ["upper", "ORGANISM_SUBDIVISION", 82, 87], ["lower airways", "MULTI-TISSUE_STRUCTURE", 92, 105], ["particle dispersion", "OBSERVATION", 42, 61], ["upper", "ANATOMY_MODIFIER", 82, 87], ["lower", "ANATOMY_MODIFIER", 92, 97], ["airways", "ANATOMY", 98, 105]]], ["2 Multiple fluorescent tracers such as Glo Germ (Glo Germ Company, Moab, Utah) and fluorescein have been used in healthcare contamination models.", [["fluorescein", "CHEMICAL", 83, 94], ["fluorescein", "CHEMICAL", 83, 94], ["fluorescein", "SIMPLE_CHEMICAL", 83, 94], ["Multiple fluorescent tracers", "TREATMENT", 2, 30], ["Glo Germ (Glo Germ Company", "TREATMENT", 39, 65], ["fluorescein", "TREATMENT", 83, 94]]], ["3, 4 For risk assessment of otolaryngology procedures, fluorescein has been the primary tracer utilized.", [["fluorescein", "CHEMICAL", 55, 66], ["fluorescein", "CHEMICAL", 55, 66], ["fluorescein", "SIMPLE_CHEMICAL", 55, 66], ["risk assessment", "TEST", 9, 24], ["otolaryngology procedures", "TREATMENT", 28, 53], ["fluorescein", "TREATMENT", 55, 66]]], ["[5] [6] [7] However, these tracers are limited due to their potential toxicity in humans and unknown capacity to fluoresce in an aerosolized form.", [["toxicity", "DISEASE", 70, 78], ["[5] [6] [7]", "SIMPLE_CHEMICAL", 0, 11], ["humans", "ORGANISM", 82, 88], ["humans", "SPECIES", 82, 88], ["humans", "SPECIES", 82, 88], ["their potential toxicity in humans", "PROBLEM", 54, 88], ["unknown capacity", "PROBLEM", 93, 109], ["toxicity", "OBSERVATION", 70, 78]]], ["Riboflavin, vitamin B2, is a water-soluble vitamin that exhibits fluorescence under UV light due to the \u03c0 conjugation and resonance present in its chemical structure.", [["Riboflavin", "CHEMICAL", 0, 10], ["vitamin B2", "CHEMICAL", 12, 22], ["vitamin", "CHEMICAL", 43, 50], ["Riboflavin", "CHEMICAL", 0, 10], ["vitamin B2", "CHEMICAL", 12, 22], ["vitamin", "CHEMICAL", 43, 50], ["Riboflavin", "SIMPLE_CHEMICAL", 0, 10], ["vitamin B2", "SIMPLE_CHEMICAL", 12, 22], ["vitamin", "SIMPLE_CHEMICAL", 43, 50], ["\u03c0", "SIMPLE_CHEMICAL", 104, 105], ["Riboflavin", "TREATMENT", 0, 10], ["vitamin B2", "TREATMENT", 12, 22], ["a water-soluble vitamin", "TREATMENT", 27, 50], ["fluorescence under UV light", "TREATMENT", 65, 92]]], ["8 Riboflavin's fluorescent properties have allowed for its use as a tracer in many different applications.", [["Riboflavin", "CHEMICAL", 2, 12], ["Riboflavin", "CHEMICAL", 2, 12], ["Riboflavin", "SIMPLE_CHEMICAL", 2, 12], ["Riboflavin's fluorescent properties", "TREATMENT", 2, 37], ["a tracer", "TREATMENT", 66, 74]]], ["In this study, we evaluate the utility of riboflavin, vitamin B2, as a fluorescent aerosol tracer, compare its properties to conventional fluorescent tracers, and explore its potential applications in human studies.Materials and MethodsThis study was conducted with approval from the University of Pittsburgh Committee for Oversight of Research and Clinical Training Involving Decedents (CORID #1054).", [["riboflavin", "CHEMICAL", 42, 52], ["vitamin B2", "CHEMICAL", 54, 64], ["riboflavin", "CHEMICAL", 42, 52], ["vitamin B2", "CHEMICAL", 54, 64], ["riboflavin", "SIMPLE_CHEMICAL", 42, 52], ["vitamin B2", "SIMPLE_CHEMICAL", 54, 64], ["human", "ORGANISM", 201, 206], ["human", "SPECIES", 201, 206], ["human", "SPECIES", 201, 206], ["this study", "TEST", 3, 13], ["riboflavin", "TREATMENT", 42, 52], ["vitamin B2", "TREATMENT", 54, 64], ["a fluorescent aerosol tracer", "TREATMENT", 69, 97], ["conventional fluorescent tracers", "TEST", 125, 157], ["human studies", "TEST", 201, 214], ["Methods", "TREATMENT", 229, 236], ["This study", "TEST", 236, 246]]], ["Vitamin B2 1 g/L in 0.9% normal saline, fluorescein 1 g/L in 0.9% normal saline, and a stock solution of a commercially available green fluorescent water tracing dye (Factor Direct Chemicals, Copiague, New York) were used as reagents.", [["Vitamin B2", "CHEMICAL", 0, 10], ["fluorescein", "CHEMICAL", 40, 51], ["Vitamin B2", "CHEMICAL", 0, 10], ["fluorescein", "CHEMICAL", 40, 51], ["Vitamin B2", "SIMPLE_CHEMICAL", 0, 10], ["saline", "SIMPLE_CHEMICAL", 32, 38], ["fluorescein", "SIMPLE_CHEMICAL", 40, 51], ["saline", "SIMPLE_CHEMICAL", 73, 79], ["Vitamin B2", "TREATMENT", 0, 10], ["fluorescein", "TREATMENT", 40, 51], ["a stock solution", "TREATMENT", 85, 101]]], ["Aerosols of these solutions were generated using an AeroEclipse II Breath Actuated Nebulizer (BAN) (Trudell Medical International, London, ON).", [["these solutions", "TREATMENT", 12, 27], ["an AeroEclipse II Breath Actuated Nebulizer", "TREATMENT", 49, 92]]], ["The BAN system was used to create aerosol particles with an average mass median aerodynamic diameter (MMAD) of 2.8 \u00b5m.", [["The BAN system", "TREATMENT", 0, 14], ["aerosol particles", "TREATMENT", 34, 51], ["average", "OBSERVATION_MODIFIER", 60, 67], ["mass", "OBSERVATION", 68, 72], ["median", "OBSERVATION_MODIFIER", 73, 79], ["aerodynamic diameter", "OBSERVATION", 80, 100], ["2.8 \u00b5m", "OBSERVATION_MODIFIER", 111, 117]]], ["9, 10 The trachea of an adult cadaver head was intubated retrograde with an 8.0 ETT with the distal tip projecting into the nasopharynx and confirmed with an endoscope.", [["trachea", "ANATOMY", 10, 17], ["cadaver head", "ANATOMY", 30, 42], ["nasopharynx", "ANATOMY", 124, 135], ["trachea", "MULTI-TISSUE_STRUCTURE", 10, 17], ["cadaver", "ORGANISM", 30, 37], ["head", "ORGANISM_SUBDIVISION", 38, 42], ["nasopharynx", "ORGAN", 124, 135], ["an 8.0 ETT", "TREATMENT", 73, 83], ["the distal tip", "TREATMENT", 89, 103], ["an endoscope", "TREATMENT", 155, 167], ["trachea", "ANATOMY", 10, 17], ["head", "ANATOMY", 38, 42], ["8.0 ETT", "OBSERVATION", 76, 83], ["distal", "OBSERVATION_MODIFIER", 93, 99], ["tip", "OBSERVATION_MODIFIER", 100, 103], ["nasopharynx", "ANATOMY", 124, 135], ["endoscope", "OBSERVATION", 158, 167]]], ["The BAN nebulizer was attached to the proximal end of the ETT and generated aerosols that traveled through the ETT and exited through the nares ( Figure 1B) .", [["nares", "ANATOMY", 138, 143], ["nares", "ORGANISM_SUBDIVISION", 138, 143], ["The BAN nebulizer", "TREATMENT", 0, 17], ["the ETT", "TREATMENT", 107, 114], ["proximal", "ANATOMY_MODIFIER", 38, 46], ["ETT", "ANATOMY", 58, 61], ["nares", "ANATOMY", 138, 143]]], ["Aerosol plumes could be visualized under A Model 170 Next Generation Impactor\u2122 (NGI\u2122) was used to collect particles into 8 stages with the following aerodynamic diameters (D 50 , cutoff diameter at 50% collection efficiency): 14.1 \u00b5m, 8.61 \u00b5m, 5.39 \u00b5m, 3.30 \u00b5m, 2.08 \u00b5m, 1.36 \u00b5m, 0.98 \u00b5m, and less than 0.98 \u00b5m.", [["Aerosol plumes", "TREATMENT", 0, 14], ["Next Generation Impactor\u2122 (NGI\u2122)", "TREATMENT", 53, 85], ["collection efficiency", "TEST", 202, 223], ["\u00b5m", "TEST", 240, 242], ["\u00b5m", "TEST", 249, 251], ["\u00b5m", "TEST", 258, 260], ["\u00b5m", "TEST", 267, 269], ["\u00b5m", "TEST", 276, 278], ["\u00b5m", "TEST", 285, 287]]], ["11, 12 Each impactor stage reflects an average particle aerodynamic diameter given an input flow rate of 15 L/min ( Figure 1A ).", [["an input flow rate", "TEST", 83, 101], ["average", "OBSERVATION_MODIFIER", 39, 46], ["particle", "OBSERVATION_MODIFIER", 47, 55], ["aerodynamic diameter", "OBSERVATION", 56, 76]]], ["This size range characterizes aerosols that are likely to reach the infraglottic airway (<10 \u00b5m) and settle into lung alveoli (<5 \u00b5m).", [["infraglottic airway", "ANATOMY", 68, 87], ["lung alveoli", "ANATOMY", 113, 125], ["airway", "ORGAN", 81, 87], ["lung alveoli", "MULTI-TISSUE_STRUCTURE", 113, 125], ["size", "OBSERVATION_MODIFIER", 5, 9], ["aerosols", "OBSERVATION", 30, 38], ["likely to", "UNCERTAINTY", 48, 57], ["infraglottic", "ANATOMY_MODIFIER", 68, 80], ["airway", "ANATOMY", 81, 87], ["lung", "ANATOMY", 113, 117], ["alveoli", "ANATOMY_MODIFIER", 118, 125]]], ["2 Each stage has a corresponding capture chamber that was lined with a removable piece of aluminum foil.", [["aluminum", "CHEMICAL", 90, 98], ["aluminum", "CHEMICAL", 90, 98], ["a corresponding capture chamber", "PROBLEM", 17, 48], ["a removable piece of aluminum foil", "TREATMENT", 69, 103], ["capture chamber", "OBSERVATION", 33, 48], ["aluminum foil", "OBSERVATION", 90, 103]]], ["The collected particulate matter on each foil was visualized under UV light following each trial.", [["The collected particulate matter on each foil", "TREATMENT", 0, 45], ["particulate", "OBSERVATION_MODIFIER", 14, 25], ["matter", "OBSERVATION", 26, 32]]], ["The nares of the cadaveric head were placed directly adjacent to the NGI\u2122 input nozzle ( Figure 1C ).", [["nares", "ANATOMY", 4, 9], ["head", "ANATOMY", 27, 31], ["nares", "ORGAN", 4, 9], ["head", "ORGAN", 27, 31], ["NGI", "DNA", 69, 72], ["nares", "ANATOMY", 4, 9], ["cadaveric head", "ANATOMY", 17, 31]]], ["Each trial lasted 2 minutes and included using the following solutions via the BAN system to generate aerosols: 0.9% normal saline, 1 g/L riboflavin (vitamin B2), 1 g/L fluorescein and a stock solution of a green fluorescent water tracer (Factor Direct Chemicals, Copiague, New York).", [["riboflavin", "CHEMICAL", 138, 148], ["vitamin B2", "CHEMICAL", 150, 160], ["fluorescein", "CHEMICAL", 169, 180], ["riboflavin", "CHEMICAL", 138, 148], ["vitamin B2", "CHEMICAL", 150, 160], ["fluorescein", "CHEMICAL", 169, 180], ["saline", "SIMPLE_CHEMICAL", 124, 130], ["riboflavin", "SIMPLE_CHEMICAL", 138, 148], ["vitamin B2", "SIMPLE_CHEMICAL", 150, 160], ["fluorescein", "SIMPLE_CHEMICAL", 169, 180], ["normal saline", "TREATMENT", 117, 130], ["L riboflavin (vitamin B2)", "TREATMENT", 136, 161], ["a stock solution", "TREATMENT", 185, 201], ["a green fluorescent water tracer", "TREATMENT", 205, 237]]], ["We also performed a trial of endonasal drilling in a cadaveric head with a coarse diamond burr (Stryker\u00a9, Kalamazoo, MI) using 1 g/L vitamin B2 solution for irrigation; in this scenario, vitamin B2 irrigation was used to coat the nasal cavity and nasopharyngeal mucosa prior to drilling and intermittently while drilling occurred ( Figure 1D ).", [["head", "ANATOMY", 63, 67], ["nasal cavity", "ANATOMY", 230, 242], ["nasopharyngeal mucosa", "ANATOMY", 247, 268], ["MI", "DISEASE", 117, 119], ["vitamin B2", "CHEMICAL", 133, 143], ["vitamin B2", "CHEMICAL", 187, 197], ["vitamin B2", "CHEMICAL", 133, 143], ["vitamin B2", "CHEMICAL", 187, 197], ["head", "ORGANISM_SUBDIVISION", 63, 67], ["vitamin B2", "SIMPLE_CHEMICAL", 133, 143], ["vitamin B2", "SIMPLE_CHEMICAL", 187, 197], ["nasal cavity", "MULTI-TISSUE_STRUCTURE", 230, 242], ["nasopharyngeal mucosa", "MULTI-TISSUE_STRUCTURE", 247, 268], ["endonasal drilling", "TREATMENT", 29, 47], ["a cadaveric head", "TREATMENT", 51, 67], ["a coarse diamond burr", "TREATMENT", 73, 94], ["Stryker\u00a9", "TREATMENT", 96, 104], ["Kalamazoo", "TREATMENT", 106, 115], ["MI)", "TREATMENT", 117, 120], ["1 g/L vitamin B2 solution", "TREATMENT", 127, 152], ["irrigation", "TREATMENT", 157, 167], ["vitamin B2 irrigation", "TREATMENT", 187, 208], ["drilling", "TREATMENT", 278, 286], ["head", "ANATOMY", 63, 67], ["nasal cavity", "ANATOMY", 230, 242], ["nasopharyngeal mucosa", "ANATOMY", 247, 268]]], ["A UV flashlight was used to visualize the filtrate at each stage in a dark room.", [["A UV flashlight", "TREATMENT", 0, 15], ["filtrate", "OBSERVATION", 42, 50]]], ["The impactor was used to determine the aerodynamic size distribution of the aerosol and small droplet particles generated from each simulation scenario.ResultsThe vitamin B2, fluorescein, and commercial green tracer dye exhibited baseline fluorescence in solution form.", [["vitamin B2", "CHEMICAL", 163, 173], ["fluorescein", "CHEMICAL", 175, 186], ["vitamin B2", "CHEMICAL", 163, 173], ["fluorescein", "CHEMICAL", 175, 186], ["vitamin B2", "SIMPLE_CHEMICAL", 163, 173], ["fluorescein", "SIMPLE_CHEMICAL", 175, 186], ["green tracer dye", "SIMPLE_CHEMICAL", 203, 219], ["The impactor", "TREATMENT", 0, 12], ["the aerosol", "TREATMENT", 72, 83], ["small droplet particles", "PROBLEM", 88, 111], ["The vitamin B2, fluorescein", "TEST", 159, 186], ["commercial green tracer dye", "PROBLEM", 192, 219], ["size", "OBSERVATION_MODIFIER", 51, 55], ["aerosol", "ANATOMY", 76, 83], ["small", "OBSERVATION_MODIFIER", 88, 93], ["droplet particles", "OBSERVATION", 94, 111]]], ["As a negative control, the BAN system was loaded with 0.9% normal saline to ensure that the saline solution did not exhibit fluorescence and that the BAN system could effectively produce aerosols detectable by the impactor.", [["saline", "SIMPLE_CHEMICAL", 66, 72], ["saline", "SIMPLE_CHEMICAL", 92, 98], ["0.9% normal saline", "TREATMENT", 54, 72], ["the saline solution", "TREATMENT", 88, 107], ["the BAN system", "TREATMENT", 146, 160]]], ["For this trial, aerosols approximately 3.30 \u00b5m or smaller were generated, but the small droplets did not appear fluorescent under UV light ( Figure 2A ; Table 1 ).", [["aerosols", "TREATMENT", 16, 24], ["the small droplets", "PROBLEM", 78, 96], ["small", "OBSERVATION_MODIFIER", 82, 87], ["droplets", "OBSERVATION", 88, 96]]], ["The 1 g/L fluorescein solution generated aerosols \u22648.61 \u00b5m.", [["fluorescein", "CHEMICAL", 10, 21], ["fluorescein", "CHEMICAL", 10, 21], ["fluorescein", "SIMPLE_CHEMICAL", 10, 21], ["The 1 g/L fluorescein solution", "TREATMENT", 0, 30]]], ["The collected particles that were between 3.30 \u00b5m and 8.61 \u00b5m in diameter were brightly fluorescent under UV light, but this diminished quickly in the matter of minutes.", [["particles", "OBSERVATION_MODIFIER", 14, 23], ["UV light", "OBSERVATION", 106, 114], ["diminished", "OBSERVATION_MODIFIER", 125, 135]]], ["A red-orange colored filtrate remained in the stages and did not appear visibly fluorescent ( Figure 2B ).", [["A red-orange colored filtrate", "PROBLEM", 0, 29], ["colored", "OBSERVATION_MODIFIER", 13, 20], ["filtrate", "OBSERVATION", 21, 29]]], ["When the commercial green tracer dye was nebulized with the BAN system, the impactor yielded red-orange colored particles \u22643.30 \u00b5m that did not appear fluorescent under UV light ( Figure 2C ).", [["green tracer dye", "SIMPLE_CHEMICAL", 20, 36], ["the commercial green tracer dye", "TREATMENT", 5, 36], ["the impactor", "TREATMENT", 72, 84], ["red-orange colored particles", "PROBLEM", 93, 121]]], ["With the nebulized vitamin B2 solution, aerosols \u22645.39 \u00b5m in diameter were generated, and the filtered particles were visibly fluorescent under UV light ( Figure 2D ).", [["vitamin B2", "CHEMICAL", 19, 29], ["vitamin B2", "CHEMICAL", 19, 29], ["vitamin B2", "SIMPLE_CHEMICAL", 19, 29], ["the nebulized vitamin B2 solution", "TREATMENT", 5, 38], ["aerosols", "TEST", 40, 48]]], ["For the endonasal drilling trial, small particles \u22643.30 \u00b5m exhibiting fluorescence were generated ( Figure 2E ).DiscussionAn effective method for tracing aerosols is integral to understanding baseline risk and designing mitigation strategies for reducing the transmission risk of SARS-CoV-2.", [["SARS", "DISEASE", 280, 284], ["SARS-CoV-2", "ORGANISM", 280, 290], ["SARS-CoV", "SPECIES", 280, 288], ["the endonasal drilling trial", "TREATMENT", 4, 32], ["small particles", "PROBLEM", 34, 49], ["tracing aerosols", "TREATMENT", 146, 162], ["mitigation strategies", "TREATMENT", 220, 241], ["SARS", "PROBLEM", 280, 284], ["CoV", "TEST", 285, 288], ["small", "OBSERVATION_MODIFIER", 34, 39]]], ["Aerosols that are \u226410 \u03bcm are of great importance due to their ability to remain airborne and travel long distances.", [["Aerosols", "TREATMENT", 0, 8]]], ["2 Particles that are 5 \u03bcm or less in diameter can penetrate the lower airways, potentially contributing to an increased severity and likelihood of infection 2, [13] [14] [15] In this study, we have compared the fluorescent properties of different tracers in aerosolized form.", [["lower airways", "ANATOMY", 64, 77], ["infection", "DISEASE", 147, 156], ["lower", "ORGANISM_SUBDIVISION", 64, 69], ["airways", "MULTI-TISSUE_STRUCTURE", 70, 77], ["[13] [14] [15", "SIMPLE_CHEMICAL", 160, 173], ["an increased severity", "PROBLEM", 107, 128], ["infection", "PROBLEM", 147, 156], ["this study", "TEST", 178, 188], ["5 \u03bcm", "OBSERVATION_MODIFIER", 21, 25], ["lower", "ANATOMY_MODIFIER", 64, 69], ["airways", "ANATOMY", 70, 77], ["increased", "OBSERVATION_MODIFIER", 110, 119], ["severity", "OBSERVATION_MODIFIER", 120, 128], ["infection", "OBSERVATION", 147, 156]]], ["Of the different fluorescent solutions analyzed, Vitamin B2 was the superior tracer based on fluorescence reliability across a range of aerosol sizes under 14.1 \u03bcm.", [["Vitamin B2", "CHEMICAL", 49, 59], ["Vitamin B2", "CHEMICAL", 49, 59], ["Vitamin B2", "SIMPLE_CHEMICAL", 49, 59], ["the different fluorescent solutions", "TREATMENT", 3, 38], ["Vitamin B2", "TREATMENT", 49, 59], ["fluorescence reliability", "TEST", 93, 117], ["a range of aerosol sizes", "TREATMENT", 125, 149], ["14.1 \u03bcm", "OBSERVATION_MODIFIER", 156, 163]]], ["Fluorescein and commercial green tracer solutions did not exhibit reliable visible fluorescence in aerosol suspension.", [["Fluorescein", "CHEMICAL", 0, 11], ["Fluorescein", "CHEMICAL", 0, 11], ["Fluorescein", "SIMPLE_CHEMICAL", 0, 11], ["Fluorescein", "TREATMENT", 0, 11], ["commercial green tracer solutions", "TREATMENT", 16, 49], ["aerosol suspension", "TREATMENT", 99, 117], ["aerosol suspension", "OBSERVATION", 99, 117]]], ["All three tracers exhibited fluorescence in solution form and thus could be used similarly in large droplet contamination trials.DiscussionVitamin B2 can be used as a coating agent for upper aerodigestive tract mucosa.", [["upper aerodigestive tract mucosa", "ANATOMY", 185, 217], ["DiscussionVitamin B2", "CHEMICAL", 129, 149], ["DiscussionVitamin B2", "CHEMICAL", 129, 149], ["DiscussionVitamin B2", "SIMPLE_CHEMICAL", 129, 149], ["upper aerodigestive tract mucosa", "MULTI-TISSUE_STRUCTURE", 185, 217], ["large droplet contamination trials", "TREATMENT", 94, 128], ["DiscussionVitamin B2", "TREATMENT", 129, 149], ["a coating agent", "TREATMENT", 165, 180], ["upper aerodigestive tract mucosa", "PROBLEM", 185, 217], ["large", "OBSERVATION_MODIFIER", 94, 99], ["droplet contamination", "OBSERVATION", 100, 121], ["upper", "ANATOMY_MODIFIER", 185, 190], ["aerodigestive tract", "ANATOMY", 191, 210], ["mucosa", "ANATOMY", 211, 217]]], ["Its fluorescent property allows for survey of aerosols and droplets generated from instrumentation of the nasal cavity or nasopharynx.", [["nasal cavity", "ANATOMY", 106, 118], ["nasopharynx", "ANATOMY", 122, 133], ["nasal cavity", "MULTI-TISSUE_STRUCTURE", 106, 118], ["nasopharynx", "ORGAN", 122, 133], ["aerosols and droplets", "TREATMENT", 46, 67], ["instrumentation of the nasal cavity or nasopharynx", "PROBLEM", 83, 133], ["instrumentation", "OBSERVATION", 83, 98], ["nasal cavity", "ANATOMY", 106, 118], ["nasopharynx", "ANATOMY", 122, 133]]], ["COVID-19 positive patients may have high viral loads in the upper aerodigestive tract, so stratifying the aerosol and droplet risk with otolaryngology procedures is important.", [["upper aerodigestive tract", "ANATOMY", 60, 85], ["COVID-19", "GENE_OR_GENE_PRODUCT", 0, 8], ["patients", "ORGANISM", 18, 26], ["upper aerodigestive", "ORGANISM_SUBDIVISION", 60, 79], ["tract", "ORGANISM_SUBDIVISION", 80, 85], ["patients", "SPECIES", 18, 26], ["COVID", "TEST", 0, 5], ["high viral loads in the upper aerodigestive tract", "PROBLEM", 36, 85], ["the aerosol", "TREATMENT", 102, 113], ["otolaryngology procedures", "TREATMENT", 136, 161], ["high viral loads", "OBSERVATION", 36, 52], ["upper", "ANATOMY_MODIFIER", 60, 65], ["aerodigestive tract", "ANATOMY", 66, 85]]], ["16 Vitamin B2 has significant advantages compared to other tracers in that it is inexpensive, readily available and has an established safety profile.", [["Vitamin B2", "CHEMICAL", 3, 13], ["Vitamin B2", "CHEMICAL", 3, 13], ["Vitamin B2", "SIMPLE_CHEMICAL", 3, 13], ["Vitamin B2", "TREATMENT", 3, 13]]], ["Physiologically, riboflavin functions as an essential coenzyme in multiple redox reactions required for cellular respiration.", [["cellular", "ANATOMY", 104, 112], ["riboflavin", "CHEMICAL", 17, 27], ["riboflavin", "CHEMICAL", 17, 27], ["riboflavin", "SIMPLE_CHEMICAL", 17, 27], ["coenzyme", "SIMPLE_CHEMICAL", 54, 62], ["cellular", "CELL", 104, 112], ["an essential coenzyme", "TREATMENT", 41, 62], ["multiple redox reactions", "TREATMENT", 66, 90], ["cellular respiration", "PROBLEM", 104, 124], ["riboflavin functions", "OBSERVATION", 17, 37], ["cellular respiration", "OBSERVATION", 104, 124]]], ["Besides its essential biochemical functions, riboflavin has therapeutic applications when administered either orally for migraine prophylaxis and cataract risk reduction or topically for treating surgery-refractory keratoconus.", [["riboflavin", "CHEMICAL", 45, 55], ["migraine", "DISEASE", 121, 129], ["cataract", "DISEASE", 146, 154], ["keratoconus", "DISEASE", 215, 226], ["riboflavin", "CHEMICAL", 45, 55], ["riboflavin", "SIMPLE_CHEMICAL", 45, 55], ["riboflavin", "TREATMENT", 45, 55], ["therapeutic applications", "TREATMENT", 60, 84], ["migraine prophylaxis", "TREATMENT", 121, 141], ["cataract risk reduction", "TREATMENT", 146, 169], ["treating surgery", "TREATMENT", 187, 203], ["refractory keratoconus", "PROBLEM", 204, 226], ["essential", "OBSERVATION_MODIFIER", 12, 21], ["biochemical functions", "OBSERVATION", 22, 43], ["keratoconus", "OBSERVATION", 215, 226]]], ["[17] [18] [19] [20] Vitamin B2 has been utilized safely as a tracer to assess medication compliance in children.", [["[17] [18] [19] [20]", "CHEMICAL", 0, 19], ["Vitamin B2", "CHEMICAL", 20, 30], ["[17] [18] [19] [20] Vitamin B2", "CHEMICAL", 0, 30], ["[17] [18] [19] [20] Vitamin B2", "SIMPLE_CHEMICAL", 0, 30], ["children", "ORGANISM", 103, 111], ["children", "SPECIES", 103, 111], ["Vitamin B2", "TREATMENT", 20, 30], ["a tracer", "TREATMENT", 59, 67]]], ["In clinical trials, the study drug can be tracked by the fluorescence of vitamin B2 excreted in the urine.", [["urine", "ANATOMY", 100, 105], ["vitamin B2", "CHEMICAL", 73, 83], ["vitamin B2", "CHEMICAL", 73, 83], ["vitamin B2", "SIMPLE_CHEMICAL", 73, 83], ["urine", "ORGANISM_SUBSTANCE", 100, 105], ["the study drug", "TEST", 20, 34], ["vitamin B2", "TREATMENT", 73, 83]]], ["[21] [22] [23] There is no defined FDA upper limit of oral daily intake due to a lack of evidence of any observable adverse effects from excess riboflavin ingestion even when consuming 400 mg per day for 3 months.", [["oral", "ANATOMY", 54, 58], ["riboflavin", "CHEMICAL", 144, 154], ["riboflavin", "CHEMICAL", 144, 154], ["[21] [22] [23]", "SIMPLE_CHEMICAL", 0, 14], ["oral", "ORGANISM_SUBDIVISION", 54, 58], ["riboflavin", "SIMPLE_CHEMICAL", 144, 154], ["any observable adverse effects", "PROBLEM", 101, 131], ["excess riboflavin ingestion", "PROBLEM", 137, 164], ["no", "UNCERTAINTY", 24, 26], ["upper limit", "OBSERVATION_MODIFIER", 39, 50]]], ["24, 25 This may be due to its limited capacity for absorption by the gastrointestinal mucosa and its rapid urinary clearance.", [["gastrointestinal mucosa", "ANATOMY", 69, 92], ["urinary", "ANATOMY", 107, 114], ["gastrointestinal mucosa", "MULTI-TISSUE_STRUCTURE", 69, 92], ["urinary", "ORGANISM_SUBSTANCE", 107, 114], ["its limited capacity", "PROBLEM", 26, 46], ["the gastrointestinal mucosa", "PROBLEM", 65, 92], ["its rapid urinary clearance", "PROBLEM", 97, 124], ["may be due to", "UNCERTAINTY", 12, 25], ["gastrointestinal mucosa", "ANATOMY", 69, 92]]], ["26 In contrast to the well-documented safety of vitamin B2, there have been multiple reports of harmful reactions to conventional tracers such as fluorescein when administered topically, intravenous, and orally.", [["intravenous", "ANATOMY", 187, 198], ["vitamin B2", "CHEMICAL", 48, 58], ["fluorescein", "CHEMICAL", 146, 157], ["vitamin B2", "CHEMICAL", 48, 58], ["fluorescein", "CHEMICAL", 146, 157], ["vitamin B2", "SIMPLE_CHEMICAL", 48, 58], ["fluorescein", "SIMPLE_CHEMICAL", 146, 157], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 187, 198], ["vitamin B2", "TREATMENT", 48, 58], ["harmful reactions", "PROBLEM", 96, 113], ["conventional tracers", "TREATMENT", 117, 137], ["fluorescein", "TREATMENT", 146, 157], ["intravenous", "TREATMENT", 187, 198], ["multiple", "OBSERVATION_MODIFIER", 76, 84]]], ["Fluorescein is a widely used fluorescent marker in ophthalmology, often administered intravenously or orally for diagnostic angiography of iris vasculature.", [["intravenously", "ANATOMY", 85, 98], ["iris vasculature", "ANATOMY", 139, 155], ["Fluorescein", "CHEMICAL", 0, 11], ["Fluorescein", "CHEMICAL", 0, 11], ["Fluorescein", "SIMPLE_CHEMICAL", 0, 11], ["intravenously", "IMMATERIAL_ANATOMICAL_ENTITY", 85, 98], ["iris vasculature", "MULTI-TISSUE_STRUCTURE", 139, 155], ["Fluorescein", "TREATMENT", 0, 11], ["diagnostic angiography", "TEST", 113, 135], ["iris vasculature", "ANATOMY", 139, 155]]], ["Despite the prevalence of fluorescein use, studies have reported 5-10% of patients experiencing adverse events from intravenous fluorescein injection that include mild transient reactions such as vomiting and nausea and more severe reactions such as anaphylaxis, cardiac arrest, shock, basilar artery ischemia, and myocardial infarction.", [["intravenous", "ANATOMY", 116, 127], ["cardiac", "ANATOMY", 263, 270], ["basilar artery", "ANATOMY", 286, 300], ["myocardial", "ANATOMY", 315, 325], ["fluorescein", "CHEMICAL", 26, 37], ["fluorescein", "CHEMICAL", 128, 139], ["vomiting", "DISEASE", 196, 204], ["nausea", "DISEASE", 209, 215], ["anaphylaxis", "DISEASE", 250, 261], ["cardiac arrest", "DISEASE", 263, 277], ["shock", "DISEASE", 279, 284], ["basilar artery ischemia", "DISEASE", 286, 309], ["myocardial infarction", "DISEASE", 315, 336], ["fluorescein", "CHEMICAL", 26, 37], ["fluorescein", "CHEMICAL", 128, 139], ["fluorescein", "SIMPLE_CHEMICAL", 26, 37], ["patients", "ORGANISM", 74, 82], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 116, 127], ["fluorescein", "SIMPLE_CHEMICAL", 128, 139], ["basilar artery", "MULTI-TISSUE_STRUCTURE", 286, 300], ["myocardial", "MULTI-TISSUE_STRUCTURE", 315, 325], ["patients", "SPECIES", 74, 82], ["studies", "TEST", 43, 50], ["adverse events", "PROBLEM", 96, 110], ["intravenous fluorescein injection", "TREATMENT", 116, 149], ["mild transient reactions", "PROBLEM", 163, 187], ["vomiting", "PROBLEM", 196, 204], ["nausea", "PROBLEM", 209, 215], ["more severe reactions", "PROBLEM", 220, 241], ["anaphylaxis", "PROBLEM", 250, 261], ["cardiac arrest", "PROBLEM", 263, 277], ["shock", "PROBLEM", 279, 284], ["basilar artery ischemia", "PROBLEM", 286, 309], ["myocardial infarction", "PROBLEM", 315, 336], ["mild", "OBSERVATION_MODIFIER", 163, 167], ["transient", "OBSERVATION_MODIFIER", 168, 177], ["reactions", "OBSERVATION", 178, 187], ["cardiac", "ANATOMY", 263, 270], ["arrest", "OBSERVATION", 271, 277], ["shock", "OBSERVATION", 279, 284], ["basilar artery", "ANATOMY", 286, 300], ["ischemia", "OBSERVATION", 301, 309], ["myocardial", "ANATOMY", 315, 325], ["infarction", "OBSERVATION", 326, 336]]], ["27, 28 Topical application of fluorescein on the corneal surface is considered generally safe when used to detect corneal injury, but there have been cases of severe allergic reactions reported.", [["corneal surface", "ANATOMY", 49, 64], ["corneal", "ANATOMY", 114, 121], ["fluorescein", "CHEMICAL", 30, 41], ["corneal injury", "DISEASE", 114, 128], ["allergic reactions", "DISEASE", 166, 184], ["fluorescein", "CHEMICAL", 30, 41], ["fluorescein", "SIMPLE_CHEMICAL", 30, 41], ["corneal surface", "MULTI-TISSUE_STRUCTURE", 49, 64], ["corneal", "TISSUE", 114, 121], ["fluorescein", "TREATMENT", 30, 41], ["corneal injury", "PROBLEM", 114, 128], ["severe allergic reactions", "PROBLEM", 159, 184], ["corneal", "ANATOMY", 49, 56], ["corneal", "ANATOMY", 114, 121], ["injury", "OBSERVATION", 122, 128], ["severe", "OBSERVATION_MODIFIER", 159, 165], ["allergic", "OBSERVATION", 166, 174]]], ["29, 30 Some have suggested requiring intradermal skin testing to determine hypersensitivity to fluorescein prior to use if an allergy is suspected, but skin testing has failed to reliably identify reactors in prospective studies.", [["skin", "ANATOMY", 49, 53], ["skin", "ANATOMY", 152, 156], ["hypersensitivity", "DISEASE", 75, 91], ["fluorescein", "CHEMICAL", 95, 106], ["allergy", "DISEASE", 126, 133], ["fluorescein", "CHEMICAL", 95, 106], ["skin", "ORGAN", 49, 53], ["fluorescein", "SIMPLE_CHEMICAL", 95, 106], ["skin", "ORGAN", 152, 156], ["intradermal skin testing", "TEST", 37, 61], ["hypersensitivity", "PROBLEM", 75, 91], ["fluorescein", "TREATMENT", 95, 106], ["an allergy", "PROBLEM", 123, 133], ["skin testing", "TEST", 152, 164], ["prospective studies", "TEST", 209, 228], ["skin", "ANATOMY", 152, 156]]], ["31 While severe adverse reactions to fluorescein may be rare, there is a lack of literature outlining the upper tolerable levels of fluorescein.", [["fluorescein", "CHEMICAL", 37, 48], ["fluorescein", "CHEMICAL", 132, 143], ["fluorescein", "CHEMICAL", 37, 48], ["fluorescein", "CHEMICAL", 132, 143], ["fluorescein", "SIMPLE_CHEMICAL", 37, 48], ["upper", "ORGANISM_SUBDIVISION", 106, 111], ["fluorescein", "SIMPLE_CHEMICAL", 132, 143], ["severe adverse reactions", "PROBLEM", 9, 33], ["fluorescein", "TREATMENT", 37, 48], ["severe", "OBSERVATION_MODIFIER", 9, 15], ["upper tolerable", "OBSERVATION_MODIFIER", 106, 121]]], ["This prohibits its safe use as a tracer in human trials to study aerosol and droplet dispersion.", [["human", "ORGANISM", 43, 48], ["human", "SPECIES", 43, 48], ["human", "SPECIES", 43, 48], ["a tracer in human trials", "TREATMENT", 31, 55], ["study aerosol", "TREATMENT", 59, 72], ["droplet dispersion", "TREATMENT", 77, 95], ["droplet dispersion", "OBSERVATION", 77, 95]]], ["Most commercially available fluorescent dyes are not approved for use in humans; many have warnings regarding contact with the skin or mucosal surfaces.", [["skin", "ANATOMY", 127, 131], ["mucosal", "ANATOMY", 135, 142], ["fluorescent dyes", "SIMPLE_CHEMICAL", 28, 44], ["humans", "ORGANISM", 73, 79], ["skin", "ORGAN", 127, 131], ["mucosal surfaces", "MULTI-TISSUE_STRUCTURE", 135, 151], ["humans", "SPECIES", 73, 79], ["humans", "SPECIES", 73, 79], ["fluorescent dyes", "TREATMENT", 28, 44], ["skin", "ANATOMY", 127, 131], ["mucosal", "ANATOMY", 135, 142], ["surfaces", "ANATOMY_MODIFIER", 143, 151]]], ["32 There were a few limitations to this study.", [["this study", "TEST", 35, 45], ["few", "OBSERVATION_MODIFIER", 16, 19]]], ["Although it was easy to visually distinguish the presence or absence of fluorescent particles collected by the impactor, we did not use a spectrophotometer to quantify the specific fluorescence intensity.", [["fluorescent particles", "PROBLEM", 72, 93], ["a spectrophotometer", "TREATMENT", 136, 155]]], ["This study did not evaluate the duration of suspension of the nebulized fluorescent particles and the effect of different environmental conditions on surface settling times.", [["surface", "ANATOMY", 150, 157], ["This study", "TEST", 0, 10], ["the nebulized fluorescent particles", "TREATMENT", 58, 93], ["environmental conditions", "OBSERVATION", 122, 146]]], ["33 In addition, our study included only a single form of otolaryngology instrumentation; however, the use of a high-powered drill in the nasopharynx is labeled as a high-risk aerosol-generating procedure and, therefore, adequately served as a positive control.", [["nasopharynx", "ANATOMY", 137, 148], ["nasopharynx", "ORGAN", 137, 148], ["our study", "TEST", 16, 25], ["otolaryngology instrumentation", "TREATMENT", 57, 87], ["a high-powered drill in the nasopharynx", "TREATMENT", 109, 148], ["a high-risk aerosol-generating procedure", "TREATMENT", 163, 203], ["a positive control", "TREATMENT", 241, 259], ["nasopharynx", "ANATOMY", 137, 148]]], ["34 Particles in the range of 20-100 \u03bcm were not collected by the impactor; thus, the fluorescence capability of these tracers in larger particles is yet to be investigated.", [["the fluorescence capability", "TEST", 81, 108], ["Particles", "OBSERVATION_MODIFIER", 3, 12]]], ["Further studies involving the use of vitamin B2 as a fluorescent aerosol and droplet tracer in different otolaryngology procedures are currently underway at our institution.DiscussionThere is a paucity in the literature regarding safe tracers to investigate aerosol and droplet risks in human trials.", [["vitamin B2", "CHEMICAL", 37, 47], ["vitamin B2", "CHEMICAL", 37, 47], ["vitamin B2", "SIMPLE_CHEMICAL", 37, 47], ["human", "ORGANISM", 287, 292], ["human", "SPECIES", 287, 292], ["human", "SPECIES", 287, 292], ["Further studies", "TEST", 0, 15], ["vitamin B2", "TREATMENT", 37, 47], ["a fluorescent aerosol", "TREATMENT", 51, 72], ["droplet tracer", "TREATMENT", 77, 91], ["different otolaryngology procedures", "TREATMENT", 95, 130], ["safe tracers", "TREATMENT", 230, 242], ["aerosol", "TREATMENT", 258, 265]]], ["We propose vitamin B2 as a safe, inexpensive, and reliable aerosol and droplet tracer to evaluate baseline risk and mitigation measures for otolaryngology procedures.", [["vitamin B2", "CHEMICAL", 11, 21], ["vitamin B2", "CHEMICAL", 11, 21], ["vitamin B2", "SIMPLE_CHEMICAL", 11, 21], ["vitamin B2", "TREATMENT", 11, 21], ["droplet tracer", "TREATMENT", 71, 85], ["mitigation measures", "TREATMENT", 116, 135], ["otolaryngology procedures", "TREATMENT", 140, 165]]], ["At our institution, we are conducting a project with human subjects utilizing vitamin B2 tracer to assess the aerosol and droplet risk associated with common otolaryngology clinic procedures.", [["vitamin B2", "CHEMICAL", 78, 88], ["vitamin B2", "CHEMICAL", 78, 88], ["human", "ORGANISM", 53, 58], ["vitamin B2", "SIMPLE_CHEMICAL", 78, 88], ["human", "SPECIES", 53, 58], ["human", "SPECIES", 53, 58], ["vitamin B2 tracer", "TREATMENT", 78, 95], ["the aerosol", "TREATMENT", 106, 117]]], ["We encourage other groups focusing on healthcare contamination models to consider vitamin B2 as a tracer especially with regards to human trials involving aerodigestive tract mucosa.ConclusionVitamin B2 is a safe, inexpensive, and reliable aerosol and droplet tracer that can be used to evaluate baseline risk and mitigation measures for otolaryngology procedures.", [["aerodigestive tract mucosa", "ANATOMY", 155, 181], ["vitamin B2", "CHEMICAL", 82, 92], ["ConclusionVitamin B2", "CHEMICAL", 182, 202], ["vitamin B2", "CHEMICAL", 82, 92], ["ConclusionVitamin B2", "CHEMICAL", 182, 202], ["vitamin B2", "SIMPLE_CHEMICAL", 82, 92], ["human", "ORGANISM", 132, 137], ["aerodigestive tract mucosa", "MULTI-TISSUE_STRUCTURE", 155, 181], ["ConclusionVitamin B2", "GENE_OR_GENE_PRODUCT", 182, 202], ["human", "SPECIES", 132, 137], ["human", "SPECIES", 132, 137], ["vitamin B2", "TREATMENT", 82, 92], ["a tracer", "TREATMENT", 96, 104], ["human trials", "TREATMENT", 132, 144], ["aerodigestive tract mucosa", "PROBLEM", 155, 181], ["reliable aerosol and droplet tracer", "TREATMENT", 231, 266], ["mitigation measures", "TREATMENT", 314, 333], ["otolaryngology procedures", "TREATMENT", 338, 363], ["aerodigestive tract", "ANATOMY", 155, 174]]], ["Its reliable suspension in small particles, longevity of its fluorescence, mucosal safety profile, and prior use in human trials illustrate its superiority as a fluorescent tracer compared to fluorescein and commercial tracer dyes.", [["mucosal", "ANATOMY", 75, 82], ["fluorescein", "CHEMICAL", 192, 203], ["fluorescein", "CHEMICAL", 192, 203], ["mucosal", "MULTI-TISSUE_STRUCTURE", 75, 82], ["human", "ORGANISM", 116, 121], ["fluorescein", "SIMPLE_CHEMICAL", 192, 203], ["tracer dyes", "SIMPLE_CHEMICAL", 219, 230], ["human", "SPECIES", 116, 121], ["human", "SPECIES", 116, 121], ["Its reliable suspension in small particles", "TREATMENT", 0, 42], ["human trials", "TREATMENT", 116, 128], ["a fluorescent tracer", "PROBLEM", 159, 179], ["fluorescein", "TEST", 192, 203], ["commercial tracer dyes", "PROBLEM", 208, 230], ["reliable", "OBSERVATION_MODIFIER", 4, 12], ["suspension", "OBSERVATION_MODIFIER", 13, 23], ["small", "OBSERVATION_MODIFIER", 27, 32], ["particles", "OBSERVATION_MODIFIER", 33, 42], ["longevity", "OBSERVATION_MODIFIER", 44, 53], ["tracer dyes", "OBSERVATION", 219, 230]]], ["These advantages of vitamin B2 makes it an ideal tracer for healthcare contamination models.Declaration of Conflicting InterestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.FundingThe author(s) received no financial support for the research, authorship, and/or publication of this article.Prior PresentationsThis project has not been presented or published in prior meetings.ORCID iDEdward S. Sim https://orcid.org/0000-0002-1632-286XSupplemental MaterialSupplemental material for this article is available online.", [["vitamin B2", "CHEMICAL", 20, 30], ["vitamin B2", "CHEMICAL", 20, 30], ["vitamin B2", "SIMPLE_CHEMICAL", 20, 30], ["vitamin B2", "TREATMENT", 20, 30], ["financial support", "TREATMENT", 296, 313]]]], "PMC7196305": [["IntroductionThe coronavirus disease 2019 (COVID-19) was first described as atypical pneumonia with unknown etiology in Wuhan, China.", [["coronavirus disease", "DISEASE", 16, 35], ["pneumonia", "DISEASE", 84, 93], ["coronavirus", "ORGANISM", 16, 27], ["coronavirus disease 2019 (COVID-19", "SPECIES", 16, 50], ["The coronavirus disease", "PROBLEM", 12, 35], ["COVID", "TEST", 42, 47], ["atypical pneumonia", "PROBLEM", 75, 93], ["coronavirus disease", "OBSERVATION", 16, 35], ["atypical", "OBSERVATION_MODIFIER", 75, 83], ["pneumonia", "OBSERVATION", 84, 93]]], ["It was subsequently shown to be caused by a novel coronavirus similar to severe acute respiratory syndrome coronavirus (SARS-CoV) and was designated as SARS-CoV-2 1,2.", [["coronavirus", "DISEASE", 50, 61], ["acute respiratory syndrome coronavirus", "DISEASE", 80, 118], ["SARS-CoV)", "DISEASE", 120, 129], ["coronavirus", "ORGANISM", 50, 61], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 73, 118], ["SARS-CoV", "ORGANISM", 120, 128], ["severe acute respiratory syndrome coronavirus", "SPECIES", 73, 118], ["SARS-CoV", "SPECIES", 120, 128], ["SARS-CoV", "SPECIES", 152, 160], ["a novel coronavirus", "PROBLEM", 42, 61], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 73, 118], ["CoV", "TEST", 157, 160], ["severe", "OBSERVATION_MODIFIER", 73, 79], ["acute", "OBSERVATION_MODIFIER", 80, 85], ["respiratory syndrome coronavirus", "OBSERVATION", 86, 118]]], ["Coronavirus outbreak has caused thousands of deaths globally 3.IntroductionSince its outbreak, there have been several studies on COVID-19 1,4-7.", [["Coronavirus", "CHEMICAL", 0, 11], ["deaths", "DISEASE", 45, 51], ["Coronavirus outbreak", "PROBLEM", 0, 20], ["several studies", "TEST", 111, 126], ["COVID", "TEST", 130, 135]]], ["Elderly patients with underlying diseases often experience adverse events, including intensive care unit (ICU) admission, acute respiratory failure, or death 1,8,9.", [["respiratory", "ANATOMY", 128, 139], ["acute respiratory failure", "DISEASE", 122, 147], ["death", "DISEASE", 152, 157], ["patients", "ORGANISM", 8, 16], ["patients", "SPECIES", 8, 16], ["underlying diseases", "PROBLEM", 22, 41], ["adverse events", "PROBLEM", 59, 73], ["acute respiratory failure", "PROBLEM", 122, 147], ["death", "PROBLEM", 152, 157], ["diseases", "OBSERVATION", 33, 41], ["acute", "OBSERVATION_MODIFIER", 122, 127], ["respiratory failure", "OBSERVATION", 128, 147]]], ["However, there is a need for more detailed information regarding the occurrence and the progression of COVID-19 pneumonia to severe and critical conditions to allow improved individual monitoring and evaluation.IntroductionChest computed tomography (CT) has been used to monitor the clinical course of COVID-19 10,11.", [["COVID", "DISEASE", 103, 108], ["pneumonia", "DISEASE", 112, 121], ["COVID-19 pneumonia to severe and critical conditions", "PROBLEM", 103, 155], ["individual monitoring", "TEST", 174, 195], ["evaluation", "TEST", 200, 210], ["IntroductionChest computed tomography", "TEST", 211, 248], ["CT", "TEST", 250, 252], ["COVID", "TEST", 302, 307], ["pneumonia", "OBSERVATION", 112, 121], ["severe", "OBSERVATION_MODIFIER", 125, 131]]], ["Radiographic features, including ground-glass opacity (GGO) and consolidation, are crucial evaluation aspects 10-15.", [["Radiographic features", "TEST", 0, 21], ["ground-glass opacity", "PROBLEM", 33, 53], ["GGO", "PROBLEM", 55, 58], ["consolidation", "PROBLEM", 64, 77], ["crucial evaluation aspects", "TEST", 83, 109], ["ground", "OBSERVATION_MODIFIER", 33, 39], ["glass opacity", "OBSERVATION", 40, 53], ["GGO", "OBSERVATION_MODIFIER", 55, 58], ["consolidation", "OBSERVATION", 64, 77]]], ["Previous studies have reported on the characteristics and evolution of COVID-19.", [["COVID-19", "GENE_OR_GENE_PRODUCT", 71, 79], ["COVID-19", "DNA", 71, 79], ["Previous studies", "TEST", 0, 16], ["COVID", "TEST", 71, 76]]], ["However, they were limited by small sample sizes and lack of quantitative radiographic characteristics; therefore, the imaging risk factors for poor clinical outcomes remain unclear.", [["small sample sizes", "PROBLEM", 30, 48], ["the imaging risk factors", "PROBLEM", 115, 139], ["poor clinical outcomes", "PROBLEM", 144, 166], ["small", "OBSERVATION_MODIFIER", 30, 35], ["sample", "OBSERVATION_MODIFIER", 36, 42], ["sizes", "OBSERVATION_MODIFIER", 43, 48]]], ["Moreover, we used an artificial intelligence (AI) system in quantitative analysis which showed productivity in disease diagnosis and control since epidemic outbreaks 16.IntroductionIn this study, we aimed to report the quantitative imaging characteristics and risk factors for adverse composite endpoints, including admission to ICU, acute respiratory failure occurrence, and shock during hospitalization in patients with COVID-19 pneumonia in Jiangsu province, China.Participants ::: MethodsIn this retrospective cohort study, we enrolled patients with laboratory-confirmed COVID-19 in Jiangsu province between 10 January and 18 February 2020.", [["respiratory", "ANATOMY", 340, 351], ["acute respiratory failure", "DISEASE", 334, 359], ["shock", "DISEASE", 376, 381], ["COVID-19", "CHEMICAL", 422, 430], ["pneumonia", "DISEASE", 431, 440], ["patients", "ORGANISM", 408, 416], ["patients", "ORGANISM", 540, 548], ["patients", "SPECIES", 408, 416], ["Participants", "SPECIES", 468, 480], ["patients", "SPECIES", 540, 548], ["an artificial intelligence (AI)", "TREATMENT", 18, 49], ["quantitative analysis", "TEST", 60, 81], ["productivity in disease diagnosis", "PROBLEM", 95, 128], ["epidemic outbreaks", "PROBLEM", 147, 165], ["this study", "TEST", 184, 194], ["adverse composite endpoints", "PROBLEM", 277, 304], ["acute respiratory failure occurrence", "PROBLEM", 334, 370], ["shock", "PROBLEM", 376, 381], ["COVID", "TEST", 422, 427], ["pneumonia", "PROBLEM", 431, 440], ["Methods", "TREATMENT", 485, 492], ["COVID", "TEST", 575, 580], ["acute", "OBSERVATION_MODIFIER", 334, 339], ["respiratory failure", "OBSERVATION", 340, 359], ["shock", "OBSERVATION", 376, 381], ["pneumonia", "OBSERVATION", 431, 440]]], ["Laboratory confirmation was based on a positive result on high-throughput sequencing or real-time reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assay of nasal and pharyngeal swab specimens 5.", [["nasal", "ANATOMY", 164, 169], ["pharyngeal swab specimens", "ANATOMY", 174, 199], ["nasal", "ORGANISM_SUBDIVISION", 164, 169], ["reverse-transcriptase", "PROTEIN", 98, 119], ["Laboratory confirmation", "TEST", 0, 23], ["RT-PCR", "TEST", 147, 153], ["nasal and pharyngeal swab specimens", "TEST", 164, 199], ["nasal", "ANATOMY", 164, 169], ["pharyngeal swab", "ANATOMY", 174, 189]]], ["We extracted clinical and initial CT findings at admission from electronic medical records in the Department of Health, Jiangsu province.", [["initial CT findings", "TEST", 26, 45]]], ["We excluded patients aged < 18 years old or with missing clinical or CT records on admission (Figure 1).Study outcomes ::: MethodsThe primary composite endpoints were admission to ICU, acute respiratory failure occurrence, or shock during hospitalization, which have been used to assess the severity of COVID-19 or other infectious diseases 8,9,17.", [["respiratory", "ANATOMY", 191, 202], ["acute respiratory failure", "DISEASE", 185, 210], ["shock", "DISEASE", 226, 231], ["COVID", "DISEASE", 303, 308], ["infectious diseases", "DISEASE", 321, 340], ["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20], ["Methods", "TREATMENT", 123, 130], ["acute respiratory failure occurrence", "PROBLEM", 185, 221], ["shock", "PROBLEM", 226, 231], ["COVID", "TEST", 303, 308], ["other infectious diseases", "PROBLEM", 315, 340], ["acute", "OBSERVATION_MODIFIER", 185, 190], ["respiratory failure", "OBSERVATION", 191, 210], ["infectious", "OBSERVATION", 321, 331]]], ["Acute respiratory failure was defined as oxygen saturation < 93%; partial pressure of oxygen in arterial blood < 60 mm Hg on room air; and/or requirement for high-flow nasal cannula therapy, non-invasive, or invasive mechanical ventilation.", [["respiratory", "ANATOMY", 6, 17], ["arterial blood", "ANATOMY", 96, 110], ["nasal", "ANATOMY", 168, 173], ["respiratory failure", "DISEASE", 6, 25], ["oxygen", "CHEMICAL", 41, 47], ["oxygen", "CHEMICAL", 86, 92], ["oxygen", "CHEMICAL", 41, 47], ["oxygen", "CHEMICAL", 86, 92], ["Hg", "CHEMICAL", 119, 121], ["oxygen", "SIMPLE_CHEMICAL", 41, 47], ["oxygen", "SIMPLE_CHEMICAL", 86, 92], ["arterial", "MULTI-TISSUE_STRUCTURE", 96, 104], ["blood", "ORGANISM_SUBSTANCE", 105, 110], ["Acute respiratory failure", "PROBLEM", 0, 25], ["oxygen saturation", "TEST", 41, 58], ["partial pressure of oxygen", "TREATMENT", 66, 92], ["arterial blood", "TEST", 96, 110], ["high-flow nasal cannula therapy", "TREATMENT", 158, 189], ["non-invasive", "TREATMENT", 191, 203], ["invasive mechanical ventilation", "TREATMENT", 208, 239], ["respiratory", "ANATOMY", 6, 17], ["failure", "OBSERVATION", 18, 25], ["pressure", "OBSERVATION_MODIFIER", 74, 82], ["mechanical ventilation", "OBSERVATION", 217, 239]]], ["Patients meeting any of the following criteria: respiratory failure requiring mechanical ventilation; presence of shock; other organ failure that requires monitoring and treatment in the ICU were admitted to ICU treatment.", [["respiratory", "ANATOMY", 48, 59], ["organ", "ANATOMY", 127, 132], ["respiratory failure", "DISEASE", 48, 67], ["shock", "DISEASE", 114, 119], ["organ failure", "DISEASE", 127, 140], ["Patients", "ORGANISM", 0, 8], ["organ", "ORGAN", 127, 132], ["Patients", "SPECIES", 0, 8], ["respiratory failure", "PROBLEM", 48, 67], ["mechanical ventilation", "TREATMENT", 78, 100], ["shock", "PROBLEM", 114, 119], ["other organ failure", "PROBLEM", 121, 140], ["treatment", "TREATMENT", 170, 179], ["ICU treatment", "TREATMENT", 208, 221], ["respiratory failure", "OBSERVATION", 48, 67], ["mechanical ventilation", "OBSERVATION", 78, 100], ["shock", "OBSERVATION", 114, 119], ["organ", "ANATOMY", 127, 132], ["failure", "OBSERVATION", 133, 140]]], ["However, patients presented respiratory failure or shock earlier than ICU admission or without ICU treatment were recorded as endpoint independently.CT imaging acquisition and AI evaluation ::: MethodsThe CT examinations were performed according to standard non-contrast chest CT protocols in each institution.", [["respiratory", "ANATOMY", 28, 39], ["respiratory failure", "DISEASE", 28, 47], ["shock", "DISEASE", 51, 56], ["patients", "ORGANISM", 9, 17], ["patients", "SPECIES", 9, 17], ["respiratory failure", "PROBLEM", 28, 47], ["shock", "PROBLEM", 51, 56], ["ICU treatment", "TREATMENT", 95, 108], ["CT imaging acquisition", "TEST", 149, 171], ["AI evaluation", "TEST", 176, 189], ["Methods", "TREATMENT", 194, 201], ["The CT examinations", "TEST", 201, 220], ["standard non-contrast chest CT protocols", "TEST", 249, 289], ["respiratory failure", "OBSERVATION", 28, 47], ["shock", "OBSERVATION", 51, 56], ["chest", "ANATOMY", 271, 276]]], ["The CT scan details are shown in Supplementary Table S1.", [["The CT scan details", "TEST", 0, 19]]], ["We quantitatively evaluated the volume, density, and location of lesions, including GGO and consolidation, in each patient.", [["lesions", "ANATOMY", 65, 72], ["lesions", "PATHOLOGICAL_FORMATION", 65, 72], ["patient", "ORGANISM", 115, 122], ["patient", "SPECIES", 115, 122], ["lesions", "PROBLEM", 65, 72], ["GGO", "PROBLEM", 84, 87], ["consolidation", "PROBLEM", 92, 105], ["volume", "OBSERVATION_MODIFIER", 32, 38], ["density", "OBSERVATION", 40, 47], ["lesions", "OBSERVATION", 65, 72], ["GGO", "OBSERVATION", 84, 87], ["consolidation", "OBSERVATION", 92, 105]]], ["These characteristics were summarized as follows: the number of lung lobes involved; lesion volume percentage in each lobe and whole lung; Hounsfield units (HU) distribution within lesions; and distance from lesion to pulmonary pleurae (Table 2).CT imaging acquisition and AI evaluation ::: MethodsWe performed lung segmentation, lesion extraction and labeling, and volume calculation using a dedicated multi-task deep learning algorithm developed for pulmonary pneumonia (Beijing Deepwise & League of PhD Technology Co.Ltd, China) 18.", [["lung lobes", "ANATOMY", 64, 74], ["lesion", "ANATOMY", 85, 91], ["lobe", "ANATOMY", 118, 122], ["lung", "ANATOMY", 133, 137], ["lesions", "ANATOMY", 181, 188], ["lesion", "ANATOMY", 208, 214], ["pulmonary pleurae", "ANATOMY", 218, 235], ["lung", "ANATOMY", 311, 315], ["lesion", "ANATOMY", 330, 336], ["pulmonary", "ANATOMY", 452, 461], ["pulmonary pneumonia", "DISEASE", 452, 471], ["lung lobes", "MULTI-TISSUE_STRUCTURE", 64, 74], ["lobe", "MULTI-TISSUE_STRUCTURE", 118, 122], ["lung", "ORGAN", 133, 137], ["lesions", "PATHOLOGICAL_FORMATION", 181, 188], ["pulmonary pleurae", "MULTI-TISSUE_STRUCTURE", 218, 235], ["lung", "ORGAN", 311, 315], ["pulmonary", "ORGAN", 452, 461], ["lesion volume percentage in each lobe and whole lung", "PROBLEM", 85, 137], ["Hounsfield units (HU) distribution within lesions", "PROBLEM", 139, 188], ["distance from lesion to pulmonary pleurae", "PROBLEM", 194, 235], ["CT imaging acquisition", "TEST", 246, 268], ["AI evaluation", "TEST", 273, 286], ["lesion extraction", "TREATMENT", 330, 347], ["labeling", "TEST", 352, 360], ["volume calculation", "TEST", 366, 384], ["pulmonary pneumonia", "PROBLEM", 452, 471], ["lung", "ANATOMY", 64, 68], ["lobes", "ANATOMY_MODIFIER", 69, 74], ["lesion", "OBSERVATION", 85, 91], ["volume", "OBSERVATION_MODIFIER", 92, 98], ["percentage", "OBSERVATION_MODIFIER", 99, 109], ["each lobe", "ANATOMY", 113, 122], ["whole", "ANATOMY_MODIFIER", 127, 132], ["lung", "ANATOMY", 133, 137], ["Hounsfield units", "OBSERVATION_MODIFIER", 139, 155], ["HU", "OBSERVATION_MODIFIER", 157, 159], ["distribution", "OBSERVATION_MODIFIER", 161, 173], ["lesions", "OBSERVATION", 181, 188], ["distance", "OBSERVATION_MODIFIER", 194, 202], ["lesion", "OBSERVATION", 208, 214], ["pulmonary", "ANATOMY", 218, 227], ["pleurae", "ANATOMY_MODIFIER", 228, 235], ["lung", "ANATOMY", 311, 315], ["lesion", "OBSERVATION", 330, 336], ["pulmonary", "ANATOMY", 452, 461], ["pneumonia", "OBSERVATION", 462, 471]]], ["A 3D U-Net was introduced for pixel-level classification with a large-scale annotated data.", [["3D U", "CELL_LINE", 2, 6], ["pixel-level classification", "TREATMENT", 30, 56]]], ["The system's accuracy was guaranteed by engineering approach and manually checked by a radiologist (Y.C.W) with > 10 years of experience in chest imaging.", [["chest", "ANATOMY", 140, 145], ["chest", "ORGANISM_SUBDIVISION", 140, 145], ["The system's accuracy", "TEST", 0, 21], ["chest imaging", "TEST", 140, 153], ["chest", "ANATOMY", 140, 145]]], ["Technical details and the accuracy of the AI method are showed in Supplementary Methods.", [["the AI method", "TEST", 38, 51]]], ["Figure 2 shows an example of pulmonary lobe and opacities segmentation.CT imaging acquisition and AI evaluation ::: MethodsFirst, we segmented each lung lobe and the bilateral lungs and calculated the volume.", [["pulmonary lobe", "ANATOMY", 29, 43], ["lung lobe", "ANATOMY", 148, 157], ["lungs", "ANATOMY", 176, 181], ["pulmonary lobe and opacities", "DISEASE", 29, 57], ["pulmonary lobe", "MULTI-TISSUE_STRUCTURE", 29, 43], ["lung lobe", "MULTI-TISSUE_STRUCTURE", 148, 157], ["lungs", "ORGAN", 176, 181], ["pulmonary lobe", "PROBLEM", 29, 43], ["opacities segmentation", "PROBLEM", 48, 70], ["CT imaging acquisition", "TEST", 71, 93], ["AI evaluation", "TEST", 98, 111], ["pulmonary lobe", "ANATOMY", 29, 43], ["opacities", "OBSERVATION", 48, 57], ["lung", "ANATOMY", 148, 152], ["lobe", "ANATOMY_MODIFIER", 153, 157], ["bilateral", "ANATOMY_MODIFIER", 166, 175], ["lungs", "ANATOMY", 176, 181], ["volume", "OBSERVATION_MODIFIER", 201, 207]]], ["Subsequently, we labeled the GGO and consolidation lesions in the corresponding lobes using the well-trained AI algorithm and computed the volume.", [["lesions", "ANATOMY", 51, 58], ["lobes", "ANATOMY", 80, 85], ["consolidation lesions", "CANCER", 37, 58], ["lobes", "ORGAN", 80, 85], ["the GGO", "PROBLEM", 25, 32], ["consolidation lesions in the corresponding lobes", "PROBLEM", 37, 85], ["computed the volume", "TEST", 126, 145], ["GGO", "OBSERVATION", 29, 32], ["consolidation", "OBSERVATION_MODIFIER", 37, 50], ["lesions", "OBSERVATION", 51, 58], ["lobes", "ANATOMY_MODIFIER", 80, 85]]], ["Based on these parameters, we calculated the number of involved lung lobes and the lesion volume percentage in each lobe (right upper lobe [RUL], right middle lobe [RML], right lower lobe [RLL], left upper lobe [LUL], and left lower lobe [LLL]) and the whole lung.", [["lung lobes", "ANATOMY", 64, 74], ["lesion", "ANATOMY", 83, 89], ["lobe", "ANATOMY", 116, 120], ["right upper lobe", "ANATOMY", 122, 138], ["RUL", "ANATOMY", 140, 143], ["right middle lobe", "ANATOMY", 146, 163], ["RML", "ANATOMY", 165, 168], ["right lower lobe", "ANATOMY", 171, 187], ["RLL", "ANATOMY", 189, 192], ["left upper lobe [LUL]", "ANATOMY", 195, 216], ["left lower lobe [LLL", "ANATOMY", 222, 242], ["whole lung", "ANATOMY", 253, 263], ["lung lobes", "MULTI-TISSUE_STRUCTURE", 64, 74], ["lobe", "ORGAN", 116, 120], ["upper lobe", "MULTI-TISSUE_STRUCTURE", 128, 138], ["lobe", "MULTI-TISSUE_STRUCTURE", 159, 163], ["lower lobe", "CANCER", 177, 187], ["upper lobe", "MULTI-TISSUE_STRUCTURE", 200, 210], ["lower lobe", "MULTI-TISSUE_STRUCTURE", 227, 237], ["lung", "ORGAN", 259, 263], ["these parameters", "TEST", 9, 25], ["the lesion volume percentage", "TEST", 79, 107], ["RUL], right middle lobe [RML], right lower lobe [RLL], left upper lobe [LUL], and left lower lobe [LLL]) and the whole lung", "PROBLEM", 140, 263], ["lung", "ANATOMY", 64, 68], ["lobes", "ANATOMY_MODIFIER", 69, 74], ["lesion", "OBSERVATION", 83, 89], ["volume", "OBSERVATION_MODIFIER", 90, 96], ["percentage", "OBSERVATION_MODIFIER", 97, 107], ["each lobe", "ANATOMY", 111, 120], ["right upper lobe", "ANATOMY", 122, 138], ["RUL", "ANATOMY_MODIFIER", 140, 143], ["right middle lobe", "ANATOMY", 146, 163], ["RML", "ANATOMY_MODIFIER", 165, 168], ["right lower lobe", "ANATOMY", 171, 187], ["RLL", "ANATOMY_MODIFIER", 189, 192], ["left upper lobe", "ANATOMY", 195, 210], ["LUL", "ANATOMY_MODIFIER", 212, 215], ["left lower lobe", "ANATOMY", 222, 237], ["LLL", "ANATOMY_MODIFIER", 239, 242], ["whole", "ANATOMY_MODIFIER", 253, 258], ["lung", "ANATOMY", 259, 263]]], ["The RUL, RML, and LUL were defined as the upper lung while the remaining lobes were defined as the lower lung.", [["upper lung", "ANATOMY", 42, 52], ["lobes", "ANATOMY", 73, 78], ["lower lung", "ANATOMY", 99, 109], ["RUL", "CANCER", 4, 7], ["LUL", "CANCER", 18, 21], ["upper", "ORGAN", 42, 47], ["lung", "ORGAN", 48, 52], ["lobes", "ORGAN", 73, 78], ["lung", "ORGAN", 105, 109], ["The RUL, RML, and LUL", "PROBLEM", 0, 21], ["RUL", "ANATOMY", 4, 7], ["RML", "OBSERVATION", 9, 12], ["LUL", "ANATOMY", 18, 21], ["upper", "ANATOMY_MODIFIER", 42, 47], ["lung", "ANATOMY", 48, 52], ["remaining lobes", "ANATOMY", 63, 78], ["lower", "ANATOMY_MODIFIER", 99, 104], ["lung", "ANATOMY", 105, 109]]], ["Subsequently, to describe the HU distribution, we measured the volume of several opacities using the following cutoff HU values: -200, -400, and -600 HU, and calculated the percentage of each HU subsection volume in the whole lesions.", [["whole lesions", "ANATOMY", 220, 233], ["lesions", "PATHOLOGICAL_FORMATION", 226, 233], ["several opacities", "PROBLEM", 73, 90], ["HU values", "TEST", 118, 127], ["the whole lesions", "PROBLEM", 216, 233], ["volume", "OBSERVATION_MODIFIER", 63, 69], ["several", "OBSERVATION_MODIFIER", 73, 80], ["opacities", "OBSERVATION", 81, 90], ["600 HU", "OBSERVATION_MODIFIER", 146, 152], ["percentage", "OBSERVATION_MODIFIER", 173, 183], ["each HU", "OBSERVATION_MODIFIER", 187, 194], ["subsection", "OBSERVATION_MODIFIER", 195, 205], ["volume", "OBSERVATION_MODIFIER", 206, 212], ["whole", "OBSERVATION_MODIFIER", 220, 225], ["lesions", "OBSERVATION", 226, 233]]], ["We described the lesion location and distribution as the median distance from every lesion voxel to pulmonary pleurae in the upper and lower lung with a lower distance indicating subpleural area distribution.Statistical analysis ::: MethodsWe reported continuous variables as the mean (standard deviation [SD]) or median (interquartile range [IQR]).", [["lesion", "ANATOMY", 17, 23], ["lesion", "ANATOMY", 84, 90], ["pulmonary pleurae", "ANATOMY", 100, 117], ["upper", "ANATOMY", 125, 130], ["lower lung", "ANATOMY", 135, 145], ["subpleural area", "ANATOMY", 179, 194], ["pulmonary pleurae", "CANCER", 100, 117], ["upper", "ORGANISM_SUBDIVISION", 125, 130], ["lung", "ORGAN", 141, 145], ["subpleural area", "MULTI-TISSUE_STRUCTURE", 179, 194], ["pulmonary pleurae in the upper and lower lung", "PROBLEM", 100, 145], ["lesion", "OBSERVATION", 17, 23], ["distribution", "OBSERVATION_MODIFIER", 37, 49], ["median", "OBSERVATION_MODIFIER", 57, 63], ["lesion", "OBSERVATION", 84, 90], ["pulmonary", "ANATOMY", 100, 109], ["pleurae", "OBSERVATION", 110, 117], ["upper", "ANATOMY_MODIFIER", 125, 130], ["lower", "ANATOMY_MODIFIER", 135, 140], ["lung", "ANATOMY", 141, 145], ["lower", "ANATOMY_MODIFIER", 153, 158], ["subpleural", "ANATOMY_MODIFIER", 179, 189]]], ["We used Student's t-test or Mann-Whitney U test to compare between-group differences (presence and non-presence of primary composite endpoints) based on distributions.", [["Student's t-test", "TEST", 8, 24], ["Whitney U test", "TEST", 33, 47]]], ["Categorical variables were presented as n (%) and compared using \u03c72 or Fisher's exact test.Statistical analysis ::: MethodsWe used multivariable logistic regression models to identify CT risk factors for the primary composite endpoints.", [["Categorical variables", "TEST", 0, 21], ["Fisher's exact test", "TEST", 71, 90], ["CT risk factors", "PROBLEM", 184, 199]]], ["Regarding clinical features, studies on COVID-19 have shown that age is a clear risk factor for death or adverse clinical outcomes 8.", [["death", "DISEASE", 96, 101], ["COVID", "TEST", 40, 45], ["death", "PROBLEM", 96, 101], ["adverse clinical outcomes", "PROBLEM", 105, 130]]], ["Therefore, we included age and the CT parameters into the multivariable logistic regression model.", [["the CT parameters", "TEST", 31, 48]]], ["We performed a sensitivity analysis on the completed cases.Statistical analysis ::: MethodsWe set statistical significance at the 2-tailed P < 0.05.", [["a sensitivity analysis", "TEST", 13, 35]]], ["All analyses were performed using SPSS (version 22.0.", [["All analyses", "TEST", 0, 12], ["SPSS (version", "TEST", 34, 47]]], ["Armonk, NY, USA).ResultsWe enrolled 625 patients with laboratory-confirmed COVID-19 from 24 designated hospitals in Jiangsu province between 10th January and 18th February 2020 (Figure 1).", [["patients", "ORGANISM", 40, 48], ["patients", "SPECIES", 40, 48], ["COVID", "TEST", 75, 80]]], ["We excluded 179 patients without initial CT scans or clinical records at admission and 25 patients aged < 18 years.", [["patients", "ORGANISM", 16, 24], ["patients", "ORGANISM", 90, 98], ["patients", "SPECIES", 16, 24], ["patients", "SPECIES", 90, 98], ["initial CT scans", "TEST", 33, 49]]], ["Consequently, we included 421 patients in the final analysis.", [["patients", "ORGANISM", 30, 38], ["patients", "SPECIES", 30, 38], ["the final analysis", "TEST", 42, 60]]], ["Among the included patients, 364/421 (86%) had a clear COVID-19 exposure history while 168/421 (46%) were imported from Wuhan.", [["patients", "ORGANISM", 19, 27], ["patients", "SPECIES", 19, 27]]], ["The median age was 48.0 years (IQR 34.0-58.0) and the male proportion was 53% (224/421).", [["IQR", "TEST", 31, 34]]], ["Fever was the most common symptom on admission (70% [294/421]), followed by coughing.", [["Fever", "DISEASE", 0, 5], ["coughing", "DISEASE", 76, 84], ["Fever", "PROBLEM", 0, 5], ["coughing", "PROBLEM", 76, 84]]], ["Moreover, 89 (21%) patients had comorbidities on admission with hypertension being the most common (17% [70/421]).ResultsUpon hospital admission, epidemiological, clinical, and laboratory data were collected with the median time from admission to the initial CT scan being 0 days (IQR: 2 days).", [["hypertension", "DISEASE", 64, 76], ["patients", "ORGANISM", 19, 27], ["patients", "SPECIES", 19, 27], ["comorbidities", "PROBLEM", 32, 45], ["hypertension", "PROBLEM", 64, 76], ["laboratory data", "TEST", 177, 192], ["the initial CT scan", "TEST", 247, 266], ["hypertension", "OBSERVATION", 64, 76]]], ["The median time from illness onset to hospital admission was 5 days (IQR: 6 days) with no statistical difference between patients with or without clinical outcome.", [["illness", "DISEASE", 21, 28], ["patients", "ORGANISM", 121, 129], ["patients", "SPECIES", 121, 129]]], ["Until 6th March 2020, there were no deaths and 350 (83%) patients were discharged.ResultsDuring the 14-day follow-up period, 64/421 (15%) patients reached a primary composite endpoint.", [["deaths", "DISEASE", 36, 42], ["patients", "ORGANISM", 57, 65], ["patients", "ORGANISM", 138, 146], ["patients", "SPECIES", 57, 65], ["patients", "SPECIES", 138, 146], ["no", "UNCERTAINTY", 33, 35]]], ["As shown in Table 1, compared with patients who did not reach an endpoint, those that did were older (57.2 [SD, 14.6] vs. 45.0 [SD, 14.9] years, P < 0.001) and had a higher fever prevalence (53/64 [83%] vs. 241/357 [68%], P = 0.02).", [["fever", "DISEASE", 173, 178], ["patients", "ORGANISM", 35, 43], ["patients", "SPECIES", 35, 43], ["a higher fever prevalence", "PROBLEM", 164, 189], ["P", "TEST", 222, 223]]], ["Patients with an endpoint had a higher comorbidity proportion, including hypertension (20/64 [31%] vs. 50/357 [14%]), coronary heart disease (4/64 [6%] vs. 3/357 [1%]), and coronary heart disease (4/64 [6%] vs. 3/357 [1%]).", [["coronary", "ANATOMY", 118, 126], ["heart", "ANATOMY", 127, 132], ["coronary", "ANATOMY", 173, 181], ["heart", "ANATOMY", 182, 187], ["hypertension", "DISEASE", 73, 85], ["coronary heart disease", "DISEASE", 118, 140], ["coronary heart disease", "DISEASE", 173, 195], ["Patients", "ORGANISM", 0, 8], ["coronary", "MULTI-TISSUE_STRUCTURE", 118, 126], ["heart", "ORGAN", 127, 132], ["heart", "ORGAN", 182, 187], ["Patients", "SPECIES", 0, 8], ["a higher comorbidity proportion", "PROBLEM", 30, 61], ["hypertension", "PROBLEM", 73, 85], ["coronary heart disease", "PROBLEM", 118, 140], ["coronary heart disease", "PROBLEM", 173, 195], ["hypertension", "OBSERVATION", 73, 85], ["coronary heart", "ANATOMY", 118, 132], ["disease", "OBSERVATION", 133, 140], ["coronary heart", "ANATOMY", 173, 187], ["disease", "OBSERVATION", 188, 195]]], ["Moreover, they had reduced white blood cell, lymphocyte, and platelet counts and increased C-reactive protein and D-dimer levels.ResultsInitial CT findings revealed that 411 patients had pneumonia opacities; moreover, the 10 patients without opacities on initial CT findings did not present an endpoint during hospitalization.", [["white blood cell", "ANATOMY", 27, 43], ["lymphocyte", "ANATOMY", 45, 55], ["platelet", "ANATOMY", 61, 69], ["pneumonia", "DISEASE", 187, 196], ["opacities", "DISEASE", 197, 206], ["opacities", "DISEASE", 242, 251], ["white blood cell", "CELL", 27, 43], ["lymphocyte", "CELL", 45, 55], ["platelet", "CELL", 61, 69], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 91, 109], ["D-dimer", "GENE_OR_GENE_PRODUCT", 114, 121], ["patients", "ORGANISM", 174, 182], ["patients", "ORGANISM", 225, 233], ["white blood cell", "CELL_TYPE", 27, 43], ["C-reactive protein", "PROTEIN", 91, 109], ["patients", "SPECIES", 174, 182], ["patients", "SPECIES", 225, 233], ["reduced white blood cell", "PROBLEM", 19, 43], ["lymphocyte", "TEST", 45, 55], ["platelet counts", "TEST", 61, 76], ["increased C-reactive protein", "PROBLEM", 81, 109], ["D-dimer levels", "TEST", 114, 128], ["ResultsInitial CT findings", "TEST", 129, 155], ["pneumonia opacities", "PROBLEM", 187, 206], ["opacities", "PROBLEM", 242, 251], ["initial CT findings", "TEST", 255, 274], ["platelet counts", "OBSERVATION", 61, 76], ["increased", "OBSERVATION_MODIFIER", 81, 90], ["-reactive protein", "OBSERVATION", 92, 109], ["pneumonia", "OBSERVATION", 187, 196], ["without", "UNCERTAINTY", 234, 241], ["opacities", "OBSERVATION", 242, 251]]], ["As shown in Table 2, CT quantitative evaluation of pulmonary lesions revealed that GGO and consolidation lesions in patients with endpoints occupied more lung lobes than those in patients without.", [["pulmonary lesions", "ANATOMY", 51, 68], ["consolidation lesions", "ANATOMY", 91, 112], ["lung lobes", "ANATOMY", 154, 164], ["pulmonary lesions", "DISEASE", 51, 68], ["GGO", "DISEASE", 83, 86], ["pulmonary lesions", "PATHOLOGICAL_FORMATION", 51, 68], ["lesions", "PATHOLOGICAL_FORMATION", 105, 112], ["patients", "ORGANISM", 116, 124], ["lung lobes", "MULTI-TISSUE_STRUCTURE", 154, 164], ["patients", "ORGANISM", 179, 187], ["patients", "SPECIES", 116, 124], ["patients", "SPECIES", 179, 187], ["CT quantitative evaluation", "TEST", 21, 47], ["pulmonary lesions", "PROBLEM", 51, 68], ["GGO", "PROBLEM", 83, 86], ["consolidation lesions", "PROBLEM", 91, 112], ["endpoints occupied more lung lobes", "PROBLEM", 130, 164], ["pulmonary", "ANATOMY", 51, 60], ["lesions", "OBSERVATION", 61, 68], ["GGO", "OBSERVATION", 83, 86], ["consolidation", "OBSERVATION_MODIFIER", 91, 104], ["lesions", "OBSERVATION", 105, 112], ["lung", "ANATOMY", 154, 158], ["lobes", "ANATOMY_MODIFIER", 159, 164]]], ["Compared with patients without endpoints, those with endpoints had a higher percentage of lesions in the bilateral lungs, as well as larger GGO and consolidation lesions in each lung lobe.", [["lesions", "ANATOMY", 90, 97], ["lungs", "ANATOMY", 115, 120], ["consolidation lesions", "ANATOMY", 148, 169], ["lung lobe", "ANATOMY", 178, 187], ["GGO", "DISEASE", 140, 143], ["patients", "ORGANISM", 14, 22], ["lesions", "PATHOLOGICAL_FORMATION", 90, 97], ["lungs", "ORGAN", 115, 120], ["consolidation lesions", "CANCER", 148, 169], ["lung lobe", "CANCER", 178, 187], ["patients", "SPECIES", 14, 22], ["a higher percentage of lesions in the bilateral lungs", "PROBLEM", 67, 120], ["larger GGO", "PROBLEM", 133, 143], ["consolidation lesions in each lung lobe", "PROBLEM", 148, 187], ["lesions", "OBSERVATION", 90, 97], ["bilateral", "ANATOMY_MODIFIER", 105, 114], ["lungs", "ANATOMY", 115, 120], ["larger", "OBSERVATION_MODIFIER", 133, 139], ["GGO", "OBSERVATION", 140, 143], ["consolidation", "OBSERVATION_MODIFIER", 148, 161], ["lesions", "OBSERVATION", 162, 169], ["each", "ANATOMY_MODIFIER", 173, 177], ["lung", "ANATOMY", 178, 182], ["lobe", "ANATOMY_MODIFIER", 183, 187]]], ["CT density of the lesion was largely distributed in the range of -200 to -600 HU and < -600 HU in patients with and without an endpoint, respectively.", [["lesion", "ANATOMY", 18, 24], ["lesion", "PATHOLOGICAL_FORMATION", 18, 24], ["patients", "ORGANISM", 98, 106], ["patients", "SPECIES", 98, 106], ["CT density of the lesion", "PROBLEM", 0, 24], ["density", "OBSERVATION", 3, 10], ["lesion", "OBSERVATION", 18, 24], ["largely", "OBSERVATION_MODIFIER", 29, 36], ["distributed", "OBSERVATION_MODIFIER", 37, 48], ["range", "OBSERVATION_MODIFIER", 56, 61], ["600 HU", "OBSERVATION_MODIFIER", 74, 80], ["600 HU", "OBSERVATION_MODIFIER", 88, 94]]], ["Peripheral distribution in all the patients was observed generally.", [["patients", "ORGANISM", 35, 43], ["patients", "SPECIES", 35, 43], ["distribution", "OBSERVATION_MODIFIER", 11, 23], ["all", "OBSERVATION_MODIFIER", 27, 30]]], ["Compared to patients without an endpoint, those with an endpoint showed lesions with a shorter distance to pulmonary pleurae.ResultsFinally, 359 patients with complete data (on age and 18 CT parameters) were included in the multivariable logistic regression model.", [["lesions", "ANATOMY", 72, 79], ["pulmonary pleurae", "ANATOMY", 107, 124], ["patients", "ORGANISM", 12, 20], ["lesions", "PATHOLOGICAL_FORMATION", 72, 79], ["pulmonary pleurae", "MULTI-TISSUE_STRUCTURE", 107, 124], ["patients", "ORGANISM", 145, 153], ["patients", "SPECIES", 12, 20], ["patients", "SPECIES", 145, 153], ["lesions", "PROBLEM", 72, 79], ["a shorter distance to pulmonary pleurae", "PROBLEM", 85, 124], ["CT parameters", "TEST", 188, 201], ["lesions", "OBSERVATION", 72, 79], ["shorter", "OBSERVATION_MODIFIER", 87, 94], ["pulmonary", "ANATOMY", 107, 116], ["pleurae", "OBSERVATION", 117, 124]]], ["As shown in Figure 3, older age (odds ratio [OR], 1.04; 95% confidence interval [CI: 1.01-1.06; P =0.003), larger consolidation lesions in the RUL (OR, 1.13; 95% CI: 1.03-1.25; P = 0.01) and LUL (OR, 1.15; 95% CI: 1.01-1.32; P =0.04) were associated with increased odds of endpoints.ResultsSensitivity logistic regression analysis with only above 3 significant variables on the completed cases showed that the 3 variables remained significance related to the composite endpoint (P<0.05).ResultsFigure 4 and 5 showed two typical cases with and without clinical endpoint during hospitalization.DiscussionIn this retrospective, cohort, and AI-assisted study, we reported the imaging risk factors associated with adverse clinical composite endpoints, including admission to ICU, acute respiratory failure, and shock during hospitalization in patients with COVID-19 pneumonia in Jiangsu province, China.", [["lesions", "ANATOMY", 128, 135], ["respiratory", "ANATOMY", 781, 792], ["RUL", "DISEASE", 143, 146], ["acute respiratory failure", "DISEASE", 775, 800], ["shock", "DISEASE", 806, 811], ["COVID-19", "CHEMICAL", 852, 860], ["pneumonia", "DISEASE", 861, 870], ["lesions", "PATHOLOGICAL_FORMATION", 128, 135], ["patients", "ORGANISM", 838, 846], ["patients", "SPECIES", 838, 846], ["CI", "TEST", 81, 83], ["P", "TEST", 96, 97], ["larger consolidation lesions in the RUL", "PROBLEM", 107, 146], ["CI", "TEST", 162, 164], ["P", "TEST", 177, 178], ["LUL", "TEST", 191, 194], ["CI", "TEST", 210, 212], ["P", "TEST", 225, 226], ["increased odds of endpoints", "PROBLEM", 255, 282], ["logistic regression analysis", "TEST", 302, 330], ["acute respiratory failure", "PROBLEM", 775, 800], ["shock", "PROBLEM", 806, 811], ["COVID", "TEST", 852, 857], ["pneumonia", "PROBLEM", 861, 870], ["larger", "OBSERVATION_MODIFIER", 107, 113], ["consolidation", "OBSERVATION_MODIFIER", 114, 127], ["lesions", "OBSERVATION", 128, 135], ["RUL", "ANATOMY", 143, 146], ["LUL", "ANATOMY", 191, 194], ["increased", "OBSERVATION_MODIFIER", 255, 264], ["acute", "OBSERVATION_MODIFIER", 775, 780], ["respiratory failure", "OBSERVATION", 781, 800], ["shock", "OBSERVATION", 806, 811], ["pneumonia", "OBSERVATION", 861, 870]]], ["Generally, patients with adverse endpoints had worsened pulmonary conditions.", [["pulmonary", "ANATOMY", 56, 65], ["patients", "ORGANISM", 11, 19], ["pulmonary", "ORGAN", 56, 65], ["patients", "SPECIES", 11, 19], ["adverse endpoints", "PROBLEM", 25, 42], ["worsened pulmonary conditions", "PROBLEM", 47, 76], ["worsened", "OBSERVATION_MODIFIER", 47, 55], ["pulmonary", "ANATOMY", 56, 65], ["conditions", "OBSERVATION", 66, 76]]], ["Specifically, older age, larger consolidation lesions in upper lungs, and lesions closer to pulmonary pleurae in lower lungs on admission were associated with higher odds of adverse composite endpoints.DiscussionOur sample comprised of 421 patients with COVID-19 from whole Jiangsu province; among them, 364 (86%) had a clear COVID-19 exposure history while 46% (168/421) were from Wuhan.", [["consolidation lesions", "ANATOMY", 32, 53], ["upper lungs", "ANATOMY", 57, 68], ["lesions", "ANATOMY", 74, 81], ["pulmonary pleurae", "ANATOMY", 92, 109], ["lower lungs", "ANATOMY", 113, 124], ["lesions", "PATHOLOGICAL_FORMATION", 46, 53], ["upper lungs", "ORGAN", 57, 68], ["lesions", "PATHOLOGICAL_FORMATION", 74, 81], ["pulmonary pleurae", "MULTI-TISSUE_STRUCTURE", 92, 109], ["lungs", "ORGAN", 119, 124], ["patients", "ORGANISM", 240, 248], ["patients", "SPECIES", 240, 248], ["larger consolidation lesions in upper lungs", "PROBLEM", 25, 68], ["lesions", "PROBLEM", 74, 81], ["adverse composite endpoints", "PROBLEM", 174, 201], ["COVID", "TEST", 254, 259], ["larger", "OBSERVATION_MODIFIER", 25, 31], ["consolidation", "OBSERVATION_MODIFIER", 32, 45], ["lesions", "OBSERVATION", 46, 53], ["upper", "ANATOMY_MODIFIER", 57, 62], ["lungs", "ANATOMY", 63, 68], ["lesions", "OBSERVATION", 74, 81], ["pulmonary", "ANATOMY", 92, 101], ["pleurae", "ANATOMY_MODIFIER", 102, 109], ["lower", "ANATOMY_MODIFIER", 113, 118], ["lungs", "ANATOMY", 119, 124], ["adverse", "OBSERVATION_MODIFIER", 174, 181], ["composite endpoints", "OBSERVATION", 182, 201]]], ["Given the combination of local and Wuhan cases, our findings could be generalizable to patients in other countries and regions where the epidemic has developed.DiscussionIn our study, 64/421 (15%) patients had primary composite endpoints during hospitalization, which is less severe than that reported in patients in Wuhan 6.", [["patients", "ORGANISM", 87, 95], ["patients", "ORGANISM", 197, 205], ["patients", "ORGANISM", 305, 313], ["patients", "SPECIES", 87, 95], ["patients", "SPECIES", 197, 205], ["patients", "SPECIES", 305, 313], ["the epidemic", "PROBLEM", 133, 145], ["our study", "TEST", 173, 182], ["primary composite endpoints", "PROBLEM", 210, 237], ["epidemic", "OBSERVATION_MODIFIER", 137, 145], ["less severe", "OBSERVATION_MODIFIER", 271, 282]]], ["A previous study reported that 50/191 (26%) patients in Wuhan were admitted to ICU and 103/191 (54%) developed respiratory failure 8.", [["respiratory", "ANATOMY", 111, 122], ["respiratory failure", "DISEASE", 111, 130], ["patients", "ORGANISM", 44, 52], ["patients", "SPECIES", 44, 52], ["A previous study", "TEST", 0, 16], ["respiratory failure", "PROBLEM", 111, 130], ["respiratory failure", "OBSERVATION", 111, 130]]], ["We found an association of older age with the development of adverse composite endpoints, which is consistent with previous findings of increasing age, immunity defects 19, and more comorbidities 1 were associated with poor outcome during COVID-19 course.DiscussionIn our study, we reported the pneumonia lesion component, amount and distribution associated with poor outcome quantitatively.", [["pneumonia", "DISEASE", 295, 304], ["adverse composite endpoints", "PROBLEM", 61, 88], ["immunity defects", "PROBLEM", 152, 168], ["COVID", "TEST", 239, 244], ["our study", "TEST", 268, 277], ["the pneumonia lesion component", "PROBLEM", 291, 321], ["adverse", "OBSERVATION_MODIFIER", 61, 68], ["composite endpoints", "OBSERVATION", 69, 88], ["consistent with", "UNCERTAINTY", 99, 114], ["increasing", "OBSERVATION_MODIFIER", 136, 146], ["immunity defects", "OBSERVATION", 152, 168], ["pneumonia", "OBSERVATION", 295, 304], ["amount", "OBSERVATION_MODIFIER", 323, 329], ["poor outcome", "OBSERVATION", 363, 375]]], ["And based on a large population, the results and conclusions may be considered specific and robust to patients with COVID-19 in clinical practice.", [["patients", "ORGANISM", 102, 110], ["patients", "SPECIES", 102, 110], ["COVID", "TEST", 116, 121], ["large", "OBSERVATION_MODIFIER", 15, 20], ["population", "OBSERVATION", 21, 31]]], ["Consolidation in upper lungs on initial CT at admission were risk factors associated with adverse endpoints after adjusting for age.", [["upper lungs", "ANATOMY", 17, 28], ["upper lungs", "ORGAN", 17, 28], ["Consolidation in upper lungs", "PROBLEM", 0, 28], ["initial CT", "TEST", 32, 42], ["risk factors", "PROBLEM", 61, 73], ["adverse endpoints", "PROBLEM", 90, 107], ["upper", "ANATOMY_MODIFIER", 17, 22], ["lungs", "ANATOMY", 23, 28]]], ["Firstly, more consolidation has been reported in patients died from COVID-19 5.", [["COVID-19", "CHEMICAL", 68, 76], ["patients", "ORGANISM", 49, 57], ["patients", "SPECIES", 49, 57], ["more consolidation", "PROBLEM", 9, 27], ["COVID", "TEST", 68, 73], ["more", "OBSERVATION_MODIFIER", 9, 13], ["consolidation", "OBSERVATION", 14, 27]]], ["Histological examinations of lung biopsy samples from patients with COVID-19 have demonstrated bilateral diffuse alveolar damage with proteinaceous and fibrous exudates, which attributed to imaging appearance on chest CT 20,21.", [["lung biopsy samples", "ANATOMY", 29, 48], ["alveolar", "ANATOMY", 113, 121], ["fibrous exudates", "ANATOMY", 152, 168], ["alveolar damage", "DISEASE", 113, 128], ["lung biopsy samples", "CANCER", 29, 48], ["patients", "ORGANISM", 54, 62], ["alveolar", "TISSUE", 113, 121], ["fibrous exudates", "TISSUE", 152, 168], ["patients", "SPECIES", 54, 62], ["Histological examinations", "TEST", 0, 25], ["lung biopsy samples", "TEST", 29, 48], ["COVID", "TEST", 68, 73], ["bilateral diffuse alveolar damage", "PROBLEM", 95, 128], ["proteinaceous and fibrous exudates", "PROBLEM", 134, 168], ["imaging appearance", "TEST", 190, 208], ["chest CT", "TEST", 212, 220], ["lung", "ANATOMY", 29, 33], ["biopsy", "OBSERVATION", 34, 40], ["bilateral", "ANATOMY_MODIFIER", 95, 104], ["diffuse", "OBSERVATION_MODIFIER", 105, 112], ["alveolar damage", "OBSERVATION", 113, 128], ["proteinaceous", "OBSERVATION_MODIFIER", 134, 147], ["fibrous exudates", "OBSERVATION", 152, 168], ["chest", "ANATOMY", 212, 217]]], ["In patients with unfavorable outcome, consolidation development accelerated, which happened in all lobes, especially in the upper lungs.DiscussionSecondly, in terms of distribution, the upper lung played an important role in risk evaluation for COVID-19 patients.", [["lobes", "ANATOMY", 99, 104], ["upper lungs", "ANATOMY", 124, 135], ["upper lung", "ANATOMY", 186, 196], ["patients", "ORGANISM", 3, 11], ["lobes", "ORGAN", 99, 104], ["upper", "ORGANISM_SUBDIVISION", 124, 129], ["lungs", "ORGAN", 130, 135], ["upper", "ORGANISM_SUBDIVISION", 186, 191], ["lung", "ORGAN", 192, 196], ["patients", "ORGANISM", 254, 262], ["patients", "SPECIES", 3, 11], ["patients", "SPECIES", 254, 262], ["unfavorable outcome", "PROBLEM", 17, 36], ["consolidation", "PROBLEM", 38, 51], ["risk evaluation", "TEST", 225, 240], ["COVID", "TEST", 245, 250], ["unfavorable", "OBSERVATION_MODIFIER", 17, 28], ["outcome", "OBSERVATION", 29, 36], ["consolidation", "OBSERVATION", 38, 51], ["accelerated", "OBSERVATION_MODIFIER", 64, 75], ["all lobes", "ANATOMY_MODIFIER", 95, 104], ["upper", "ANATOMY_MODIFIER", 124, 129], ["lungs", "ANATOMY", 130, 135], ["upper", "ANATOMY_MODIFIER", 186, 191], ["lung", "ANATOMY", 192, 196]]], ["Previous studies reported worse symptoms related to more pulmonary lesions 10,13,15,23.", [["pulmonary lesions", "ANATOMY", 57, 74], ["pulmonary", "ORGAN", 57, 66], ["Previous studies", "TEST", 0, 16], ["worse symptoms", "PROBLEM", 26, 40], ["more pulmonary lesions", "PROBLEM", 52, 74], ["pulmonary", "ANATOMY", 57, 66], ["lesions", "OBSERVATION", 67, 74]]], ["Our study of 421 COVID-19 patients suggested an increased pulmonary lesion in bilateral upper lungs were independent risk factors for adverse clinical outcomes, which as far as we know, has not been reported.", [["pulmonary lesion", "ANATOMY", 58, 74], ["upper lungs", "ANATOMY", 88, 99], ["pulmonary lesion", "DISEASE", 58, 74], ["patients", "ORGANISM", 26, 34], ["pulmonary", "ORGAN", 58, 67], ["upper lungs", "ORGAN", 88, 99], ["patients", "SPECIES", 26, 34], ["Our study", "TEST", 0, 9], ["COVID", "TEST", 17, 22], ["an increased pulmonary lesion in bilateral upper lungs", "PROBLEM", 45, 99], ["increased", "OBSERVATION_MODIFIER", 48, 57], ["pulmonary", "ANATOMY", 58, 67], ["lesion", "OBSERVATION", 68, 74], ["bilateral", "ANATOMY_MODIFIER", 78, 87], ["upper", "ANATOMY_MODIFIER", 88, 93], ["lungs", "ANATOMY", 94, 99]]], ["This finding is of significant clinical implications, not only in providing us a simpler way to identify high risk patients on CT, but also has potential to extend to chest radiographs, where upper lobe consolidations are easy to be perceived.", [["chest", "ANATOMY", 167, 172], ["upper lobe", "ANATOMY", 192, 202], ["patients", "ORGANISM", 115, 123], ["upper lobe", "MULTI-TISSUE_STRUCTURE", 192, 202], ["patients", "SPECIES", 115, 123], ["CT", "TEST", 127, 129], ["chest radiographs", "TEST", 167, 184], ["upper lobe consolidations", "PROBLEM", 192, 217], ["significant", "OBSERVATION_MODIFIER", 19, 30], ["chest", "ANATOMY", 167, 172], ["upper lobe", "ANATOMY", 192, 202], ["consolidations", "OBSERVATION", 203, 217]]], ["(Figure 6).DiscussionApart from consolidation, GGO is also the most common CT characteristics in COVID-19 pneumonia 14,15.", [["pneumonia", "DISEASE", 106, 115], ["consolidation", "PROBLEM", 32, 45], ["GGO", "PROBLEM", 47, 50], ["COVID", "TEST", 97, 102], ["pneumonia", "PROBLEM", 106, 115], ["consolidation", "OBSERVATION", 32, 45], ["GGO", "OBSERVATION", 47, 50], ["pneumonia", "OBSERVATION", 106, 115]]], ["Previous findings showed that there was GGO at the early disease stage, which showed an increasing followed by a decreasing growth trend, while consolidation development was delayed and after the GGO in general 10,22,23.", [["Previous findings", "TEST", 0, 17], ["GGO", "PROBLEM", 40, 43], ["the early disease stage", "PROBLEM", 47, 70], ["a decreasing growth trend", "PROBLEM", 111, 136], ["consolidation", "PROBLEM", 144, 157], ["the GGO", "TEST", 192, 199], ["GGO", "OBSERVATION", 40, 43], ["early", "OBSERVATION_MODIFIER", 51, 56], ["disease", "OBSERVATION", 57, 64], ["increasing", "OBSERVATION_MODIFIER", 88, 98], ["decreasing", "OBSERVATION_MODIFIER", 113, 123], ["growth", "OBSERVATION_MODIFIER", 124, 130], ["trend", "OBSERVATION_MODIFIER", 131, 136], ["consolidation", "OBSERVATION", 144, 157]]], ["We observed a positive correlation of the GGO in lower lungs and poor outcome.", [["lower lungs", "ANATOMY", 49, 60], ["GGO", "DISEASE", 42, 45], ["lungs", "ORGAN", 55, 60], ["the GGO in lower lungs", "PROBLEM", 38, 60], ["GGO", "OBSERVATION", 42, 45], ["lower", "ANATOMY_MODIFIER", 49, 54], ["lungs", "ANATOMY", 55, 60], ["poor outcome", "OBSERVATION", 65, 77]]], ["And GGO lesions on admission have been reported in severe cases of other respiratory viral diseases, including SARS and Middle East respiratory syndrome 24-26.DiscussionAdditionally, our study revealed there was a negative correlation of the distance to pleurae with diffuse peripheral distribution in lower lungs (OR: 0.91, 95%CI 0.83-1.0; P = 0.07) showing deterioration signs related to adverse endpoints.", [["GGO lesions", "ANATOMY", 4, 15], ["pleurae", "ANATOMY", 254, 261], ["lower lungs", "ANATOMY", 302, 313], ["respiratory viral diseases", "DISEASE", 73, 99], ["SARS", "DISEASE", 111, 115], ["Middle East respiratory syndrome", "DISEASE", 120, 152], ["GGO lesions", "CANCER", 4, 15], ["pleurae", "CANCER", 254, 261], ["lungs", "ORGAN", 308, 313], ["Middle East respiratory syndrome 24-26", "SPECIES", 120, 158], ["GGO lesions", "PROBLEM", 4, 15], ["other respiratory viral diseases", "PROBLEM", 67, 99], ["SARS", "PROBLEM", 111, 115], ["Middle East respiratory syndrome", "PROBLEM", 120, 152], ["our study", "TEST", 183, 192], ["diffuse peripheral distribution in lower lungs", "PROBLEM", 267, 313], ["CI", "TEST", 328, 330], ["P", "TEST", 341, 342], ["deterioration signs", "PROBLEM", 359, 378], ["adverse endpoints", "PROBLEM", 390, 407], ["GGO", "OBSERVATION_MODIFIER", 4, 7], ["lesions", "OBSERVATION", 8, 15], ["severe", "OBSERVATION_MODIFIER", 51, 57], ["respiratory", "ANATOMY", 73, 84], ["viral diseases", "OBSERVATION", 85, 99], ["Middle", "ANATOMY_MODIFIER", 120, 126], ["respiratory syndrome", "OBSERVATION", 132, 152], ["diffuse", "OBSERVATION_MODIFIER", 267, 274], ["peripheral", "ANATOMY_MODIFIER", 275, 285], ["distribution", "ANATOMY_MODIFIER", 286, 298], ["lower", "ANATOMY_MODIFIER", 302, 307], ["lungs", "ANATOMY", 308, 313]]], ["Subpleural distribution is another common finding in COVID-19 pneumonia.", [["Subpleural", "ANATOMY", 0, 10], ["pneumonia", "DISEASE", 62, 71], ["Subpleural", "MULTI-TISSUE_STRUCTURE", 0, 10], ["COVID-19", "SPECIES", 53, 61], ["Subpleural distribution", "PROBLEM", 0, 23], ["pneumonia", "PROBLEM", 62, 71], ["pneumonia", "OBSERVATION", 62, 71]]], ["Here, we measured the distance from every lesion voxel to pulmonary pleurae as a description of the lesion location and distribution.", [["lesion", "ANATOMY", 42, 48], ["pulmonary pleurae", "ANATOMY", 58, 75], ["lesion", "ANATOMY", 100, 106], ["pulmonary pleurae", "MULTI-TISSUE_STRUCTURE", 58, 75], ["lesion", "OBSERVATION", 42, 48], ["pulmonary", "ANATOMY", 58, 67], ["pleurae", "OBSERVATION", 68, 75], ["lesion", "OBSERVATION", 100, 106], ["distribution", "OBSERVATION_MODIFIER", 120, 132]]], ["We observed generally peripheral distribution in all the patients, which is consistent with previous reports 14,15,23.DiscussionFinally, our study presented additional value of AI in COVID-19 researches apart from construction of diagnosis models 16, 27.", [["patients", "ORGANISM", 57, 65], ["patients", "SPECIES", 57, 65], ["our study", "TEST", 137, 146], ["AI", "PROBLEM", 177, 179], ["COVID", "TEST", 183, 188], ["diagnosis models", "TEST", 230, 246], ["generally", "OBSERVATION_MODIFIER", 12, 21], ["peripheral", "OBSERVATION_MODIFIER", 22, 32], ["distribution", "OBSERVATION_MODIFIER", 33, 45], ["consistent with", "UNCERTAINTY", 76, 91]]], ["AI played a significant role in this study and showed potential in COVID-19 diagnosis and patient monitoring.", [["patient", "ORGANISM", 90, 97], ["patient", "SPECIES", 90, 97], ["this study", "TEST", 32, 42], ["COVID", "TEST", 67, 72], ["patient monitoring", "TEST", 90, 108], ["significant", "OBSERVATION_MODIFIER", 12, 23]]], ["Based on high accuracy of lung and lesion segmentation from AI system, we measured the precise volume of opacities with different components, multiple HU blocks and location respectively.", [["lung", "ANATOMY", 26, 30], ["lesion", "ANATOMY", 35, 41], ["opacities", "DISEASE", 105, 114], ["lung", "ORGAN", 26, 30], ["high accuracy of lung and lesion segmentation from AI system", "PROBLEM", 9, 69], ["opacities", "PROBLEM", 105, 114], ["multiple HU blocks", "TREATMENT", 142, 160], ["high", "OBSERVATION_MODIFIER", 9, 13], ["lung", "ANATOMY", 26, 30], ["lesion", "OBSERVATION", 35, 41], ["precise", "OBSERVATION_MODIFIER", 87, 94], ["volume", "OBSERVATION_MODIFIER", 95, 101], ["opacities", "OBSERVATION", 105, 114], ["different", "OBSERVATION_MODIFIER", 120, 129], ["components", "OBSERVATION_MODIFIER", 130, 140], ["multiple", "OBSERVATION_MODIFIER", 142, 150], ["HU blocks", "OBSERVATION", 151, 160]]], ["This method is superior to those studies based on visual evaluation 22-24 which may vary from person to person.", [["person", "SPECIES", 94, 100], ["person", "SPECIES", 104, 110], ["those studies", "TEST", 27, 40], ["visual evaluation", "TEST", 50, 67]]], ["The accuracy of lesion extraction is critical for risk factor identification in multivariate regression in our study.", [["lesion", "ANATOMY", 16, 22], ["lesion", "CANCER", 16, 22], ["lesion extraction", "TREATMENT", 16, 33], ["our study", "TEST", 107, 116], ["lesion", "OBSERVATION", 16, 22]]], ["Moreover, the process of segmentation by AI only takes few minutes per patient making large scale quantification analysis possible.DiscussionThis study has several limitations.", [["patient", "ORGANISM", 71, 78], ["patient", "SPECIES", 71, 78], ["large scale quantification analysis", "TEST", 86, 121], ["This study", "TEST", 141, 151]]], ["Second, although we analyzed imaging risk factors, we did not analyze the effects of other previously reported clinical characteristics associated with death or other fatal endpoints.", [["death", "DISEASE", 152, 157], ["death", "PROBLEM", 152, 157], ["other fatal endpoints", "PROBLEM", 161, 182]]], ["Third, we assessed quantitative CT characteristics; however, we did not extract high-throughput imaging features, including histogram and texture.", [["quantitative CT characteristics", "TEST", 19, 50], ["histogram", "TEST", 124, 133], ["texture", "OBSERVATION_MODIFIER", 138, 145]]], ["Moreover, the risk factors might have been affected by unadjusted confounders or unmeasured factors.", [["the risk factors", "PROBLEM", 10, 26], ["unmeasured factors", "PROBLEM", 81, 99]]], ["Therefore, future studies should consider clinical factors, as well as CT features and deep radiological features.ConclusionsTo our knowledge, this is the largest retrospective, cohort, and AI-assisted study on patients with COVID-19 to report on imaging risk factors associated with a clinical outcome.", [["patients", "ORGANISM", 211, 219], ["patients", "SPECIES", 211, 219], ["future studies", "TEST", 11, 25], ["CT features", "TEST", 71, 82], ["deep radiological features", "TEST", 87, 113], ["COVID", "TEST", 225, 230], ["imaging risk factors", "PROBLEM", 247, 267], ["deep", "ANATOMY_MODIFIER", 87, 91]]], ["We found that older age and larger consolidation in upper lungs on admission were associated with higher odds of adverse composite endpoints, including admission to ICU, acute respiratory failure, or shock during hospitalization.", [["upper lungs", "ANATOMY", 52, 63], ["respiratory", "ANATOMY", 176, 187], ["acute respiratory failure", "DISEASE", 170, 195], ["shock", "DISEASE", 200, 205], ["upper", "ORGANISM_SUBDIVISION", 52, 57], ["lungs", "ORGAN", 58, 63], ["larger consolidation in upper lungs", "PROBLEM", 28, 63], ["adverse composite endpoints", "PROBLEM", 113, 140], ["acute respiratory failure", "PROBLEM", 170, 195], ["shock", "PROBLEM", 200, 205], ["larger", "OBSERVATION_MODIFIER", 28, 34], ["consolidation", "OBSERVATION", 35, 48], ["upper", "ANATOMY_MODIFIER", 52, 57], ["lungs", "ANATOMY", 58, 63], ["acute", "OBSERVATION_MODIFIER", 170, 175], ["respiratory failure", "OBSERVATION", 176, 195], ["shock", "OBSERVATION", 200, 205]]], ["The finding provided us a simpler way to identify high risk patients on CT that the elder with large consolidation in upper lungs should be paid more attention during the treatment of COVID-19.", [["upper lungs", "ANATOMY", 118, 129], ["COVID-19", "CHEMICAL", 184, 192], ["patients", "ORGANISM", 60, 68], ["upper", "ORGANISM_SUBDIVISION", 118, 123], ["lungs", "ORGAN", 124, 129], ["patients", "SPECIES", 60, 68], ["CT", "TEST", 72, 74], ["large consolidation in upper lungs", "PROBLEM", 95, 129], ["COVID", "TEST", 184, 189], ["large", "OBSERVATION_MODIFIER", 95, 100], ["consolidation", "OBSERVATION", 101, 114], ["upper", "ANATOMY_MODIFIER", 118, 123], ["lungs", "ANATOMY", 124, 129]]], ["Initial CT evaluation and identification of these risk factors could be helpful toward the monitoring of COVID-19.", [["COVID-19", "CHEMICAL", 105, 113], ["Initial CT evaluation", "TEST", 0, 21], ["these risk factors", "PROBLEM", 44, 62], ["the monitoring", "TEST", 87, 101], ["COVID", "TEST", 105, 110]]]], "fa6b3fafeedf308826d58db91499b7c09f172310": [["BackgroundPost-weaning diarrhea (PWD) due to Escherichia coli is an economically important disease in pig production worldwide, affecting pigs during the first 2 weeks after weaning and characterized by sudden death or diarrhea, dehydration, and growth retardation in surviving piglets [1, 2] .", [["diarrhea", "DISEASE", 23, 31], ["PWD", "DISEASE", 33, 36], ["Escherichia coli", "DISEASE", 45, 61], ["death", "DISEASE", 210, 215], ["diarrhea", "DISEASE", 219, 227], ["dehydration", "DISEASE", 229, 240], ["growth retardation", "DISEASE", 246, 264], ["Escherichia coli", "ORGANISM", 45, 61], ["pig", "ORGANISM", 102, 105], ["pigs", "ORGANISM", 138, 142], ["piglets", "ORGANISM", 278, 285], ["Escherichia coli", "SPECIES", 45, 61], ["pig", "SPECIES", 102, 105], ["pigs", "SPECIES", 138, 142], ["Escherichia coli", "SPECIES", 45, 61], ["pig", "SPECIES", 102, 105], ["pigs", "SPECIES", 138, 142], ["weaning diarrhea", "PROBLEM", 15, 31], ["Escherichia coli", "PROBLEM", 45, 61], ["sudden death", "PROBLEM", 203, 215], ["diarrhea", "PROBLEM", 219, 227], ["dehydration", "PROBLEM", 229, 240], ["growth retardation", "PROBLEM", 246, 264], ["Escherichia coli", "OBSERVATION", 45, 61], ["economically", "OBSERVATION_MODIFIER", 68, 80], ["pig production", "OBSERVATION", 102, 116], ["diarrhea", "OBSERVATION", 219, 227]]], ["Furthermore, many stress factors associated with the weaning period, such as removal from the sow, dietary changes, adapting to a new environment, mixing of pigs from different farms and histological changes in the small intestine, may negatively affect the response of immune system and lead to an intestinal gut dysfunction in pigs [3] [4] [5] .", [["small intestine", "ANATOMY", 215, 230], ["immune system", "ANATOMY", 270, 283], ["intestinal gut", "ANATOMY", 299, 313], ["gut dysfunction", "DISEASE", 310, 325], ["pigs", "ORGANISM", 157, 161], ["small intestine", "ORGAN", 215, 230], ["immune system", "ANATOMICAL_SYSTEM", 270, 283], ["intestinal gut", "ORGANISM_SUBDIVISION", 299, 313], ["pigs", "ORGANISM", 329, 333], ["pigs", "SPECIES", 157, 161], ["pigs", "SPECIES", 329, 333], ["pigs", "SPECIES", 157, 161], ["many stress factors", "PROBLEM", 13, 32], ["removal", "TREATMENT", 77, 84], ["dietary changes", "PROBLEM", 99, 114], ["mixing of pigs", "TREATMENT", 147, 161], ["histological changes in the small intestine", "PROBLEM", 187, 230], ["immune system", "PROBLEM", 270, 283], ["an intestinal gut dysfunction", "PROBLEM", 296, 325], ["small intestine", "ANATOMY", 215, 230], ["intestinal gut", "ANATOMY", 299, 313], ["dysfunction", "OBSERVATION", 314, 325]]], ["Post-weaning diarrhea is usually associated with proliferation of enterotoxigenic E. coli (ETEC) [2, 6] .", [["diarrhea", "DISEASE", 13, 21], ["enterotoxigenic E. coli", "DISEASE", 66, 89], ["enterotoxigenic E. coli", "ORGANISM", 66, 89], ["E. coli", "SPECIES", 82, 89], ["E. coli", "SPECIES", 82, 89], ["ETEC", "SPECIES", 91, 95], ["weaning diarrhea", "PROBLEM", 5, 21], ["enterotoxigenic E. coli", "PROBLEM", 66, 89], ["enterotoxigenic", "OBSERVATION_MODIFIER", 66, 81], ["E. coli", "OBSERVATION_MODIFIER", 82, 89]]], ["This pathotype is characterized by the production of enterotoxins and adhesins, both essential for disease development [7] , the predominant adhesins in PWD being F4 and F18 [6, 8] .", [["enterotoxins", "GENE_OR_GENE_PRODUCT", 53, 65], ["enterotoxins", "PROTEIN", 53, 65], ["adhesins", "PROTEIN", 70, 78], ["This pathotype", "PROBLEM", 0, 14], ["enterotoxins", "PROBLEM", 53, 65], ["adhesins", "PROBLEM", 70, 78], ["disease development", "PROBLEM", 99, 118], ["enterotoxins", "OBSERVATION", 53, 65]]], ["Small intestinal adhesion and subsequent colonization by ETEC in pigs is mediated by F4 or F18 specific receptors, the existence and function of these receptors being crucial to determine the susceptibility of pigs to ETEC infections [7] .", [["intestinal", "ANATOMY", 6, 16], ["infections", "DISEASE", 223, 233], ["intestinal", "ORGAN", 6, 16], ["pigs", "ORGANISM", 65, 69], ["F4", "GENE_OR_GENE_PRODUCT", 85, 87], ["F18", "GENE_OR_GENE_PRODUCT", 91, 94], ["pigs", "ORGANISM", 210, 214], ["ETEC", "ORGANISM", 218, 222], ["F4", "PROTEIN", 85, 87], ["F18 specific receptors", "PROTEIN", 91, 113], ["pigs", "SPECIES", 65, 69], ["pigs", "SPECIES", 210, 214], ["ETEC", "SPECIES", 57, 61], ["pigs", "SPECIES", 65, 69], ["pigs", "SPECIES", 210, 214], ["ETEC", "SPECIES", 218, 222], ["Small intestinal adhesion", "PROBLEM", 0, 25], ["subsequent colonization", "PROBLEM", 30, 53], ["ETEC in pigs", "TREATMENT", 57, 69], ["these receptors", "PROBLEM", 145, 160], ["ETEC infections", "PROBLEM", 218, 233], ["intestinal", "ANATOMY", 6, 16], ["adhesion", "OBSERVATION", 17, 25], ["colonization", "OBSERVATION_MODIFIER", 41, 53]]], ["The predominant serogroup of ETEC associated with PWD in pigs worldwide is O149, commonly in the combination O149: LT: STa: STb: EAST1: F4ac [2] .", [["ETEC", "DISEASE", 29, 33], ["ETEC", "ORGANISM", 29, 33], ["pigs", "ORGANISM", 57, 61], ["STa", "GENE_OR_GENE_PRODUCT", 119, 122], ["pigs", "SPECIES", 57, 61], ["ETEC", "SPECIES", 29, 33], ["pigs", "SPECIES", 57, 61], ["ETEC", "PROBLEM", 29, 33], ["EAST1", "TEST", 129, 134], ["F4ac", "TEST", 136, 140], ["predominant", "OBSERVATION_MODIFIER", 4, 15], ["serogroup", "OBSERVATION_MODIFIER", 16, 25], ["LT", "ANATOMY", 115, 117]]], ["Colistin, a polymyxin antibiotic produced by Paenibacillus polymyxa var colistinus [9] , is widely used for the control of PWD in pigs [10] .", [["Colistin", "CHEMICAL", 0, 8], ["polymyxin", "CHEMICAL", 12, 21], ["Paenibacillus polymyxa var colistinus [9]", "CHEMICAL", 45, 86], ["Colistin", "CHEMICAL", 0, 8], ["polymyxin", "CHEMICAL", 12, 21], ["Colistin", "SIMPLE_CHEMICAL", 0, 8], ["polymyxin", "SIMPLE_CHEMICAL", 12, 21], ["Paenibacillus polymyxa", "ORGANISM", 45, 67], ["var", "ORGANISM", 68, 71], ["colistinus", "ORGANISM", 72, 82], ["pigs", "ORGANISM", 130, 134], ["Paenibacillus", "SPECIES", 45, 58], ["polymyxa var colistinus", "SPECIES", 59, 82], ["pigs", "SPECIES", 130, 134], ["Paenibacillus polymyxa var colistinus", "SPECIES", 45, 82], ["Colistin", "TREATMENT", 0, 8], ["a polymyxin antibiotic", "TREATMENT", 10, 32]]], ["However, in humans this antibiotic is now considered as the last therapeutic option for the treatment of infections caused by multidrug-resistant Gram-negative bacteria (MDR-GNB) such as Pseudomonas aeruginosa, Acinetobacter baumannii, Klebsiella pneumoniae and Enterobacter species [11, 12] .BackgroundOn the other hand, in the last several years, studies have reported the isolation of colistin-resistant E. coli from pigs [13, 14] , the proportion reaching 35% in some countries [15] .", [["infections", "DISEASE", 105, 115], ["Pseudomonas aeruginosa", "DISEASE", 187, 209], ["colistin", "CHEMICAL", 388, 396], ["colistin", "CHEMICAL", 388, 396], ["humans", "ORGANISM", 12, 18], ["Gram-negative bacteria", "SIMPLE_CHEMICAL", 146, 168], ["MDR-GNB", "ORGANISM", 170, 177], ["Pseudomonas aeruginosa", "ORGANISM", 187, 209], ["Acinetobacter baumannii", "ORGANISM", 211, 234], ["Klebsiella pneumoniae", "ORGANISM", 236, 257], ["Enterobacter species", "ORGANISM", 262, 282], ["colistin", "SIMPLE_CHEMICAL", 388, 396], ["E. coli", "ORGANISM", 407, 414], ["pigs", "ORGANISM", 420, 424], ["humans", "SPECIES", 12, 18], ["Pseudomonas aeruginosa", "SPECIES", 187, 209], ["Acinetobacter baumannii", "SPECIES", 211, 234], ["Klebsiella pneumoniae", "SPECIES", 236, 257], ["E. coli", "SPECIES", 407, 414], ["pigs", "SPECIES", 420, 424], ["humans", "SPECIES", 12, 18], ["Pseudomonas aeruginosa", "SPECIES", 187, 209], ["Acinetobacter baumannii", "SPECIES", 211, 234], ["Klebsiella pneumoniae", "SPECIES", 236, 257], ["E. coli", "SPECIES", 407, 414], ["this antibiotic", "TREATMENT", 19, 34], ["infections", "PROBLEM", 105, 115], ["multidrug-resistant Gram-negative bacteria", "PROBLEM", 126, 168], ["MDR", "PROBLEM", 170, 173], ["GNB", "PROBLEM", 174, 177], ["Pseudomonas aeruginosa", "PROBLEM", 187, 209], ["Acinetobacter baumannii", "PROBLEM", 211, 234], ["Klebsiella pneumoniae", "PROBLEM", 236, 257], ["Enterobacter species", "PROBLEM", 262, 282], ["colistin", "PROBLEM", 388, 396], ["resistant E. coli", "PROBLEM", 397, 414], ["infections", "OBSERVATION", 105, 115], ["negative bacteria", "OBSERVATION", 151, 168], ["Klebsiella pneumoniae", "OBSERVATION", 236, 257], ["Enterobacter species", "OBSERVATION", 262, 282], ["hand", "ANATOMY", 316, 320], ["E. coli", "OBSERVATION", 407, 414]]], ["Until recently, resistance to colistin had only been associated with non-transferable genome mediated mutation.", [["colistin", "CHEMICAL", 30, 38], ["colistin", "CHEMICAL", 30, 38], ["colistin", "SIMPLE_CHEMICAL", 30, 38], ["colistin", "TREATMENT", 30, 38], ["non-transferable genome mediated mutation", "PROBLEM", 69, 110]]], ["However, in 2015, a stable plasmidmediated gene, mcr-1, encoding a phosphoethanolamine transferase conferring resistance to colistin was identified in certain GNB, such as E. coli and Salmonella, isolated from various origins including farm animals, raw meat and humans, in several countries [16] [17] [18] .", [["meat", "ANATOMY", 254, 258], ["phosphoethanolamine", "CHEMICAL", 67, 86], ["colistin", "CHEMICAL", 124, 132], ["phosphoethanolamine", "CHEMICAL", 67, 86], ["colistin", "CHEMICAL", 124, 132], ["mcr-1", "GENE_OR_GENE_PRODUCT", 49, 54], ["phosphoethanolamine transferase", "GENE_OR_GENE_PRODUCT", 67, 98], ["colistin", "SIMPLE_CHEMICAL", 124, 132], ["GNB", "CANCER", 159, 162], ["E. coli", "ORGANISM", 172, 179], ["Salmonella", "ORGANISM", 184, 194], ["meat", "ORGANISM_SUBDIVISION", 254, 258], ["humans", "ORGANISM", 263, 269], ["plasmidmediated gene", "DNA", 27, 47], ["mcr-1", "DNA", 49, 54], ["phosphoethanolamine transferase", "PROTEIN", 67, 98], ["E. coli", "SPECIES", 172, 179], ["meat", "SPECIES", 254, 258], ["humans", "SPECIES", 263, 269], ["E. coli", "SPECIES", 172, 179], ["humans", "SPECIES", 263, 269], ["mcr", "TEST", 49, 52], ["a phosphoethanolamine transferase", "TREATMENT", 65, 98], ["colistin", "TREATMENT", 124, 132], ["certain GNB", "PROBLEM", 151, 162], ["E. coli", "PROBLEM", 172, 179], ["Salmonella", "PROBLEM", 184, 194], ["E. coli", "OBSERVATION", 172, 179]]], ["The discovery of a mechanism for horizontal transfer of colistin resistance, and hence the potential for interspecies transfers, gave rise to a strong reaction in the scientific community regarding the potential reduction of colistin effectiveness in human medicine [19] .", [["colistin", "CHEMICAL", 56, 64], ["colistin", "CHEMICAL", 225, 233], ["colistin", "CHEMICAL", 56, 64], ["colistin", "CHEMICAL", 225, 233], ["colistin", "SIMPLE_CHEMICAL", 56, 64], ["colistin", "SIMPLE_CHEMICAL", 225, 233], ["human", "ORGANISM", 251, 256], ["human", "SPECIES", 251, 256], ["human", "SPECIES", 251, 256], ["horizontal transfer of colistin resistance", "TREATMENT", 33, 75], ["a strong reaction", "PROBLEM", 142, 159], ["colistin effectiveness in human medicine", "TREATMENT", 225, 265]]], ["Food producing animals, and in particular pigs, have been singled out as the most potential reservoirs for spread and amplification of colistin resistance [19] .", [["colistin", "CHEMICAL", 135, 143], ["colistin", "CHEMICAL", 135, 143], ["pigs", "ORGANISM", 42, 46], ["colistin", "SIMPLE_CHEMICAL", 135, 143], ["pigs", "SPECIES", 42, 46], ["pigs", "SPECIES", 42, 46], ["colistin resistance", "PROBLEM", 135, 154]]], ["Thus, scientists and regulatory agencies such as the European Medicine Agency (EMA) have recommended reducing the use of colistin in animal production and to restrict its use to the treatment of sick animals as a last resort option [20] .", [["colistin", "CHEMICAL", 121, 129], ["colistin", "CHEMICAL", 121, 129], ["colistin", "SIMPLE_CHEMICAL", 121, 129], ["colistin", "TREATMENT", 121, 129], ["sick animals", "TREATMENT", 195, 207], ["a last resort option", "TREATMENT", 211, 231]]], ["In addition, several studies have reported coexistence of the mcr-1 gene with genes encoding the production of extended-spectrum \u03b2-lactamase (ESBL) and carbapenemase enzymes [21] [22] [23] .", [["mcr-1", "GENE_OR_GENE_PRODUCT", 62, 67], ["extended-spectrum \u03b2-lactamase", "GENE_OR_GENE_PRODUCT", 111, 140], ["ESBL", "GENE_OR_GENE_PRODUCT", 142, 146], ["mcr-1 gene", "DNA", 62, 72], ["extended-spectrum \u03b2-lactamase", "PROTEIN", 111, 140], ["ESBL", "PROTEIN", 142, 146], ["carbapenemase enzymes", "PROTEIN", 152, 173], ["several studies", "TEST", 13, 28], ["the mcr", "TEST", 58, 65], ["ESBL", "TEST", 142, 146], ["carbapenemase enzymes", "TEST", 152, 173]]], ["This constitutes an additional degree of concern about the risk of spread of resistance against antimicrobials of very high importance in human medicine.", [["human", "ORGANISM", 138, 143], ["human", "SPECIES", 138, 143], ["human", "SPECIES", 138, 143], ["antimicrobials", "TREATMENT", 96, 110], ["human medicine", "TREATMENT", 138, 152]]], ["Furthermore, a high prevalence of ESBL-positive E. coli isolated from PWD piglets has been reported [24] .", [["ESBL-positive", "GENE_OR_GENE_PRODUCT", 34, 47], ["E. coli", "ORGANISM", 48, 55], ["PWD piglets", "ORGANISM", 70, 81], ["ESBL", "PROTEIN", 34, 38], ["E. coli", "SPECIES", 48, 55], ["piglets", "SPECIES", 74, 81], ["E. coli", "SPECIES", 48, 55], ["ESBL", "TEST", 34, 38], ["positive E. coli", "PROBLEM", 39, 55], ["PWD piglets", "TREATMENT", 70, 81], ["E. coli", "OBSERVATION_MODIFIER", 48, 55]]], ["Taken together, these findings underline the need to better understand PWD risk factors and to find alternatives to antimicrobials and particularly to colistin in pigs for the control of PWD in order to manage antimicrobial resistance and maintain at the same time livestock productivity.", [["colistin", "CHEMICAL", 151, 159], ["colistin", "CHEMICAL", 151, 159], ["colistin", "SIMPLE_CHEMICAL", 151, 159], ["pigs", "ORGANISM", 163, 167], ["pigs", "SPECIES", 163, 167], ["pigs", "SPECIES", 163, 167], ["PWD risk factors", "PROBLEM", 71, 87], ["antimicrobials", "TREATMENT", 116, 130], ["colistin", "TREATMENT", 151, 159], ["PWD", "TREATMENT", 187, 190], ["antimicrobial resistance", "TREATMENT", 210, 234], ["antimicrobial resistance", "OBSERVATION", 210, 234]]], ["Hence, the aim of the present review was to provide an overview of risk factors of PWD as well as an update of information on the extent of colistin use in PWD control worldwide in terms of quantities and microbiological outcomes.", [["colistin", "CHEMICAL", 140, 148], ["colistin", "CHEMICAL", 140, 148], ["colistin", "SIMPLE_CHEMICAL", 140, 148], ["colistin use", "TREATMENT", 140, 152], ["PWD control", "TREATMENT", 156, 167]]], ["In addition, alternative strategies to the use of colistin for the control of this disease are described and discussed.", [["colistin", "CHEMICAL", 50, 58], ["colistin", "CHEMICAL", 50, 58], ["colistin", "SIMPLE_CHEMICAL", 50, 58], ["colistin", "TREATMENT", 50, 58], ["this disease", "PROBLEM", 78, 90]]], ["Finally, a practical approach is proposed for the control of the PWD in its various phases.BackgroundThe prevalence of colistin resistance in pigs and the possible link between colistin pharmacokinetic/pharmacodynamic (PK/PD) and emergence of resistance in Enterobacteriaceae in swine, as well as the aspects that should be considered to ensure judicious use of colistin in swine production, have been investigated in our last two reviews [18, 25] .Search strategy and selection criteriaArticles published in peer-reviewed journals were searched in the international online databases PubMed, Web of Science, and Scopus.", [["colistin", "CHEMICAL", 119, 127], ["colistin", "CHEMICAL", 177, 185], ["colistin", "CHEMICAL", 362, 370], ["colistin", "CHEMICAL", 119, 127], ["colistin", "CHEMICAL", 177, 185], ["colistin", "CHEMICAL", 362, 370], ["colistin", "SIMPLE_CHEMICAL", 119, 127], ["pigs", "ORGANISM", 142, 146], ["colistin", "SIMPLE_CHEMICAL", 177, 185], ["colistin", "SIMPLE_CHEMICAL", 362, 370], ["pigs", "SPECIES", 142, 146], ["swine", "SPECIES", 279, 284], ["swine", "SPECIES", 374, 379], ["pigs", "SPECIES", 142, 146], ["swine", "SPECIES", 279, 284], ["swine", "SPECIES", 374, 379], ["a practical approach", "TREATMENT", 9, 29], ["colistin resistance in pigs", "TREATMENT", 119, 146], ["colistin pharmacokinetic", "TREATMENT", 177, 201], ["pharmacodynamic (PK/PD", "TREATMENT", 202, 224], ["resistance", "PROBLEM", 243, 253], ["Enterobacteriaceae", "PROBLEM", 257, 275], ["colistin", "TREATMENT", 362, 370], ["Search strategy", "TREATMENT", 449, 464], ["colistin resistance", "OBSERVATION", 119, 138], ["Enterobacteriaceae", "OBSERVATION", 257, 275]]], ["The studies were selected based on language (English or French) and accessibility to the full manuscript version.", [["The studies", "TEST", 0, 11]]], ["Relevant scientific papers were identified using the keyword combinations (piglet OR swine OR pig OR weaned OR sows AND (post-weaning diarrhea), (postweaning), (E. coli), (colistin), (colistin resistance), (colistin use), (colistin indications), AND (pig OR swine OR weaned pigs OR antibiotics in pigs OR colistin in pigs OR E. coli in pigs OR post-weaning diarrhea OR weanling diet in pigs AND (feed strategies) OR (alternatives measures) OR (alternatives to antibiotics) OR (preventive strategies) OR (additives).", [["diarrhea", "DISEASE", 134, 142], ["colistin", "CHEMICAL", 172, 180], ["colistin", "CHEMICAL", 184, 192], ["colistin", "CHEMICAL", 207, 215], ["colistin", "CHEMICAL", 223, 231], ["colistin", "CHEMICAL", 305, 313], ["diarrhea", "DISEASE", 357, 365], ["colistin", "CHEMICAL", 172, 180], ["colistin", "CHEMICAL", 184, 192], ["colistin", "CHEMICAL", 207, 215], ["colistin", "CHEMICAL", 223, 231], ["colistin", "CHEMICAL", 305, 313], ["piglet", "ORGANISM", 75, 81], ["pig", "ORGANISM", 94, 97], ["E. coli", "ORGANISM", 161, 168], ["colistin", "SIMPLE_CHEMICAL", 172, 180], ["colistin", "SIMPLE_CHEMICAL", 184, 192], ["colistin", "SIMPLE_CHEMICAL", 207, 215], ["colistin", "SIMPLE_CHEMICAL", 223, 231], ["pig", "ORGANISM", 251, 254], ["pigs", "ORGANISM", 274, 278], ["pigs", "ORGANISM", 297, 301], ["colistin", "SIMPLE_CHEMICAL", 305, 313], ["pigs", "ORGANISM", 317, 321], ["E. coli", "ORGANISM", 325, 332], ["pigs", "ORGANISM", 336, 340], ["swine", "SPECIES", 85, 90], ["pig", "SPECIES", 94, 97], ["E. coli", "SPECIES", 161, 168], ["pig", "SPECIES", 251, 254], ["swine", "SPECIES", 258, 263], ["pigs", "SPECIES", 274, 278], ["pigs", "SPECIES", 297, 301], ["pigs", "SPECIES", 317, 321], ["E. coli", "SPECIES", 325, 332], ["pigs", "SPECIES", 336, 340], ["weanling", "SPECIES", 369, 377], ["pigs", "SPECIES", 386, 390], ["pig", "SPECIES", 94, 97], ["E. coli", "SPECIES", 161, 168], ["pig", "SPECIES", 251, 254], ["swine", "SPECIES", 258, 263], ["pigs", "SPECIES", 274, 278], ["pigs", "SPECIES", 297, 301], ["pigs", "SPECIES", 317, 321], ["E. coli", "SPECIES", 325, 332], ["pigs", "SPECIES", 336, 340], ["pigs", "SPECIES", 386, 390], ["diarrhea", "PROBLEM", 134, 142], ["E. coli)", "PROBLEM", 161, 169], ["colistin", "TREATMENT", 172, 180], ["colistin resistance", "TREATMENT", 184, 203], ["colistin indications", "TREATMENT", 223, 243], ["antibiotics", "TREATMENT", 282, 293], ["colistin", "TREATMENT", 305, 313], ["E. coli in pigs", "TREATMENT", 325, 340], ["diarrhea", "PROBLEM", 357, 365], ["weanling diet in pigs AND (feed strategies", "TREATMENT", 369, 411], ["alternatives measures)", "TREATMENT", 417, 439], ["antibiotics)", "TREATMENT", 460, 472]]], ["After applying the inclusion and exclusion criteria, 271 citations were considered potentially eligible for inclusion in this review.Risk factors for post-weaning diarrhea in pigsPost-weaning diarrhea is an economically important enteric disease in pigs due to financial losses [1] .", [["diarrhea", "DISEASE", 163, 171], ["diarrhea", "DISEASE", 192, 200], ["enteric disease", "DISEASE", 230, 245], ["pigs", "ORGANISM", 175, 179], ["pigs", "ORGANISM", 249, 253], ["pigs", "SPECIES", 175, 179], ["pigs", "SPECIES", 249, 253], ["pigs", "SPECIES", 175, 179], ["pigs", "SPECIES", 249, 253], ["exclusion criteria", "TEST", 33, 51], ["Risk factors", "PROBLEM", 133, 145], ["diarrhea", "PROBLEM", 163, 171], ["diarrhea", "PROBLEM", 192, 200], ["enteric disease", "PROBLEM", 230, 245], ["financial losses", "PROBLEM", 261, 277]]], ["This disease occurs most frequently within the 2 weeks after weaning and is characterized by a profuse diarrhea, dehydration, significant mortality and loss of body weight of surviving pigs [2] .", [["body", "ANATOMY", 160, 164], ["diarrhea", "DISEASE", 103, 111], ["dehydration", "DISEASE", 113, 124], ["body", "ORGANISM_SUBDIVISION", 160, 164], ["pigs", "ORGANISM", 185, 189], ["pigs", "SPECIES", 185, 189], ["This disease", "PROBLEM", 0, 12], ["a profuse diarrhea", "PROBLEM", 93, 111], ["dehydration", "PROBLEM", 113, 124], ["significant mortality", "PROBLEM", 126, 147], ["loss of body weight", "PROBLEM", 152, 171], ["disease", "OBSERVATION", 5, 12], ["profuse", "OBSERVATION_MODIFIER", 95, 102], ["diarrhea", "OBSERVATION", 103, 111], ["significant", "OBSERVATION_MODIFIER", 126, 137], ["mortality", "OBSERVATION", 138, 147]]], ["Mortality associated with this disease may reach 20-30% over a 1-to 2-month time span among infected weaned pigs during acute outbreaks of PWD [1] .Risk factors for post-weaning diarrhea in pigsPWD is a multifactorial disease where the exact cause has not yet been identified [26] (Fig. 1) .", [["diarrhea", "DISEASE", 178, 186], ["pigsPWD", "DISEASE", 190, 197], ["pigs", "ORGANISM", 108, 112], ["pigs", "SPECIES", 108, 112], ["pigs", "SPECIES", 108, 112], ["this disease", "PROBLEM", 26, 38], ["Risk factors", "PROBLEM", 148, 160], ["weaning diarrhea", "PROBLEM", 170, 186], ["a multifactorial disease", "PROBLEM", 201, 225], ["multifactorial", "OBSERVATION_MODIFIER", 203, 217], ["disease", "OBSERVATION", 218, 225]]], ["The occurrence of PWD in pigs involves interactions between the sow, piglet, environment, ETEC bacteria and livestock management [27] .Predisposing factorsPost-weaning diarrhea is usually associated with the proliferation of one or more strains of \u03b2-hemolytic ETEC in the small intestine of pigs, in particular those that express fimbrial adhesins F4 (K88) or F18 [2] .", [["piglet", "ANATOMY", 69, 75], ["small intestine", "ANATOMY", 272, 287], ["diarrhea", "DISEASE", 168, 176], ["pigs", "ORGANISM", 25, 29], ["sow", "ORGANISM_SUBDIVISION", 64, 67], ["piglet", "ORGANISM_SUBDIVISION", 69, 75], ["\u03b2-hemolytic ETEC", "GENE_OR_GENE_PRODUCT", 248, 264], ["small intestine", "ORGAN", 272, 287], ["pigs", "ORGANISM", 291, 295], ["fimbrial adhesins F4", "GENE_OR_GENE_PRODUCT", 330, 350], ["fimbrial adhesins", "PROTEIN", 330, 347], ["F4", "PROTEIN", 348, 350], ["K88", "PROTEIN", 352, 355], ["F18", "PROTEIN", 360, 363], ["pigs", "SPECIES", 25, 29], ["sow", "SPECIES", 64, 67], ["piglet", "SPECIES", 69, 75], ["pigs", "SPECIES", 291, 295], ["pigs", "SPECIES", 25, 29], ["pigs", "SPECIES", 291, 295], ["PWD in pigs", "TREATMENT", 18, 29], ["ETEC bacteria", "PROBLEM", 90, 103], ["livestock management", "TREATMENT", 108, 128], ["Predisposing factors", "PROBLEM", 135, 155], ["weaning diarrhea", "PROBLEM", 160, 176], ["\u03b2-hemolytic ETEC", "PROBLEM", 248, 264], ["small intestine", "ANATOMY", 272, 287]]], ["Thus, small intestinal epithelial cell adhesion and subsequent colonization by ETEC is mediated by F4-or F18-specific receptors (F4R or F18R), the existence and function of which are crucial in determining the susceptibility of pigs to ETEC infection [2, 7] .", [["intestinal epithelial cell", "ANATOMY", 12, 38], ["ETEC infection", "DISEASE", 236, 250], ["intestinal epithelial cell", "CELL", 12, 38], ["ETEC", "GENE_OR_GENE_PRODUCT", 79, 83], ["F4", "GENE_OR_GENE_PRODUCT", 99, 101], ["F18", "GENE_OR_GENE_PRODUCT", 105, 108], ["F4R", "GENE_OR_GENE_PRODUCT", 129, 132], ["F18R", "GENE_OR_GENE_PRODUCT", 136, 140], ["pigs", "ORGANISM", 228, 232], ["ETEC", "ORGANISM", 236, 240], ["F4", "PROTEIN", 99, 101], ["F18", "PROTEIN", 105, 108], ["specific receptors", "PROTEIN", 109, 127], ["F4R", "PROTEIN", 129, 132], ["F18R", "PROTEIN", 136, 140], ["pigs", "SPECIES", 228, 232], ["pigs", "SPECIES", 228, 232], ["ETEC", "SPECIES", 236, 240], ["small intestinal epithelial cell adhesion", "PROBLEM", 6, 47], ["subsequent colonization", "PROBLEM", 52, 75], ["ETEC", "PROBLEM", 79, 83], ["ETEC infection", "PROBLEM", 236, 250], ["small", "OBSERVATION_MODIFIER", 6, 11], ["intestinal", "ANATOMY", 12, 22], ["epithelial cell adhesion", "OBSERVATION", 23, 47], ["colonization", "OBSERVATION_MODIFIER", 63, 75], ["infection", "OBSERVATION", 241, 250]]], ["The genetic predisposition of the pig is primordial for the development of PWD [28] .Predisposing factorsIn addition, conditions related to pregnancy and parturition of the sow such as litter size, parity, and postpartum dysgalactia syndrome are significant in the predisposition of piglets to microbial infection [27, 29] .", [["postpartum dysgalactia syndrome", "DISEASE", 210, 241], ["microbial infection", "DISEASE", 294, 313], ["pig", "ORGANISM", 34, 37], ["sow", "ORGANISM_SUBDIVISION", 173, 176], ["litter", "ORGANISM_SUBDIVISION", 185, 191], ["piglets", "ORGANISM", 283, 290], ["Predisposing factors", "PROTEIN", 85, 105], ["pig", "SPECIES", 34, 37], ["sow", "SPECIES", 173, 176], ["pig", "SPECIES", 34, 37], ["PWD", "PROBLEM", 75, 78], ["Predisposing factors", "PROBLEM", 85, 105], ["pregnancy", "PROBLEM", 140, 149], ["postpartum dysgalactia syndrome", "PROBLEM", 210, 241], ["microbial infection", "PROBLEM", 294, 313], ["size", "OBSERVATION_MODIFIER", 192, 196], ["significant", "OBSERVATION_MODIFIER", 246, 257]]], ["The sow placenta is not permeable to maternal immunoglobulin transport and therefore newborn piglets acquire maternal immunoglobulin from colostrum during the first 24-48 h of life [5] .", [["placenta", "ANATOMY", 8, 16], ["colostrum", "ANATOMY", 138, 147], ["sow placenta", "ORGAN", 4, 16], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 46, 60], ["piglets", "ORGANISM", 93, 100], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 118, 132], ["colostrum", "ORGANISM_SUBSTANCE", 138, 147], ["immunoglobulin", "PROTEIN", 46, 60], ["maternal immunoglobulin", "PROTEIN", 109, 132], ["piglets", "SPECIES", 93, 100], ["maternal immunoglobulin transport", "TREATMENT", 37, 70], ["newborn piglets acquire maternal immunoglobulin", "TREATMENT", 85, 132]]], ["Moreover, the post-weaning period is a critical phase in the pig's life when the intestinal immune system is immature, and the sow milk removal, and consequent discontinuation of nutritive intake of the IgA present in this milk, contributes to increase susceptibility of pigs to microbial infections [31] .", [["intestinal immune system", "ANATOMY", 81, 105], ["milk", "ANATOMY", 131, 135], ["milk", "ANATOMY", 223, 227], ["infections", "DISEASE", 289, 299], ["pig", "ORGANISM", 61, 64], ["intestinal", "ORGAN", 81, 91], ["milk", "ORGANISM_SUBDIVISION", 131, 135], ["IgA", "GENE_OR_GENE_PRODUCT", 203, 206], ["milk", "ORGANISM_SUBSTANCE", 223, 227], ["pigs", "ORGANISM", 271, 275], ["IgA", "PROTEIN", 203, 206], ["pig", "SPECIES", 61, 64], ["pigs", "SPECIES", 271, 275], ["pig", "SPECIES", 61, 64], ["pigs", "SPECIES", 271, 275], ["the pig's life", "TREATMENT", 57, 71], ["the sow milk removal", "TREATMENT", 123, 143], ["microbial infections", "PROBLEM", 279, 299], ["intestinal immune", "ANATOMY", 81, 98]]], ["Indeed, unlike other food animals, the sow's milk is particularly rich in IgA compared to colostrum [32] .", [["milk", "ANATOMY", 45, 49], ["milk", "ORGANISM_SUBSTANCE", 45, 49], ["IgA", "GENE_OR_GENE_PRODUCT", 74, 77], ["colostrum", "ORGANISM_SUBSTANCE", 90, 99], ["IgA", "PROTEIN", 74, 77], ["the sow's milk", "TREATMENT", 35, 49]]], ["Studies investigating the profitability of weaning pigs at an early age, before 21 days, have further encouraged moving away from this practice to weaning pigs no earlier than 26 days of age to reduce the occurrence of PWD [30, 33] .", [["pigs", "ORGANISM", 51, 55], ["pigs", "ORGANISM", 155, 159], ["pigs", "SPECIES", 51, 55], ["pigs", "SPECIES", 155, 159], ["pigs", "SPECIES", 51, 55], ["pigs", "SPECIES", 155, 159], ["weaning pigs", "TREATMENT", 43, 55]]], ["In the European Union (EU), many pig producers wean piglets at 21 days of age.", [["pig", "ORGANISM", 33, 36], ["piglets", "ORGANISM", 52, 59], ["pig", "SPECIES", 33, 36], ["piglets", "SPECIES", 52, 59], ["pig", "SPECIES", 33, 36], ["many pig producers", "TREATMENT", 28, 46]]], ["However welfare legislation encourages weaning no earlier than 28 days of age in the absence of cleaned housing sections to ensure that healthy pigs are transferred into nursery accommodation [34] .", [["pigs", "ORGANISM", 144, 148], ["pigs", "SPECIES", 144, 148], ["pigs", "SPECIES", 144, 148], ["welfare legislation", "TREATMENT", 8, 27]]], ["Moreover, studies suggest that increasing weaning age reduces stress associated with this period and allows pigs to have a more mature gastrointestinal tract and become increasingly familiar with solid feed during lactation with an improvement in growth performance and in immune response [34, 35] .Predisposing factorsFeed intake is usually reduced initially after weaning and the pig may develop anorexia of variable duration and extent between farms, depending on livestock management and the nature of the feed [36] .", [["gastrointestinal tract", "ANATOMY", 135, 157], ["anorexia", "DISEASE", 398, 406], ["pigs", "ORGANISM", 108, 112], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 135, 157], ["pig", "ORGANISM", 382, 385], ["Predisposing factors", "PROTEIN", 299, 319], ["pigs", "SPECIES", 108, 112], ["pig", "SPECIES", 382, 385], ["pigs", "SPECIES", 108, 112], ["pig", "SPECIES", 382, 385], ["studies", "TEST", 10, 17], ["a more mature gastrointestinal tract", "PROBLEM", 121, 157], ["Predisposing factors", "PROBLEM", 299, 319], ["anorexia", "PROBLEM", 398, 406], ["livestock management", "TREATMENT", 467, 487], ["increasing", "OBSERVATION_MODIFIER", 31, 41], ["gastrointestinal tract", "ANATOMY", 135, 157], ["reduced", "OBSERVATION_MODIFIER", 342, 349], ["anorexia", "OBSERVATION", 398, 406]]], ["Madec et al. [30] reported that the low feed intake over the first week after weaning is strongly correlated with the risk of disease occurrence over the post-weaning period.", [["disease occurrence", "PROBLEM", 126, 144], ["the post-weaning period", "TREATMENT", 150, 173], ["disease", "OBSERVATION", 126, 133]]], ["Underfeeding during weaning reduces growth performance of pigs, and contributes to intestinal inflammation and adversely affects villous height and crypt depth [3] .", [["intestinal", "ANATOMY", 83, 93], ["villous", "ANATOMY", 129, 136], ["crypt", "ANATOMY", 148, 153], ["inflammation", "DISEASE", 94, 106], ["pigs", "ORGANISM", 58, 62], ["intestinal", "ORGAN", 83, 93], ["villous", "TISSUE", 129, 136], ["crypt", "TISSUE", 148, 153], ["pigs", "SPECIES", 58, 62], ["pigs", "SPECIES", 58, 62], ["intestinal inflammation", "PROBLEM", 83, 106], ["crypt depth", "PROBLEM", 148, 159], ["intestinal", "ANATOMY", 83, 93], ["inflammation", "OBSERVATION", 94, 106], ["crypt depth", "OBSERVATION", 148, 159]]], ["This morphological disruption of the intestinal mucosa promotes the creation of an ideal environment for the multiplication of bacteria such as E. coli and allows toxins and bacteria to cross the epithelium as a result of this inflammation [37] (Fig. 2) .Contributing factorsHousing factors, population density, parity segregated production and the feeding regimen after weaning play a role in the development of PWD [38] .", [["intestinal mucosa", "ANATOMY", 37, 54], ["epithelium", "ANATOMY", 196, 206], ["inflammation", "DISEASE", 227, 239], ["intestinal mucosa", "MULTI-TISSUE_STRUCTURE", 37, 54], ["E. coli", "ORGANISM", 144, 151], ["epithelium", "TISSUE", 196, 206], ["E. coli", "SPECIES", 144, 151], ["E. coli", "SPECIES", 144, 151], ["This morphological disruption of the intestinal mucosa", "PROBLEM", 0, 54], ["bacteria", "PROBLEM", 127, 135], ["E. coli", "PROBLEM", 144, 151], ["toxins", "PROBLEM", 163, 169], ["bacteria", "PROBLEM", 174, 182], ["this inflammation", "PROBLEM", 222, 239], ["population density", "PROBLEM", 292, 310], ["parity segregated production", "PROBLEM", 312, 340], ["the feeding regimen", "TREATMENT", 345, 364], ["disruption", "OBSERVATION", 19, 29], ["intestinal mucosa", "ANATOMY", 37, 54], ["population", "OBSERVATION_MODIFIER", 292, 302], ["density", "OBSERVATION", 303, 310]]], ["It is beyond the scope of this review to discuss in detail all the ideal conditions for pig housing during the post-weaning period, but to highlight the most important, as reviewed by Le Dividich and Herpin [39] , it is essential to provide the correct environmental temperature, 26-28 \u00b0C, to maintain pigs in their thermo-neutral zone.", [["pig", "ORGANISM", 88, 91], ["pigs", "ORGANISM", 302, 306], ["pigs", "SPECIES", 302, 306], ["pig", "SPECIES", 88, 91], ["pig housing", "TREATMENT", 88, 99]]], ["Chilling reduces intestinal peristaltic activity and consequently increases bacterial colonization, and low temperatures in weaner facilities appears to be responsible for a more severe course of PWD [40] .", [["intestinal", "ANATOMY", 17, 27], ["intestinal", "ORGAN", 17, 27], ["Chilling", "PROBLEM", 0, 8], ["intestinal peristaltic activity", "PROBLEM", 17, 48], ["bacterial colonization", "PROBLEM", 76, 98], ["low temperatures in weaner facilities", "PROBLEM", 104, 141], ["PWD", "PROBLEM", 196, 199], ["intestinal", "ANATOMY", 17, 27], ["peristaltic activity", "OBSERVATION", 28, 48], ["increases", "OBSERVATION_MODIFIER", 66, 75], ["bacterial", "OBSERVATION_MODIFIER", 76, 85], ["colonization", "OBSERVATION", 86, 98], ["low temperatures", "OBSERVATION_MODIFIER", 104, 120]]], ["Also, it has been shown that automatic temperature control in the weaners housing reduces considerably the prevalence of PWD [38] .", [["automatic temperature control", "TREATMENT", 29, 58], ["automatic", "OBSERVATION_MODIFIER", 29, 38], ["temperature", "OBSERVATION_MODIFIER", 39, 50]]], ["Wathes and Whittemore [41] reviewed several recommendations to prevent pig diseases by appropriate housing and environmental management.", [["pig diseases", "DISEASE", 71, 83], ["pig", "ORGANISM", 71, 74], ["pig", "SPECIES", 71, 74], ["pig", "SPECIES", 71, 74], ["pig diseases", "PROBLEM", 71, 83], ["environmental management", "TREATMENT", 111, 135]]], ["These approaches involve avoiding drafts while removing moisture and gases using adequate ventilation.", [["moisture and gases", "TREATMENT", 56, 74], ["adequate ventilation", "TREATMENT", 81, 101]]], ["Most often, flat decks are used instead of soiled bedding for weaned piglets; however it was reported that this practice is accompanied by more tail and belly lesions among pigs [42] .", [["tail", "ANATOMY", 144, 148], ["belly lesions", "ANATOMY", 153, 166], ["piglets", "ORGANISM", 69, 76], ["tail", "ORGANISM_SUBDIVISION", 144, 148], ["belly lesions", "PATHOLOGICAL_FORMATION", 153, 166], ["piglets", "SPECIES", 69, 76], ["pigs", "SPECIES", 173, 177], ["soiled bedding", "TREATMENT", 43, 57], ["more tail and belly lesions", "PROBLEM", 139, 166], ["belly", "ANATOMY", 153, 158], ["lesions", "OBSERVATION", 159, 166]]], ["Moreover, the removal of manure and soiled bedding on a regular basis is also important to reduce the microbial load on farms.Contributing factorsA contradiction was found in the scientific literature concerning the impact of herd size on the prevalence of PWD in pigs.", [["herd", "ORGANISM_SUBDIVISION", 226, 230], ["pigs", "ORGANISM", 264, 268], ["pigs", "SPECIES", 264, 268], ["pigs", "SPECIES", 264, 268], ["the removal of manure", "TREATMENT", 10, 31], ["soiled bedding", "TREATMENT", 36, 50], ["PWD in pigs", "TREATMENT", 257, 268], ["size", "OBSERVATION_MODIFIER", 231, 235]]], ["Indeed, Laine and collaborators reported that in Finland, the increase in pig's herd size was associated with a higher risk of PWD in pigs [38] .", [["pig", "ORGANISM", 74, 77], ["herd", "ORGANISM_SUBDIVISION", 80, 84], ["pigs", "ORGANISM", 134, 138], ["pig", "SPECIES", 74, 77], ["pigs", "SPECIES", 134, 138], ["pig", "SPECIES", 74, 77], ["pigs", "SPECIES", 134, 138], ["pig's herd size", "TREATMENT", 74, 89], ["increase", "OBSERVATION_MODIFIER", 62, 70], ["size", "OBSERVATION_MODIFIER", 85, 89]]], ["While, in Canada, Amezuca et al. [43] reported that PWD occurred on a variety of farm types and sizes.", [["sizes", "OBSERVATION_MODIFIER", 96, 101]]], ["However, a link between stocking density and PWD was described in pig's farms in some countries [30, 44] .", [["pig", "ORGANISM", 66, 69], ["pig", "SPECIES", 66, 69], ["pig", "SPECIES", 66, 69], ["a link between stocking density", "PROBLEM", 9, 40], ["PWD", "PROBLEM", 45, 48], ["density", "OBSERVATION", 33, 40]]], ["Mixing piglets from different farms is a common practice in pig husbandry, particularly at weaning.", [["piglets", "ORGANISM", 7, 14], ["pig", "ORGANISM", 60, 63], ["piglets", "SPECIES", 7, 14], ["pig", "SPECIES", 60, 63], ["pig", "SPECIES", 60, 63], ["pig husbandry", "TREATMENT", 60, 73]]], ["This mixing can result in fighting as the pigs strive to establish dominance relationships, with most aggressive interactions being typically shown during the first few hours after grouping [45] .", [["pigs", "ORGANISM", 42, 46], ["pigs", "SPECIES", 42, 46], ["pigs", "SPECIES", 42, 46]]], ["It has been reported that the hierarchical behaviour among pigs leads to very significant differences in food and water consumption on farms [46] .", [["pigs", "ORGANISM", 59, 63], ["water", "SIMPLE_CHEMICAL", 114, 119], ["pigs", "SPECIES", 59, 63]]], ["Production based on segregated sow parities was proposed as a solution to reduce the impact of the social hierarchy.", [["a solution", "TREATMENT", 60, 70], ["social hierarchy", "OBSERVATION", 99, 115]]], ["This system of grouping according to the sow's farrowing rank reduces disease challenge by reducing variation in the immune status of the piglets [47] .Contributing factorsIt was shown that the prevalence of PWD was higher on farms that fed weaned piglets only twice a day with a restricted amount of feed than on farms that provided more than two meals per day with or without feed restriction [38] .", [["piglets", "ORGANISM", 138, 145], ["piglets", "ORGANISM", 248, 255], ["piglets", "SPECIES", 138, 145], ["piglets", "SPECIES", 248, 255], ["disease challenge", "PROBLEM", 70, 87], ["Contributing factors", "PROBLEM", 152, 172], ["PWD", "PROBLEM", 208, 211], ["higher", "OBSERVATION_MODIFIER", 216, 222]]], ["In addition, Amezuca et al. [43] reported that the occurrence of PWD was greater with pelleted feed and inadequate feeder space per piglet in the pen.Contributing factorsA previously mentioned, PWD is a complex disease that may result from interaction between several infectious agents.", [["feeder space", "ANATOMY", 115, 127], ["piglet", "ANATOMY", 132, 138], ["piglet", "ORGANISM_SUBDIVISION", 132, 138], ["pelleted feed", "TREATMENT", 86, 99], ["inadequate feeder space", "PROBLEM", 104, 127], ["a complex disease", "PROBLEM", 201, 218], ["several infectious agents", "TREATMENT", 260, 285], ["feeder space", "OBSERVATION", 115, 127], ["complex", "OBSERVATION_MODIFIER", 203, 210], ["disease", "OBSERVATION", 211, 218], ["infectious", "OBSERVATION", 268, 278]]], ["However, most epidemiological studies have focussed on monitoring the effect of only one pathogen in the occurrence of this disease, and there is inadequate information concerning other relevant enteric pathogens such as viruses and parasites.", [["epidemiological studies", "TEST", 14, 37], ["this disease", "PROBLEM", 119, 131], ["relevant enteric pathogens", "PROBLEM", 186, 212], ["parasites", "PROBLEM", 233, 242], ["disease", "OBSERVATION", 124, 131]]], ["Some investigations of mixed infections in PWD showed that rotavirus was considered to be an important enteric pathogen in weaned piglets with a prevalence of 77.5%, followed by E. coli, coccidia, sapovirus and Cryptosporidium parvum with prevalence of 55, 10, 2.5 and 2.5% respectively [48] .", [["infections", "DISEASE", 29, 39], ["Cryptosporidium parvum", "DISEASE", 211, 233], ["rotavirus", "ORGANISM", 59, 68], ["piglets", "ORGANISM", 130, 137], ["E. coli", "ORGANISM", 178, 185], ["coccidia", "ORGANISM", 187, 195], ["Cryptosporidium parvum", "ORGANISM", 211, 233], ["piglets", "SPECIES", 130, 137], ["E. coli", "SPECIES", 178, 185], ["Cryptosporidium parvum", "SPECIES", 211, 233], ["rotavirus", "SPECIES", 59, 68], ["E. coli", "SPECIES", 178, 185], ["Cryptosporidium parvum", "SPECIES", 211, 233], ["mixed infections in PWD", "PROBLEM", 23, 46], ["rotavirus", "PROBLEM", 59, 68], ["an important enteric pathogen", "PROBLEM", 90, 119], ["E. coli", "PROBLEM", 178, 185], ["coccidia", "PROBLEM", 187, 195], ["sapovirus", "PROBLEM", 197, 206], ["Cryptosporidium parvum", "PROBLEM", 211, 233], ["prevalence", "TEST", 239, 249], ["mixed", "OBSERVATION_MODIFIER", 23, 28], ["infections", "OBSERVATION", 29, 39], ["Cryptosporidium parvum", "OBSERVATION", 211, 233]]], ["In addition, infection by the porcine reproductive and respiratory syndrome virus (PRRSv) results in an impairment of the immune response of piglets, permitting ETEC to cause a septicemia leading to death [49] .", [["infection", "DISEASE", 13, 22], ["porcine reproductive and respiratory syndrome", "DISEASE", 30, 75], ["ETEC", "CHEMICAL", 161, 165], ["septicemia", "DISEASE", 177, 187], ["death", "DISEASE", 199, 204], ["porcine reproductive and respiratory syndrome virus", "ORGANISM", 30, 81], ["PRRSv", "CANCER", 83, 88], ["piglets", "ORGANISM", 141, 148], ["porcine", "SPECIES", 30, 37], ["piglets", "SPECIES", 141, 148], ["ETEC", "SPECIES", 161, 165], ["infection", "PROBLEM", 13, 22], ["the porcine reproductive", "PROBLEM", 26, 50], ["respiratory syndrome virus", "PROBLEM", 55, 81], ["a septicemia", "PROBLEM", 175, 187], ["death", "PROBLEM", 199, 204], ["infection", "OBSERVATION", 13, 22], ["respiratory syndrome", "OBSERVATION", 55, 75], ["septicemia", "OBSERVATION", 177, 187]]], ["However, these data were reported more than 10 years ago and are unlikely to reflect the current epidemiologic situation.Determining factorsETEC is the most common cause of PWD in pigs.", [["factorsETEC", "GENE_OR_GENE_PRODUCT", 133, 144], ["pigs", "ORGANISM", 180, 184], ["pigs", "SPECIES", 180, 184], ["pigs", "SPECIES", 180, 184], ["unlikely to reflect", "UNCERTAINTY", 65, 84]]], ["This pathotype is characterized by the production of enterotoxins and adhesins, both essential for disease development.", [["enterotoxins", "PROTEIN", 53, 65], ["adhesins", "PROTEIN", 70, 78], ["This pathotype", "PROBLEM", 0, 14], ["enterotoxins", "PROBLEM", 53, 65], ["adhesins", "PROBLEM", 70, 78], ["disease development", "PROBLEM", 99, 118], ["enterotoxins", "OBSERVATION", 53, 65]]], ["Enterotoxins produced by ETEC may be heat stable [STa, STb, or enteroaggregative E. coli heat stable enterotoxin 1 (EAST1)] or heat labile (LT) [2] .", [["Enterotoxins", "CHEMICAL", 0, 12], ["ETEC", "CHEMICAL", 25, 29], ["Enterotoxins", "SIMPLE_CHEMICAL", 0, 12], ["ETEC", "ORGANISM", 25, 29], ["STa", "SIMPLE_CHEMICAL", 50, 53], ["STb", "SIMPLE_CHEMICAL", 55, 58], ["E. coli", "ORGANISM", 81, 88], ["heat stable enterotoxin 1", "GENE_OR_GENE_PRODUCT", 89, 114], ["E. coli", "SPECIES", 81, 88], ["E. coli", "SPECIES", 81, 88], ["Enterotoxins", "PROBLEM", 0, 12], ["STb", "PROBLEM", 55, 58], ["enteroaggregative E. coli heat", "PROBLEM", 63, 93], ["enterotoxin", "PROBLEM", 101, 112], ["heat labile (LT)", "TREATMENT", 127, 143], ["stable", "OBSERVATION", 42, 48]]], ["Enterotoxin genes are on plasmids of ETEC bacteria and act on the intestinal epithelium of pigs [7] .Determining factorsIn pigs, the most frequently found fimbrial adhesins of ETEC are K88 (F4), K99 (F5), 987P (F6), F41, and F18 [40] .", [["intestinal epithelium", "ANATOMY", 66, 87], ["Enterotoxin", "GENE_OR_GENE_PRODUCT", 0, 11], ["ETEC bacteria", "GENE_OR_GENE_PRODUCT", 37, 50], ["intestinal epithelium", "TISSUE", 66, 87], ["pigs", "ORGANISM", 91, 95], ["pigs", "ORGANISM", 123, 127], ["fimbrial adhesins", "GENE_OR_GENE_PRODUCT", 155, 172], ["ETEC", "GENE_OR_GENE_PRODUCT", 176, 180], ["K88", "GENE_OR_GENE_PRODUCT", 185, 188], ["Enterotoxin genes", "DNA", 0, 17], ["plasmids", "DNA", 25, 33], ["fimbrial adhesins", "PROTEIN", 155, 172], ["ETEC", "PROTEIN", 176, 180], ["K88", "PROTEIN", 185, 188], ["F4", "PROTEIN", 190, 192], ["F5", "PROTEIN", 200, 202], ["F6", "PROTEIN", 211, 213], ["F41", "PROTEIN", 216, 219], ["pigs", "SPECIES", 91, 95], ["pigs", "SPECIES", 123, 127], ["ETEC", "SPECIES", 37, 41], ["pigs", "SPECIES", 123, 127], ["Enterotoxin genes", "PROBLEM", 0, 17], ["ETEC bacteria", "PROBLEM", 37, 50], ["K99", "TEST", 195, 198], ["F41", "TEST", 216, 219], ["intestinal epithelium", "ANATOMY", 66, 87]]], ["F4-positive and F18 ETEC (ETEC: F4 and ETEC: F18) strains represent the major cause of PWD in pigs.", [["F4", "GENE_OR_GENE_PRODUCT", 0, 2], ["F18 ETEC", "GENE_OR_GENE_PRODUCT", 16, 24], ["ETEC: F4", "GENE_OR_GENE_PRODUCT", 26, 34], ["ETEC: F18)", "GENE_OR_GENE_PRODUCT", 39, 49], ["pigs", "ORGANISM", 94, 98], ["F4", "PROTEIN", 0, 2], ["pigs", "SPECIES", 94, 98], ["pigs", "SPECIES", 94, 98], ["ETEC", "PROBLEM", 39, 43], ["strains", "PROBLEM", 50, 57]]], ["F4 are flexible fimbriae that occur as the F4ab, F4ac, or F4ad variant, the F4ac variant being by far the most important type encountered in PWD [50] .", [["F4", "GENE_OR_GENE_PRODUCT", 0, 2], ["fimbriae", "GENE_OR_GENE_PRODUCT", 16, 24], ["F4ab", "GENE_OR_GENE_PRODUCT", 43, 47], ["F4ac", "GENE_OR_GENE_PRODUCT", 49, 53], ["F4ad", "GENE_OR_GENE_PRODUCT", 58, 62], ["F4ac", "GENE_OR_GENE_PRODUCT", 76, 80], ["F4", "PROTEIN", 0, 2], ["fimbriae", "PROTEIN", 16, 24], ["F4ab", "PROTEIN", 43, 47], ["F4ac", "PROTEIN", 49, 53], ["F4ad variant", "PROTEIN", 58, 70], ["F4ac variant", "PROTEIN", 76, 88], ["flexible fimbriae", "PROBLEM", 7, 24]]], ["The F4 fimbriae mediate bacterial attachment to F4 receptors (F4R), present on the small intestinal brush borders of villous enterocytes allowing ETEC to survive and persist in the small intestine and cause diarrhea [51] .", [["intestinal brush borders", "ANATOMY", 89, 113], ["villous enterocytes", "ANATOMY", 117, 136], ["small intestine", "ANATOMY", 181, 196], ["diarrhea", "DISEASE", 207, 215], ["F4 fimbriae", "GENE_OR_GENE_PRODUCT", 4, 15], ["F4 receptors", "GENE_OR_GENE_PRODUCT", 48, 60], ["F4R", "GENE_OR_GENE_PRODUCT", 62, 65], ["villous enterocytes", "TISSUE", 117, 136], ["small intestine", "ORGAN", 181, 196], ["F4 fimbriae", "PROTEIN", 4, 15], ["F4 receptors", "PROTEIN", 48, 60], ["F4R", "PROTEIN", 62, 65], ["villous enterocytes", "CELL_TYPE", 117, 136], ["villous enterocytes", "PROBLEM", 117, 136], ["ETEC", "PROBLEM", 146, 150], ["diarrhea", "PROBLEM", 207, 215], ["bacterial attachment", "OBSERVATION", 24, 44], ["small", "OBSERVATION_MODIFIER", 83, 88], ["intestinal", "ANATOMY", 89, 99], ["brush", "ANATOMY_MODIFIER", 100, 105], ["villous enterocytes", "OBSERVATION", 117, 136], ["small intestine", "ANATOMY", 181, 196]]], ["Thus, attachment of ETEC to the pig intestinal mucosa is a crucial step in the pathogenesis and the initiation of PWD.", [["intestinal mucosa", "ANATOMY", 36, 53], ["ETEC", "GENE_OR_GENE_PRODUCT", 20, 24], ["pig", "ORGANISM", 32, 35], ["intestinal mucosa", "MULTI-TISSUE_STRUCTURE", 36, 53], ["pig", "SPECIES", 32, 35], ["pig", "SPECIES", 32, 35], ["ETEC", "PROBLEM", 20, 24], ["PWD", "PROBLEM", 114, 117], ["intestinal mucosa", "ANATOMY", 36, 53]]], ["Two antigenic variants of F18 fimbriae exist: F18ab (F107) and F18ac (2134P and 8813).", [["F18 fimbriae", "GENE_OR_GENE_PRODUCT", 26, 38], ["F18 fimbriae", "PROTEIN", 26, 38], ["antigenic variants", "OBSERVATION", 4, 22]]], ["F18ac is commonly associated with ETEC causing PWD, whereas F18ab is often involved in oedema disease [52] .", [["ETEC", "DISEASE", 34, 38], ["oedema", "DISEASE", 87, 93], ["F18ac", "GENE_OR_GENE_PRODUCT", 0, 5], ["F18ab", "GENE_OR_GENE_PRODUCT", 60, 65], ["oedema", "PATHOLOGICAL_FORMATION", 87, 93], ["F18ac", "PROTEIN", 0, 5], ["F18ab", "PROTEIN", 60, 65], ["ETEC", "PROBLEM", 34, 38], ["PWD", "PROBLEM", 47, 50], ["oedema disease", "PROBLEM", 87, 101], ["oedema", "OBSERVATION", 87, 93]]], ["No cross protection between F18ab and F18ac was observed on vaccination against F18 variants [53] .", [["F18ab", "GENE_OR_GENE_PRODUCT", 28, 33], ["F18ac", "GENE_OR_GENE_PRODUCT", 38, 43], ["F18ab", "PROTEIN", 28, 33], ["F18ac", "PROTEIN", 38, 43], ["vaccination", "TREATMENT", 60, 71], ["cross protection", "OBSERVATION", 3, 19]]], ["A nonfimbrial adhesin identified as AIDA (adhesin involved in diffuse adherence) has been observed to be associated with ETEC strains recovered from pigs with PWD [54] .", [["AIDA", "CHEMICAL", 36, 40], ["AIDA", "GENE_OR_GENE_PRODUCT", 36, 40], ["pigs", "ORGANISM", 149, 153], ["nonfimbrial adhesin", "PROTEIN", 2, 21], ["AIDA", "PROTEIN", 36, 40], ["adhesin", "PROTEIN", 42, 49], ["pigs", "SPECIES", 149, 153], ["pigs", "SPECIES", 149, 153], ["A nonfimbrial adhesin", "PROBLEM", 0, 21], ["ETEC strains", "PROBLEM", 121, 133], ["diffuse", "OBSERVATION_MODIFIER", 62, 69]]], ["In this study, 50.0% of isolates were ETEC-aidA + .", [["ETEC", "CHEMICAL", 38, 42], ["ETEC", "ORGANISM", 38, 42], ["this study", "TEST", 3, 13], ["isolates", "TEST", 24, 32], ["ETEC", "TEST", 38, 42]]], ["Moreover, it has been demonstrated that the expression of AIDA by a diarrheagenic E. coli strain (AIDA-I + , STb + ) was essential for pig's intestinal colonization and for in vitro bacterial autoaggregation and biofilm formation [55] .Determining factorsPorcine pathogenic E. coli involved in PWD typically belong to serogroups O8, O138, O139, O141, O147, O157 and O149, the latter being the predominant serogroup in most countries [56, 57] .", [["intestinal", "ANATOMY", 141, 151], ["biofilm", "ANATOMY", 212, 219], ["AIDA", "CHEMICAL", 58, 62], ["AIDA", "GENE_OR_GENE_PRODUCT", 58, 62], ["E. coli", "ORGANISM", 82, 89], ["strain", "ORGANISM", 90, 96], ["AIDA-I +", "GENE_OR_GENE_PRODUCT", 98, 106], ["STb +", "SIMPLE_CHEMICAL", 109, 114], ["pig", "ORGANISM", 135, 138], ["intestinal", "ORGAN", 141, 151], ["Porcine pathogenic", "ORGANISM", 255, 273], ["E. coli", "ORGANISM", 274, 281], ["E. coli", "SPECIES", 82, 89], ["pig", "SPECIES", 135, 138], ["Porcine", "SPECIES", 255, 262], ["E. coli", "SPECIES", 274, 281], ["E. coli", "SPECIES", 82, 89], ["pig", "SPECIES", 135, 138], ["E. coli", "SPECIES", 274, 281], ["O157", "SPECIES", 357, 361], ["a diarrheagenic E. coli strain", "PROBLEM", 66, 96], ["STb", "PROBLEM", 109, 112], ["pig's intestinal colonization", "PROBLEM", 135, 164], ["vitro bacterial autoaggregation", "PROBLEM", 176, 207], ["Porcine pathogenic E. coli", "PROBLEM", 255, 281], ["essential for", "UNCERTAINTY", 121, 134], ["intestinal", "ANATOMY", 141, 151], ["colonization", "OBSERVATION", 152, 164], ["E. coli", "OBSERVATION", 274, 281], ["predominant", "OBSERVATION_MODIFIER", 393, 404], ["serogroup", "OBSERVATION_MODIFIER", 405, 414]]], ["However, O serogroup and virulence gene patterns vary from region to region and over time [2] .Determining factorsPathogenesis of porcine enteric colibacillosis has been reviewed extensively elsewhere [7, 40, 57] .", [["enteric colibacillosis", "DISEASE", 138, 160], ["O serogroup", "GENE_OR_GENE_PRODUCT", 9, 20], ["porcine", "ORGANISM", 130, 137], ["porcine", "SPECIES", 130, 137], ["virulence gene patterns", "TREATMENT", 25, 48], ["porcine enteric colibacillosis", "PROBLEM", 130, 160], ["porcine", "OBSERVATION_MODIFIER", 130, 137], ["enteric", "OBSERVATION_MODIFIER", 138, 145], ["colibacillosis", "OBSERVATION", 146, 160]]], ["Indeed, piglets ingest ETEC found in their environment, especially derived from mammary glands of their mother and from the farrowing room or from the pen environment on arrival in the nursery (Fig. 2) .", [["mammary glands", "ANATOMY", 80, 94], ["ETEC", "CHEMICAL", 23, 27], ["piglets", "ORGANISM", 8, 15], ["mammary glands", "ORGAN", 80, 94], ["piglets", "SPECIES", 8, 15]]], ["These ETEC originate from the gut of piglets with ETEC diarrhea, or subclinical carrier animals at the farm [57] .", [["gut", "ANATOMY", 30, 33], ["ETEC diarrhea", "DISEASE", 50, 63], ["gut", "ORGANISM_SUBDIVISION", 30, 33], ["piglets", "ORGANISM", 37, 44], ["piglets", "SPECIES", 37, 44], ["ETEC", "SPECIES", 50, 54], ["These ETEC", "PROBLEM", 0, 10], ["ETEC diarrhea", "PROBLEM", 50, 63], ["subclinical carrier animals", "PROBLEM", 68, 95]]], ["ETEC bacteria adhere to pig's small intestinal epithelium, causes an increase of water and electrolytes secretion into the intestinal lumen generated by the release of enterotoxins, and alter the functions of enterocytes by increasing secretion and reducing absorption [7] .", [["intestinal epithelium", "ANATOMY", 36, 57], ["intestinal lumen", "ANATOMY", 123, 139], ["enterocytes", "ANATOMY", 209, 220], ["pig", "ORGANISM", 24, 27], ["small intestinal epithelium", "TISSUE", 30, 57], ["water", "SIMPLE_CHEMICAL", 81, 86], ["intestinal lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 123, 139], ["enterocytes", "CELL", 209, 220], ["enterotoxins", "PROTEIN", 168, 180], ["enterocytes", "CELL_TYPE", 209, 220], ["pig", "SPECIES", 24, 27], ["pig", "SPECIES", 24, 27], ["ETEC bacteria", "PROBLEM", 0, 13], ["pig's small intestinal epithelium", "TREATMENT", 24, 57], ["an increase of water and electrolytes secretion into the intestinal lumen", "PROBLEM", 66, 139], ["enterotoxins", "TREATMENT", 168, 180], ["increasing secretion", "PROBLEM", 224, 244], ["intestinal epithelium", "ANATOMY", 36, 57], ["increase", "OBSERVATION_MODIFIER", 69, 77], ["intestinal lumen", "ANATOMY", 123, 139]]], ["Excessive secretion of electrolytes and water leads to dehydration, metabolic acidosis, osmotic diarrhea and possible death [28, [58] [59] [60] (Fig. 2 ).", [["dehydration", "DISEASE", 55, 66], ["metabolic acidosis", "DISEASE", 68, 86], ["diarrhea", "DISEASE", 96, 104], ["death", "DISEASE", 118, 123], ["water", "SIMPLE_CHEMICAL", 40, 45], ["Excessive secretion of electrolytes", "PROBLEM", 0, 35], ["dehydration", "PROBLEM", 55, 66], ["metabolic acidosis", "PROBLEM", 68, 86], ["osmotic diarrhea", "PROBLEM", 88, 104], ["death", "PROBLEM", 118, 123], ["metabolic acidosis", "OBSERVATION", 68, 86]]], ["It has been widely reported in the scientific literature that ETEC challenge in pigs was not associated with significant macroscopic lesions or morphological changes in the intestinal mucosa resulting from the toxic activity of ETEC enterotoxins [57, 61, 62] .", [["lesions", "ANATOMY", 133, 140], ["intestinal mucosa", "ANATOMY", 173, 190], ["ETEC", "CHEMICAL", 62, 66], ["ETEC", "ORGANISM", 62, 66], ["pigs", "ORGANISM", 80, 84], ["macroscopic lesions", "PATHOLOGICAL_FORMATION", 121, 140], ["intestinal mucosa", "MULTI-TISSUE_STRUCTURE", 173, 190], ["ETEC enterotoxins", "GENE_OR_GENE_PRODUCT", 228, 245], ["ETEC enterotoxins", "PROTEIN", 228, 245], ["pigs", "SPECIES", 80, 84], ["pigs", "SPECIES", 80, 84], ["ETEC challenge", "TREATMENT", 62, 76], ["significant macroscopic lesions", "PROBLEM", 109, 140], ["morphological changes in the intestinal mucosa", "PROBLEM", 144, 190], ["ETEC enterotoxins", "PROBLEM", 228, 245], ["widely", "OBSERVATION_MODIFIER", 12, 18], ["not associated with", "UNCERTAINTY", 89, 108], ["significant", "OBSERVATION_MODIFIER", 109, 120], ["macroscopic", "OBSERVATION_MODIFIER", 121, 132], ["lesions", "OBSERVATION", 133, 140], ["morphological changes", "OBSERVATION", 144, 165], ["intestinal mucosa", "ANATOMY", 173, 190], ["toxic", "OBSERVATION_MODIFIER", 210, 215], ["activity", "OBSERVATION_MODIFIER", 216, 224]]], ["However, other studies have reported that the necropsy of challenged pigs with ETEC or naturally infected animals, has revealed several lesions such as; dehydration, dilation of the stomach and the small intestines, gastric infarcts in the mucosa of the stomach, and congestion of the mucosa of both the small intestine and the colon [57, 63] .", [["lesions", "ANATOMY", 136, 143], ["stomach", "ANATOMY", 182, 189], ["small intestines", "ANATOMY", 198, 214], ["gastric infarcts", "ANATOMY", 216, 232], ["mucosa", "ANATOMY", 240, 246], ["stomach", "ANATOMY", 254, 261], ["mucosa", "ANATOMY", 285, 291], ["small intestine", "ANATOMY", 304, 319], ["colon", "ANATOMY", 328, 333], ["ETEC", "CHEMICAL", 79, 83], ["dehydration", "DISEASE", 153, 164], ["dilation of the stomach", "DISEASE", 166, 189], ["gastric infarcts", "DISEASE", 216, 232], ["pigs", "ORGANISM", 69, 73], ["lesions", "PATHOLOGICAL_FORMATION", 136, 143], ["stomach", "ORGAN", 182, 189], ["intestines", "ORGAN", 204, 214], ["gastric", "ORGAN", 216, 223], ["mucosa", "MULTI-TISSUE_STRUCTURE", 240, 246], ["stomach", "ORGAN", 254, 261], ["mucosa", "MULTI-TISSUE_STRUCTURE", 285, 291], ["small intestine", "ORGAN", 304, 319], ["colon", "ORGAN", 328, 333], ["pigs", "SPECIES", 69, 73], ["pigs", "SPECIES", 69, 73], ["ETEC", "SPECIES", 79, 83], ["other studies", "TEST", 9, 22], ["ETEC", "PROBLEM", 79, 83], ["naturally infected animals", "PROBLEM", 87, 113], ["several lesions", "PROBLEM", 128, 143], ["dehydration", "PROBLEM", 153, 164], ["dilation of the stomach and the small intestines", "PROBLEM", 166, 214], ["gastric infarcts in the mucosa of the stomach", "PROBLEM", 216, 261], ["congestion of the mucosa of both the small intestine and the colon", "PROBLEM", 267, 333], ["several", "OBSERVATION_MODIFIER", 128, 135], ["lesions", "OBSERVATION", 136, 143], ["dehydration", "OBSERVATION", 153, 164], ["dilation", "OBSERVATION", 166, 174], ["stomach", "ANATOMY", 182, 189], ["small intestines", "ANATOMY", 198, 214], ["gastric", "ANATOMY", 216, 223], ["infarcts", "OBSERVATION", 224, 232], ["mucosa", "ANATOMY_MODIFIER", 240, 246], ["stomach", "ANATOMY", 254, 261], ["congestion", "OBSERVATION", 267, 277], ["mucosa", "ANATOMY_MODIFIER", 285, 291], ["both", "ANATOMY_MODIFIER", 295, 299], ["small intestine", "ANATOMY", 304, 319], ["colon", "ANATOMY", 328, 333]]], ["Furthermore, ETEC infections in pigs may also result in a shock syndrome with hemorrhagic gastroenteritis, congestion, renal hemorrhage, and thrombi in the mucosa of the stomach and small intestine [64] [65] [66] .", [["renal", "ANATOMY", 119, 124], ["thrombi", "ANATOMY", 141, 148], ["mucosa", "ANATOMY", 156, 162], ["stomach", "ANATOMY", 170, 177], ["small intestine", "ANATOMY", 182, 197], ["ETEC infections", "DISEASE", 13, 28], ["shock", "DISEASE", 58, 63], ["hemorrhagic gastroenteritis", "DISEASE", 78, 105], ["congestion", "DISEASE", 107, 117], ["renal hemorrhage", "DISEASE", 119, 135], ["thrombi", "DISEASE", 141, 148], ["pigs", "ORGANISM", 32, 36], ["renal", "ORGAN", 119, 124], ["thrombi", "PATHOLOGICAL_FORMATION", 141, 148], ["mucosa", "MULTI-TISSUE_STRUCTURE", 156, 162], ["stomach", "ORGAN", 170, 177], ["intestine", "ORGAN", 188, 197], ["pigs", "SPECIES", 32, 36], ["ETEC", "SPECIES", 13, 17], ["pigs", "SPECIES", 32, 36], ["ETEC infections", "PROBLEM", 13, 28], ["a shock syndrome", "PROBLEM", 56, 72], ["hemorrhagic gastroenteritis", "PROBLEM", 78, 105], ["congestion", "PROBLEM", 107, 117], ["renal hemorrhage", "PROBLEM", 119, 135], ["thrombi in the mucosa of the stomach and small intestine", "PROBLEM", 141, 197], ["infections", "OBSERVATION", 18, 28], ["shock syndrome", "OBSERVATION", 58, 72], ["hemorrhagic", "OBSERVATION_MODIFIER", 78, 89], ["gastroenteritis", "OBSERVATION", 90, 105], ["congestion", "OBSERVATION", 107, 117], ["renal", "ANATOMY", 119, 124], ["hemorrhage", "OBSERVATION", 125, 135], ["thrombi", "OBSERVATION", 141, 148], ["mucosa", "ANATOMY", 156, 162], ["stomach", "ANATOMY", 170, 177], ["small intestine", "ANATOMY", 182, 197]]], ["Moreover, intestinal ETEC infections in pigs might be associated with secondary septicemia [66] and inactivation of the hemolysin structural gene (hlyA) of an ETEC: F4 challenge strain did not decrease the incidence of this septicemia in orally challenged gnotobiotic piglets [66] .", [["intestinal", "ANATOMY", 10, 20], ["ETEC infections", "DISEASE", 21, 36], ["septicemia", "DISEASE", 80, 90], ["septicemia", "DISEASE", 224, 234], ["intestinal ETEC", "ORGANISM", 10, 25], ["pigs", "ORGANISM", 40, 44], ["hemolysin structural gene", "GENE_OR_GENE_PRODUCT", 120, 145], ["hlyA", "GENE_OR_GENE_PRODUCT", 147, 151], ["piglets", "ORGANISM", 268, 275], ["hemolysin structural gene", "DNA", 120, 145], ["hlyA", "DNA", 147, 151], ["pigs", "SPECIES", 40, 44], ["piglets", "SPECIES", 268, 275], ["pigs", "SPECIES", 40, 44], ["intestinal ETEC infections", "PROBLEM", 10, 36], ["secondary septicemia", "PROBLEM", 70, 90], ["this septicemia", "PROBLEM", 219, 234], ["intestinal", "ANATOMY", 10, 20], ["ETEC", "OBSERVATION_MODIFIER", 21, 25], ["infections", "OBSERVATION", 26, 36], ["secondary", "OBSERVATION_MODIFIER", 70, 79], ["septicemia", "OBSERVATION", 80, 90], ["septicemia", "OBSERVATION", 224, 234]]], ["Thus, macroscopic lesions of shock syndrome and septicemia related to ETEC infection in the post weaning period in pigs are probably the consequence of the rapid release of bacterial LPS from the pig's intestine into the systemic circulation [57] .", [["lesions", "ANATOMY", 18, 25], ["intestine", "ANATOMY", 202, 211], ["shock syndrome", "DISEASE", 29, 43], ["septicemia", "DISEASE", 48, 58], ["ETEC", "CHEMICAL", 70, 74], ["infection", "DISEASE", 75, 84], ["LPS", "CHEMICAL", 183, 186], ["lesions", "PATHOLOGICAL_FORMATION", 18, 25], ["pigs", "ORGANISM", 115, 119], ["LPS", "SIMPLE_CHEMICAL", 183, 186], ["pig", "ORGANISM", 196, 199], ["intestine", "ORGAN", 202, 211], ["pigs", "SPECIES", 115, 119], ["pig", "SPECIES", 196, 199], ["pigs", "SPECIES", 115, 119], ["pig", "SPECIES", 196, 199], ["macroscopic lesions", "PROBLEM", 6, 25], ["shock syndrome", "PROBLEM", 29, 43], ["septicemia", "PROBLEM", 48, 58], ["ETEC infection", "PROBLEM", 70, 84], ["bacterial LPS", "PROBLEM", 173, 186], ["macroscopic", "OBSERVATION_MODIFIER", 6, 17], ["lesions", "OBSERVATION", 18, 25], ["shock syndrome", "OBSERVATION", 29, 43], ["septicemia", "OBSERVATION", 48, 58], ["ETEC", "OBSERVATION_MODIFIER", 70, 74], ["infection", "OBSERVATION", 75, 84], ["probably the consequence", "UNCERTAINTY", 124, 148], ["rapid", "OBSERVATION_MODIFIER", 156, 161], ["bacterial LPS", "OBSERVATION", 173, 186], ["intestine", "ANATOMY", 202, 211], ["systemic circulation", "ANATOMY", 221, 241]]], ["On the other hand, microscopically, ETEC challenge in pigs has been associated with a greater villous atrophy and a large crypt depth reduction in all segments of the intestine of challenged animals [67] .Determining factorsETEC isolates from pig farms with PWD may show a high frequency of resistance to multiple antimicrobials [1, 68] .", [["villous", "ANATOMY", 94, 101], ["crypt", "ANATOMY", 122, 127], ["intestine", "ANATOMY", 167, 176], ["ETEC", "CHEMICAL", 36, 40], ["atrophy", "DISEASE", 102, 109], ["pigs", "ORGANISM", 54, 58], ["villous", "TISSUE", 94, 101], ["crypt", "PATHOLOGICAL_FORMATION", 122, 127], ["intestine", "ORGAN", 167, 176], ["factorsETEC", "GENE_OR_GENE_PRODUCT", 217, 228], ["pig", "ORGANISM", 243, 246], ["pigs", "SPECIES", 54, 58], ["pig", "SPECIES", 243, 246], ["pigs", "SPECIES", 54, 58], ["pig", "SPECIES", 243, 246], ["ETEC challenge", "TREATMENT", 36, 50], ["a greater villous atrophy", "PROBLEM", 84, 109], ["a large crypt depth reduction", "TREATMENT", 114, 143], ["factorsETEC isolates", "TREATMENT", 217, 237], ["pig farms", "TREATMENT", 243, 252], ["PWD", "TREATMENT", 258, 261], ["greater", "OBSERVATION_MODIFIER", 86, 93], ["villous", "OBSERVATION_MODIFIER", 94, 101], ["atrophy", "OBSERVATION", 102, 109], ["large", "OBSERVATION_MODIFIER", 116, 121], ["crypt depth", "OBSERVATION", 122, 133], ["reduction", "OBSERVATION_MODIFIER", 134, 143], ["all segments", "ANATOMY_MODIFIER", 147, 159], ["intestine", "ANATOMY", 167, 176]]], ["Nevertheless, there is no indication that drug resistance enhances the virulence of ETEC, although virulence genes are sometimes associated with drug resistance genes [56] .Determining factorsPorcine attaching and effacing E. coli (AEEC) induce intestinal lesions similar to those produced by enteropathogenic E. coli (EPEC) in humans, and this pathotype is found in pigs with PWD [40] .", [["AEEC", "ANATOMY", 232, 236], ["intestinal lesions", "ANATOMY", 245, 263], ["ETEC", "DISEASE", 84, 88], ["intestinal lesions", "DISEASE", 245, 263], ["ETEC", "GENE_OR_GENE_PRODUCT", 84, 88], ["Porcine", "ORGANISM", 192, 199], ["E. coli", "ORGANISM", 223, 230], ["AEEC", "CANCER", 232, 236], ["intestinal lesions", "PATHOLOGICAL_FORMATION", 245, 263], ["enteropathogenic E. coli", "ORGANISM", 293, 317], ["EPEC", "CELL", 319, 323], ["humans", "ORGANISM", 328, 334], ["pigs", "ORGANISM", 367, 371], ["virulence genes", "DNA", 99, 114], ["drug resistance genes", "DNA", 145, 166], ["Porcine", "SPECIES", 192, 199], ["E. coli", "SPECIES", 223, 230], ["E. coli", "SPECIES", 310, 317], ["humans", "SPECIES", 328, 334], ["pigs", "SPECIES", 367, 371], ["ETEC", "SPECIES", 84, 88], ["E. coli", "SPECIES", 223, 230], ["E. coli", "SPECIES", 310, 317], ["EPEC", "SPECIES", 319, 323], ["humans", "SPECIES", 328, 334], ["pigs", "SPECIES", 367, 371], ["drug resistance", "PROBLEM", 42, 57], ["ETEC", "PROBLEM", 84, 88], ["virulence genes", "PROBLEM", 99, 114], ["drug resistance genes", "PROBLEM", 145, 166], ["Porcine attaching and effacing E. coli (AEEC)", "PROBLEM", 192, 237], ["intestinal lesions", "PROBLEM", 245, 263], ["enteropathogenic E. coli", "PROBLEM", 293, 317], ["EPEC", "PROBLEM", 319, 323], ["this pathotype", "PROBLEM", 340, 354], ["no indication", "UNCERTAINTY", 23, 36], ["coli", "OBSERVATION_MODIFIER", 226, 230], ["intestinal", "ANATOMY", 245, 255], ["lesions", "OBSERVATION", 256, 263], ["enteropathogenic", "OBSERVATION_MODIFIER", 293, 309], ["E. coli", "OBSERVATION", 310, 317]]], ["These E. coli carry the eae gene encoding a 94 kDa outer membrane protein (intimin) which is responsible for intimate attachment to epithelial cells.", [["epithelial cells", "ANATOMY", 132, 148], ["E. coli", "ORGANISM", 6, 13], ["eae", "GENE_OR_GENE_PRODUCT", 24, 27], ["outer membrane", "CELLULAR_COMPONENT", 51, 65], ["intimin", "GENE_OR_GENE_PRODUCT", 75, 82], ["epithelial cells", "CELL", 132, 148], ["eae gene", "DNA", 24, 32], ["94 kDa outer membrane protein", "PROTEIN", 44, 73], ["intimin", "PROTEIN", 75, 82], ["epithelial cells", "CELL_TYPE", 132, 148], ["E. coli", "SPECIES", 6, 13], ["E. coli", "SPECIES", 6, 13], ["intimate attachment to epithelial cells", "PROBLEM", 109, 148], ["coli", "OBSERVATION", 9, 13], ["responsible for", "UNCERTAINTY", 93, 108], ["epithelial cells", "OBSERVATION", 132, 148]]], ["However, the pathogenic significance of porcine EAE positive isolates in weaned pigs is still unknown [2] .", [["EAE", "DISEASE", 48, 51], ["porcine", "ORGANISM", 40, 47], ["pigs", "ORGANISM", 80, 84], ["pigs", "SPECIES", 80, 84], ["pigs", "SPECIES", 80, 84], ["porcine EAE positive isolates", "PROBLEM", 40, 69]]], ["Furthermore, identification of porcine EPEC is difficult and many veterinary diagnostic laboratories do not routinely screen for this pathotype of E. coli, isolates of which do not usually possess any of virulence factors of classic PWD or oedema strains [40] .Extent of colistin use in weaned pigs worldwideThe global demand for colistin in agriculture is expected to reach 16,500 tons by the year 2021, this being one of the least expensive classes of antimicrobials available in veterinary medicine in some countries [17] .", [["oedema", "DISEASE", 240, 246], ["colistin", "CHEMICAL", 271, 279], ["colistin", "CHEMICAL", 330, 338], ["colistin", "CHEMICAL", 271, 279], ["colistin", "CHEMICAL", 330, 338], ["porcine", "ORGANISM", 31, 38], ["EPEC", "ORGANISM", 39, 43], ["E. coli", "ORGANISM", 147, 154], ["colistin", "SIMPLE_CHEMICAL", 271, 279], ["pigs", "ORGANISM", 294, 298], ["colistin", "SIMPLE_CHEMICAL", 330, 338], ["virulence factors", "PROTEIN", 204, 221], ["E. coli", "SPECIES", 147, 154], ["pigs", "SPECIES", 294, 298], ["porcine", "SPECIES", 31, 38], ["E. coli", "SPECIES", 147, 154], ["pigs", "SPECIES", 294, 298], ["porcine EPEC", "PROBLEM", 31, 43], ["E. coli", "PROBLEM", 147, 154], ["classic PWD", "PROBLEM", 225, 236], ["oedema strains", "PROBLEM", 240, 254], ["colistin", "TREATMENT", 271, 279], ["colistin", "TREATMENT", 330, 338], ["antimicrobials", "TREATMENT", 454, 468], ["porcine EPEC", "OBSERVATION", 31, 43], ["E. coli", "OBSERVATION", 147, 154], ["oedema", "OBSERVATION", 240, 246], ["colistin", "OBSERVATION", 271, 279]]], ["Thus, the pricing structure makes colistin particularly attractive for use in pig production.", [["colistin", "CHEMICAL", 34, 42], ["colistin", "CHEMICAL", 34, 42], ["colistin", "SIMPLE_CHEMICAL", 34, 42], ["pig", "ORGANISM", 78, 81], ["pig", "SPECIES", 78, 81], ["colistin", "TREATMENT", 34, 42]]], ["Since the inception of its clinical use in 1960, colistin has been used in pig production in many countries for the treatment and prevention of digestive disorders caused by Enterobacteriaceae, and even sometimes for growth promotion over long periods, to improve growth rate and feed conversion efficiency in pigs [18, 69, 70] .", [["digestive", "ANATOMY", 144, 153], ["colistin", "CHEMICAL", 49, 57], ["digestive disorders", "DISEASE", 144, 163], ["colistin", "CHEMICAL", 49, 57], ["colistin", "SIMPLE_CHEMICAL", 49, 57], ["pig", "ORGANISM", 75, 78], ["digestive", "ORGAN", 144, 153], ["pigs", "ORGANISM", 310, 314], ["pigs", "SPECIES", 310, 314], ["pig", "SPECIES", 75, 78], ["pigs", "SPECIES", 310, 314], ["colistin", "TREATMENT", 49, 57], ["the treatment", "TREATMENT", 112, 125], ["digestive disorders", "PROBLEM", 144, 163], ["Enterobacteriaceae", "PROBLEM", 174, 192], ["Enterobacteriaceae", "OBSERVATION", 174, 192]]], ["In certain countries such as Canada, where colistin has not been approved for use in pigs, a rapid increase in resistance of ETEC to a wide range of antimicrobials has prompted the use of colistin in weaned pigs under the veterinarian's responsibility [71] .", [["colistin", "CHEMICAL", 43, 51], ["ETEC", "DISEASE", 125, 129], ["colistin", "CHEMICAL", 188, 196], ["colistin", "CHEMICAL", 43, 51], ["colistin", "CHEMICAL", 188, 196], ["colistin", "SIMPLE_CHEMICAL", 43, 51], ["pigs", "ORGANISM", 85, 89], ["colistin", "SIMPLE_CHEMICAL", 188, 196], ["pigs", "ORGANISM", 207, 211], ["pigs", "SPECIES", 85, 89], ["pigs", "SPECIES", 207, 211], ["pigs", "SPECIES", 85, 89], ["ETEC", "SPECIES", 125, 129], ["pigs", "SPECIES", 207, 211], ["colistin", "TREATMENT", 43, 51], ["ETEC", "PROBLEM", 125, 129], ["a wide range of antimicrobials", "TREATMENT", 133, 163], ["colistin", "TREATMENT", 188, 196], ["rapid", "OBSERVATION_MODIFIER", 93, 98], ["increase", "OBSERVATION_MODIFIER", 99, 107]]], ["However, current data on the total quantities of colistin used in pigs worldwide have been difficult to obtain accurately [70] .", [["colistin", "CHEMICAL", 49, 57], ["colistin", "CHEMICAL", 49, 57], ["colistin", "SIMPLE_CHEMICAL", 49, 57], ["pigs", "ORGANISM", 66, 70], ["pigs", "SPECIES", 66, 70], ["pigs", "SPECIES", 66, 70], ["colistin", "TREATMENT", 49, 57]]], ["Some data, for example in Denmark, indicate that the use of colistin for the treatment of sows increased between 2002 and 2008 [72] .", [["colistin", "CHEMICAL", 60, 68], ["colistin", "CHEMICAL", 60, 68], ["colistin", "SIMPLE_CHEMICAL", 60, 68], ["sows", "ORGANISM", 90, 94], ["colistin", "TREATMENT", 60, 68], ["the treatment", "TREATMENT", 73, 86]]], ["Of the two forms of colistin commercially available, colistin sulfate (CS) and colistin methanesulphonate sodium (CMS), and only CS is approved in pig production in some countries [18] .", [["colistin", "CHEMICAL", 20, 28], ["colistin sulfate", "CHEMICAL", 53, 69], ["CS", "CHEMICAL", 71, 73], ["colistin methanesulphonate sodium", "CHEMICAL", 79, 112], ["CMS", "CHEMICAL", 114, 117], ["CS", "CHEMICAL", 129, 131], ["colistin", "CHEMICAL", 20, 28], ["colistin sulfate", "CHEMICAL", 53, 69], ["CS", "CHEMICAL", 71, 73], ["colistin methanesulphonate sodium", "CHEMICAL", 79, 112], ["CMS", "CHEMICAL", 114, 117], ["colistin", "SIMPLE_CHEMICAL", 20, 28], ["colistin sulfate", "SIMPLE_CHEMICAL", 53, 69], ["CS", "SIMPLE_CHEMICAL", 71, 73], ["colistin methanesulphonate sodium", "SIMPLE_CHEMICAL", 79, 112], ["pig", "ORGANISM", 147, 150], ["pig", "SPECIES", 147, 150], ["colistin", "TREATMENT", 20, 28], ["colistin sulfate (CS)", "TREATMENT", 53, 74], ["colistin methanesulphonate sodium", "TREATMENT", 79, 112]]], ["Usually it is administered orally in the drinking water at the dose of 50,000 IU/kg body weight every 12 h for 3 or 5 days [25] .", [["body", "ANATOMY", 84, 88], ["body", "ORGANISM_SUBDIVISION", 84, 88]]], ["Colistin is mostly used in monotherapy in pigs, although it may be combined with other antimicrobials, such as amoxicillin, for the treatment of PWD [25, 73] .Colistin use in post weaning diarrhea on farmsDue to its activity directed against GNB, colistin is widely used for the control of PWD in pigs [10, 74] .", [["Colistin", "CHEMICAL", 0, 8], ["amoxicillin", "CHEMICAL", 111, 122], ["Colistin", "CHEMICAL", 159, 167], ["diarrhea", "DISEASE", 188, 196], ["GNB", "CHEMICAL", 242, 245], ["colistin", "CHEMICAL", 247, 255], ["Colistin", "CHEMICAL", 0, 8], ["amoxicillin", "CHEMICAL", 111, 122], ["Colistin", "CHEMICAL", 159, 167], ["colistin", "CHEMICAL", 247, 255], ["Colistin", "SIMPLE_CHEMICAL", 0, 8], ["pigs", "ORGANISM", 42, 46], ["amoxicillin", "SIMPLE_CHEMICAL", 111, 122], ["Colistin", "SIMPLE_CHEMICAL", 159, 167], ["GNB", "SIMPLE_CHEMICAL", 242, 245], ["colistin", "SIMPLE_CHEMICAL", 247, 255], ["pigs", "ORGANISM", 297, 301], ["pigs", "SPECIES", 42, 46], ["pigs", "SPECIES", 297, 301], ["pigs", "SPECIES", 42, 46], ["pigs", "SPECIES", 297, 301], ["Colistin", "TREATMENT", 0, 8], ["monotherapy in pigs", "TREATMENT", 27, 46], ["other antimicrobials", "TREATMENT", 81, 101], ["amoxicillin", "TREATMENT", 111, 122], ["Colistin", "TREATMENT", 159, 167], ["diarrhea", "PROBLEM", 188, 196], ["GNB", "PROBLEM", 242, 245], ["colistin", "TREATMENT", 247, 255]]], ["Two surveys conducted in pig farms in Belgium, in 2006 [73] , and 2012 [74] confirmed that colistin was the most frequently used antimicrobial for the control of PWD, being mostly used prophylactically.", [["colistin", "CHEMICAL", 91, 99], ["colistin", "CHEMICAL", 91, 99], ["pig", "ORGANISM", 25, 28], ["colistin", "SIMPLE_CHEMICAL", 91, 99], ["pig", "SPECIES", 25, 28], ["pig", "SPECIES", 25, 28], ["colistin", "TREATMENT", 91, 99], ["antimicrobial", "TREATMENT", 129, 142], ["the control of PWD", "TREATMENT", 147, 165]]], ["However, colistin was underdosed in 90 and 53% of the cases, in the first and the second survey respectively.", [["colistin", "CHEMICAL", 9, 17], ["colistin", "CHEMICAL", 9, 17], ["colistin", "SIMPLE_CHEMICAL", 9, 17], ["colistin", "TREATMENT", 9, 17]]], ["In Germany, it was reported that intestinal diseases in weaners were commonly treated with colistin, pigs being treated 9.7 days (median) per 100 days with this antibiotic, although tetracycline and tylosin were also used in approximately equal amounts [75] .", [["intestinal", "ANATOMY", 33, 43], ["intestinal diseases", "DISEASE", 33, 52], ["colistin", "CHEMICAL", 91, 99], ["tetracycline", "CHEMICAL", 182, 194], ["tylosin", "CHEMICAL", 199, 206], ["colistin", "CHEMICAL", 91, 99], ["tetracycline", "CHEMICAL", 182, 194], ["tylosin", "CHEMICAL", 199, 206], ["intestinal", "ORGAN", 33, 43], ["colistin", "SIMPLE_CHEMICAL", 91, 99], ["pigs", "ORGANISM", 101, 105], ["tetracycline", "SIMPLE_CHEMICAL", 182, 194], ["tylosin", "SIMPLE_CHEMICAL", 199, 206], ["pigs", "SPECIES", 101, 105], ["pigs", "SPECIES", 101, 105], ["intestinal diseases in weaners", "PROBLEM", 33, 63], ["colistin", "TREATMENT", 91, 99], ["pigs", "TREATMENT", 101, 105], ["this antibiotic", "TREATMENT", 156, 171], ["tetracycline", "TREATMENT", 182, 194], ["tylosin", "TREATMENT", 199, 206], ["intestinal", "ANATOMY", 33, 43], ["diseases", "OBSERVATION", 44, 52]]], ["In a study in France, it was reported that 90% of pig farms used colistin during the post-weaning period [10] .", [["colistin", "CHEMICAL", 65, 73], ["colistin", "CHEMICAL", 65, 73], ["pig", "ORGANISM", 50, 53], ["colistin", "SIMPLE_CHEMICAL", 65, 73], ["pig", "SPECIES", 50, 53], ["pig", "SPECIES", 50, 53], ["a study", "TEST", 3, 10], ["pig farms", "TREATMENT", 50, 59], ["colistin", "TREATMENT", 65, 73], ["the post-weaning period", "TREATMENT", 81, 104]]], ["In Vietnam, a survey conducted on pig farms representing three different animal production systems (farm household, semiindustrial and industrial) showed that colistin was the most commonly used antimicrobial for prevention and therapy of gastrointestinal disorders in pigs [76] .Colistin use in post weaning diarrhea on farmsIt has been reported that China is the country with the greatest use of colistin in pigs worldwide [17] , although we did not find any reports in the literature on surveys of colistin use in this country in the post-weaning period.", [["gastrointestinal", "ANATOMY", 239, 255], ["colistin", "CHEMICAL", 159, 167], ["gastrointestinal disorders", "DISEASE", 239, 265], ["Colistin", "CHEMICAL", 280, 288], ["diarrhea", "DISEASE", 309, 317], ["colistin", "CHEMICAL", 398, 406], ["colistin", "CHEMICAL", 501, 509], ["colistin", "CHEMICAL", 159, 167], ["Colistin", "CHEMICAL", 280, 288], ["colistin", "CHEMICAL", 398, 406], ["colistin", "CHEMICAL", 501, 509], ["pig", "ORGANISM", 34, 37], ["colistin", "SIMPLE_CHEMICAL", 159, 167], ["gastrointestinal", "ORGAN", 239, 255], ["pigs", "ORGANISM", 269, 273], ["Colistin", "SIMPLE_CHEMICAL", 280, 288], ["colistin", "SIMPLE_CHEMICAL", 398, 406], ["pigs", "ORGANISM", 410, 414], ["colistin", "SIMPLE_CHEMICAL", 501, 509], ["pig", "SPECIES", 34, 37], ["pigs", "SPECIES", 269, 273], ["pigs", "SPECIES", 410, 414], ["pig", "SPECIES", 34, 37], ["pigs", "SPECIES", 410, 414], ["pig farms", "TREATMENT", 34, 43], ["colistin", "TREATMENT", 159, 167], ["antimicrobial", "TREATMENT", 195, 208], ["therapy", "TREATMENT", 228, 235], ["gastrointestinal disorders", "PROBLEM", 239, 265], ["Colistin", "TREATMENT", 280, 288], ["diarrhea", "PROBLEM", 309, 317], ["colistin", "TREATMENT", 398, 406], ["colistin", "TREATMENT", 501, 509], ["gastrointestinal", "ANATOMY", 239, 255]]], ["Overall, colistin is widely used in the management of the PWD, with a lot of differences between countries in terms of quantities used and modality of administration [18] .Microbiological and clinical outcomes of colistin use in controlled conditionsMost of the recent studies conducted in pigs have used CS in experimental conditions for the control of diarrhea in the post-weaning period ( Table 1) .", [["colistin", "CHEMICAL", 9, 17], ["colistin", "CHEMICAL", 213, 221], ["diarrhea", "DISEASE", 354, 362], ["colistin", "CHEMICAL", 9, 17], ["colistin", "CHEMICAL", 213, 221], ["colistin", "SIMPLE_CHEMICAL", 9, 17], ["colistin", "SIMPLE_CHEMICAL", 213, 221], ["pigs", "ORGANISM", 290, 294], ["pigs", "SPECIES", 290, 294], ["pigs", "SPECIES", 290, 294], ["colistin", "TREATMENT", 9, 17], ["the PWD", "TREATMENT", 54, 61], ["colistin use", "TREATMENT", 213, 225], ["the recent studies", "TEST", 258, 276], ["experimental conditions", "TREATMENT", 311, 334], ["diarrhea", "PROBLEM", 354, 362], ["colistin", "OBSERVATION", 9, 17]]], ["Several of these studies were performed to examine the effectiveness of alternative substances to colistin in the treatment of PWD [77, 78] .Microbiological and clinical outcomes of colistin use in controlled conditionsIt is often difficult to compare results between studies, because of the variability in the dose of CS used, treatment duration, and the experimental design of the study.", [["colistin", "CHEMICAL", 98, 106], ["colistin", "CHEMICAL", 182, 190], ["colistin", "CHEMICAL", 98, 106], ["colistin", "CHEMICAL", 182, 190], ["colistin", "SIMPLE_CHEMICAL", 98, 106], ["colistin", "SIMPLE_CHEMICAL", 182, 190], ["these studies", "TEST", 11, 24], ["alternative substances", "TREATMENT", 72, 94], ["colistin", "TREATMENT", 98, 106], ["colistin use", "TREATMENT", 182, 194], ["studies", "TEST", 268, 275], ["treatment duration", "TREATMENT", 328, 346], ["the study", "TEST", 379, 388]]], ["In Table 1 , we have summarized the main results reported in the literature concerning fecal E. coli shedding and pig performance following oral CS treatment.", [["oral", "ANATOMY", 140, 144], ["CS", "CHEMICAL", 145, 147], ["fecal E. coli", "ORGANISM", 87, 100], ["pig", "ORGANISM", 114, 117], ["oral", "ORGANISM_SUBDIVISION", 140, 144], ["E. coli", "SPECIES", 93, 100], ["pig", "SPECIES", 114, 117], ["E. coli", "SPECIES", 93, 100], ["pig", "SPECIES", 114, 117], ["fecal E. coli shedding", "PROBLEM", 87, 109], ["pig performance", "TREATMENT", 114, 129], ["oral CS treatment", "TREATMENT", 140, 157], ["E. coli", "OBSERVATION", 93, 100]]], ["Several studies have also followed histological (i.e. intestinal mucosa morphology) and biochemical (e.g. d-lactate, nitric oxide, xylose, etc.) parameters subsequent to CS use in the post-weaning period in pigs [78, 79] .", [["intestinal mucosa", "ANATOMY", 54, 71], ["lactate", "CHEMICAL", 108, 115], ["nitric oxide", "CHEMICAL", 117, 129], ["xylose", "CHEMICAL", 131, 137], ["lactate", "CHEMICAL", 108, 115], ["nitric oxide", "CHEMICAL", 117, 129], ["xylose", "CHEMICAL", 131, 137], ["intestinal mucosa", "MULTI-TISSUE_STRUCTURE", 54, 71], ["lactate", "SIMPLE_CHEMICAL", 108, 115], ["nitric oxide", "SIMPLE_CHEMICAL", 117, 129], ["xylose", "SIMPLE_CHEMICAL", 131, 137], ["pigs", "ORGANISM", 207, 211], ["pigs", "SPECIES", 207, 211], ["pigs", "SPECIES", 207, 211], ["Several studies", "TEST", 0, 15], ["d-lactate", "TEST", 106, 115], ["nitric oxide", "TREATMENT", 117, 129], ["xylose", "TREATMENT", 131, 137], ["intestinal mucosa", "ANATOMY", 54, 71]]], ["In order to evaluate the effect of colistin on fecal E. coli shedding, bacterial quantification was performed in most studies using culture methods [28, 77] , whereas other studies used real-time PCR [79, 80] .", [["colistin", "CHEMICAL", 35, 43], ["colistin", "CHEMICAL", 35, 43], ["colistin", "SIMPLE_CHEMICAL", 35, 43], ["fecal E. coli", "ORGANISM", 47, 60], ["E. coli", "SPECIES", 53, 60], ["E. coli", "SPECIES", 53, 60], ["colistin", "TREATMENT", 35, 43], ["fecal E. coli shedding", "PROBLEM", 47, 69], ["bacterial quantification", "TEST", 71, 95], ["culture methods", "TEST", 132, 147], ["other studies", "TEST", 167, 180], ["PCR", "TEST", 196, 199]]], ["Furthermore, the oral use of a high dose of colistin in healthy piglets was not associated with a major perturbation in the pig gut microbiota as demonstrated by a high-throughput sequencing method [80] .Microbiological and clinical outcomes of colistin use in controlled conditionsAlthough colistin has been used in some studies to promote animal growth, data were not conclusive to support the effectiveness of this practice [81] .", [["oral", "ANATOMY", 17, 21], ["gut", "ANATOMY", 128, 131], ["colistin", "CHEMICAL", 44, 52], ["colistin", "CHEMICAL", 245, 253], ["colistin", "CHEMICAL", 291, 299], ["colistin", "CHEMICAL", 44, 52], ["colistin", "CHEMICAL", 245, 253], ["colistin", "CHEMICAL", 291, 299], ["oral", "ORGANISM_SUBDIVISION", 17, 21], ["colistin", "SIMPLE_CHEMICAL", 44, 52], ["piglets", "ORGANISM", 64, 71], ["pig", "ORGANISM", 124, 127], ["gut", "ORGANISM_SUBDIVISION", 128, 131], ["colistin", "SIMPLE_CHEMICAL", 245, 253], ["colistin", "SIMPLE_CHEMICAL", 291, 299], ["piglets", "SPECIES", 64, 71], ["pig", "SPECIES", 124, 127], ["pig", "SPECIES", 124, 127], ["a high dose of colistin", "TREATMENT", 29, 52], ["a major perturbation in the pig gut microbiota", "PROBLEM", 96, 142], ["colistin use", "TREATMENT", 245, 257], ["colistin", "TREATMENT", 291, 299], ["some studies", "TEST", 317, 329], ["perturbation", "OBSERVATION", 104, 116]]], ["In this study, no difference was observed between the CS treated and the control group in terms of average daily gain per day (ADG/day) [81] .", [["this study", "TEST", 3, 13]]], ["Also, the economic benefits of antimicrobial growth promotion in modern farms have been questioned [82] , the benefit of this use being associated with poor hygiene on farms.Alternative strategies to colistin for post-weaning diarrhea controlReduced colistin usage in livestock and particularly in swine is highly promoted worldwide and is required in Europe as a public health measure to reduce colistin resistance spread, and to prevent the loss of polymyxins effectiveness in human medicine [25] .", [["colistin", "CHEMICAL", 200, 208], ["diarrhea", "DISEASE", 226, 234], ["colistin", "CHEMICAL", 250, 258], ["colistin", "CHEMICAL", 396, 404], ["polymyxins", "CHEMICAL", 451, 461], ["colistin", "CHEMICAL", 200, 208], ["colistin", "CHEMICAL", 250, 258], ["colistin", "CHEMICAL", 396, 404], ["colistin", "SIMPLE_CHEMICAL", 200, 208], ["colistin", "SIMPLE_CHEMICAL", 250, 258], ["swine", "ORGANISM", 298, 303], ["colistin", "SIMPLE_CHEMICAL", 396, 404], ["polymyxins", "SIMPLE_CHEMICAL", 451, 461], ["human", "ORGANISM", 479, 484], ["swine", "SPECIES", 298, 303], ["human", "SPECIES", 479, 484], ["swine", "SPECIES", 298, 303], ["human", "SPECIES", 479, 484], ["antimicrobial growth promotion", "TREATMENT", 31, 61], ["Alternative strategies", "TREATMENT", 174, 196], ["colistin", "TREATMENT", 200, 208], ["weaning diarrhea control", "TREATMENT", 218, 242], ["Reduced colistin usage", "PROBLEM", 242, 264], ["colistin resistance spread", "PROBLEM", 396, 422], ["polymyxins effectiveness", "TREATMENT", 451, 475], ["colistin", "OBSERVATION", 250, 258]]], ["Furthermore, concurrent treatment with colistin in piglets was associated with the isolation of resistant bacteria from the earliest days of treatment [28] .", [["colistin", "CHEMICAL", 39, 47], ["colistin", "CHEMICAL", 39, 47], ["colistin", "SIMPLE_CHEMICAL", 39, 47], ["piglets", "ORGANISM", 51, 58], ["piglets", "SPECIES", 51, 58], ["colistin", "TREATMENT", 39, 47], ["resistant bacteria", "PROBLEM", 96, 114], ["treatment", "TREATMENT", 141, 150], ["resistant", "OBSERVATION_MODIFIER", 96, 105], ["bacteria", "OBSERVATION", 106, 114]]], ["Almost all studies conducted on isolates from pigs worldwide to screen mcr-1 gene presence in enterobacterial species reported that colistin resistant isolates harboring this gene also showed resistance to one or several classes of antimicrobials conventionally used in swine such as: aminoglycoside, sulphonamide, trimethoprim, tetracycline, quinolone, lincosamide, \u03b2-lactam, and third generation cephalosporin [83] [84] [85] [86] .Alternative strategies to colistin for post-weaning diarrhea controlHowever, to ensure swine welfare, productivity and reduced mortality associated with PWD, alternatives to colistin and other antimicrobials, especially those of critical importance for human health, are essential in pigs.", [["colistin", "CHEMICAL", 132, 140], ["aminoglycoside", "CHEMICAL", 285, 299], ["sulphonamide", "CHEMICAL", 301, 313], ["trimethoprim", "CHEMICAL", 315, 327], ["tetracycline", "CHEMICAL", 329, 341], ["quinolone", "CHEMICAL", 343, 352], ["lincosamide", "CHEMICAL", 354, 365], ["\u03b2-lactam", "CHEMICAL", 367, 375], ["cephalosporin", "CHEMICAL", 398, 411], ["colistin", "CHEMICAL", 459, 467], ["diarrhea", "DISEASE", 485, 493], ["colistin", "CHEMICAL", 607, 615], ["colistin", "CHEMICAL", 132, 140], ["aminoglycoside", "CHEMICAL", 285, 299], ["sulphonamide", "CHEMICAL", 301, 313], ["trimethoprim", "CHEMICAL", 315, 327], ["tetracycline", "CHEMICAL", 329, 341], ["quinolone", "CHEMICAL", 343, 352], ["lincosamide", "CHEMICAL", 354, 365], ["\u03b2-lactam", "CHEMICAL", 367, 375], ["cephalosporin", "CHEMICAL", 398, 411], ["colistin", "CHEMICAL", 459, 467], ["colistin", "CHEMICAL", 607, 615], ["pigs", "ORGANISM", 46, 50], ["mcr-1", "GENE_OR_GENE_PRODUCT", 71, 76], ["colistin", "SIMPLE_CHEMICAL", 132, 140], ["aminoglycoside", "SIMPLE_CHEMICAL", 285, 299], ["sulphonamide", "SIMPLE_CHEMICAL", 301, 313], ["trimethoprim", "SIMPLE_CHEMICAL", 315, 327], ["tetracycline", "SIMPLE_CHEMICAL", 329, 341], ["quinolone", "SIMPLE_CHEMICAL", 343, 352], ["lincosamide", "SIMPLE_CHEMICAL", 354, 365], ["\u03b2-lactam", "SIMPLE_CHEMICAL", 367, 375], ["cephalosporin [83] [84] [85] [86]", "SIMPLE_CHEMICAL", 398, 431], ["colistin", "SIMPLE_CHEMICAL", 459, 467], ["colistin", "SIMPLE_CHEMICAL", 607, 615], ["human", "ORGANISM", 686, 691], ["pigs", "ORGANISM", 717, 721], ["mcr", "DNA", 71, 74], ["pigs", "SPECIES", 46, 50], ["swine", "SPECIES", 270, 275], ["swine", "SPECIES", 520, 525], ["human", "SPECIES", 686, 691], ["pigs", "SPECIES", 717, 721], ["pigs", "SPECIES", 46, 50], ["swine", "SPECIES", 270, 275], ["swine", "SPECIES", 520, 525], ["human", "SPECIES", 686, 691], ["pigs", "SPECIES", 717, 721], ["all studies", "TEST", 7, 18], ["screen mcr", "TEST", 64, 74], ["enterobacterial species", "PROBLEM", 94, 117], ["colistin resistant isolates", "TREATMENT", 132, 159], ["antimicrobials", "TREATMENT", 232, 246], ["aminoglycoside", "TREATMENT", 285, 299], ["sulphonamide", "TREATMENT", 301, 313], ["trimethoprim", "TREATMENT", 315, 327], ["tetracycline", "TREATMENT", 329, 341], ["quinolone", "TREATMENT", 343, 352], ["lincosamide", "TREATMENT", 354, 365], ["\u03b2-lactam", "TREATMENT", 367, 375], ["third generation cephalosporin", "TREATMENT", 381, 411], ["colistin", "TREATMENT", 459, 467], ["diarrhea control", "TREATMENT", 485, 501], ["reduced mortality", "PROBLEM", 552, 569], ["PWD", "TREATMENT", 586, 589], ["colistin", "TREATMENT", 607, 615], ["other antimicrobials", "TREATMENT", 620, 640]]], ["There is a major debate over the terminology 'alternative to antibiotics' because we do not propose substances with antibacterial activity but rather substances that act on bacteria indirectly, either by stimulating the host immune system, by the release of substances that have antibacterial activity or by improving the host gut health and consequently growth performance [87] .", [["gut", "ANATOMY", 327, 330], ["gut", "ORGANISM_SUBDIVISION", 327, 330], ["antibiotics", "TREATMENT", 61, 72], ["antibacterial activity", "TREATMENT", 116, 138], ["bacteria", "PROBLEM", 173, 181], ["antibacterial activity", "PROBLEM", 279, 301]]], ["Thus, we will use the terminology \u00abstrategies\u00bb or \u00abmeasures\u00bb to describe alternatives to antimicrobials.", [["antimicrobials", "TREATMENT", 89, 103]]], ["Due to the multifactorial etiology of PWD, finding case-specific preventive measures against this disease is a challenge for both researchers and veterinarians.", [["PWD", "PROBLEM", 38, 41], ["this disease", "PROBLEM", 93, 105]]], ["Here we give an overview of these preventive strategies, focusing on the most practical and promising ones for the control of PWD in pigs.Preventive measuresIn the literature, many alternatives to antimicrobial usage in food-producing animals have been reported and discussed [87] [88] [89] [90] .", [["pigs", "ORGANISM", 133, 137], ["animals", "ORGANISM", 235, 242], ["[87] [88] [89] [90]", "SIMPLE_CHEMICAL", 276, 295], ["pigs", "SPECIES", 133, 137], ["pigs", "SPECIES", 133, 137], ["these preventive strategies", "TREATMENT", 28, 55], ["PWD in pigs", "TREATMENT", 126, 137], ["Preventive measures", "TREATMENT", 138, 157], ["antimicrobial usage", "TREATMENT", 197, 216]]], ["The most promising way to mitigate the development of colistin resistance is to reduce the use of antimicrobials at the farm level (Table 2 ).", [["colistin", "CHEMICAL", 54, 62], ["colistin", "CHEMICAL", 54, 62], ["colistin", "SIMPLE_CHEMICAL", 54, 62], ["colistin resistance", "TREATMENT", 54, 73], ["antimicrobials", "TREATMENT", 98, 112], ["colistin resistance", "OBSERVATION", 54, 73]]], ["There are documented relationships between housing conditions and incidence of PWD in pig herds; Madec et al. [30] claimed that prevention of PWD disorders could be based solely on the control of zootechnical conditions.", [["PWD disorders", "DISEASE", 142, 155], ["pig", "ORGANISM", 86, 89], ["pig", "SPECIES", 86, 89], ["pig", "SPECIES", 86, 89], ["PWD in pig herds", "TREATMENT", 79, 95], ["PWD disorders", "PROBLEM", 142, 155], ["zootechnical conditions", "TREATMENT", 196, 219]]], ["Moreover, stocking density reduction could be considered as a paramount strategy to decrease occurrence of PWD as well as other diseases in pigs [91] .", [["pigs", "ORGANISM", 140, 144], ["pigs", "SPECIES", 140, 144], ["stocking density reduction", "TREATMENT", 10, 36], ["a paramount strategy", "TREATMENT", 60, 80], ["PWD", "PROBLEM", 107, 110], ["other diseases", "PROBLEM", 122, 136], ["stocking density", "OBSERVATION", 10, 26]]], ["Thus, improvement of breeding conditions in pig farms is a crucial measure to reduce the susceptibility of animals to microbial infections and consequently to reduce the use of antimicrobials in pig production [28] .", [["infections", "DISEASE", 128, 138], ["pig", "ORGANISM", 44, 47], ["pig", "ORGANISM", 195, 198], ["pig", "SPECIES", 44, 47], ["pig", "SPECIES", 44, 47], ["pig", "SPECIES", 195, 198], ["breeding conditions", "PROBLEM", 21, 40], ["pig farms", "TREATMENT", 44, 53], ["microbial infections", "PROBLEM", 118, 138], ["antimicrobials", "TREATMENT", 177, 191], ["improvement", "OBSERVATION_MODIFIER", 6, 17]]], ["The management strategies around weaning should focus on measures that avoid any kind of stress for pigs.", [["pigs", "ORGANISM", 100, 104], ["pigs", "SPECIES", 100, 104], ["pigs", "SPECIES", 100, 104], ["The management strategies", "TREATMENT", 0, 25], ["measures", "TREATMENT", 57, 65]]], ["These measures include preventing the spread of infection, providing the pigs with good thermal comfort, giving them adapted feed and allowing access to this feed for all pigs.", [["infection", "DISEASE", 48, 57], ["pigs", "ORGANISM", 73, 77], ["pigs", "ORGANISM", 171, 175], ["pigs", "SPECIES", 73, 77], ["pigs", "SPECIES", 171, 175], ["pigs", "SPECIES", 73, 77], ["infection", "PROBLEM", 48, 57], ["this feed", "TREATMENT", 153, 162], ["spread", "OBSERVATION_MODIFIER", 38, 44], ["infection", "OBSERVATION", 48, 57]]], ["Considerable research has been performed into developing diets for weaners and there is now a range of high quality diets that are readily digested by the early-weaned pig [31] .", [["pig", "ORGANISM", 168, 171], ["pig", "SPECIES", 168, 171], ["pig", "SPECIES", 168, 171], ["weaners", "TREATMENT", 67, 74]]], ["The main purposes of these diets are to achieve A powerful oral immunogen The proposed immunization procedure required large quantities of F4 [8] Leads to a specific mucosal immune response Antigen degraded by the pH of the stomach and by digestive enzymesPreventive measuresLeads to a significant reduction in fecal excretion of ETEC: F4Preventive measuresUsually required mucosal adjuvant such as Cholera toxinPreventive measuresBreeding of resistant pigs Very effective approach Expensive process [2] Greatly reduces the total amount of antimicrobials used on farmsLack of techniques for a large-scale selectionReduces the selection pressure Development of other adherence mechanisms high post-weaning feed intakes and minimize duration of post-weaning anorexia and consequently growth retardation.", [["oral", "ANATOMY", 59, 63], ["mucosal", "ANATOMY", 166, 173], ["stomach", "ANATOMY", 224, 231], ["digestive enzymes", "ANATOMY", 239, 256], ["fecal", "ANATOMY", 311, 316], ["mucosal", "ANATOMY", 374, 381], ["anorexia", "DISEASE", 756, 764], ["growth retardation", "DISEASE", 782, 800], ["oral", "ORGANISM_SUBDIVISION", 59, 63], ["mucosal", "ORGAN", 166, 173], ["stomach", "ORGAN", 224, 231], ["fecal", "ORGANISM_SUBSTANCE", 311, 316], ["mucosal", "MULTI-TISSUE_STRUCTURE", 374, 381], ["pigs", "ORGANISM", 453, 457], ["digestive enzymes", "PROTEIN", 239, 256], ["pigs", "SPECIES", 453, 457], ["pigs", "SPECIES", 453, 457], ["A powerful oral immunogen", "TREATMENT", 48, 73], ["The proposed immunization procedure", "TREATMENT", 74, 109], ["large quantities of F4", "TREATMENT", 119, 141], ["a specific mucosal immune response Antigen", "TEST", 155, 197], ["digestive enzymes", "TEST", 239, 256], ["Preventive measuresLeads", "TREATMENT", 256, 280], ["a significant reduction", "TREATMENT", 284, 307], ["F4Preventive measures", "TREATMENT", 336, 357], ["mucosal adjuvant", "TREATMENT", 374, 390], ["Cholera toxinPreventive measures", "TREATMENT", 399, 431], ["resistant pigs", "TREATMENT", 443, 457], ["the total amount of antimicrobials", "TREATMENT", 520, 554], ["farmsLack of techniques", "TREATMENT", 563, 586], ["a large-scale selection", "TREATMENT", 591, 614], ["the selection pressure", "TREATMENT", 622, 644], ["other adherence mechanisms", "PROBLEM", 660, 686], ["weaning anorexia", "PROBLEM", 748, 764], ["consequently growth retardation", "PROBLEM", 769, 800], ["main", "OBSERVATION_MODIFIER", 4, 8], ["large", "OBSERVATION_MODIFIER", 119, 124], ["stomach", "ANATOMY", 224, 231], ["significant", "OBSERVATION_MODIFIER", 286, 297], ["reduction", "OBSERVATION_MODIFIER", 298, 307], ["fecal excretion", "OBSERVATION", 311, 326], ["mucosal", "ANATOMY", 374, 381], ["adjuvant", "OBSERVATION", 382, 390], ["resistant pigs", "OBSERVATION", 443, 457], ["growth retardation", "OBSERVATION", 782, 800]]], ["It has been reported that the presence of some ingredients in the feed for weaners, such as soybeans, seems to favor the occurrence of PWD [92] .", [["soybeans", "SPECIES", 92, 100], ["some", "OBSERVATION_MODIFIER", 42, 46], ["ingredients", "OBSERVATION", 47, 58]]], ["This could be due to the presence of trypsin inhibitors or antigens inducing a localized immune response [2] .", [["trypsin", "GENE_OR_GENE_PRODUCT", 37, 44], ["trypsin", "PROTEIN", 37, 44], ["trypsin inhibitors", "TREATMENT", 37, 55]]], ["Furthermore, it was shown that soya bean meal (SBM) reduced duodenal specific activities of most intestinal enzymes and increased crypt depth in pigs [93] .", [["duodenal", "ANATOMY", 60, 68], ["intestinal", "ANATOMY", 97, 107], ["crypt", "ANATOMY", 130, 135], ["duodenal", "MULTI-TISSUE_STRUCTURE", 60, 68], ["intestinal", "ORGAN", 97, 107], ["crypt depth", "TISSUE", 130, 141], ["pigs", "ORGANISM", 145, 149], ["intestinal enzymes", "PROTEIN", 97, 115], ["bean", "SPECIES", 36, 40], ["pigs", "SPECIES", 145, 149], ["soya bean", "SPECIES", 31, 40], ["soya bean meal", "TREATMENT", 31, 45], ["most intestinal enzymes", "TEST", 92, 115], ["increased crypt depth", "PROBLEM", 120, 141], ["duodenal", "ANATOMY", 60, 68], ["increased", "OBSERVATION_MODIFIER", 120, 129], ["crypt depth", "OBSERVATION", 130, 141]]], ["Thus, such ingredients should be avoided in feed of early-weaned pigs.", [["pigs", "ORGANISM", 65, 69], ["pigs", "SPECIES", 65, 69]]], ["In addition, feeds with decreased protein content and the addition of organic acid to reduce gastric pH were found to decrease E. coli colonization and to minimize PWD prevalence [31] .", [["gastric", "ANATOMY", 93, 100], ["organic acid", "CHEMICAL", 70, 82], ["organic acid", "SIMPLE_CHEMICAL", 70, 82], ["gastric", "ORGAN", 93, 100], ["E. coli", "ORGANISM", 127, 134], ["E. coli", "SPECIES", 127, 134], ["E. coli", "SPECIES", 127, 134], ["feeds", "TREATMENT", 13, 18], ["decreased protein content", "PROBLEM", 24, 49], ["organic acid", "TREATMENT", 70, 82], ["gastric pH", "PROBLEM", 93, 103], ["E. coli colonization", "PROBLEM", 127, 147], ["gastric", "ANATOMY", 93, 100], ["coli colonization", "OBSERVATION", 130, 147]]], ["The scientific community increasingly recognizes the importance of communication and awareness among farmers in relation to antimicrobial resistance, as reflected by the growing number of publications in this area in recent years [18, 94] .", [["antimicrobial resistance", "TREATMENT", 124, 148], ["antimicrobial resistance", "OBSERVATION", 124, 148], ["growing", "OBSERVATION_MODIFIER", 170, 177], ["number", "OBSERVATION_MODIFIER", 178, 184]]], ["This suggests that farmers' perceptions, and the factors affecting their behaviour, need to be better understood if effective measures associated responsible and prudent use of antimicrobials are to be implemented successfully.Lack of techniques for a large-scale selectionMoreover, effective diagnostic tools are essential for veterinarians to confirm the bacterial etiology of PWD and to determine the antimicrobial susceptibility of the identified bacterial strain.", [["antimicrobials", "TREATMENT", 177, 191], ["a large-scale selection", "TREATMENT", 250, 273], ["PWD", "PROBLEM", 379, 382], ["bacterial strain", "PROBLEM", 451, 467], ["bacterial strain", "OBSERVATION", 451, 467]]], ["The laboratory diagnosis is particularly important in PWD to avoid the inappropriate use of antimicrobials.", [["antimicrobials", "TREATMENT", 92, 106]]], ["DNA-based molecular detection methods such multiplex PCR based on the detection of ETEC virulence genes are rapidly becoming part of the routine laboratory diagnosis of PWD, and these genes are used as a biomarkers of ETEC strain [7, 58] .Lack of techniques for a large-scale selectionIn several countries, implementation of financial penalties for high antimicrobial users is proposed as a method to reduce antimicrobial usage and pig farmers would receive a financial bonus when they use alternative methods or when they greatly reduce antimicrobial use on their farms [94] .", [["ETEC", "DISEASE", 218, 222], ["DNA", "CELLULAR_COMPONENT", 0, 3], ["ETEC virulence", "GENE_OR_GENE_PRODUCT", 83, 97], ["pig", "ORGANISM", 432, 435], ["ETEC virulence genes", "DNA", 83, 103], ["pig", "SPECIES", 432, 435], ["ETEC", "SPECIES", 83, 87], ["ETEC", "SPECIES", 218, 222], ["pig", "SPECIES", 432, 435], ["DNA", "TEST", 0, 3], ["multiplex PCR", "TEST", 43, 56], ["ETEC virulence genes", "PROBLEM", 83, 103], ["PWD", "PROBLEM", 169, 172], ["ETEC strain", "PROBLEM", 218, 229], ["a large-scale selection", "TREATMENT", 262, 285], ["financial penalties", "TREATMENT", 325, 344], ["high antimicrobial users", "TREATMENT", 349, 373], ["a method", "TREATMENT", 389, 397], ["antimicrobial usage", "TREATMENT", 408, 427], ["pig farmers", "TREATMENT", 432, 443], ["a financial bonus", "TREATMENT", 458, 475], ["alternative methods", "TREATMENT", 490, 509]]], ["Vaccination seems to be an effective approach to reduce the occurrence of PWD and to reduce infection pressure and increase immunity in the pig population [2] .", [["infection", "DISEASE", 92, 101], ["pig", "ORGANISM", 140, 143], ["pig", "SPECIES", 140, 143], ["pig", "SPECIES", 140, 143], ["Vaccination", "TREATMENT", 0, 11], ["PWD", "PROBLEM", 74, 77], ["infection pressure", "PROBLEM", 92, 110], ["infection", "OBSERVATION", 92, 101], ["increase", "OBSERVATION_MODIFIER", 115, 123]]], ["Several studies conducted in pigs confirm a reduction of antimicrobial usage after vaccination [95] .", [["pigs", "ORGANISM", 29, 33], ["pigs", "SPECIES", 29, 33], ["pigs", "SPECIES", 29, 33], ["Several studies", "TEST", 0, 15], ["antimicrobial usage", "TREATMENT", 57, 76]]], ["In fact, vaccination against the porcine proliferative enteropathy caused by Lawsonia intracellularis reduced the need for therapeutic oxytetracycline administration in Danish pigs [96] .", [["enteropathy", "DISEASE", 55, 66], ["Lawsonia intracellularis", "CHEMICAL", 77, 101], ["oxytetracycline", "CHEMICAL", 135, 150], ["oxytetracycline", "CHEMICAL", 135, 150], ["porcine", "ORGANISM", 33, 40], ["Lawsonia intracellularis", "ORGANISM", 77, 101], ["oxytetracycline", "SIMPLE_CHEMICAL", 135, 150], ["pigs", "ORGANISM", 176, 180], ["Lawsonia intracellularis", "SPECIES", 77, 101], ["pigs", "SPECIES", 176, 180], ["porcine", "SPECIES", 33, 40], ["Lawsonia intracellularis", "SPECIES", 77, 101], ["vaccination", "TREATMENT", 9, 20], ["the porcine proliferative enteropathy", "PROBLEM", 29, 66], ["Lawsonia intracellularis", "PROBLEM", 77, 101], ["therapeutic oxytetracycline administration", "TREATMENT", 123, 165], ["proliferative enteropathy", "OBSERVATION", 41, 66], ["Lawsonia intracellularis", "OBSERVATION", 77, 101]]], ["Live attenuated and wild type avirulent E. coli vaccines appear to be promising for the control of ETEC infections and live vaccine against ETEC: F4, is now available in Canada and Europe [97] .", [["ETEC infections", "DISEASE", 99, 114], ["ETEC", "CHEMICAL", 140, 144], ["wild type avirulent", "ORGANISM", 20, 39], ["E. coli", "ORGANISM", 40, 47], ["ETEC", "ORGANISM", 99, 103], ["avirulent E. coli", "SPECIES", 30, 47], ["E. coli", "SPECIES", 40, 47], ["ETEC", "SPECIES", 99, 103], ["ETEC", "SPECIES", 140, 144], ["Live attenuated", "PROBLEM", 0, 15], ["wild type avirulent E. coli vaccines", "TREATMENT", 20, 56], ["ETEC infections", "PROBLEM", 99, 114], ["live vaccine", "TREATMENT", 119, 131]]], ["This vaccine is added to the drinking water and recommended for the vaccination of healthy weaned pigs of 17 days or more.", [["pigs", "ORGANISM", 98, 102], ["pigs", "SPECIES", 98, 102], ["This vaccine", "TREATMENT", 0, 12]]], ["Clinical studies confirmed that administration of this vaccine significantly reduced intestinal colonization by virulent ETEC: F4 and the accumulation of fluid in the intestines after an experimental challenge [98] .", [["intestinal", "ANATOMY", 85, 95], ["fluid", "ANATOMY", 154, 159], ["intestines", "ANATOMY", 167, 177], ["intestinal", "ORGAN", 85, 95], ["fluid", "ORGANISM_SUBSTANCE", 154, 159], ["intestines", "ORGAN", 167, 177], ["ETEC", "SPECIES", 121, 125], ["Clinical studies", "TEST", 0, 16], ["this vaccine", "TREATMENT", 50, 62], ["intestinal colonization", "PROBLEM", 85, 108], ["the accumulation of fluid in the intestines", "PROBLEM", 134, 177], ["an experimental challenge", "TREATMENT", 184, 209], ["intestinal", "ANATOMY", 85, 95], ["colonization", "OBSERVATION", 96, 108], ["accumulation", "OBSERVATION_MODIFIER", 138, 150], ["fluid", "OBSERVATION", 154, 159], ["intestines", "ANATOMY", 167, 177]]], ["The immunity in piglets begins 7 days after oral vaccination, however, since PWD caused by ETEC: F4 occurs shortly, in the first week, after weaning, an immune trough may exist in the first days after weaning during which the pigs are not protected [97] .", [["oral", "ANATOMY", 44, 48], ["piglets", "ORGANISM", 16, 23], ["oral", "ORGANISM_SUBDIVISION", 44, 48], ["pigs", "ORGANISM", 226, 230], ["piglets", "SPECIES", 16, 23], ["pigs", "SPECIES", 226, 230], ["ETEC", "SPECIES", 91, 95], ["pigs", "SPECIES", 226, 230], ["oral vaccination", "TREATMENT", 44, 60], ["an immune trough", "TEST", 150, 166]]], ["Thus, the time of the administration of this vaccine should be adjusted.", [["this vaccine", "TREATMENT", 40, 52]]], ["In addition, clinical trials of vaccination against ETEC: F18 has been carried out in pigs.", [["ETEC", "CHEMICAL", 52, 56], ["ETEC", "ORGANISM", 52, 56], ["pigs", "ORGANISM", 86, 90], ["pigs", "SPECIES", 86, 90], ["ETEC", "SPECIES", 52, 56], ["pigs", "SPECIES", 86, 90], ["vaccination", "TREATMENT", 32, 43]]], ["Genetically susceptible pigs were vaccinated orally on three consecutive days, beginning 10 days before weaning with a live F18ac-positive E. coli vaccine [53] .", [["F18ac", "CHEMICAL", 124, 129], ["pigs", "ORGANISM", 24, 28], ["F18ac", "GENE_OR_GENE_PRODUCT", 124, 129], ["E. coli", "ORGANISM", 139, 146], ["pigs", "SPECIES", 24, 28], ["E. coli vaccine", "SPECIES", 139, 154], ["pigs", "SPECIES", 24, 28], ["E. coli", "SPECIES", 139, 146], ["Genetically susceptible pigs", "TREATMENT", 0, 28], ["a live F18ac", "TREATMENT", 117, 129], ["positive E. coli vaccine", "TREATMENT", 130, 154]]], ["In this study, a significant rise in F18ac-specific serum IgA and a 3 Log CFU decrease in fecal shedding of the F18ac-positive challenge strain was observed compared to the unvaccinated group.", [["serum", "ANATOMY", 52, 57], ["fecal", "ANATOMY", 90, 95], ["F18ac", "CHEMICAL", 112, 117], ["F18ac", "GENE_OR_GENE_PRODUCT", 37, 42], ["serum", "ORGANISM_SUBSTANCE", 52, 57], ["IgA", "GENE_OR_GENE_PRODUCT", 58, 61], ["fecal", "ORGANISM_SUBSTANCE", 90, 95], ["F18ac", "GENE_OR_GENE_PRODUCT", 112, 117], ["F18ac", "PROTEIN", 37, 42], ["serum IgA", "PROTEIN", 52, 61], ["this study", "TEST", 3, 13], ["a significant rise", "PROBLEM", 15, 33], ["F18ac", "TEST", 37, 42], ["serum IgA", "TEST", 52, 61], ["fecal shedding", "PROBLEM", 90, 104], ["the F18ac", "TEST", 108, 117], ["positive challenge strain", "PROBLEM", 118, 143], ["significant", "OBSERVATION_MODIFIER", 17, 28], ["rise", "OBSERVATION_MODIFIER", 29, 33], ["decrease", "OBSERVATION_MODIFIER", 78, 86], ["fecal shedding", "OBSERVATION", 90, 104]]], ["However, this vaccine did not induce protective immunity against ETEC: F18.", [["ETEC", "ORGANISM", 65, 69], ["ETEC", "SPECIES", 65, 69], ["this vaccine", "TREATMENT", 9, 21]]], ["On the other hand, it was shown that a minor subunit of F18 (FedF) alone or genetically fused to F4 FaeG subunit or conjugated to F4 fimbriae induced protective anti-F18 antibodies in pigs [99] .", [["FedF", "CHEMICAL", 61, 65], ["F18", "GENE_OR_GENE_PRODUCT", 56, 59], ["FedF", "GENE_OR_GENE_PRODUCT", 61, 65], ["F4 FaeG", "GENE_OR_GENE_PRODUCT", 97, 104], ["conjugated to F4 fimbriae", "GENE_OR_GENE_PRODUCT", 116, 141], ["anti-F18 antibodies", "GENE_OR_GENE_PRODUCT", 161, 180], ["pigs", "ORGANISM", 184, 188], ["F18", "PROTEIN", 56, 59], ["FedF", "PROTEIN", 61, 65], ["F4 FaeG subunit", "PROTEIN", 97, 112], ["F4 fimbriae", "PROTEIN", 130, 141], ["anti-F18 antibodies", "PROTEIN", 161, 180], ["pigs", "SPECIES", 184, 188], ["pigs", "SPECIES", 184, 188], ["a minor subunit of F18 (FedF)", "TREATMENT", 37, 66]]], ["In general, the success of a vaccine against PWD depends largely on the identification of the most prevalent ETEC pathotype present in the farm, resulting in matching of the appropriate protective antigens with the adhesin produced by the ETEC present on the farm, and administering it at the optimal time [7] .", [["ETEC", "ORGANISM", 109, 113], ["protective antigens", "PROTEIN", 186, 205], ["adhesin", "PROTEIN", 215, 222], ["ETEC", "SPECIES", 109, 113], ["a vaccine", "TREATMENT", 27, 36]]], ["For vaccines consisting of live F4 or F18ac-positive E. coli, it is often recommended to vaccinate suckling pigs to obtain a strong mucosal immunity production, IgA, before weaning.", [["mucosal", "ANATOMY", 132, 139], ["F18ac", "GENE_OR_GENE_PRODUCT", 38, 43], ["E. coli", "ORGANISM", 53, 60], ["pigs", "ORGANISM", 108, 112], ["mucosal", "MULTI-TISSUE_STRUCTURE", 132, 139], ["IgA", "GENE_OR_GENE_PRODUCT", 161, 164], ["IgA", "PROTEIN", 161, 164], ["E. coli", "SPECIES", 53, 60], ["pigs", "SPECIES", 108, 112], ["E. coli", "SPECIES", 53, 60], ["pigs", "SPECIES", 108, 112], ["vaccines", "TREATMENT", 4, 12], ["F18ac", "TEST", 38, 43], ["positive E. coli", "PROBLEM", 44, 60], ["E. coli", "OBSERVATION_MODIFIER", 53, 60]]], ["However, our knowledge is very limited about the effect of maternal antibodies on the survival of these vaccine strains in the intestine of pigs of this age.", [["intestine", "ANATOMY", 127, 136], ["intestine", "ORGAN", 127, 136], ["pigs", "ORGANISM", 140, 144], ["maternal antibodies", "PROTEIN", 59, 78], ["pigs", "SPECIES", 140, 144], ["pigs", "SPECIES", 140, 144], ["maternal antibodies", "PROBLEM", 59, 78], ["these vaccine strains", "TREATMENT", 98, 119], ["intestine", "ANATOMY", 127, 136]]], ["Also, there is no cross protection against ETEC strains expressing a different fimbria or toxin.", [["ETEC", "ORGANISM", 43, 47], ["fimbria", "GENE_OR_GENE_PRODUCT", 79, 86], ["fimbria or toxin", "PROTEIN", 79, 95], ["ETEC", "SPECIES", 43, 47], ["cross protection", "TREATMENT", 18, 34], ["ETEC strains", "PROBLEM", 43, 55], ["a different fimbria or toxin", "PROBLEM", 67, 95], ["no", "UNCERTAINTY", 15, 17], ["cross protection", "OBSERVATION_MODIFIER", 18, 34], ["different", "OBSERVATION_MODIFIER", 69, 78], ["fimbria", "OBSERVATION_MODIFIER", 79, 86]]], ["Recently, plantbased vaccines for protection of pigs against ETEC were investigated.", [["ETEC", "DISEASE", 61, 65], ["pigs", "ORGANISM", 48, 52], ["ETEC", "ORGANISM", 61, 65], ["pigs", "SPECIES", 48, 52], ["pigs", "SPECIES", 48, 52], ["ETEC", "SPECIES", 61, 65], ["plantbased vaccines", "TREATMENT", 10, 29], ["protection of pigs", "TREATMENT", 34, 52], ["ETEC", "PROBLEM", 61, 65]]], ["A rice-based cholera vaccine expressing the choleratoxin (CT) subunit B (CTB) (MucoRice-CTB) was tested in pigs for protection against LT-ETEC infection [100] .", [["choleratoxin", "CHEMICAL", 44, 56], ["MucoRice-CTB", "CHEMICAL", 79, 91], ["infection", "DISEASE", 143, 152], ["cholera", "ORGANISM", 13, 20], ["choleratoxin (CT) subunit B", "GENE_OR_GENE_PRODUCT", 44, 71], ["CTB", "GENE_OR_GENE_PRODUCT", 73, 76], ["MucoRice-CTB", "GENE_OR_GENE_PRODUCT", 79, 91], ["pigs", "ORGANISM", 107, 111], ["LT-ETEC", "GENE_OR_GENE_PRODUCT", 135, 142], ["choleratoxin (CT) subunit B", "PROTEIN", 44, 71], ["CTB", "PROTEIN", 73, 76], ["MucoRice", "PROTEIN", 79, 87], ["CTB", "PROTEIN", 88, 91], ["rice", "SPECIES", 2, 6], ["pigs", "SPECIES", 107, 111], ["rice", "SPECIES", 2, 6], ["pigs", "SPECIES", 107, 111], ["A rice-based cholera vaccine", "TREATMENT", 0, 28], ["the choleratoxin (CT) subunit B (CTB) (MucoRice-CTB)", "TREATMENT", 40, 92], ["ETEC infection", "PROBLEM", 138, 152], ["infection", "OBSERVATION", 143, 152]]], ["CTB-based vaccines can target not only F4-type but also F18-type ETECs, and this vaccine also induced maternal CTB-specific IgG and IgA in the colostrum and milk of sows after farrowing.", [["F18-type ETECs", "ANATOMY", 56, 70], ["colostrum", "ANATOMY", 143, 152], ["milk", "ANATOMY", 157, 161], ["CTB", "CHEMICAL", 0, 3], ["CTB", "SIMPLE_CHEMICAL", 0, 3], ["F18-type ETECs", "CELL", 56, 70], ["CTB", "GENE_OR_GENE_PRODUCT", 111, 114], ["IgG", "GENE_OR_GENE_PRODUCT", 124, 127], ["IgA", "GENE_OR_GENE_PRODUCT", 132, 135], ["colostrum", "ORGANISM_SUBSTANCE", 143, 152], ["milk", "ORGANISM_SUBSTANCE", 157, 161], ["sows", "ORGANISM", 165, 169], ["F18", "PROTEIN", 56, 59], ["CTB", "PROTEIN", 111, 114], ["IgG", "PROTEIN", 124, 127], ["IgA", "PROTEIN", 132, 135], ["colostrum", "SPECIES", 143, 152], ["CTB-based vaccines", "TREATMENT", 0, 18], ["this vaccine", "TREATMENT", 76, 88], ["maternal CTB", "PROBLEM", 102, 114], ["specific IgG", "TEST", 115, 127], ["colostrum", "ANATOMY", 143, 152]]], ["CTB-specific antibodies were also secreted into the gut lumen of weaned pigs and reduced intestinal loop fluid accumulation upon ETEC challenge, indicating a protective effect of this vaccine against ETEC diarrhea [100] .", [["gut lumen", "ANATOMY", 52, 61], ["intestinal loop fluid", "ANATOMY", 89, 110], ["ETEC", "CHEMICAL", 129, 133], ["diarrhea", "DISEASE", 205, 213], ["CTB", "SIMPLE_CHEMICAL", 0, 3], ["gut lumen", "MULTI-TISSUE_STRUCTURE", 52, 61], ["pigs", "ORGANISM", 72, 76], ["intestinal loop", "MULTI-TISSUE_STRUCTURE", 89, 104], ["fluid", "ORGANISM_SUBSTANCE", 105, 110], ["ETEC", "ORGANISM", 200, 204], ["CTB-specific antibodies", "PROTEIN", 0, 23], ["pigs", "SPECIES", 72, 76], ["pigs", "SPECIES", 72, 76], ["ETEC", "SPECIES", 129, 133], ["ETEC", "SPECIES", 200, 204], ["CTB", "TEST", 0, 3], ["specific antibodies", "TEST", 4, 23], ["weaned pigs", "TREATMENT", 65, 76], ["reduced intestinal loop fluid accumulation", "TREATMENT", 81, 123], ["ETEC challenge", "TREATMENT", 129, 143], ["this vaccine", "TREATMENT", 179, 191], ["ETEC diarrhea", "PROBLEM", 200, 213], ["gut", "ANATOMY", 52, 55], ["lumen", "ANATOMY_MODIFIER", 56, 61], ["weaned pigs", "OBSERVATION", 65, 76], ["intestinal", "ANATOMY", 89, 99], ["loop fluid", "OBSERVATION", 100, 110]]], ["However, the cost of these vaccines is very high and, unlike open-air farming, the production of transgenic plants for biotherapeutic use is very demanding.", [["these vaccines", "TREATMENT", 21, 35], ["open-air farming", "TREATMENT", 61, 77], ["transgenic plants", "TREATMENT", 97, 114], ["high", "OBSERVATION_MODIFIER", 44, 48], ["air farming", "OBSERVATION", 66, 77]]], ["Moreover, the procedures for manufacturing and processing of plant-based pharmaceuticals are not well defined.", [["the procedures", "TREATMENT", 10, 24], ["manufacturing", "TREATMENT", 29, 42], ["plant-based pharmaceuticals", "TREATMENT", 61, 88], ["plant", "OBSERVATION_MODIFIER", 61, 66], ["pharmaceuticals", "OBSERVATION", 73, 88]]], ["Thus, a large-scale production of these vaccines not envisaged, at least in the near future.", [["a large-scale production", "TREATMENT", 6, 30], ["these vaccines", "TREATMENT", 34, 48], ["large", "OBSERVATION_MODIFIER", 8, 13]]], ["Current progress in the development of subunit vaccines against ETEC associated with diarrhea in humans and animals has been reviewed extensively elsewhere [97, 101] .", [["ETEC", "DISEASE", 64, 68], ["diarrhea", "DISEASE", 85, 93], ["ETEC", "ORGANISM", 64, 68], ["humans", "ORGANISM", 97, 103], ["humans", "SPECIES", 97, 103], ["ETEC", "SPECIES", 64, 68], ["humans", "SPECIES", 97, 103], ["subunit vaccines", "TREATMENT", 39, 55], ["ETEC", "PROBLEM", 64, 68], ["diarrhea", "PROBLEM", 85, 93], ["diarrhea", "OBSERVATION", 85, 93]]], ["However, none of these subunit vaccines has been marketed in swine.Lack of techniques for a large-scale selectionThe selection of animals genetically resistant to ETEC F4 and/or F18 is considered as a radical solution to eliminate the PWD in a swine herd.", [["ETEC", "CHEMICAL", 163, 167], ["F18", "CHEMICAL", 178, 181], ["swine", "ORGANISM", 61, 66], ["ETEC F4", "ORGANISM", 163, 170], ["swine", "SPECIES", 61, 66], ["swine", "SPECIES", 244, 249], ["swine", "SPECIES", 61, 66], ["swine", "SPECIES", 244, 249], ["these subunit vaccines", "TREATMENT", 17, 39], ["a large-scale selection", "TREATMENT", 90, 113], ["ETEC F4", "TREATMENT", 163, 170], ["a radical solution", "TREATMENT", 199, 217]]], ["Pigs that are resistant to ETEC: F4 and/or F18 do not express intestinal receptors for these fimbrial types [2] .", [["intestinal", "ANATOMY", 62, 72], ["Pigs", "ORGANISM", 0, 4], ["F18", "GENE_OR_GENE_PRODUCT", 43, 46], ["intestinal", "ORGAN", 62, 72], ["F18", "PROTEIN", 43, 46], ["intestinal receptors", "PROTEIN", 62, 82], ["Pigs", "SPECIES", 0, 4], ["Pigs", "TREATMENT", 0, 4], ["resistant", "OBSERVATION_MODIFIER", 14, 23], ["intestinal", "ANATOMY", 62, 72]]], ["The expression of these receptors is genetically determined and inherited in a dominant way and the loci controlling F4R and F18R expression are located on separate chromosomes.", [["chromosomes", "ANATOMY", 165, 176], ["F4R", "GENE_OR_GENE_PRODUCT", 117, 120], ["F18R", "GENE_OR_GENE_PRODUCT", 125, 129], ["chromosomes", "CELLULAR_COMPONENT", 165, 176], ["F4R", "DNA", 117, 120], ["F18R", "DNA", 125, 129], ["chromosomes", "DNA", 165, 176]]], ["The gene underlying resistance to F4ab/ac ETEC has been assigned to porcine chromosome 13, whereas the F4ad ETEC receptor is located on another chromosome that was not identified [102] .", [["chromosome 13", "ANATOMY", 76, 89], ["chromosome", "ANATOMY", 144, 154], ["F4ab/ac ETEC", "GENE_OR_GENE_PRODUCT", 34, 46], ["porcine chromosome 13", "GENE_OR_GENE_PRODUCT", 68, 89], ["F4ad ETEC receptor", "GENE_OR_GENE_PRODUCT", 103, 121], ["chromosome", "CELLULAR_COMPONENT", 144, 154], ["F4ab", "DNA", 34, 38], ["ac ETEC", "PROTEIN", 39, 46], ["porcine chromosome 13", "DNA", 68, 89], ["F4ad ETEC receptor", "PROTEIN", 103, 121], ["F4ab/ac ETEC", "TREATMENT", 34, 46], ["resistance", "OBSERVATION_MODIFIER", 20, 30]]], ["A PCR-RFLP test has been developed to allow genotyping for F4ab/ac ETEC resistance/susceptibility [103] .", [["F4ab", "GENE_OR_GENE_PRODUCT", 59, 63], ["F4ab", "PROTEIN", 59, 63], ["A PCR", "TEST", 0, 5], ["RFLP test", "TEST", 6, 15], ["genotyping", "TEST", 44, 54], ["F4ab", "TEST", 59, 63]]], ["Three different genotypes were observed and were identified as resistant (RR), susceptible heterozygote (SR) and susceptible homozygote (SS).", [["Three different genotypes", "PROBLEM", 0, 25], ["RR", "TEST", 74, 76], ["susceptible heterozygote", "PROBLEM", 79, 103]]], ["However, it cannot be predicted if additional types of adhesive fimbriae or new variants of known types will emerge which could bind to yet unidentified receptors and could cause outbreaks of diarrhea and mortality in the nursery [2] .", [["diarrhea", "DISEASE", 192, 200], ["adhesive fimbriae", "GENE_OR_GENE_PRODUCT", 55, 72], ["adhesive fimbriae", "PROTEIN", 55, 72], ["adhesive fimbriae", "PROBLEM", 55, 72], ["diarrhea", "PROBLEM", 192, 200]]], ["It is difficult to understand the reasons behind the non-exploration of the genetic breeding for ETEC resistant pigs to reduce economic losses associated with PWD and to reduce the use of antimicrobials on farms.", [["ETEC", "CHEMICAL", 97, 101], ["ETEC", "ORGANISM", 97, 101], ["pigs", "ORGANISM", 112, 116], ["pigs", "SPECIES", 112, 116], ["pigs", "SPECIES", 112, 116], ["ETEC resistant pigs", "TREATMENT", 97, 116], ["economic losses", "PROBLEM", 127, 142], ["PWD", "TREATMENT", 159, 162], ["antimicrobials on farms", "TREATMENT", 188, 211]]], ["It was shown in an early study that F4 susceptible piglets tend to have better growth performance then F4 resistant ones [104] .", [["piglets", "ORGANISM", 51, 58], ["piglets", "SPECIES", 51, 58], ["an early study", "TEST", 16, 30]]], ["Also, heterozygous F4R \u2212 piglets are not passively protected from infection by ETEC: F4 strains [105] .Feed additivesIn pigs, PWD can be controlled using various preventive strategies without using antimicrobials (Table 3) .", [["infection", "DISEASE", 66, 75], ["F4R \u2212 piglets", "ORGANISM", 19, 32], ["pigs", "ORGANISM", 120, 124], ["piglets", "SPECIES", 25, 32], ["pigs", "SPECIES", 120, 124], ["pigs", "SPECIES", 120, 124], ["infection", "PROBLEM", 66, 75], ["Feed additives", "TREATMENT", 103, 117], ["PWD", "TREATMENT", 126, 129], ["various preventive strategies", "TREATMENT", 154, 183], ["antimicrobials", "TREATMENT", 198, 212], ["infection", "OBSERVATION", 66, 75]]], ["Feed supplements such as zinc oxide, organic acids, pre-probiotics, synbiotics, dehydrated porcine plasma, antimicrobial peptides, specific egg yolk and bacteriophages [31, 89, [106] [107] [108] [109] [110] have been used in weanling pigs to enhance growth, feed efficiency and to reduce PWD.", [["plasma", "ANATOMY", 99, 105], ["egg yolk", "ANATOMY", 140, 148], ["zinc oxide", "CHEMICAL", 25, 35], ["organic acids", "CHEMICAL", 37, 50], ["pre-probiotics", "CHEMICAL", 52, 66], ["zinc oxide", "CHEMICAL", 25, 35], ["zinc oxide", "SIMPLE_CHEMICAL", 25, 35], ["organic acids", "SIMPLE_CHEMICAL", 37, 50], ["pre-probiotics", "SIMPLE_CHEMICAL", 52, 66], ["synbiotics", "SIMPLE_CHEMICAL", 68, 78], ["porcine", "ORGANISM", 91, 98], ["plasma", "ORGANISM_SUBSTANCE", 99, 105], ["egg yolk", "MULTI-TISSUE_STRUCTURE", 140, 148], ["pigs", "ORGANISM", 234, 238], ["porcine", "SPECIES", 91, 98], ["pigs", "SPECIES", 234, 238], ["porcine", "SPECIES", 91, 98], ["pigs", "SPECIES", 234, 238], ["Feed supplements", "TREATMENT", 0, 16], ["zinc oxide", "TREATMENT", 25, 35], ["organic acids", "TREATMENT", 37, 50], ["pre-probiotics", "TREATMENT", 52, 66], ["synbiotics", "TREATMENT", 68, 78], ["dehydrated porcine plasma", "TREATMENT", 80, 105], ["antimicrobial peptides", "TREATMENT", 107, 129], ["specific egg yolk", "TEST", 131, 148], ["bacteriophages", "TEST", 153, 167]]], ["Here we give an overview of these feed strategies, focusing on the most used practices showing clinical effectiveness in reducing symptoms of PWD and ETEC attachment to enterocytes.Feed additivesZinc oxide: it has been shown that the addition of zinc (Zn) as zinc oxide (ZnO) at the levels of 2400-3000 ppm in pig feed was effective in the reducing of PWD and mortality and in improving growth performance in weaned pigs [111, 112] .", [["enterocytes", "ANATOMY", 169, 180], ["Zinc oxide", "CHEMICAL", 195, 205], ["zinc", "CHEMICAL", 246, 250], ["Zn", "CHEMICAL", 252, 254], ["zinc oxide", "CHEMICAL", 259, 269], ["ZnO", "CHEMICAL", 271, 274], ["Zinc oxide", "CHEMICAL", 195, 205], ["zinc", "CHEMICAL", 246, 250], ["Zn", "CHEMICAL", 252, 254], ["zinc oxide", "CHEMICAL", 259, 269], ["ZnO", "CHEMICAL", 271, 274], ["enterocytes", "CELL", 169, 180], ["Zinc oxide", "SIMPLE_CHEMICAL", 195, 205], ["zinc", "SIMPLE_CHEMICAL", 246, 250], ["Zn", "SIMPLE_CHEMICAL", 252, 254], ["zinc oxide", "SIMPLE_CHEMICAL", 259, 269], ["ZnO", "SIMPLE_CHEMICAL", 271, 274], ["pig", "ORGANISM", 310, 313], ["pigs", "ORGANISM", 416, 420], ["enterocytes", "CELL_TYPE", 169, 180], ["pigs", "SPECIES", 416, 420], ["ETEC", "SPECIES", 150, 154], ["pig", "SPECIES", 310, 313], ["pigs", "SPECIES", 416, 420], ["these feed strategies", "TREATMENT", 28, 49], ["reducing symptoms", "PROBLEM", 121, 138], ["PWD", "PROBLEM", 142, 145], ["ETEC attachment to enterocytes", "PROBLEM", 150, 180], ["Feed additives", "TREATMENT", 181, 195], ["Zinc oxide", "TREATMENT", 195, 205], ["zinc (Zn)", "TREATMENT", 246, 255], ["zinc oxide (ZnO)", "TREATMENT", 259, 275], ["pig feed", "TREATMENT", 310, 318], ["enterocytes", "ANATOMY", 169, 180]]], ["However, Amezcua and collaborators [1] reported an important proportion of farms with PWD occurrence using high levels of ZnO.", [["ZnO.", "CHEMICAL", 122, 126], ["ZnO.", "CHEMICAL", 122, 126], ["ZnO.", "SIMPLE_CHEMICAL", 122, 126]]], ["Also, several studies reported an increased proportion of E. coli isolates resistant to tetracycline and sulfonamides in pigs fed with high zinc doses [113, 114] .", [["tetracycline", "CHEMICAL", 88, 100], ["sulfonamides", "CHEMICAL", 105, 117], ["zinc", "CHEMICAL", 140, 144], ["tetracycline", "CHEMICAL", 88, 100], ["sulfonamides", "CHEMICAL", 105, 117], ["zinc", "CHEMICAL", 140, 144], ["E. coli", "ORGANISM", 58, 65], ["tetracycline", "SIMPLE_CHEMICAL", 88, 100], ["sulfonamides", "SIMPLE_CHEMICAL", 105, 117], ["pigs", "ORGANISM", 121, 125], ["zinc", "SIMPLE_CHEMICAL", 140, 144], ["E. coli", "SPECIES", 58, 65], ["pigs", "SPECIES", 121, 125], ["E. coli", "SPECIES", 58, 65], ["pigs", "SPECIES", 121, 125], ["several studies", "TEST", 6, 21], ["E. coli isolates", "PROBLEM", 58, 74], ["tetracycline", "TREATMENT", 88, 100], ["sulfonamides", "TREATMENT", 105, 117], ["high zinc doses", "TREATMENT", 135, 150], ["increased", "OBSERVATION_MODIFIER", 34, 43], ["E. coli isolates", "OBSERVATION", 58, 74]]], ["This may explain why antimicrobial resistance persists even in the absence of antimicrobial exposure [115, 116] .", [["antimicrobial resistance", "PROBLEM", 21, 45], ["may explain", "UNCERTAINTY", 5, 16], ["antimicrobial resistance", "OBSERVATION", 21, 45]]], ["Moreover, the use of high zinc levels in pig feeds has led to heavy metal contamination in the soil, raising environmental concerns [115] .", [["zinc", "CHEMICAL", 26, 30], ["zinc", "CHEMICAL", 26, 30], ["zinc", "SIMPLE_CHEMICAL", 26, 30], ["pig", "ORGANISM", 41, 44], ["pig", "SPECIES", 41, 44], ["pig", "SPECIES", 41, 44], ["high zinc levels in pig feeds", "TREATMENT", 21, 50], ["heavy metal contamination", "PROBLEM", 62, 87]]], ["Recently, Bouwhuis et al. [117] reported that organic zinc [zinc methionine (ZnM)] could be used as a substitute for the inorganic zinc (ZnO) in the pig diet.", [["zinc", "CHEMICAL", 54, 58], ["zinc methionine", "CHEMICAL", 60, 75], ["ZnM", "CHEMICAL", 77, 80], ["inorganic zinc", "CHEMICAL", 121, 135], ["ZnO", "CHEMICAL", 137, 140], ["zinc", "CHEMICAL", 54, 58], ["zinc methionine", "CHEMICAL", 60, 75], ["ZnM", "CHEMICAL", 77, 80], ["zinc", "CHEMICAL", 131, 135], ["ZnO", "CHEMICAL", 137, 140], ["organic zinc [zinc methionine", "SIMPLE_CHEMICAL", 46, 75], ["ZnM", "SIMPLE_CHEMICAL", 77, 80], ["inorganic zinc", "SIMPLE_CHEMICAL", 121, 135], ["ZnO", "SIMPLE_CHEMICAL", 137, 140], ["pig", "ORGANISM", 149, 152], ["pig", "SPECIES", 149, 152], ["pig", "SPECIES", 149, 152], ["organic zinc [zinc methionine (ZnM)", "TREATMENT", 46, 81], ["the inorganic zinc (ZnO)", "TREATMENT", 117, 141]]], ["In fact, organic zinc can be supplemented in lower doses (up to 500 mg/kg feed) compared to ZnO [117] .", [["zinc", "CHEMICAL", 17, 21], ["ZnO", "CHEMICAL", 92, 95], ["zinc", "CHEMICAL", 17, 21], ["ZnO", "CHEMICAL", 92, 95], ["organic zinc", "SIMPLE_CHEMICAL", 9, 21], ["organic zinc", "TREATMENT", 9, 21]]], ["In this study, the inclusion of ZnM resulted in improved faecal scores and the intestinal architecture compared to that observed in pigs supplemented with ZnO.Feed additivesOrganic acids such as citric, fumaric, lactic, propionic, benzoic and formic acids showed beneficial effects in the pig gastrointestinal tract.", [["faecal", "ANATOMY", 57, 63], ["intestinal", "ANATOMY", 79, 89], ["gastrointestinal tract", "ANATOMY", 293, 315], ["ZnM", "CHEMICAL", 32, 35], ["ZnO", "CHEMICAL", 155, 158], ["citric, fumaric, lactic, propionic, benzoic and formic acids", "CHEMICAL", 195, 255], ["ZnM", "CHEMICAL", 32, 35], ["ZnO", "CHEMICAL", 155, 158], ["citric, fumaric, lactic, propionic, benzoic and formic acids", "CHEMICAL", 195, 255], ["ZnM", "SIMPLE_CHEMICAL", 32, 35], ["faecal", "ORGANISM_SUBSTANCE", 57, 63], ["intestinal architecture", "MULTI-TISSUE_STRUCTURE", 79, 102], ["pigs", "ORGANISM", 132, 136], ["ZnO", "SIMPLE_CHEMICAL", 155, 158], ["Organic acids", "SIMPLE_CHEMICAL", 173, 186], ["citric", "SIMPLE_CHEMICAL", 195, 201], ["fumaric", "SIMPLE_CHEMICAL", 203, 210], ["lactic", "SIMPLE_CHEMICAL", 212, 218], ["propionic", "SIMPLE_CHEMICAL", 220, 229], ["benzoic", "SIMPLE_CHEMICAL", 231, 238], ["formic acids", "SIMPLE_CHEMICAL", 243, 255], ["pig", "ORGANISM", 289, 292], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 293, 315], ["pigs", "SPECIES", 132, 136], ["pig", "SPECIES", 289, 292], ["pigs", "SPECIES", 132, 136], ["pig", "SPECIES", 289, 292], ["this study", "TEST", 3, 13], ["ZnM", "TREATMENT", 32, 35], ["improved faecal scores", "PROBLEM", 48, 70], ["ZnO", "TREATMENT", 155, 158], ["Feed additives", "TREATMENT", 159, 173], ["Organic acids", "TREATMENT", 173, 186], ["citric, fumaric", "TREATMENT", 195, 210], ["lactic, propionic", "TREATMENT", 212, 229], ["benzoic", "TREATMENT", 231, 238], ["formic acids", "TREATMENT", 243, 255], ["beneficial effects in the pig gastrointestinal tract", "PROBLEM", 263, 315], ["improved", "OBSERVATION_MODIFIER", 48, 56], ["faecal scores", "OBSERVATION", 57, 70], ["intestinal", "ANATOMY", 79, 89], ["pig", "ANATOMY_MODIFIER", 289, 292], ["gastrointestinal tract", "ANATOMY", 293, 315]]], ["In fact, the use of organic acids in weaned piglets was associated with a reduction of stomach pH [118] .", [["stomach", "ANATOMY", 87, 94], ["organic acids", "CHEMICAL", 20, 33], ["organic acids", "SIMPLE_CHEMICAL", 20, 33], ["piglets", "ORGANISM", 44, 51], ["stomach", "ORGAN", 87, 94], ["piglets", "SPECIES", 44, 51], ["organic acids", "TREATMENT", 20, 33], ["a reduction of stomach pH", "PROBLEM", 72, 97], ["stomach", "ANATOMY", 87, 94]]], ["With this effect, organic acids generate a hostile gastric environment for bacterial survival.", [["gastric", "ANATOMY", 51, 58], ["organic acids", "CHEMICAL", 18, 31], ["organic acids", "SIMPLE_CHEMICAL", 18, 31], ["gastric", "ORGAN", 51, 58], ["organic acids", "TREATMENT", 18, 31], ["a hostile gastric environment", "TREATMENT", 41, 70], ["bacterial survival", "TREATMENT", 75, 93]]], ["Moreover, organic acids promote the conversion of pepsinogen into pepsin in the stomach of pigs, and promote the activity of this enzyme [108] .", [["stomach", "ANATOMY", 80, 87], ["organic acids", "CHEMICAL", 10, 23], ["organic acids", "SIMPLE_CHEMICAL", 10, 23], ["pepsinogen", "GENE_OR_GENE_PRODUCT", 50, 60], ["pepsin", "GENE_OR_GENE_PRODUCT", 66, 72], ["stomach", "ORGAN", 80, 87], ["pigs", "ORGANISM", 91, 95], ["pepsinogen", "PROTEIN", 50, 60], ["pepsin", "PROTEIN", 66, 72], ["pigs", "SPECIES", 91, 95], ["organic acids", "TREATMENT", 10, 23], ["pepsinogen into pepsin", "TREATMENT", 50, 72], ["this enzyme", "TEST", 125, 136], ["stomach", "ANATOMY", 80, 87]]], ["On the other hand, decreasing the intestinal pH is probably not a primary effect of feeding organic acids in pigs.", [["intestinal", "ANATOMY", 34, 44], ["organic acids", "CHEMICAL", 92, 105], ["intestinal", "ORGAN", 34, 44], ["organic acids", "SIMPLE_CHEMICAL", 92, 105], ["pigs", "ORGANISM", 109, 113], ["pigs", "SPECIES", 109, 113], ["pigs", "SPECIES", 109, 113], ["decreasing the intestinal pH", "PROBLEM", 19, 47], ["feeding organic acids", "TREATMENT", 84, 105], ["intestinal", "ANATOMY", 34, 44], ["probably not", "UNCERTAINTY", 51, 63], ["organic acids", "OBSERVATION", 92, 105]]], ["Indeed, Risley et al. [119] reported a non significant decrease in the pH of the small intestine in 3-week-old weanling pigs fed with a diet supplemented with 1.5% fumaric or citric acid.", [["small intestine", "ANATOMY", 81, 96], ["fumaric", "CHEMICAL", 164, 171], ["citric acid", "CHEMICAL", 175, 186], ["fumaric", "CHEMICAL", 164, 171], ["citric acid", "CHEMICAL", 175, 186], ["small intestine", "ORGAN", 81, 96], ["pigs", "ORGANISM", 120, 124], ["fumaric", "SIMPLE_CHEMICAL", 164, 171], ["citric acid", "SIMPLE_CHEMICAL", 175, 186], ["pigs", "SPECIES", 120, 124], ["pigs", "SPECIES", 120, 124], ["a non significant decrease in the pH of the small intestine", "PROBLEM", 37, 96], ["1.5% fumaric", "TREATMENT", 159, 171], ["citric acid", "TREATMENT", 175, 186], ["significant", "OBSERVATION_MODIFIER", 43, 54], ["decrease", "OBSERVATION", 55, 63], ["small intestine", "ANATOMY", 81, 96]]], ["Addition of organic acids to weaned pig diets improved growth performance and health [31] as well as the local immunity in the jejunum epithelium [120] .", [["jejunum epithelium", "ANATOMY", 127, 145], ["organic acids", "CHEMICAL", 12, 25], ["organic acids", "SIMPLE_CHEMICAL", 12, 25], ["pig", "ORGANISM", 36, 39], ["jejunum epithelium", "TISSUE", 127, 145], ["pig", "SPECIES", 36, 39], ["pig", "SPECIES", 36, 39], ["organic acids", "TREATMENT", 12, 25], ["pig diets", "TREATMENT", 36, 45], ["jejunum", "ANATOMY", 127, 134]]], ["It was reported that regardless of the organic acids used in the feed, these compounds reduced the incidence and severity of diarrhea in pigs, and improved the performance of the treated group compared to that of the negative control group [121] .Feed additivesPrebiotics are selectively fermented components of feed, indigestible by the host animal, that modulate the gut microbiota to benefit host health.", [["gut", "ANATOMY", 369, 372], ["organic acids", "CHEMICAL", 39, 52], ["diarrhea", "DISEASE", 125, 133], ["Prebiotics", "CHEMICAL", 261, 271], ["organic acids", "SIMPLE_CHEMICAL", 39, 52], ["pigs", "ORGANISM", 137, 141], ["Prebiotics", "SIMPLE_CHEMICAL", 261, 271], ["gut", "ORGANISM_SUBDIVISION", 369, 372], ["pigs", "SPECIES", 137, 141], ["pigs", "SPECIES", 137, 141], ["the organic acids", "TREATMENT", 35, 52], ["diarrhea", "PROBLEM", 125, 133], ["Feed additivesPrebiotics", "TREATMENT", 247, 271], ["diarrhea", "OBSERVATION", 125, 133]]], ["Resulting effects include the stimulation of short-chain fatty acid (SCFA) production and the proliferation of bifidobacteria and lactic acid bacteria such as Lactobacillus spp. and Bifidobacterium spp.", [["fatty acid", "CHEMICAL", 57, 67], ["SCFA", "CHEMICAL", 69, 73], ["lactic acid", "CHEMICAL", 130, 141], ["Lactobacillus spp.", "CHEMICAL", 159, 177], ["short-chain fatty acid", "CHEMICAL", 45, 67], ["SCFA", "CHEMICAL", 69, 73], ["lactic acid", "CHEMICAL", 130, 141], ["short-chain fatty acid", "SIMPLE_CHEMICAL", 45, 67], ["SCFA", "SIMPLE_CHEMICAL", 69, 73], ["bifidobacteria", "SIMPLE_CHEMICAL", 111, 125], ["lactic acid", "SIMPLE_CHEMICAL", 130, 141], ["Lactobacillus spp.", "ORGANISM", 159, 177], ["Bifidobacterium spp", "ORGANISM", 182, 201], ["Lactobacillus spp.", "SPECIES", 159, 177], ["Lactobacillus spp.", "SPECIES", 159, 177], ["the stimulation", "TREATMENT", 26, 41], ["short-chain fatty acid (SCFA) production", "PROBLEM", 45, 85], ["bifidobacteria", "PROBLEM", 111, 125], ["lactic acid bacteria", "PROBLEM", 130, 150], ["Lactobacillus spp.", "PROBLEM", 159, 177], ["Bifidobacterium spp", "PROBLEM", 182, 201], ["Bifidobacterium spp", "OBSERVATION", 182, 201]]], ["Common prebiotics include inulin and oligosaccharides such as galactooligosaccharides (GOS) and fructooligosaccharides (FOS) [124] .", [["inulin", "CHEMICAL", 26, 32], ["galactooligosaccharides", "CHEMICAL", 62, 85], ["galactooligosaccharides", "CHEMICAL", 62, 85], ["fructooligosaccharides", "CHEMICAL", 96, 118], ["inulin", "SIMPLE_CHEMICAL", 26, 32], ["oligosaccharides", "SIMPLE_CHEMICAL", 37, 53], ["galactooligosaccharides", "SIMPLE_CHEMICAL", 62, 85], ["GOS", "SIMPLE_CHEMICAL", 87, 90], ["fructooligosaccharides", "SIMPLE_CHEMICAL", 96, 118], ["FOS", "SIMPLE_CHEMICAL", 120, 123], ["Common prebiotics", "TREATMENT", 0, 17], ["inulin and oligosaccharides", "TREATMENT", 26, 53]]], ["Pigs fed with chito-oligosaccharides (COS) showed better overall intestinal health (based on villi height), improved performance (measured by body weight gain and feed conversion ratio) and higher Lactobacillus counts than those found in control pigs or pigs receiving diets supplemented with chlortetracycline [125] .", [["intestinal", "ANATOMY", 65, 75], ["villi", "ANATOMY", 93, 98], ["body", "ANATOMY", 142, 146], ["chito-oligosaccharides", "CHEMICAL", 14, 36], ["chlortetracycline", "CHEMICAL", 293, 310], ["chlortetracycline", "CHEMICAL", 293, 310], ["Pigs", "ORGANISM", 0, 4], ["chito-oligosaccharides", "SIMPLE_CHEMICAL", 14, 36], ["intestinal", "ORGAN", 65, 75], ["villi", "MULTI-TISSUE_STRUCTURE", 93, 98], ["body", "ORGANISM_SUBDIVISION", 142, 146], ["Lactobacillus", "SIMPLE_CHEMICAL", 197, 210], ["pigs", "ORGANISM", 246, 250], ["pigs", "ORGANISM", 254, 258], ["chlortetracycline", "SIMPLE_CHEMICAL", 293, 310], ["Pigs", "SPECIES", 0, 4], ["pigs", "SPECIES", 246, 250], ["pigs", "SPECIES", 254, 258], ["Pigs", "SPECIES", 0, 4], ["pigs", "SPECIES", 246, 250], ["pigs", "SPECIES", 254, 258], ["feed conversion ratio", "TREATMENT", 163, 184], ["higher Lactobacillus counts", "PROBLEM", 190, 217], ["chlortetracycline", "TREATMENT", 293, 310], ["intestinal", "ANATOMY", 65, 75]]], ["Also, fermented ingredients, such as non-starch polysaccharide hydrolysis products of soybean meal (SBM) in weaned pig feed, were found to interfere with attachment of ETEC to enterocytes and were beneficial in maintaining fluid balance during ETEC infection [126] .", [["enterocytes", "ANATOMY", 176, 187], ["fluid", "ANATOMY", 223, 228], ["infection", "DISEASE", 249, 258], ["SBM", "ORGANISM_SUBDIVISION", 100, 103], ["pig", "ORGANISM", 115, 118], ["ETEC", "GENE_OR_GENE_PRODUCT", 168, 172], ["enterocytes", "CELL", 176, 187], ["fluid", "ORGANISM_SUBSTANCE", 223, 228], ["enterocytes", "CELL_TYPE", 176, 187], ["soybean", "SPECIES", 86, 93], ["pig", "SPECIES", 115, 118], ["soybean", "SPECIES", 86, 93], ["pig", "SPECIES", 115, 118], ["ETEC", "SPECIES", 244, 248], ["fermented ingredients", "TREATMENT", 6, 27], ["non-starch polysaccharide hydrolysis products", "TREATMENT", 37, 82], ["soybean meal", "TREATMENT", 86, 98], ["weaned pig feed", "TREATMENT", 108, 123], ["fluid balance", "TEST", 223, 236], ["ETEC infection", "PROBLEM", 244, 258], ["fermented ingredients", "OBSERVATION", 6, 27]]], ["It was shown that the prebiotic \u03b2-galactomannan (\u03b2GM) inhibited the in vitro adhesion of ETEC on the cell surface of porcine intestinal IPI-2I cells, and decreased the mRNA ETECinduced gene expression of pro-inflammatory cytokines such as TNF-\u03b1, IL-6, GM-CSF and chemokines on intestinal IPI-2I cells [127] .Feed additivesProbiotics such as lactic acid bacteria, Bacillus and yeasts are live microbial feed supplements [122] .", [["cell surface", "ANATOMY", 101, 113], ["intestinal IPI-2I cells", "ANATOMY", 125, 148], ["intestinal IPI-2I cells", "ANATOMY", 277, 300], ["\u03b2-galactomannan", "CHEMICAL", 32, 47], ["\u03b2GM", "CHEMICAL", 49, 52], ["lactic acid", "CHEMICAL", 341, 352], ["\u03b2-galactomannan", "CHEMICAL", 32, 47], ["lactic acid", "CHEMICAL", 341, 352], ["\u03b2-galactomannan", "SIMPLE_CHEMICAL", 32, 47], ["\u03b2GM", "SIMPLE_CHEMICAL", 49, 52], ["ETEC", "CELL", 89, 93], ["cell surface", "CELLULAR_COMPONENT", 101, 113], ["porcine", "ORGANISM", 117, 124], ["intestinal IPI-2I cells", "CELL", 125, 148], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 239, 244], ["IL-6", "GENE_OR_GENE_PRODUCT", 246, 250], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 252, 258], ["intestinal IPI-2I cells", "CELL", 277, 300], ["lactic acid", "SIMPLE_CHEMICAL", 341, 352], ["porcine intestinal IPI-2I cells", "CELL_LINE", 117, 148], ["pro-inflammatory cytokines", "PROTEIN", 204, 230], ["TNF", "PROTEIN", 239, 242], ["IL-6", "PROTEIN", 246, 250], ["GM", "PROTEIN", 252, 254], ["CSF", "PROTEIN", 255, 258], ["chemokines", "PROTEIN", 263, 273], ["intestinal IPI-2I cells", "CELL_LINE", 277, 300], ["porcine", "SPECIES", 117, 124], ["the prebiotic \u03b2-galactomannan (\u03b2GM)", "PROBLEM", 18, 53], ["ETEC", "PROBLEM", 89, 93], ["pro-inflammatory cytokines", "TEST", 204, 230], ["TNF", "TEST", 239, 242], ["IL", "TEST", 246, 248], ["intestinal IPI", "TEST", 277, 291], ["Feed additivesProbiotics", "TREATMENT", 308, 332], ["lactic acid bacteria", "PROBLEM", 341, 361], ["Bacillus", "PROBLEM", 363, 371], ["yeasts", "PROBLEM", 376, 382], ["microbial feed supplements", "TREATMENT", 392, 418], ["intestinal", "ANATOMY", 125, 135], ["2I cells", "OBSERVATION", 140, 148], ["pro-inflammatory cytokines", "OBSERVATION", 204, 230], ["intestinal", "ANATOMY", 277, 287]]], ["Probiotic bacteria have also been shown to produce antimicrobial molecules, such as bacteriocins, and to inhibit the production of bacterial toxins or the adhesion of pathogens to the intestinal mucosa [123] .", [["intestinal mucosa", "ANATOMY", 184, 201], ["intestinal mucosa", "MULTI-TISSUE_STRUCTURE", 184, 201], ["Probiotic bacteria", "PROBLEM", 0, 18], ["antimicrobial molecules", "PROBLEM", 51, 74], ["bacteriocins", "TREATMENT", 84, 96], ["bacterial toxins", "PROBLEM", 131, 147], ["the adhesion of pathogens", "PROBLEM", 151, 176], ["antimicrobial molecules", "OBSERVATION", 51, 74], ["intestinal mucosa", "ANATOMY", 184, 201]]], ["Several studies demonstrated that pre-treatment with certain probiotics, such as L. rhamnosus, was effective in reducing diarrhea in experimental ETEC: F4 PWD in pigs, possibly via the modulation of the intestinal microbiota, enhancement of intestinal antibody defense, and regulation of production of systemic inflammatory cytokine [128] .", [["intestinal", "ANATOMY", 203, 213], ["intestinal", "ANATOMY", 241, 251], ["diarrhea", "DISEASE", 121, 129], ["L. rhamnosus", "ORGANISM", 81, 93], ["pigs", "ORGANISM", 162, 166], ["intestinal", "ORGAN", 203, 213], ["intestinal", "ORGAN", 241, 251], ["antibody", "GENE_OR_GENE_PRODUCT", 252, 260], ["systemic inflammatory cytokine", "PROTEIN", 302, 332], ["L. rhamnosus", "SPECIES", 81, 93], ["pigs", "SPECIES", 162, 166], ["L. rhamnosus", "SPECIES", 81, 93], ["ETEC", "SPECIES", 146, 150], ["pigs", "SPECIES", 162, 166], ["Several studies", "TEST", 0, 15], ["certain probiotics", "TREATMENT", 53, 71], ["L. rhamnosus", "PROBLEM", 81, 93], ["reducing diarrhea", "PROBLEM", 112, 129], ["intestinal antibody defense", "PROBLEM", 241, 268], ["systemic inflammatory cytokine", "PROBLEM", 302, 332], ["rhamnosus", "OBSERVATION", 84, 93], ["intestinal microbiota", "ANATOMY", 203, 224], ["intestinal", "ANATOMY", 241, 251], ["antibody defense", "OBSERVATION", 252, 268], ["systemic", "OBSERVATION_MODIFIER", 302, 310], ["inflammatory", "OBSERVATION_MODIFIER", 311, 323]]], ["Recently, Lane et al. [129] reported that L. acidophilus supplementation (0.2%) in the weaned pig diet resulted in higher Lactobacillus counts and lower E. coli counts, as well as an increase in ADG and the average daily feed intake in supplemented pigs compared to the basal diet pigs.", [["L. acidophilus", "CHEMICAL", 42, 56], ["L. acidophilus", "ORGANISM", 42, 56], ["pig", "ORGANISM", 94, 97], ["Lactobacillus", "SIMPLE_CHEMICAL", 122, 135], ["E. coli", "ORGANISM", 153, 160], ["ADG", "SIMPLE_CHEMICAL", 195, 198], ["pigs", "ORGANISM", 249, 253], ["pigs", "ORGANISM", 281, 285], ["L. acidophilus", "SPECIES", 42, 56], ["pig", "SPECIES", 94, 97], ["E. coli", "SPECIES", 153, 160], ["pigs", "SPECIES", 249, 253], ["pigs", "SPECIES", 281, 285], ["L. acidophilus", "SPECIES", 42, 56], ["pig", "SPECIES", 94, 97], ["E. coli", "SPECIES", 153, 160], ["pigs", "SPECIES", 249, 253], ["L. acidophilus supplementation", "TREATMENT", 42, 72], ["the weaned pig diet", "TREATMENT", 83, 102], ["higher Lactobacillus counts", "PROBLEM", 115, 142], ["lower E. coli counts", "PROBLEM", 147, 167], ["an increase in ADG", "PROBLEM", 180, 198], ["higher", "OBSERVATION_MODIFIER", 115, 121], ["Lactobacillus counts", "OBSERVATION", 122, 142], ["coli counts", "OBSERVATION", 156, 167], ["increase", "OBSERVATION_MODIFIER", 183, 191]]], ["A Bacillus licheniformis and Bacillus subtilis spore mixture (BLS-mix) was effective in preventing loss of intestinal epithelial barrier integrity after a challenge with ETEC:Benefits Limitations ReferencesZinc oxide Inhibition of bacterial adhesion to the intestinal mucosaBenefits Limitations ReferencesHigh levels increased PWD [112, 115] Stimulated growth rate Soil heavy metal contaminationMaintained intestinal mucosal integrity Bacterial resistanceModulated immune functions Co-resistanceMaintained intestinal mucosal integrity Bacterial resistanceOrganic acids Decreased pH in the stomach Exact modes of action still unknown [108] Improved growth performance Anti microbial activities is different between acids Reduced PWD Prebiotics, probiotics and synbiotics Improved intestinal health Sometimes contradictory studies on their effectiveness [127, 130] Improved growth performance Lack of information on the potential synergism between pre-and probiotics Reduced ETEC: F4 attachment to the ileal mucosaReduced diarrheaSpray dried plasma (SDP) Improved growth performance High cost [111] Reduced incidence and severity of diarrhea Required rigorous control during the preparation processReduced diarrheaReduced the markers of intestinal inflammation Potential source of pathogens?Maintained mucosal integrityAntimicrobial peptides (AMPs) Improved growth performance The pharmacokinetics in vivo is unknown [89, 139] Decreased diarrhea Bacterial resistanceReduced the markers of intestinal inflammationEnhance immune function Cocktails of AMPs might be used to mitigate selection for resistance Specific egg yolk antibodies Improved growth performance High cost [111] Decreased diarrhea Antibodies are sometime not specific against the infecting ETEC strains on farms Maintained intestinal mucosal integrityBacteriophagesReduced E. coli mucosal adhesion Narrow spectrum of activity [144] Maintained intestinal mucosal integrity Development of bacterial resistanceBacteriophagesDecreased diarrhea A combination of phages is needed F4 in experimental PWD [130] .", [["intestinal epithelial barrier", "ANATOMY", 107, 136], ["intestinal", "ANATOMY", 257, 267], ["intestinal mucosal", "ANATOMY", 406, 424], ["intestinal mucosal", "ANATOMY", 506, 524], ["stomach", "ANATOMY", 589, 596], ["intestinal", "ANATOMY", 779, 789], ["ileal", "ANATOMY", 1000, 1005], ["plasma", "ANATOMY", 1040, 1046], ["intestinal", "ANATOMY", 1235, 1245], ["mucosal", "ANATOMY", 1300, 1307], ["intestinal", "ANATOMY", 1487, 1497], ["egg yolk", "ANATOMY", 1612, 1620], ["intestinal mucosal", "ANATOMY", 1787, 1805], ["mucosal", "ANATOMY", 1845, 1852], ["intestinal mucosal", "ANATOMY", 1907, 1925], ["ETEC", "CHEMICAL", 170, 174], ["Zinc oxide", "CHEMICAL", 206, 216], ["resistanceOrganic acids", "CHEMICAL", 545, 568], ["Prebiotics", "CHEMICAL", 732, 742], ["ETEC", "CHEMICAL", 973, 977], ["diarrhea", "DISEASE", 1131, 1139], ["intestinal inflammation", "DISEASE", 1235, 1258], ["diarrhea", "DISEASE", 1435, 1443], ["intestinal inflammation", "DISEASE", 1487, 1510], ["diarrhea", "DISEASE", 1686, 1694], ["diarrhea", "DISEASE", 1995, 2003], ["Zinc oxide", "CHEMICAL", 206, 216], ["resistanceOrganic acids", "CHEMICAL", 545, 568], ["Bacillus licheniformis", "ORGANISM", 2, 24], ["Bacillus subtilis", "ORGANISM", 29, 46], ["intestinal epithelial barrier", "TISSUE", 107, 136], ["Zinc oxide", "SIMPLE_CHEMICAL", 206, 216], ["intestinal", "ORGAN", 257, 267], ["intestinal mucosal", "MULTI-TISSUE_STRUCTURE", 406, 424], ["intestinal mucosal", "MULTI-TISSUE_STRUCTURE", 506, 524], ["stomach", "ORGAN", 589, 596], ["intestinal", "ORGAN", 779, 789], ["plasma", "ORGANISM_SUBSTANCE", 1040, 1046], ["intestinal", "ORGAN", 1235, 1245], ["mucosal integrityAntimicrobial peptides", "GENE_OR_GENE_PRODUCT", 1300, 1339], ["intestinal", "ORGAN", 1487, 1497], ["AMPs", "GENE_OR_GENE_PRODUCT", 1547, 1551], ["ETEC", "ORGANISM", 1754, 1758], ["intestinal mucosal", "MULTI-TISSUE_STRUCTURE", 1787, 1805], ["intestinal mucosal", "MULTI-TISSUE_STRUCTURE", 1907, 1925], ["egg yolk antibodies", "PROTEIN", 1612, 1631], ["Bacillus licheniformis", "SPECIES", 2, 24], ["Bacillus subtilis", "SPECIES", 29, 46], ["E. coli", "SPECIES", 1837, 1844], ["Bacillus licheniformis", "SPECIES", 2, 24], ["Bacillus subtilis", "SPECIES", 29, 46], ["ETEC", "SPECIES", 1754, 1758], ["E. coli", "SPECIES", 1837, 1844], ["A Bacillus licheniformis", "TEST", 0, 24], ["Bacillus subtilis spore mixture", "PROBLEM", 29, 60], ["intestinal epithelial barrier integrity", "TREATMENT", 107, 146], ["Zinc oxide Inhibition", "TREATMENT", 206, 227], ["bacterial adhesion", "PROBLEM", 231, 249], ["the intestinal mucosaBenefits", "TEST", 253, 282], ["High levels increased PWD", "PROBLEM", 305, 330], ["Stimulated growth rate", "TEST", 342, 364], ["Soil heavy metal contamination", "PROBLEM", 365, 395], ["Bacterial resistance", "PROBLEM", 435, 455], ["immune functions", "TEST", 465, 481], ["Co-resistance", "TEST", 482, 495], ["Bacterial resistanceOrganic acids", "TEST", 535, 568], ["Decreased pH in the stomach", "PROBLEM", 569, 596], ["acids Reduced PWD Prebiotics", "TREATMENT", 714, 742], ["probiotics", "TREATMENT", 744, 754], ["synbiotics", "TREATMENT", 759, 769], ["pre-and probiotics", "TREATMENT", 946, 964], ["the ileal mucosaReduced diarrheaSpray dried plasma (SDP", "TREATMENT", 996, 1051], ["diarrhea", "PROBLEM", 1131, 1139], ["rigorous control", "TREATMENT", 1149, 1165], ["the preparation process", "TREATMENT", 1173, 1196], ["Reduced diarrheaReduced", "PROBLEM", 1196, 1219], ["intestinal inflammation", "PROBLEM", 1235, 1258], ["pathogens", "PROBLEM", 1279, 1288], ["mucosal integrityAntimicrobial peptides", "TREATMENT", 1300, 1339], ["Decreased diarrhea", "PROBLEM", 1425, 1443], ["intestinal inflammation", "PROBLEM", 1487, 1510], ["AMPs", "TREATMENT", 1547, 1551], ["resistance", "PROBLEM", 1592, 1602], ["Specific egg yolk antibodies", "TEST", 1603, 1631], ["High cost", "PROBLEM", 1660, 1669], ["Decreased diarrhea Antibodies", "PROBLEM", 1676, 1705], ["the infecting ETEC strains", "PROBLEM", 1740, 1766], ["intestinal mucosal integrityBacteriophages", "TREATMENT", 1787, 1829], ["Reduced E. coli mucosal adhesion", "PROBLEM", 1829, 1861], ["intestinal mucosal integrity", "TREATMENT", 1907, 1935], ["bacterial resistanceBacteriophages", "PROBLEM", 1951, 1985], ["Decreased diarrhea", "PROBLEM", 1985, 2003], ["Bacillus licheniformis", "OBSERVATION", 2, 24], ["intestinal epithelial", "ANATOMY", 107, 128], ["barrier integrity", "OBSERVATION", 129, 146], ["intestinal", "ANATOMY", 257, 267], ["intestinal mucosal", "ANATOMY", 406, 424], ["intestinal mucosal", "ANATOMY", 506, 524], ["stomach", "ANATOMY", 589, 596], ["intestinal", "ANATOMY", 779, 789], ["ileal", "ANATOMY", 1000, 1005], ["intestinal", "ANATOMY", 1235, 1245], ["inflammation", "OBSERVATION", 1246, 1258], ["pathogens", "OBSERVATION", 1279, 1288], ["mucosal integrityAntimicrobial", "ANATOMY", 1300, 1330], ["intestinal", "ANATOMY", 1487, 1497], ["inflammation", "OBSERVATION", 1498, 1510], ["intestinal mucosal", "ANATOMY", 1787, 1805], ["coli mucosal", "OBSERVATION", 1840, 1852], ["adhesion", "OBSERVATION_MODIFIER", 1853, 1861], ["Narrow", "OBSERVATION_MODIFIER", 1862, 1868], ["activity", "OBSERVATION_MODIFIER", 1881, 1889], ["intestinal mucosal", "ANATOMY", 1907, 1925], ["bacterial resistance", "OBSERVATION", 1951, 1971], ["Bacteriophages", "OBSERVATION_MODIFIER", 1971, 1985], ["Decreased", "OBSERVATION_MODIFIER", 1985, 1994], ["diarrhea", "OBSERVATION", 1995, 2003]]], ["In addition, it was shown that the feeding of pigs with live yeast Saccharomyces cerevisiae enhanced their growth and reduced the duration and the severity of PWD caused by ETEC [131] .", [["PWD", "DISEASE", 159, 162], ["ETEC", "CHEMICAL", 173, 177], ["pigs", "ORGANISM", 46, 50], ["yeast Saccharomyces cerevisiae", "ORGANISM", 61, 91], ["pigs", "SPECIES", 46, 50], ["yeast", "SPECIES", 61, 66], ["Saccharomyces cerevisiae", "SPECIES", 67, 91], ["pigs", "SPECIES", 46, 50], ["yeast", "SPECIES", 61, 66], ["Saccharomyces cerevisiae", "SPECIES", 67, 91], ["live yeast Saccharomyces", "TREATMENT", 56, 80], ["PWD", "PROBLEM", 159, 162]]], ["It has been demonstrated that the administration of a mixture of two probiotics, Pediococcus acidilactici and Saccharomyces cerevisiae boulardii, in the feed of challenged weaned pigs reduced ETEC: F4 attachment to the ileal mucosa in comparison with the group treated with chlortetracycline and tiamulin [103] .", [["ileal mucosa", "ANATOMY", 219, 231], ["Pediococcus acidilactici", "CHEMICAL", 81, 105], ["chlortetracycline", "CHEMICAL", 274, 291], ["tiamulin", "CHEMICAL", 296, 304], ["chlortetracycline", "CHEMICAL", 274, 291], ["tiamulin", "CHEMICAL", 296, 304], ["Pediococcus acidilactici", "ORGANISM", 81, 105], ["Saccharomyces cerevisiae boulardii", "ORGANISM", 110, 144], ["pigs", "ORGANISM", 179, 183], ["ileal mucosa", "MULTI-TISSUE_STRUCTURE", 219, 231], ["chlortetracycline", "SIMPLE_CHEMICAL", 274, 291], ["tiamulin", "SIMPLE_CHEMICAL", 296, 304], ["Pediococcus acidilactici", "SPECIES", 81, 105], ["Saccharomyces cerevisiae", "SPECIES", 110, 134], ["boulardii", "SPECIES", 135, 144], ["pigs", "SPECIES", 179, 183], ["Pediococcus acidilactici", "SPECIES", 81, 105], ["Saccharomyces cerevisiae boulardii", "SPECIES", 110, 144], ["pigs", "SPECIES", 179, 183], ["a mixture of two probiotics", "TREATMENT", 52, 79], ["Pediococcus acidilactici", "TREATMENT", 81, 105], ["Saccharomyces cerevisiae boulardii", "TREATMENT", 110, 144], ["chlortetracycline", "TREATMENT", 274, 291], ["tiamulin", "TREATMENT", 296, 304], ["ileal mucosa", "ANATOMY", 219, 231]]], ["Synbiotics refers to a combination of probiotic and prebiotic approaches; it is possible that a prebiotic that confers gastrointestinal health benefits could selectively increase the population and/or activity of probiotics in the gut [132] .", [["gastrointestinal", "ANATOMY", 119, 135], ["gut", "ANATOMY", 231, 234], ["Synbiotics", "DISEASE", 0, 10], ["gastrointestinal", "ORGAN", 119, 135], ["Synbiotics", "TREATMENT", 0, 10], ["probiotic", "TREATMENT", 38, 47], ["prebiotic approaches", "TREATMENT", 52, 72], ["probiotics", "TREATMENT", 213, 223]]], ["Synbiotics can be either complementary or synergistic.", [["Synbiotics", "DISEASE", 0, 10], ["Synbiotics", "TREATMENT", 0, 10]]], ["Complementary synbiotics consist of a probiotic and a prebiotic selected independently to confer benefits to the host.", [["Complementary synbiotics", "TREATMENT", 0, 24], ["a probiotic", "TREATMENT", 36, 47]]], ["On the other hand, synergistic synbiotics are comprised of a prebiotic chosen specifically for the selected probiotic to potentiate its effect in the gut [133] .", [["gut", "ANATOMY", 150, 153], ["synbiotics", "SIMPLE_CHEMICAL", 31, 41], ["gut", "ORGANISM_SUBDIVISION", 150, 153], ["synergistic synbiotics", "TREATMENT", 19, 41], ["a prebiotic", "TREATMENT", 59, 70], ["the selected probiotic", "TREATMENT", 95, 117], ["gut", "ANATOMY", 150, 153]]], ["It was shown that the combination of raw potato starch and a probiotic had a beneficial effect on pig growth performance and resulted in a reduction of diarrhea and increased microbial diversity in the gut of weaned pigs challenged with an ETEC: F4 strain [134] .", [["gut", "ANATOMY", 202, 205], ["potato starch", "CHEMICAL", 41, 54], ["diarrhea", "DISEASE", 152, 160], ["starch", "SIMPLE_CHEMICAL", 48, 54], ["pig", "ORGANISM", 98, 101], ["gut", "ORGANISM_SUBDIVISION", 202, 205], ["pigs", "ORGANISM", 216, 220], ["potato", "SPECIES", 41, 47], ["pig", "SPECIES", 98, 101], ["pigs", "SPECIES", 216, 220], ["potato", "SPECIES", 41, 47], ["pig", "SPECIES", 98, 101], ["pigs", "SPECIES", 216, 220], ["raw potato starch", "TREATMENT", 37, 54], ["a probiotic", "TREATMENT", 59, 70], ["pig growth performance", "TREATMENT", 98, 120], ["diarrhea", "PROBLEM", 152, 160], ["increased microbial diversity", "PROBLEM", 165, 194], ["F4 strain", "PROBLEM", 246, 255], ["diarrhea", "OBSERVATION", 152, 160], ["increased", "OBSERVATION_MODIFIER", 165, 174], ["microbial diversity", "OBSERVATION", 175, 194]]], ["Also, Guerra-Ordaz et al. [135] showed that following a challenge of pigs with pathogenic E. coli (O149:K91:H10), administration of a prebiotic oligosaccharide, lactulose, in the feed resulted in improved weight gain, increased lactobacilli and the proportion of butyric acid in the colon, and less inflammation due to a reduction of the pig major acutephase protein (Pig-MAP) in serum.", [["colon", "ANATOMY", 283, 288], ["serum", "ANATOMY", 380, 385], ["lactulose", "CHEMICAL", 161, 170], ["weight gain", "DISEASE", 205, 216], ["lactobacilli", "CHEMICAL", 228, 240], ["butyric acid", "CHEMICAL", 263, 275], ["inflammation", "DISEASE", 299, 311], ["lactulose", "CHEMICAL", 161, 170], ["butyric acid", "CHEMICAL", 263, 275], ["pigs", "ORGANISM", 69, 73], ["E. coli", "ORGANISM", 90, 97], ["O149:K91:H10", "ORGANISM", 99, 111], ["lactulose", "SIMPLE_CHEMICAL", 161, 170], ["lactobacilli", "SIMPLE_CHEMICAL", 228, 240], ["butyric acid", "SIMPLE_CHEMICAL", 263, 275], ["colon", "ORGAN", 283, 288], ["pig", "ORGANISM", 338, 341], ["acutephase protein", "GENE_OR_GENE_PRODUCT", 348, 366], ["Pig-MAP", "GENE_OR_GENE_PRODUCT", 368, 375], ["serum", "ORGANISM_SUBSTANCE", 380, 385], ["pig major acutephase protein", "PROTEIN", 338, 366], ["Pig", "PROTEIN", 368, 371], ["MAP", "PROTEIN", 372, 375], ["pigs", "SPECIES", 69, 73], ["E. coli", "SPECIES", 90, 97], ["pig", "SPECIES", 338, 341], ["pigs", "SPECIES", 69, 73], ["E. coli", "SPECIES", 90, 97], ["pig", "SPECIES", 338, 341], ["pathogenic E. coli", "PROBLEM", 79, 97], ["a prebiotic oligosaccharide", "TREATMENT", 132, 159], ["lactulose", "TREATMENT", 161, 170], ["improved weight gain", "PROBLEM", 196, 216], ["increased lactobacilli", "PROBLEM", 218, 240], ["butyric acid in the colon", "PROBLEM", 263, 288], ["less inflammation", "PROBLEM", 294, 311], ["the pig major acutephase protein", "PROBLEM", 334, 366], ["increased", "OBSERVATION_MODIFIER", 218, 227], ["lactobacilli", "OBSERVATION", 228, 240], ["butyric acid", "OBSERVATION", 263, 275], ["colon", "ANATOMY", 283, 288], ["less", "OBSERVATION_MODIFIER", 294, 298], ["inflammation", "OBSERVATION", 299, 311]]], ["Administration of Lactobacillus plantarum in the feed promoted lactobacilli growth, modulated fermentative activity, reduced inflammation, and improved intestinal mucosa function and showed a tendency to reduce diarrhea.", [["intestinal mucosa", "ANATOMY", 152, 169], ["Lactobacillus plantarum", "CHEMICAL", 18, 41], ["lactobacilli", "CHEMICAL", 63, 75], ["inflammation", "DISEASE", 125, 137], ["diarrhea", "DISEASE", 211, 219], ["Lactobacillus plantarum", "ORGANISM", 18, 41], ["lactobacilli", "SIMPLE_CHEMICAL", 63, 75], ["intestinal mucosa", "MULTI-TISSUE_STRUCTURE", 152, 169], ["Lactobacillus plantarum", "SPECIES", 18, 41], ["Lactobacillus plantarum", "SPECIES", 18, 41], ["Lactobacillus plantarum", "TREATMENT", 18, 41], ["the feed", "TREATMENT", 45, 53], ["lactobacilli growth", "PROBLEM", 63, 82], ["modulated fermentative activity", "PROBLEM", 84, 115], ["reduced inflammation", "PROBLEM", 117, 137], ["improved intestinal mucosa function", "PROBLEM", 143, 178], ["a tendency", "PROBLEM", 190, 200], ["diarrhea", "PROBLEM", 211, 219], ["Lactobacillus plantarum", "OBSERVATION", 18, 41], ["lactobacilli growth", "OBSERVATION", 63, 82], ["fermentative activity", "OBSERVATION", 94, 115], ["reduced", "OBSERVATION_MODIFIER", 117, 124], ["inflammation", "OBSERVATION", 125, 137], ["improved", "OBSERVATION_MODIFIER", 143, 151], ["intestinal mucosa", "ANATOMY", 152, 169]]], ["The application of a synbiotic diet resulted in the benefits of both diet regimes, thus being an example of a complementary synbiotic [135] .BacteriophagesSpray dried plasma (SDP) is a protein rich product obtained from the industrial fractionation of blood from healthy animals [106] .", [["plasma", "ANATOMY", 167, 173], ["blood", "ANATOMY", 252, 257], ["SDP", "CHEMICAL", 175, 178], ["plasma", "ORGANISM_SUBSTANCE", 167, 173], ["SDP", "SIMPLE_CHEMICAL", 175, 178], ["blood", "ORGANISM_SUBSTANCE", 252, 257], ["a synbiotic diet", "TREATMENT", 19, 35], ["both diet regimes", "TREATMENT", 64, 81], ["BacteriophagesSpray dried plasma (SDP", "TREATMENT", 141, 178], ["a protein rich product", "TREATMENT", 183, 205]]], ["It was shown that addition of SDP to the feed improved growth performance, and protects pigs against ETEC: F4 infection by reducing the intestinal expression of inflammatory cytokines such as TNF-\u03b1 and interleukin-8 and maintaining mucosal integrity, and enhancing specific antibody defense [111] .", [["intestinal", "ANATOMY", 136, 146], ["mucosal", "ANATOMY", 232, 239], ["ETEC", "CHEMICAL", 101, 105], ["infection", "DISEASE", 110, 119], ["SDP", "SIMPLE_CHEMICAL", 30, 33], ["pigs", "ORGANISM", 88, 92], ["intestinal", "ORGAN", 136, 146], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 192, 197], ["interleukin-8", "GENE_OR_GENE_PRODUCT", 202, 215], ["mucosal", "MULTI-TISSUE_STRUCTURE", 232, 239], ["inflammatory cytokines", "PROTEIN", 161, 183], ["TNF", "PROTEIN", 192, 195], ["interleukin-8", "PROTEIN", 202, 215], ["pigs", "SPECIES", 88, 92], ["pigs", "SPECIES", 88, 92], ["ETEC", "SPECIES", 101, 105], ["SDP", "TREATMENT", 30, 33], ["ETEC", "PROBLEM", 101, 105], ["F4 infection", "PROBLEM", 107, 119], ["inflammatory cytokines", "PROBLEM", 161, 183], ["TNF", "TEST", 192, 195], ["interleukin", "TEST", 202, 213], ["enhancing specific antibody defense", "TEST", 255, 290], ["infection", "OBSERVATION", 110, 119], ["intestinal", "ANATOMY", 136, 146], ["inflammatory", "OBSERVATION_MODIFIER", 161, 173], ["mucosal integrity", "ANATOMY", 232, 249]]], ["Spray dried plasma (SDPP) of porcine origin has been pinpointed as a potential source for the coronavirus in a recent epidemic of porcine epidemic diarrhea (PED) [136] .", [["plasma", "ANATOMY", 12, 18], ["SDPP", "CHEMICAL", 20, 24], ["coronavirus", "DISEASE", 94, 105], ["porcine epidemic diarrhea", "DISEASE", 130, 155], ["PED", "DISEASE", 157, 160], ["plasma", "ORGANISM_SUBSTANCE", 12, 18], ["SDPP", "SIMPLE_CHEMICAL", 20, 24], ["porcine", "ORGANISM", 29, 36], ["coronavirus", "ORGANISM", 94, 105], ["porcine", "ORGANISM", 130, 137], ["porcine", "SPECIES", 29, 36], ["porcine", "SPECIES", 130, 137], ["porcine epidemic diarrhea (PED)", "SPECIES", 130, 161], ["Spray dried plasma (SDPP) of porcine origin", "TREATMENT", 0, 43], ["the coronavirus", "PROBLEM", 90, 105], ["porcine epidemic diarrhea", "PROBLEM", 130, 155], ["porcine origin", "OBSERVATION", 29, 43], ["coronavirus", "OBSERVATION", 94, 105]]], ["Thus, spray-dried chicken plasma (SDCP) has been evaluated as a replacement for SDPP in weaned pigs.", [["plasma", "ANATOMY", 26, 32], ["SDCP", "CHEMICAL", 34, 38], ["SDPP", "CHEMICAL", 80, 84], ["chicken", "ORGANISM", 18, 25], ["plasma", "ORGANISM_SUBSTANCE", 26, 32], ["SDCP", "SIMPLE_CHEMICAL", 34, 38], ["SDPP", "SIMPLE_CHEMICAL", 80, 84], ["pigs", "ORGANISM", 95, 99], ["chicken", "SPECIES", 18, 25], ["pigs", "SPECIES", 95, 99], ["chicken", "SPECIES", 18, 25], ["pigs", "SPECIES", 95, 99], ["spray", "TREATMENT", 6, 11], ["dried chicken plasma (SDCP)", "TREATMENT", 12, 39], ["a replacement", "TREATMENT", 62, 75], ["SDPP", "TREATMENT", 80, 84]]], ["Indeed, the effect of SDCP on serum biochemistry, intestinal barrier function, immune parameters, and the expression of intestinal development-related genes in piglets was similar to SDPP [137] .", [["serum", "ANATOMY", 30, 35], ["intestinal barrier", "ANATOMY", 50, 68], ["intestinal", "ANATOMY", 120, 130], ["SDCP", "CHEMICAL", 22, 26], ["SDCP", "CHEMICAL", 22, 26], ["SDCP", "SIMPLE_CHEMICAL", 22, 26], ["serum", "ORGANISM_SUBSTANCE", 30, 35], ["intestinal barrier", "MULTI-TISSUE_STRUCTURE", 50, 68], ["intestinal", "ORGAN", 120, 130], ["piglets", "ORGANISM", 160, 167], ["piglets", "SPECIES", 160, 167], ["serum biochemistry", "TEST", 30, 48], ["intestinal barrier function", "TEST", 50, 77], ["immune parameters", "TEST", 79, 96], ["intestinal development", "PROBLEM", 120, 142], ["related genes in piglets", "PROBLEM", 143, 167], ["SDPP", "TEST", 183, 187], ["intestinal", "ANATOMY", 50, 60], ["intestinal", "ANATOMY", 120, 130]]], ["Nevertheless, a study has provided evidence that PED virus is inactivated during the SDPP production process [138] .BacteriophagesAntimicrobial peptides (AMPs) are small molecules constituting an important part of the innate immune system.", [["PED virus", "ORGANISM", 49, 58], ["SDPP", "SIMPLE_CHEMICAL", 85, 89], ["Antimicrobial peptides", "GENE_OR_GENE_PRODUCT", 130, 152], ["AMPs", "GENE_OR_GENE_PRODUCT", 154, 158], ["a study", "TEST", 14, 21], ["PED virus", "PROBLEM", 49, 58], ["the SDPP production process", "PROBLEM", 81, 108], ["BacteriophagesAntimicrobial peptides", "TREATMENT", 116, 152], ["AMPs", "TEST", 154, 158], ["small molecules", "PROBLEM", 164, 179], ["small", "OBSERVATION_MODIFIER", 164, 169]]], ["They may present antibacterial, antifungal, antiparasitic, and antiviral activities, and are increasingly of interest as alternatives to classic antibiotics [88] .", [["antibacterial", "TREATMENT", 17, 30], ["antifungal", "TREATMENT", 32, 42], ["antiparasitic", "TREATMENT", 44, 57], ["antiviral activities", "TREATMENT", 63, 83], ["classic antibiotics", "TREATMENT", 137, 156], ["antibacterial", "OBSERVATION_MODIFIER", 17, 30]]], ["AMPs such as lactoferrin, cecropin, defensin, plectasin and bacteriocins showed beneficial effects on growth performance, nutrient digestibility, small intestinal morphology and gut microbiota in pigs [89] .", [["intestinal", "ANATOMY", 152, 162], ["gut microbiota", "ANATOMY", 178, 192], ["plectasin", "CHEMICAL", 46, 55], ["AMPs", "GENE_OR_GENE_PRODUCT", 0, 4], ["lactoferrin", "GENE_OR_GENE_PRODUCT", 13, 24], ["cecropin", "GENE_OR_GENE_PRODUCT", 26, 34], ["defensin", "GENE_OR_GENE_PRODUCT", 36, 44], ["plectasin", "GENE_OR_GENE_PRODUCT", 46, 55], ["intestinal", "ORGAN", 152, 162], ["gut microbiota", "MULTI-TISSUE_STRUCTURE", 178, 192], ["pigs", "ORGANISM", 196, 200], ["lactoferrin", "PROTEIN", 13, 24], ["defensin", "PROTEIN", 36, 44], ["pigs", "SPECIES", 196, 200], ["AMPs", "TREATMENT", 0, 4], ["lactoferrin", "TREATMENT", 13, 24], ["cecropin", "TREATMENT", 26, 34], ["defensin", "TREATMENT", 36, 44], ["plectasin", "TREATMENT", 46, 55], ["bacteriocins", "TREATMENT", 60, 72], ["beneficial effects", "PROBLEM", 80, 98], ["growth performance", "TEST", 102, 120], ["nutrient digestibility", "PROBLEM", 122, 144], ["small intestinal morphology", "PROBLEM", 146, 173], ["small", "OBSERVATION_MODIFIER", 146, 151], ["intestinal morphology", "OBSERVATION_MODIFIER", 152, 173]]], ["Available data on the effect of AMPs on swine health and especially in the control of PWD have been reviewed extensively elsewhere [89, 139] .", [["swine", "SPECIES", 40, 45], ["swine", "SPECIES", 40, 45], ["AMPs on swine health", "TREATMENT", 32, 52]]], ["Antimicrobial lactoferrin peptides are one of the most commonly used AMPs in pig feeds.", [["lactoferrin", "GENE_OR_GENE_PRODUCT", 14, 25], ["pig", "ORGANISM", 77, 80], ["pig", "SPECIES", 77, 80], ["pig", "SPECIES", 77, 80], ["Antimicrobial lactoferrin peptides", "TREATMENT", 0, 34], ["AMPs in pig feeds", "TREATMENT", 69, 86]]], ["More recently, it was shown in a murine model of intestinal inflammation that treatment with porcine lactoferrinderived peptide LFP-20 was effective in the prevention of histological damage, the inflammatory response and the disruption of tight junction structure induced by LPS in the intestine [140] .", [["intestinal", "ANATOMY", 49, 59], ["tight junction", "ANATOMY", 239, 253], ["intestine", "ANATOMY", 286, 295], ["intestinal inflammation", "DISEASE", 49, 72], ["LFP-20", "CHEMICAL", 128, 134], ["LPS", "CHEMICAL", 275, 278], ["murine", "ORGANISM", 33, 39], ["intestinal", "ORGAN", 49, 59], ["porcine", "ORGANISM", 93, 100], ["LFP-20", "GENE_OR_GENE_PRODUCT", 128, 134], ["tight junction", "CELLULAR_COMPONENT", 239, 253], ["LPS", "SIMPLE_CHEMICAL", 275, 278], ["intestine", "ORGAN", 286, 295], ["murine", "SPECIES", 33, 39], ["porcine", "SPECIES", 93, 100], ["porcine", "SPECIES", 93, 100], ["intestinal inflammation", "PROBLEM", 49, 72], ["porcine lactoferrinderived peptide LFP", "TREATMENT", 93, 131], ["histological damage", "PROBLEM", 170, 189], ["the inflammatory response", "PROBLEM", 191, 216], ["the disruption of tight junction structure", "PROBLEM", 221, 263], ["intestinal", "ANATOMY", 49, 59], ["inflammation", "OBSERVATION", 60, 72], ["damage", "OBSERVATION", 183, 189], ["inflammatory response", "OBSERVATION", 195, 216], ["tight junction", "OBSERVATION", 239, 253], ["LPS", "OBSERVATION_MODIFIER", 275, 278], ["intestine", "ANATOMY", 286, 295]]], ["Colicins, a class of bacteriocins produced by E. coli and closely related species, have been shown to inhibit the activities of ETEC: F4 and F18 strains in vitro and in vivo, and improve the growth performance, reduce the incidence of PWD and the expression of the IL-1\u03b2 and TNF-\u03b2 genes in ileal tissues of pigs [141] .", [["ileal tissues", "ANATOMY", 290, 303], ["Colicins", "CHEMICAL", 0, 8], ["Colicins", "CHEMICAL", 0, 8], ["Colicins", "SIMPLE_CHEMICAL", 0, 8], ["E. coli", "ORGANISM", 46, 53], ["F18 strains", "ORGANISM", 141, 152], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 265, 270], ["TNF-\u03b2", "GENE_OR_GENE_PRODUCT", 275, 280], ["ileal tissues", "TISSUE", 290, 303], ["pigs", "ORGANISM", 307, 311], ["IL-1\u03b2 and TNF-\u03b2 genes", "DNA", 265, 286], ["E. coli", "SPECIES", 46, 53], ["pigs", "SPECIES", 307, 311], ["E. coli", "SPECIES", 46, 53], ["Colicins", "PROBLEM", 0, 8], ["bacteriocins", "TREATMENT", 21, 33], ["E. coli", "PROBLEM", 46, 53], ["PWD", "PROBLEM", 235, 238], ["the IL", "TEST", 261, 267], ["TNF", "TREATMENT", 275, 278], ["E. coli", "OBSERVATION", 46, 53], ["ileal tissues", "ANATOMY", 290, 303]]], ["On the other hand, resistance to AMPs has been observed in vitro in GNB such as E. coli [142] .", [["AMPs", "GENE_OR_GENE_PRODUCT", 33, 37], ["GNB", "CANCER", 68, 71], ["E. coli", "ORGANISM", 80, 87], ["E. coli", "SPECIES", 80, 87], ["E. coli", "SPECIES", 80, 87], ["AMPs", "TREATMENT", 33, 37], ["vitro in GNB", "PROBLEM", 59, 71], ["E. coli", "PROBLEM", 80, 87]]], ["Thus, the use of AMPs in pig farms needs careful and controlled implementation to limit possible resistance development and cocktails of AMPs might be useful to mitigate selection for resistance [88] .BacteriophagesSpecific egg yolk antibodies: The chicken egg yolk is a source of large quantities of relatively inexpensive IgY antibodies [2] .", [["egg yolk", "ANATOMY", 224, 232], ["egg yolk", "ANATOMY", 257, 265], ["pig", "ORGANISM", 25, 28], ["AMPs", "GENE_OR_GENE_PRODUCT", 137, 141], ["egg yolk antibodies", "GENE_OR_GENE_PRODUCT", 224, 243], ["chicken", "ORGANISM", 249, 256], ["egg yolk", "MULTI-TISSUE_STRUCTURE", 257, 265], ["IgY", "GENE_OR_GENE_PRODUCT", 324, 327], ["egg yolk antibodies", "PROTEIN", 224, 243], ["IgY antibodies", "PROTEIN", 324, 338], ["pig", "SPECIES", 25, 28], ["chicken", "SPECIES", 249, 256], ["pig", "SPECIES", 25, 28], ["chicken", "SPECIES", 249, 256], ["AMPs in pig farms", "TREATMENT", 17, 34], ["resistance development", "PROBLEM", 97, 119], ["AMPs", "TREATMENT", 137, 141], ["resistance", "PROBLEM", 184, 194], ["Bacteriophages", "TEST", 201, 215], ["The chicken egg yolk", "TREATMENT", 245, 265], ["relatively inexpensive IgY antibodies", "PROBLEM", 301, 338], ["egg yolk antibodies", "OBSERVATION", 224, 243], ["egg yolk", "OBSERVATION", 257, 265], ["large", "OBSERVATION_MODIFIER", 281, 286]]], ["Several studies reported that specific chicken antibodies provide protection against ETEC infections in pigs [111] .", [["ETEC infections", "DISEASE", 85, 100], ["chicken", "ORGANISM", 39, 46], ["ETEC", "ORGANISM", 85, 89], ["pigs", "ORGANISM", 104, 108], ["chicken antibodies", "PROTEIN", 39, 57], ["chicken", "SPECIES", 39, 46], ["pigs", "SPECIES", 104, 108], ["chicken", "SPECIES", 39, 46], ["ETEC", "SPECIES", 85, 89], ["Several studies", "TEST", 0, 15], ["specific chicken antibodies", "TREATMENT", 30, 57], ["ETEC infections", "PROBLEM", 85, 100]]], ["Despite the effectiveness of this practice, we have not found in the recent literature (last 5 years) any studies evaluating the use of specific egg yolk antibodies in PWD control.", [["egg yolk", "ANATOMY", 145, 153], ["egg yolk antibodies", "GENE_OR_GENE_PRODUCT", 145, 164], ["egg yolk antibodies", "PROTEIN", 145, 164], ["any studies", "TEST", 102, 113], ["specific egg yolk antibodies", "TREATMENT", 136, 164], ["PWD control", "TREATMENT", 168, 179]]], ["This is probably the consequence of the non-profitability in pig production of this practice, or the lack of protection against ETEC challenge or PWD occurrence, possibly because the antibodies contained in the eggs are not specific against the infected ETEC strains present on the farm [143] .BacteriophagesBacteriophages are highly species-specific viruses that can infect and kill bacteria.", [["eggs", "ANATOMY", 211, 215], ["ETEC", "CHEMICAL", 128, 132], ["pig", "ORGANISM", 61, 64], ["ETEC", "ORGANISM", 128, 132], ["ETEC strains", "ORGANISM", 254, 266], ["antibodies", "PROTEIN", 183, 193], ["pig", "SPECIES", 61, 64], ["ETEC", "SPECIES", 128, 132], ["ETEC", "SPECIES", 254, 258], ["ETEC challenge", "TREATMENT", 128, 142], ["the antibodies", "TEST", 179, 193], ["the infected ETEC strains", "PROBLEM", 241, 266], ["BacteriophagesBacteriophages", "PROBLEM", 294, 322], ["highly species", "PROBLEM", 327, 341], ["specific viruses", "PROBLEM", 342, 358], ["kill bacteria", "PROBLEM", 379, 392], ["probably the consequence", "UNCERTAINTY", 8, 32], ["infected", "OBSERVATION_MODIFIER", 245, 253]]], ["They have been widely evaluated in clinical trials to treat bacterial infections in pigs as an alternative to antibiotics use [144] .", [["bacterial infections", "DISEASE", 60, 80], ["pigs", "ORGANISM", 84, 88], ["pigs", "SPECIES", 84, 88], ["pigs", "SPECIES", 84, 88], ["bacterial infections", "PROBLEM", 60, 80], ["an alternative to antibiotics", "TREATMENT", 92, 121]]], ["Recently, it was reported that dietary supplementation with bacteriophages for the treatment of PWD caused by an ETEC: F4 strain in an experimental model, was effective in reducing rectal temperature, faecal consistency score, E. coli adhesion score in the ileum and caecum, and villous height/crypt depth ratio (VH/CD) in the duodenum and jejunum [145] .", [["rectal", "ANATOMY", 181, 187], ["faecal", "ANATOMY", 201, 207], ["ileum", "ANATOMY", 257, 262], ["caecum", "ANATOMY", 267, 273], ["villous", "ANATOMY", 279, 286], ["crypt", "ANATOMY", 294, 299], ["duodenum", "ANATOMY", 327, 335], ["jejunum", "ANATOMY", 340, 347], ["PWD", "DISEASE", 96, 99], ["rectal", "ORGANISM_SUBDIVISION", 181, 187], ["faecal", "ORGANISM_SUBDIVISION", 201, 207], ["ileum", "MULTI-TISSUE_STRUCTURE", 257, 262], ["caecum", "MULTI-TISSUE_STRUCTURE", 267, 273], ["villous", "TISSUE", 279, 286], ["crypt depth", "TISSUE", 294, 305], ["duodenum", "MULTI-TISSUE_STRUCTURE", 327, 335], ["jejunum", "ORGAN", 340, 347], ["E. coli", "SPECIES", 227, 234], ["E. coli", "SPECIES", 227, 234], ["dietary supplementation", "TREATMENT", 31, 54], ["bacteriophages", "TREATMENT", 60, 74], ["PWD", "PROBLEM", 96, 99], ["F4 strain", "PROBLEM", 119, 128], ["faecal consistency score", "TEST", 201, 225], ["E. coli adhesion score in the ileum and caecum", "PROBLEM", 227, 273], ["villous height/crypt depth ratio", "TEST", 279, 311], ["coli adhesion", "OBSERVATION", 230, 243], ["ileum", "ANATOMY", 257, 262], ["caecum", "ANATOMY", 267, 273], ["villous", "ANATOMY_MODIFIER", 279, 286], ["crypt depth", "OBSERVATION", 294, 305], ["duodenum", "ANATOMY", 327, 335], ["jejunum", "ANATOMY", 340, 347]]], ["However, there are several disadvantages associated with the use of phage therapy in swine.", [["swine", "ORGANISM", 85, 90], ["swine", "SPECIES", 85, 90], ["swine", "SPECIES", 85, 90], ["phage therapy", "TREATMENT", 68, 81], ["several", "OBSERVATION_MODIFIER", 19, 26], ["disadvantages", "OBSERVATION", 27, 40]]], ["Phages have a narrow spectrum of activity directed against a limited number of bacteria and the possible development of bacterial resistance against phages has to be considered [144] .", [["Phages", "TREATMENT", 0, 6], ["bacteria", "PROBLEM", 79, 87], ["bacterial resistance against phages", "PROBLEM", 120, 155], ["narrow spectrum", "OBSERVATION_MODIFIER", 14, 29], ["bacteria", "OBSERVATION", 79, 87], ["bacterial resistance", "OBSERVATION", 120, 140]]], ["To overcome the narrow spectrum of activity, some recent studies have reported beneficial effects of a bacteriophage cocktail used in the feed for weanling pigs.", [["weanling pigs", "ORGANISM", 147, 160], ["pigs", "SPECIES", 156, 160], ["pigs", "SPECIES", 156, 160], ["some recent studies", "TEST", 45, 64], ["a bacteriophage cocktail", "TREATMENT", 101, 125], ["weanling pigs", "TREATMENT", 147, 160], ["narrow spectrum", "OBSERVATION_MODIFIER", 16, 31]]], ["This combination resulted in enhanced growth performance and gut health of pigs, although the combination of phages with probiotics did not show any additional effect [109] .", [["gut", "ANATOMY", 61, 64], ["gut", "ORGANISM_SUBDIVISION", 61, 64], ["pigs", "ORGANISM", 75, 79], ["pigs", "SPECIES", 75, 79], ["pigs", "SPECIES", 75, 79], ["enhanced growth performance", "PROBLEM", 29, 56], ["probiotics", "TREATMENT", 121, 131], ["growth", "OBSERVATION_MODIFIER", 38, 44]]], ["Some authors have considered that the development of phage-resistant bacteria could be positive for the host [146] .", [["phage-resistant bacteria", "PROBLEM", 53, 77]]], ["In fact, resistance to phages can reduce the fitness of the bacteria and could thereby impair their competitive capacity and consequently their ability to colonize the intestinal mucosa of the host [146] .BacteriophagesOthers: Several studies have documented a significant improvement of weight gain, and feed conversion, as well as the reduction of the incidence, severity and duration of diarrhea in weaned pigs fed diets supplemented with substances such as: exogenous enzymes [147] , milk products [148] , clay minerals [149] , and medicinal plants [150] .", [["intestinal mucosa", "ANATOMY", 168, 185], ["weight gain", "DISEASE", 288, 299], ["diarrhea", "DISEASE", 390, 398], ["[147] , milk products [148] , clay minerals", "CHEMICAL", 480, 523], ["intestinal mucosa", "MULTI-TISSUE_STRUCTURE", 168, 185], ["pigs", "ORGANISM", 409, 413], ["milk", "ORGANISM_SUBSTANCE", 488, 492], ["clay minerals", "SIMPLE_CHEMICAL", 510, 523], ["exogenous enzymes", "PROTEIN", 462, 479], ["pigs", "SPECIES", 409, 413], ["pigs", "SPECIES", 409, 413], ["phages", "TREATMENT", 23, 29], ["the bacteria", "PROBLEM", 56, 68], ["their competitive capacity", "PROBLEM", 94, 120], ["Several studies", "TEST", 227, 242], ["weight gain", "PROBLEM", 288, 299], ["diarrhea", "PROBLEM", 390, 398], ["milk products", "TREATMENT", 488, 501], ["intestinal mucosa", "ANATOMY", 168, 185], ["significant", "OBSERVATION_MODIFIER", 261, 272], ["improvement", "OBSERVATION_MODIFIER", 273, 284]]], ["Although many peer-reviewed studies discussing these substances are available in the scientific literature, most of the clinical studies were performed in experimental conditions.", [["the clinical studies", "TEST", 116, 136]]], ["More research is needed to evaluate the potential effectiveness of these substances under field conditions for the control of PWD in pigs.Results of comparative studiesSeveral studies have been carried out in experimental conditions to assess the effectiveness of alternatives to colistin for the control of PWD in pigs (Table 4 ).", [["colistin", "CHEMICAL", 280, 288], ["colistin", "CHEMICAL", 280, 288], ["pigs", "ORGANISM", 133, 137], ["colistin", "SIMPLE_CHEMICAL", 280, 288], ["pigs", "ORGANISM", 315, 319], ["pigs", "SPECIES", 133, 137], ["pigs", "SPECIES", 315, 319], ["pigs", "SPECIES", 133, 137], ["pigs", "SPECIES", 315, 319], ["these substances", "TREATMENT", 67, 83], ["PWD in pigs", "TREATMENT", 126, 137], ["comparative studies", "TEST", 149, 168], ["Several studies", "TEST", 168, 183], ["colistin", "TREATMENT", 280, 288]]], ["Here, we give an overview of studies published in 2015 or 2016.Results of comparative studiesSeveral recent experimental studies have now shown that some alternatives (Table 4 ) resulted in similar or superior clinical outcomes compared to colistin for improving growth performance and intestinal integrity and in reducing of incidence of diarrhea in weaned pigs.", [["intestinal", "ANATOMY", 286, 296], ["colistin", "CHEMICAL", 240, 248], ["diarrhea", "DISEASE", 339, 347], ["colistin", "CHEMICAL", 240, 248], ["colistin", "SIMPLE_CHEMICAL", 240, 248], ["intestinal", "ORGAN", 286, 296], ["pigs", "ORGANISM", 358, 362], ["pigs", "SPECIES", 358, 362], ["pigs", "SPECIES", 358, 362], ["studies", "TEST", 29, 36], ["comparative studies", "TEST", 74, 93], ["recent experimental studies", "TEST", 101, 128], ["colistin", "TREATMENT", 240, 248], ["improving growth performance", "PROBLEM", 253, 281], ["intestinal integrity", "TREATMENT", 286, 306], ["diarrhea", "PROBLEM", 339, 347], ["intestinal", "ANATOMY", 286, 296], ["diarrhea", "OBSERVATION", 339, 347]]], ["In fact, no difference was observed in growth performance of weaned pigs supplemented with hop \u03b2-acids (120, 240, or 360 mg/kg) or colistin (40 mg/kg) during a trial period of 35 days [151] .", [["\u03b2-acids", "CHEMICAL", 95, 102], ["colistin", "CHEMICAL", 131, 139], ["\u03b2-acids", "CHEMICAL", 95, 102], ["colistin", "CHEMICAL", 131, 139], ["pigs", "ORGANISM", 68, 72], ["\u03b2-acids", "SIMPLE_CHEMICAL", 95, 102], ["colistin", "SIMPLE_CHEMICAL", 131, 139], ["pigs", "SPECIES", 68, 72], ["pigs", "SPECIES", 68, 72], ["hop \u03b2-acids", "TREATMENT", 91, 102], ["colistin", "TREATMENT", 131, 139], ["no", "UNCERTAINTY", 9, 11]]], ["Moreover, the supplementation of weaned pigs with two Macrocephala flavored powder (3000 mg/kg) increased significantly villus height in the duodenum and jejunum compared to that observed in colistin (300 mg/kg) supplemented pigs [152] .", [["villus", "ANATOMY", 120, 126], ["duodenum", "ANATOMY", 141, 149], ["jejunum", "ANATOMY", 154, 161], ["Macrocephala flavored powder", "CHEMICAL", 54, 82], ["colistin", "CHEMICAL", 191, 199], ["colistin", "CHEMICAL", 191, 199], ["pigs", "ORGANISM", 40, 44], ["villus", "MULTI-TISSUE_STRUCTURE", 120, 126], ["duodenum", "ORGAN", 141, 149], ["jejunum", "ORGAN", 154, 161], ["colistin", "SIMPLE_CHEMICAL", 191, 199], ["pigs", "ORGANISM", 225, 229], ["pigs", "SPECIES", 40, 44], ["pigs", "SPECIES", 225, 229], ["pigs", "SPECIES", 40, 44], ["weaned pigs", "TREATMENT", 33, 44], ["two Macrocephala flavored powder", "TREATMENT", 50, 82], ["increased significantly villus height in the duodenum and jejunum", "PROBLEM", 96, 161], ["colistin", "TREATMENT", 191, 199], ["duodenum", "ANATOMY", 141, 149], ["jejunum", "ANATOMY", 154, 161]]], ["However, these studies (Table 4 ), were conducted in experimental conditions and in most cases in healthy weaned pigs.", [["pigs", "ORGANISM", 113, 117], ["pigs", "SPECIES", 113, 117], ["pigs", "SPECIES", 113, 117], ["these studies", "TEST", 9, 22]]], ["Thus, further research is needed to demonstrate the stability and the efficacy of such alternatives (probiotics, AMPs, medicinal plants) in field conditions as well as the safety of these substances in animals and for consumers.", [["such alternatives", "TREATMENT", 82, 99], ["probiotics", "TREATMENT", 101, 111], ["AMPs", "TREATMENT", 113, 117], ["medicinal plants", "TREATMENT", 119, 135]]], ["Also, work is needed to optimize the doses of these substances to incorporate in the feed to ensure their effectiveness in PWD control.", [["these substances", "TREATMENT", 46, 62], ["PWD control", "TREATMENT", 123, 134]]], ["The financial cost and the ease of administration of such alternatives are the other important criteria that should be taken into consideration in pig production.Limits and perspectivesA long and growing list of compounds have been tested for their ability to replace colistin or other antibiotics for the control of PWD in pigs.", [["colistin", "CHEMICAL", 268, 276], ["colistin", "CHEMICAL", 268, 276], ["pig", "ORGANISM", 147, 150], ["colistin", "SIMPLE_CHEMICAL", 268, 276], ["pigs", "ORGANISM", 324, 328], ["pigs", "SPECIES", 324, 328], ["pig", "SPECIES", 147, 150], ["pigs", "SPECIES", 324, 328], ["administration of such alternatives", "TREATMENT", 35, 70], ["colistin", "TREATMENT", 268, 276], ["other antibiotics", "TREATMENT", 280, 297], ["PWD in pigs", "TREATMENT", 317, 328]]], ["However, it is difficult to identify a single \"ideal\" solution for PWD management.", [["a single \"ideal\" solution", "TREATMENT", 37, 62], ["PWD management", "TREATMENT", 67, 81]]], ["Also, as was discussed above, PWD is a multifactorial disease and the exact overall etiology has not yet been fully elucidated, making it difficult to choose suitable alternatives.", [["a multifactorial disease", "PROBLEM", 37, 61], ["multifactorial", "OBSERVATION_MODIFIER", 39, 53], ["disease", "OBSERVATION", 54, 61]]], ["Oral administration of specificantibody-containing egg yolk, or SDP to weaned piglets showed in some cases no protection against ETEC strains or PWD outcomes, likely because the contained antibodies were not specific against the infecting ETEC strains present on the farm [2] .", [["Oral", "ANATOMY", 0, 4], ["egg yolk", "ANATOMY", 51, 59], ["Oral", "ORGANISM_SUBDIVISION", 0, 4], ["specificantibody", "SIMPLE_CHEMICAL", 23, 39], ["egg yolk", "MULTI-TISSUE_STRUCTURE", 51, 59], ["SDP", "SIMPLE_CHEMICAL", 64, 67], ["piglets", "ORGANISM", 78, 85], ["ETEC", "ORGANISM", 239, 243], ["antibodies", "PROTEIN", 188, 198], ["piglets", "SPECIES", 78, 85], ["ETEC", "SPECIES", 129, 133], ["ETEC", "SPECIES", 239, 243], ["specificantibody-containing egg yolk", "TREATMENT", 23, 59], ["SDP", "PROBLEM", 64, 67], ["ETEC strains", "PROBLEM", 129, 141], ["PWD outcomes", "PROBLEM", 145, 157], ["the contained antibodies", "PROBLEM", 174, 198], ["the infecting ETEC strains", "PROBLEM", 225, 251]]], ["The composition of plant extracts, organic acids and probiotics is complex and knowledge regarding their mechanisms of action is poor, resulting in variable results and safety risks [87] .", [["extracts", "ANATOMY", 25, 33], ["organic acids", "CHEMICAL", 35, 48], ["extracts", "ORGANISM_SUBSTANCE", 25, 33], ["organic acids", "SIMPLE_CHEMICAL", 35, 48], ["plant extracts", "TREATMENT", 19, 33], ["organic acids", "TREATMENT", 35, 48], ["probiotics", "TREATMENT", 53, 63], ["plant extracts", "OBSERVATION", 19, 33]]], ["Synergy mechanisms of probiotics and prebiotics are not very well known nor well studied [133] .", [["probiotics", "TREATMENT", 22, 32], ["prebiotics", "TREATMENT", 37, 47]]], ["Although AMPs and bacteriophages helped in the treatment of PWD, the bacterial resistance risk, the high cost and the narrow antibacterial spectrum of these alternatives reduce their practical use on farms [88] .", [["AMPs", "GENE_OR_GENE_PRODUCT", 9, 13], ["AMPs", "TREATMENT", 9, 13], ["bacteriophages", "TREATMENT", 18, 32], ["PWD", "PROBLEM", 60, 63], ["the bacterial resistance risk", "PROBLEM", 65, 94], ["the high cost", "PROBLEM", 96, 109], ["the narrow antibacterial spectrum", "TREATMENT", 114, 147], ["these alternatives", "TREATMENT", 151, 169], ["bacterial resistance", "OBSERVATION", 69, 89], ["narrow antibacterial", "OBSERVATION_MODIFIER", 118, 138]]], ["Vaccination is one of the most promising strategies for the control of PWD in pigs both in terms of preventive ability and cost-effectiveness [97] .", [["pigs", "ORGANISM", 78, 82], ["pigs", "SPECIES", 78, 82], ["pigs", "SPECIES", 78, 82], ["Vaccination", "TREATMENT", 0, 11], ["PWD in pigs", "TREATMENT", 71, 82]]], ["The control of production parameters (temperature, ventilation, density, sanitation, biosafety, improvement of feed quality) are crucial factors for the control of PWD and the reduction of the use of antimicrobials during the post-weaning period [28] .", [["production parameters", "TEST", 15, 36], ["ventilation", "TREATMENT", 51, 62], ["sanitation", "TREATMENT", 73, 83], ["crucial factors", "PROBLEM", 129, 144], ["PWD", "TREATMENT", 164, 167], ["antimicrobials", "TREATMENT", 200, 214], ["the post-weaning period", "TREATMENT", 222, 245]]], ["However, the improvement of farm conditions and management requires investment and awareness of pig farmers.", [["pig", "ORGANISM", 96, 99], ["pig", "SPECIES", 96, 99], ["pig", "SPECIES", 96, 99], ["farm conditions", "PROBLEM", 28, 43], ["management", "TREATMENT", 48, 58], ["pig farmers", "TREATMENT", 96, 107], ["improvement", "OBSERVATION_MODIFIER", 13, 24], ["farm conditions", "OBSERVATION", 28, 43]]], ["Furthermore, the use of regular diagnostic testing is crucial to ensure an appropriate choice of the antimicrobial and to monitor its effectiveness on farms.", [["regular diagnostic testing", "TEST", 24, 50], ["the antimicrobial", "TREATMENT", 97, 114]]], ["Thus, efforts to improve microbiological laboratory detection methods are of paramount importance to help the veterinarian to act rapidly at an early stage of the disease [153] .Limits and perspectivesFor the management of PWD in different stages of its evolution, we propose a comprehensive approach that involves producers, the nutrition industry, veterinarians, the diagnostic laboratory, and researchers (Fig. 3) .", [["microbiological laboratory detection methods", "TEST", 25, 69], ["the disease", "PROBLEM", 159, 170], ["PWD", "PROBLEM", 223, 226], ["different stages", "OBSERVATION_MODIFIER", 230, 246]]], ["The absence of a well-identified etiology of PWD and of an effective alternative to antimicrobials requires a close collaboration between the different stakeholders to reduce antibiotic resistance and economic losses caused by this disease in swine.ConclusionsDespite the progress that has been observed in modern pig farms during the last decade to prevent infectious diseases and improve global animal health, PWD remains a problem that causes significant economic losses in pig production.", [["infectious diseases", "DISEASE", 358, 377], ["swine", "ORGANISM", 243, 248], ["pig", "ORGANISM", 314, 317], ["pig", "ORGANISM", 477, 480], ["swine", "SPECIES", 243, 248], ["pig", "SPECIES", 314, 317], ["swine", "SPECIES", 243, 248], ["pig", "SPECIES", 314, 317], ["pig", "SPECIES", 477, 480], ["PWD", "PROBLEM", 45, 48], ["antimicrobials", "TREATMENT", 84, 98], ["antibiotic resistance", "TREATMENT", 175, 196], ["economic losses", "PROBLEM", 201, 216], ["this disease in swine", "PROBLEM", 227, 248], ["infectious diseases", "PROBLEM", 358, 377], ["significant economic losses in pig production", "PROBLEM", 446, 491], ["antibiotic resistance", "OBSERVATION", 175, 196], ["infectious", "OBSERVATION", 358, 368], ["significant", "OBSERVATION_MODIFIER", 446, 457], ["economic", "OBSERVATION_MODIFIER", 458, 466], ["losses", "OBSERVATION", 467, 473], ["pig production", "OBSERVATION", 477, 491]]], ["Antibiotics have contributed significantly to mitigate the economic losses caused by infectious diseases and particularly PWD in swine.", [["infectious diseases", "DISEASE", 85, 104], ["swine", "ORGANISM", 129, 134], ["swine", "SPECIES", 129, 134], ["swine", "SPECIES", 129, 134], ["Antibiotics", "TREATMENT", 0, 11], ["the economic losses", "PROBLEM", 55, 74], ["infectious diseases", "PROBLEM", 85, 104], ["infectious", "OBSERVATION", 85, 95]]], ["However, increasing bacterial resistance leading to therapeutic failures on farms as well as the greater vigilance of consumers regarding antimicrobial residues, have resulted in more intensive research and a large number of clinical trials for the development of alternatives to antimicrobials.", [["increasing bacterial resistance", "PROBLEM", 9, 40], ["therapeutic failures on farms", "PROBLEM", 52, 81], ["antimicrobial residues", "TREATMENT", 138, 160], ["clinical trials", "TREATMENT", 225, 240], ["antimicrobials", "TREATMENT", 280, 294], ["increasing", "OBSERVATION_MODIFIER", 9, 19], ["bacterial resistance", "OBSERVATION", 20, 40], ["therapeutic", "OBSERVATION_MODIFIER", 52, 63], ["failures", "OBSERVATION", 64, 72], ["antimicrobial residues", "OBSERVATION", 138, 160], ["large", "OBSERVATION_MODIFIER", 209, 214]]], ["Thus, several alternatives have been developed, some of which have been commercialized for the management of PWD in pigs.", [["pigs", "ORGANISM", 116, 120], ["pigs", "SPECIES", 116, 120], ["pigs", "SPECIES", 116, 120], ["PWD in pigs", "TREATMENT", 109, 120]]], ["However, the effectiveness of these news therapies has been variable from one farm to another due to the management of livestock and farm conditions.", [["these news therapies", "TREATMENT", 30, 50]]], ["AlthoughTable 4 Effects of colistin compared to alternative measures for control of post weaning diarrhoea (PWD) in pigsLive yeast: Saccharomyces cerevisiae HP healthy pigs, CP challenged pigs, NA not available a,b Values within a row with different superscripts differ significantly at P < 0.05 c Diarrhea occurrence was calculated as the proportion of days in which pigs showed clinical signs of diarrhea d Number of pig days with diarrhoea score \u22652 e Jejunum f log (copies/g) some alternatives have shown comparable efficacy to antimicrobials or colistin in the control of PWD, there is still a considerable gap between these alternatives and antibiotics concerning their effectiveness in PWD control.", [["colistin", "CHEMICAL", 27, 35], ["diarrhoea", "DISEASE", 97, 106], ["Diarrhea", "DISEASE", 298, 306], ["diarrhea", "DISEASE", 398, 406], ["diarrhoea", "DISEASE", 433, 442], ["colistin", "CHEMICAL", 549, 557], ["colistin", "CHEMICAL", 27, 35], ["colistin", "CHEMICAL", 549, 557], ["colistin", "SIMPLE_CHEMICAL", 27, 35], ["pigsLive yeast", "ORGANISM", 116, 130], ["Saccharomyces cerevisiae HP", "ORGANISM", 132, 159], ["healthy pigs", "ORGANISM", 160, 172], ["CP challenged pigs", "ORGANISM", 174, 192], ["NA", "MULTI-TISSUE_STRUCTURE", 194, 196], ["pigs", "ORGANISM", 368, 372], ["pig", "ORGANISM", 419, 422], ["colistin", "SIMPLE_CHEMICAL", 549, 557], ["yeast", "SPECIES", 125, 130], ["Saccharomyces cerevisiae", "SPECIES", 132, 156], ["pigs", "SPECIES", 168, 172], ["pigs", "SPECIES", 188, 192], ["pigs", "SPECIES", 368, 372], ["pig", "SPECIES", 419, 422], ["yeast", "SPECIES", 125, 130], ["Saccharomyces cerevisiae", "SPECIES", 132, 156], ["pigs", "SPECIES", 188, 192], ["pigs", "SPECIES", 368, 372], ["pig", "SPECIES", 419, 422], ["colistin", "TREATMENT", 27, 35], ["alternative measures", "TREATMENT", 48, 68], ["post weaning diarrhoea", "PROBLEM", 84, 106], ["CP", "PROBLEM", 174, 176], ["Diarrhea", "PROBLEM", 298, 306], ["diarrhea", "PROBLEM", 398, 406], ["diarrhoea score", "PROBLEM", 433, 448], ["some alternatives", "TREATMENT", 479, 496], ["antimicrobials", "TREATMENT", 531, 545], ["colistin", "TREATMENT", 549, 557], ["these alternatives", "TREATMENT", 623, 641], ["antibiotics", "TREATMENT", 646, 657], ["PWD control", "TREATMENT", 692, 703], ["diarrhea", "OBSERVATION", 398, 406], ["Jejunum", "ANATOMY", 454, 461]]], ["Control of housing conditions and vaccination are the most promising strategies for the prevention of PWD in pigs and for reducing of the overall use of antimicrobials on farms.", [["pigs", "ORGANISM", 109, 113], ["pigs", "SPECIES", 109, 113], ["pigs", "SPECIES", 109, 113], ["housing conditions", "TREATMENT", 11, 29], ["vaccination", "TREATMENT", 34, 45], ["PWD in pigs", "TREATMENT", 102, 113], ["antimicrobials on farms", "TREATMENT", 153, 176]]], ["However, the establishment and the effectiveness of these strategies depend on the involvement of all stakeholders in pig farming.", [["pig", "ORGANISM", 118, 121], ["pig", "SPECIES", 118, 121], ["pig", "SPECIES", 118, 121], ["these strategies", "TREATMENT", 52, 68], ["pig farming", "TREATMENT", 118, 129]]], ["Judicious use of antimicrobials in pigs and continued development of alternatives to antimicrobials and colistin remains a priority to ensure a long-term sustainable development in pigs.", [["colistin", "CHEMICAL", 104, 112], ["colistin", "CHEMICAL", 104, 112], ["pigs", "ORGANISM", 35, 39], ["colistin", "SIMPLE_CHEMICAL", 104, 112], ["pigs", "ORGANISM", 181, 185], ["pigs", "SPECIES", 35, 39], ["pigs", "SPECIES", 181, 185], ["pigs", "SPECIES", 35, 39], ["pigs", "SPECIES", 181, 185], ["antimicrobials in pigs", "TREATMENT", 17, 39], ["antimicrobials", "TREATMENT", 85, 99], ["colistin", "TREATMENT", 104, 112]]]]}